

Sunday, 14. March 2021

Non-Profit Symposium

08:30 - 10:00

Auditorium 2

IS02 - Latest developments in hematopoietic cell transplantation - Sorbonne University (ATERHIT) non-profit symposium

Chair: Arnon Nagler, IL

Chair: Bipin Savani, US

IS2-1	Haplo transplant for AML <i>Speaker:</i> Arnon Nagler, IL	08:30 - 08:48
IS2-2	Haplo transplant for the elderly <i>Speaker:</i> Didier Blaise, FR	08:48 - 09:06
IS2-3	Monoclonal antibodies in ALL <i>Speaker:</i> Eolia Brissot, FR	09:06 - 09:24
IS2-4	Monoclonal antibodies in Hodgkin lymphoma <i>Speaker:</i> Ali Bazarbachi, LB	09:24 - 09:42
IS2-5	Allogeneic transplantation after CAR T-cell therapy <i>Speaker:</i> Bipin Savani, US	09:42 - 10:00

Non-Profit Symposium

08:30 - 10:00

Auditorium 3

IS03 - Multiple myeloma in 2021: the IFM global perspective - IFM non-profit symposium

Chair: Mohamad Mohty, FR

Chair: Jean-Luc Harousseau, FR

IS3-1	Introduction <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:32
IS3-2	What's new for induction prior to ASCT? <i>Speaker:</i> Philippe Moreau, FR	08:32 - 08:53
IS3-3	What's new in the elderly setting? <i>Speaker:</i> Thierry Facon, FR	08:53 - 09:14
IS3-4	Monoclonal antibodies for relapse after ASCT <i>Speaker:</i> Mohamad Mohty, FR	09:14 - 09:35
IS3-5	Requirements for functional cure in myeloma <i>Speaker:</i> Jean-Luc Harousseau, FR	09:35 - 09:56
IS3-6	Conclusion <i>Speaker:</i> Mohamad Mohty, FR	09:56 - 09:58

Non-Profit Symposium

08:30 - 10:00

Auditorium 4

IS04 - Dilemma in allogeneic hematopoietic transplantation for myelofibrosis - SFGM-TC non-profit symposium

Chair: Jacques Olivier Bay, FR

Chair: Thierry Guillaume, FR

IS4-1	Impact of HSCT in ruxolitinib area <i>Speaker:</i> Marie Robin, FR	08:30 - 08:50
IS4-2	Transplantation with an alternative donor: Results and perspectives <i>Speaker:</i> Nicolaus Kröger, DE	08:50 - 09:10
IS4-3	Liver specificities in myelofibrosis and impact on transplantation procedure <i>Speaker:</i> Audrey Payance, FR	09:10 - 09:30
IS4-4	Q&A	09:30 - 10:00

Industrial Theatre

08:30 - 18:45

IT

IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session

This session is available throughout the whole congress

Chair: Amir Hefni, GB

Chair: David Kuzan, US

Chair: Carolin Barth, CH

Industrial Theatre

08:30 - 18:45

IT

Industry Theatre sessions

Industrial Theatre

08:30 - 18:45

IT

IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session

This session is available throughout the whole congress

Chair: Volker Witt, AT

Industrial Theatre

08:30 - 18:45

IT

IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre session

This session is available throughout the whole congress

Chair: Dick Sundh, AU

Oral Session

08:30 - 18:45

On-Demand Library

OS08 - Oral session 8: Graft versus Host Disease I

This session is available in our on-demand library throughout the whole congress

OS8-1	GVHD PROPHYLAXIS WITH POST TRANSPLANTATION	08:30 - 08:30
-------	---	---------------

	CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A / METHOTREXATE POST ALLOGENEIC TRANSPLANTATION (HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE ALWP/EBMT <i>Speaker:</i> Arnon Nagler, IL	
OS8-2	BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE ROCKSTAR STUDY (KD025-213) <i>Speaker:</i> Corey Cutler, US	08:30 - 08:30
OS8-3	A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Hanaa A. Fatoum, SA	08:30 - 08:30
OS8-4	RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM THE RANDOMIZED, PHASE 3 REACH2 STUDY <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:30
OS8-5	IMPACT OF CHRONIC GVHD SEVERITY AND STEROID RESPONSE ON THE QUALITY OF LIFE IN PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: FINDINGS FROM A REAL-WORLD STUDY <i>Speaker:</i> Sylvie Lachance, CA	08:30 - 08:30
OS8-6	SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM <i>Speaker:</i> Florent Malard, FR	08:30 - 08:30
OS8-7	REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER ALLO-HSCT <i>Speaker:</i> Marie T Rubio, FR	08:30 - 08:30
OS8-8	PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD STUDY <i>Speaker:</i> Nada Hamad, AU	08:30 - 08:30

Oral Session
08:30 - 18:45

On-Demand Library

OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering

This session is available in our on-demand library throughout the whole congress

OS1-1	MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT	08:30 - 08:30
-------	--	---------------

IMMUNOSUPPRESSIVE PROPERTIES

Speaker: Kevin Goncalves, US

OS1-2	EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34⁺ CELL MOBILIZATION IN HEALTHY VOLUNTEERS <i>Speaker:</i> Hideki Goto, JP	08:30 - 08:30
OS1-3	THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Rumesh Chandar, IN	08:30 - 08:30
OS1-4	THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT REJECTION AND GRAFT VERSUS HOST DISEASE IN CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION <i>Speaker:</i> Satish Meena, IN	08:30 - 08:30
OS1-5	OUTCOME AND IMMUNE RECONSTITUTION AFTER TCR$\alpha\beta$/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL RELATED DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Lucia Prezioso, IT	08:30 - 08:30
OS1-6	THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE <i>Speaker:</i> Muhammad Ameen, SA	08:30 - 08:30
OS1-7	POST-TRANSPLANT OUTCOMES OF CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TREATED WITH EMAPALUMAB <i>Speaker:</i> Michael Jordan, US	08:30 - 08:30
OS1-8	WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE <i>Speaker:</i> Maria Escolar, US	08:30 - 08:30

Oral Session
08:30 - 18:45

On-Demand Library

OS03 - Oral session 3: CARs II

This session is available in our on-demand library throughout the whole congress

OS3-1	CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY OF THE APPROACH <i>Speaker:</i> Olga Molostova, RU	08:30 - 08:30
OS3-2	CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2 CARTITUDE-1 STUDY	08:30 - 08:30

	<i>Speaker:</i> Andrzej Jakubowiak, US	
OS3-3	PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS WITH RELAPSED/REFRACTORY MCL IN ZUMA-2	08:30 - 08:30
	<i>Speaker:</i> Michael L. Wang, US	
OS3-4	REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN SPAIN	08:30 - 08:30
	<i>Speaker:</i> Mi Kwon, ES	
OS3-5	HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY	08:30 - 08:30
	<i>Speaker:</i> Dasom Lee, US	
OS3-6	DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS ARE ASSOCIATED WITH NEUROTOXICITY	08:30 - 08:30
	<i>Speaker:</i> Madhavi Lakkaraja, US	
OS3-7	COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-T THERAPY	08:30 - 08:30
	<i>Speaker:</i> Zhao-Yanli Zhao, CN	
OS3-8	THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF GD2+ SARCOMAS	08:30 - 08:30
	<i>Speaker:</i> Antonio Camera, IT	

Educational
08:30 - 18:45

On-Demand Library

E09 - Allogeneic HSCT in MDS and MPN

This session is available in our on-demand library throughout the whole congress

E9-1	Definition of graft failure/relapse after allo-HCT in myelofibrosis	-
	<i>Speaker:</i> Donal McLornan, GB	
E9-2	Allogeneic HSCT in patients with therapy-related MDS/AML	-
	<i>Speaker:</i> Marie Robin, FR	
E9-3	The role of maintenance therapy after allogeneic HSCT in MDS	-
	<i>Speaker:</i> Francesco Onida, IT	

On Demand Library
08:30 - 18:45

On-Demand Library

On Demand Library

Oral Session

08:30 - 18:45

On-Demand Library

OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others

This session is available in our on-demand library throughout the whole congress

OS20-1	HLA EVOLUTIONARY DIVERGENCE INFLUENCES CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Speaker:</i> Simona Pagliuca, US	08:30 - 08:40
OS20-2	OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511 PATIENTS <i>Speaker:</i> Richard K Burt, US	08:40 - 08:50
OS20-3	EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A REAL WORLD EXPERIENCE <i>Speaker:</i> Varun Mehra, GB	08:50 - 09:00
OS20-4	THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Speaker:</i> Carmelo Gurnari, US	09:00 - 09:10
OS20-5	HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS: CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES <i>Speaker:</i> Alexey Polushin, RU	09:10 - 09:20
OS20-6	HLA MUTATIONS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM OF IMMUNE ESCAPE <i>Speaker:</i> Carmelo Gurnari, US	09:20 - 09:30
OS20-7	HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:30 - 09:40
OS20-8	IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS <i>Speaker:</i> Alice Mariottini, IT	09:40 - 09:50

Oral Session

08:30 - 18:45

On-Demand Library

OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I

This session is available in our on-demand library throughout the whole congress

OS4-1	INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) TREATED IN THE PHASE 3 NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212)	08:30 - 08:40
-------	--	---------------

STUDIES

Speaker: Isabelle Thuret, FR

OS4-2	NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE TREATMENT OF ADULT HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES <i>Speaker:</i> Alessandro Rambaldi, IT	08:40 - 08:50
OS4-3	CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T-CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Eliana Ruggiero, IT	08:50 - 09:00
OS4-4	CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY IN MPSIIIA <i>Speaker:</i> Jane Louise Kinsella, GB	09:00 - 09:10
OS4-5	EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Dalia Sheta, DE	09:10 - 09:20
OS4-6	REAL-WORLD EFFECTIVENESS AND SAFETY OF BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST RELAPSE <i>Speaker:</i> Alessandro Rambaldi, IT	09:20 - 09:30
OS4-7	GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY <i>Speaker:</i> Paulien van Houten, NL	09:30 - 09:40
OS4-8	IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC ANALYSES FROM THE PEGASUS STUDY <i>Speaker:</i> David Cella, US	09:40 - 09:50

Oral Session
08:30 - 18:45

On-Demand Library

OS17 - Oral session 17: Acute Leukemia II

This session is available in our on-demand library throughout the whole congress

OS17-1	TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: IMPROVEMENT OF SURVIVAL IN RECENT YEARS <i>Speaker:</i> Ali Bazarbachi, LB	08:30 - 08:30
OS17-2	HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK	08:30 - 08:30

	OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE NUCLEAR CONSORTIUM <i>Speaker:</i> José Sánchez Maldonado, ES	
OS17-3	COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA <i>Speaker:</i> Annalisa Ruggeri, ES	08:30 - 08:30
OS17-4	REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION <i>Speaker:</i> Sarah Morin, CH	08:30 - 08:30
OS17-5	VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT (HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Vincenzo Federico, IT	08:30 - 08:30
OS17-6	TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Speaker:</i> Nico Gagelmann, DE	08:30 - 08:30
OS17-7	STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL DONOR FOR PEDIATRIC PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE STUDY <i>Speaker:</i> Charlotte Nazon, FR	08:30 - 08:30
OS17-8	COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD <i>Speaker:</i> Gabriele Magliano, IT	08:30 - 08:30

Oral Session
08:30 - 18:45

On-Demand Library

OS16 - Oral session 16: Acute Leukemia I

This session is available in our on-demand library throughout the whole congress

OS16-1	IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE EBMT <i>Speaker:</i> Justin Loke, GB	08:30 - 08:40
OS16-2	IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELOYDYSPLASTIC SYNDROME: A JOIN STUDY BY THE ALWP AND THE CMWP <i>Speaker:</i> Eolia Brissot, FR	08:40 - 08:50
OS16-3	THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T CELL DEPLETED HAPLOIDENTICAL STEM CELL	08:50 - 09:00

	TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A STUDY FROM THE ALWP / EBMT <i>Speaker:</i> Arnon Nagler, IL	
OS16-4	NON-T DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER ONE VS TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT <i>Speaker:</i> Arnon Nagler, IL	09:00 - 09:10
OS16-5	PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND ALL. A STUDY FROM THE ALWP-EBMT <i>Speaker:</i> Sabine Blum, CH	09:10 - 09:20
OS16-6	IMPACT OF ALLOGENIC TRANSPLANTATION IN THE TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS. COMPARISON BETWEEN MYELOABLATIVE VS REDUCE INTENSITY CONDITIONINGS <i>Speaker:</i> Claudia Núñez-Torrón, ES	09:20 - 09:30
OS16-7	THE DISEASE BURDEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE TO PATIENTS WITH SECONDARY LEUKEMIA <i>Speaker:</i> Claudia Núñez-Torrón, ES	09:30 - 09:40
OS16-8	PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL TRANSPLANTATION. STUDY OF 132 PATIENTS <i>Speaker:</i> Christelle Ferra Coll, ES	09:40 - 09:50

Working Party Session
08:30 - 18:45

On-Demand Library

IDWP - Infectious Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

IDWP-1	IDWP update <i>Speaker:</i> Rafael de la Cámara, ES	-
IDWP-2	Current scientific proposals of IDWP <i>Speaker:</i> Dina Averbuch, IL	-
IDWP-3	CMV T-cell immunity monitoring: is it time to incorporate it in clinical practices? <i>Speaker:</i> Roy Chemaly, US	-
IDWP-4	What is new in the field of Gram-negative infections in SCT patients? <i>Speaker:</i> Dina Averbuch, IL	-
IDWP-5	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation	-

	<i>Speaker:</i> Jose Luis Piñana, ES	
IDWP-6	Hepatitis C and hepatitis E in SCT <i>Speaker:</i> Malgorzata Mikulska, IT	-
IDWP-7	Central nervous system (CNS) complications following HSCT <i>Speaker:</i> Martin Schmidt-Hieber, DE	-

Educational
08:30 - 18:45

On-Demand Library

E08 - New challenges in infectious complications

This session is available in our on-demand library throughout the whole congress

E8-1	T-cell therapy for infections in SCT patients: An experimental treatment or a real choice for the practice? <i>Speaker:</i> Patrizia Comoli, IT	-
E8-2	Infectious complications with new drugs in Hematology <i>Speaker:</i> Georg Maschmeyer, DE	-
E8-3	The blood virome of HSCT Recipients: Much more than viremia by CMV, EBV, HH6V and adenovirus <i>Speaker:</i> Marie-Celine Zanella, CH	-

Oral Session
08:30 - 18:45

On-Demand Library

OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes

This session is available in our on-demand library throughout the whole congress

OS18-1	GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS WITH MYELOID NEOPLASIA <i>Speaker:</i> Carmelo Gurnari, US	08:30 - 08:30
OS18-2	RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA. A STUDY OF THE EBMT-CMWP <i>Speaker:</i> Alicia Rovó, CH	08:30 - 08:30
OS18-3	CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A RETROSPECTIVE ANALYSIS FROM THE CHRONIC MALIGNANCIES WORKING PARTY <i>Speaker:</i> Christof Scheid, DE	08:30 - 08:30
OS18-4	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM AFTER BREAST CANCER TREATMENT: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT <i>Speaker:</i> Mitja Nabergoj, CH	08:30 - 08:30
OS18-5	IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-	08:30 - 08:30

CMWP STUDY

Speaker: Nicolaus Kröger, DE

OS18-6	ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Speaker: Elena Morozova, RU	08:30 - 08:30
OS18-7	DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML Speaker: Christian Niederwieser, DE	08:30 - 08:30
OS18-8	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT PERIOD Speaker: Anna Czyz, PL	08:30 - 08:30

Oral Session
08:30 - 18:45

On-Demand Library

OS10 - Oral session 10: COVID-19

This session is available in our on-demand library throughout the whole congress

OS10-1	A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS ADOPTIVE THERAPY IN COVID19 Speaker: Antonio Pérez-Martínez, ES	08:30 - 08:40
OS10-2	THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY Speaker: Angharad Pryce, GB	08:40 - 08:50
OS10-3	IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT Speaker: Sara Ghorashian, GB	08:50 - 09:00
OS10-4	OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE FROM A SEVERELY AFFECTED AREA (BERGAMO) Speaker: Maria Caterina Mico', IT	09:00 - 09:10
OS10-5	ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS AFTER COVID-19 INFECTION Speaker: Maximilian Christopeit, DE	09:10 - 09:20
OS10-6	INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION CENTERS AND THE PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE 2020	09:20 - 09:30

Speaker: Fernando Barroso Duarte, BR

OS10-7 **CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC PROGENITOR CELLS IN THE CURRENT SARS-CoV-2 PANDEMIC: EXPERIENCE OF A SINGLE CENTRE** 09:30 - 09:40

Speaker: Dolores Moreno, ES

OS10-8 **IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH CORD BLOOD UNITS. ON BEHALF THE AGENCY OF BIOMEDICINE, EUROCORD AND THE SFGM-TC** 09:40 - 09:50

Speaker: Hanadi Rafii - El Ayoubi, FR

Data Management

08:30 - 18:45

On-Demand Library

DM05 - Education session 5

This session is available in our on-demand library throughout the whole congress

DM5-1 **Hematopoietic Cell Transplantation-Comorbidity Index 'Sorrer Score'** -

Speaker: Bronwen Shaw, US

Oral Session

08:30 - 18:45

On-Demand Library

OS21 - Oral session 21: Multiple Myeloma

This session is available in our on-demand library throughout the whole congress

OS21-1 **MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA** 08:30 - 08:30

Speaker: Harsh Parmar, US

OS21-2 **AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT – A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP** 08:30 - 08:30

Speaker: Joanna Drozd-Sokołowska, PL

OS21-3 **ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP ANALYSIS** 08:30 - 08:30

Speaker: Mohamad Mohty, FR

OS21-4 **AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM STEM CELL TRANSPLANTATION AND MAINTENANCE WITH THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA (MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-STUDY** 08:30 - 08:30

Speaker: Nicolaus Kröger, DE

OS21-5 **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A** 08:30 - 08:30

	STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL DISEASE <i>Speaker:</i> Jean Roy, CA	
OS21-6	ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY <i>Speaker:</i> Laurent Garderet, FR	08:30 - 08:30
OS21-7	COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) <i>Speaker:</i> Sergio Giralt, US	08:30 - 08:30
OS21-8	CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE-CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL TRIALS OF DARATUMUMAB <i>Speaker:</i> Katja Weisel, DE	08:30 - 08:30

Lab Technicians Day
08:30 - 18:45

On-Demand Library

LT1 - Lab Technicians Day: Specialized cell processing

This session is available in our on-demand library throughout the whole congress

LT1-1	Bone marrow processing: Techniques and results <i>Speaker:</i> Boris Calmels, FR	-
LT1-2	Technical aspects and performance TCRab/CD19 depletion <i>Speaker:</i> Kasper Westinga, NL	-
LT1-3	Donor selection and GMP-compliant manufacturing of virus-specific T-cells <i>Speaker:</i> Britta Eiz-Vesper, DE	-

Oral Session
08:30 - 18:45

On-Demand Library

OS02 - Oral session 2: CARs I

This session is available in our on-demand library throughout the whole congress

OS2-1	CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Deepu Madduri, US	08:30 - 08:40
OS2-2	PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) <i>Speaker:</i> Olalekan O. Oluwole, US	08:40 - 08:50

OS2-3	MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA <i>Speaker:</i> David Maloney, US	08:50 - 09:00
OS2-4	STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA BLASTS <i>Speaker:</i> Concetta Quintarelli, IT	09:00 - 09:10
OS2-5	CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19 CAR T-CELL THERAPY <i>Speaker:</i> Jordan Gauthier, US	09:10 - 09:20
OS2-6	OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING: INITIAL RESULTS FROM THE OUTREACH STUDY <i>Speaker:</i> John E. Godwin, US	09:20 - 09:30
OS2-7	BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T CELLS AT EU OR EBMT AFFILIATED PROGRAMS <i>Speaker:</i> Christian Chabannon, FR	09:30 - 09:40
OS2-8	ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF THE SHELF” STRATEGY TO TREAT CD123^{POS} CHILDHOOD ACUTE MYELOID LEUKAEMIA <i>Speaker:</i> Simona Caruso, IT	09:40 - 09:50

Data Management
08:30 - 18:45

On-Demand Library

DM09 - Education session 9

This session is available in our on-demand library throughout the whole congress

DM9-1	Follow up forms - How to get a chronological overview of the patient history and follow up <i>Speaker:</i> Elena Ferrer Martínez del Peral, ES	-
-------	--	---

Oral Session
08:30 - 18:45

On-Demand Library

OS09 - Oral session 9: Graft versus Host Disease II

This session is available in our on-demand library throughout the whole congress

OS9-1	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN HUMANS <i>Speaker:</i> Robert Zeiser, DE	08:30 - 08:30
OS9-2	RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-	08:30 - 08:30

	VS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL <i>Speaker:</i> Franco Locatelli, IT	
OS9-3	DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT? <i>Speaker:</i> Ivan Moiseev, RU	08:30 - 08:30
OS9-4	A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Michelle Hudspeth, US	08:30 - 08:30
OS9-5	THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY <i>Speaker:</i> Junya Kanda, JP	08:30 - 08:30
OS9-6	EARLY RECONSTITUTION OF CD6+ T CELLS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL ANTIBODY ITOLIZUMAB <i>Speaker:</i> Benedetta Rambaldi, US	08:30 - 08:30
OS9-7	MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Erik Thiele Orberg, DE	08:30 - 08:30
OS9-8	ASSOCIATION OF GENE POLYMORPHISMS IN CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Paula Muñoz, ES	08:30 - 08:30

Oral Session
08:30 - 18:45

On-Demand Library

OS13 - Oral session 13: Transplant Complications I

This session is available in our on-demand library throughout the whole congress

OS13-1	FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:30
OS13-2	ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE ANALYSIS FROM THE EBMT	08:30 - 08:30

	<i>Speaker:</i> Olaf Penack, DE	
OS13-3	DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:30
OS13-4	EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:30
OS13-5	EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE MORTALITY AND THE RISK OF INTENSIVE CARE UNIT ADMISSION AT PRE-TRANSPLANT EVALUATION <i>Speaker:</i> Marta Peña Domingo, ES	08:30 - 08:30
OS13-6	THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Midori Nakagaki, AU	08:30 - 08:30
OS13-7	IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY <i>Speaker:</i> Aldo A Acosta-Medina, US	08:30 - 08:30
OS13-8	RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD <i>Speaker:</i> Bernd Gruhn, DE	08:30 - 08:30

Data Management

08:30 - 18:45

On-Demand Library

DM07 - Education session 7

This session is available in our on-demand library throughout the whole congress

DM7-1	Minimal residual disease (MRD) <i>Speaker:</i> Johannes Schetelig, DE	-
-------	---	---

Oral Session

08:30 - 18:45

On-Demand Library

OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II

This session is available in our on-demand library throughout the whole congress

OS5-1	HEMATOPOIETIC STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH): BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF	08:30 - 08:40
-------	--	---------------

EARLY CLINICAL RESPONSE

Speaker: Maria Ester Bernardo, IT

OS5-2	OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH TABELCLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Susan Prockop, US	08:40 - 08:50
OS5-3	RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY <i>Speaker:</i> Markus Mapara, US	08:50 - 09:00
OS5-4	DURABLE CLINICAL OUTCOMES FOLLOWING BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH TRANSFUSION-DEPENDENT α-THALASSEMIA (TDT) <i>Speaker:</i> Franco Locatelli, IT	09:00 - 09:10
OS5-5	OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT) <i>Speaker:</i> Carolyn Mulroney, US	09:10 - 09:20
OS5-6	IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Francesca Patriarca, IT	09:20 - 09:30
OS5-7	MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR THE IDENTIFICATION OF HIGH-RISK PATIENTS AND TREATMENT WITH T-CELL IMMUNOTHERAPY <i>Speaker:</i> Anastasia Papadopoulou, GR	09:30 - 09:40
OS5-8	NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT TRANSDUCTION AND CROSS-CORRECTION MECHANISMS USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH <i>Speaker:</i> Jane E Potter, GB	09:40 - 09:50
Paed4-2	EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34⁺ HEMATOPOIETIC STEM AND PROGENITOR CELLS IN TRANSFUSION-DEPENDENT α-THALASSEMIA AND SICKLE CELL DISEASE <i>Speaker:</i> Selim Corbacioglu, DE	09:50 - 10:00

Working Party Session

08:30 - 18:45

On-Demand Library

CMWP - Chronic Malignancies Working Party Session

This session is available in our on-demand library throughout the whole congress

CMWP-1	Scientific activity of the CMWP <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	08:30 - 08:30
CMWP-3	Who and when in the course of disease to transplant? - Myelofibrosis <i>Speaker:</i> Donal McLornan, GB	08:30 - 08:30
CMWP-4	Is Chronic Myeloid Leukaemia still an indication for allo-HCT? <i>Speaker:</i> Yves Chalandon, CH	08:30 - 08:30
CMWP-5	Is Chronic Lymphocytic Leukemia still an indication for allo-HCT? <i>Speaker:</i> Peter Dreger, DE	08:30 - 08:30

Oral Session

08:30 - 18:45

On-Demand Library

OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia

This session is available in our on-demand library throughout the whole congress

OS19-1	INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL) <i>Speaker:</i> Catherine Thieblemont, FR	08:30 - 08:30
OS19-2	LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) <i>Speaker:</i> Caron A. Jacobson, US	08:30 - 08:30
OS19-3	PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) <i>Speaker:</i> Caron A. Jacobson, US	08:30 - 08:30
OS19-4	ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) <i>Speaker:</i> Michael L. Wang, US	08:30 - 08:30
OS19-5	VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE CRUCIAL CONSORTIUM <i>Speaker:</i> Antonio José Cabrera-Serrano, ES	08:30 - 08:30
OS19-6	EVALUATION OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN	08:30 - 08:30

	PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) <i>Speaker:</i> Natalie L. Smith, US	
OS19-7	ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA (DLBCL) IN A GERMAN TERTIARY HOSPITAL <i>Speaker:</i> Bernhard Alexander Mörtl, DE	08:30 - 08:30
OS19-8	LONG TERM OUTCOMES OF ALLOGENEIC TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Alexander Glover, GB	08:30 - 08:30
<i>Oral Session</i> 08:30 - 18:45		On-Demand Library
OS15 - Oral session 15: Conditioning Regimens		
This session is available in our on-demand library throughout the whole congress		
OS15-1	BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA <i>Speaker:</i> Sylvie Lachance, CA	08:30 - 08:40
OS15-2	MICROBIOTA INJURY IS CONDITIONING REGIMEN-DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS <i>Speaker:</i> Roni Shouval, US	08:40 - 08:50
OS15-3	THE IMPACT OF PULMONARY FUNCTION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION <i>Speaker:</i> Jesus Duque-Afonso, DE	08:50 - 09:00
OS15-4	HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Khalid Halahleh, JO	09:00 - 09:10
OS15-5	THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION :A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369 CONTROLS <i>Speaker:</i> Federica Sora, IT	09:10 - 09:20
OS15-6	IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL BLOOD COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE ALONE <i>Speaker:</i> Giorgia Battipaglia, IT	09:20 - 09:30
OS15-7	HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE	09:30 - 09:40

MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS

Speaker: Donata Backhaus, DE

OS15-8	SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	09:40 - 09:50
	Speaker: Eduardo Rodríguez-Arbolí, ES	

Oral Session
08:30 - 18:45

On-Demand Library

OS12 - Oral session 12: Infectious Diseases II

This session is available in our on-demand library throughout the whole congress

OS12-1	NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY GROUP	08:30 - 08:30
	Speaker: Dina Averbuch, IL	
OS12-2	COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY	08:30 - 08:30
	Speaker: Marina Popova, RU	
OS12-3	COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Speaker: Yuliya Rogacheva, RU	
OS12-4	FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTS	08:30 - 08:30
	Speaker: Chiara Rosignoli, IT	
OS12-5	CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE	08:30 - 08:30
	Speaker: Anke Verlinden, BE	
OS12-6	COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS THAT AFFECT THE SURVIVAL OF PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	Speaker: Anna Czyz, PL	
OS12-7	IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; SINGLE CENTER EXPERIENCE	08:30 - 08:30
	Speaker: Eshrak Al-Shaibani, CA	
OS12-8	STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER	08:30 - 08:30

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH POST-TRANSPLANT
CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6
REACTIVATION**

Speaker: Kenichiro Takeda, JP

Oral Session

08:30 - 18:45

On-Demand Library

OS11 - Oral session 11: Infectious Diseases I

This session is available in our on-demand library throughout the whole congress

OS11-1	POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE ASPBIOMICS CONSORTIUM <i>Speaker:</i> Ana Moniz-Díez, ES	08:30 - 08:40
OS11-2	THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Speaker:</i> Nipat Chuleerarux, TH	08:40 - 08:50
OS11-3	IMMUNE RECONSTITUTION DURING CMV PROPHYLAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Ilaria Cutini, IT	08:50 - 09:00
OS11-4	LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE <i>Speaker:</i> Massimo Martino, IT	09:00 - 09:10
OS11-5	PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED APPROACH. RESULTS IN 112 PATIENTS <i>Speaker:</i> Amado Karduss -Urueta, CO	09:10 - 09:20
OS11-6	PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A TERTIARY REFERRAL CENTER IN INDIA <i>Speaker:</i> Harika Varla, IN	09:20 - 09:30
OS11-7	THE MANAGEMENT OF CLOSTRIDIODES DIFFICILE INFECTIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY <i>Speaker:</i> Agnieszka Piekarska, PL	09:30 - 09:40
OS11-8	CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH	09:40 - 09:50

HEMATOLOGY MALIGNANCIES: A REAL-WORLD OBSERVATIONAL STUDY

Speaker: Sizhou Feng, CN

Industry Symposium

08:30 - 18:45

On-Demand Library

IS38 - CMV management in high-risk patients - Biotest Industry Symposium

This session is available in our on-demand library throughout the whole congress

Chair: Fabio Ciceri, IT

IS38-1	A scoring system to define patients at high risk for CMV Speaker: Ibrahim Yakoub-Agha, FR	-
IS38-2	How to manage CMV high-risk patients Speaker: Michele Malagola, IT	-
IS38-3	The immunological benefits of CMV-specific immunoglobulins Speaker: Javier Carbone, ES	-

Lab Technicians Day

08:30 - 18:45

On-Demand Library

LT2 - Lab Technicians Day: Cell product testing, validation and characterization

This session is available in our on-demand library throughout the whole congress

LT2-1	Quality control assessment of ATMP phenotype and functionality using flow cytometry Speaker: Willemijn Hobo, NL	-
LT2-2	Flow cytometry-based CD34 enumeration Speaker: Harry Dolstra, NL	-
LT2-3	Flow cytometric in-process and quality control for CAR T cell manufacturing Speaker: Ulrike Köhl, DE	-

Data Management

08:30 - 18:45

On-Demand Library

DM06 - Education session 6

This session is available in our on-demand library throughout the whole congress

DM6-1	Response in Multiple Myeloma Speaker: Meral Beksac, TR	-
-------	--	---

Workshop

08:30 - 18:45

On-Demand Library

W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?

This session is available in our on-demand library throughout the whole congress

W14-1	A matched unrelated donor Speaker: Bronwen Shaw, US	-
W14-2	A haploidentical donor	-

	<i>Speaker:</i> Mi Kwon, ES	
W14-3	When to choose cord blood <i>Speaker:</i> Filippo Milano, US	-
W14-4	Do we have to challenge our current donor hierarchy for patients with hemoglobinopathies? <i>Speaker:</i> Selim Corbacioglu, DE	-

Workshop

08:30 - 18:45

On-Demand Library

W13 - CARs beyond T cells: A focus on next generation CAR-NK cells

This session is available in our on-demand library throughout the whole congress

W13-1	CAR NK cells as an "off the shelf" immunotherapy <i>Speaker:</i> Ulrike Köhl, DE	-
W13-2	CARs and ADCC to make off-the-shelf NK cells specific against hematologic malignancies <i>Speaker:</i> Jeffrey Miller, US	-
W13-3	Target NKG2D ligands on tumor cells <i>Speaker:</i> Antonio Pérez-Martínez, ES	-

Educational

08:30 - 18:45

On-Demand Library

E11 - Management of early complications in an ambulatory/outpatient setting

This session is available in our on-demand library throughout the whole congress

E11-1	Early infectious complications <i>Speaker:</i> Jan Styczynski, PL	-
E11-2	Non-infective complications: GVHD and organ toxicity <i>Speaker:</i> Gerhard Hildebrandt, US	-
E11-3	The Hospital Clínic experience <i>Speaker:</i> Francesc Fernández-Avilés, ES	-

Quality Management

08:30 - 18:45

On-Demand Library

QM5 - Quality Management Oral Abstracts

This session is available in our on-demand library throughout the whole congress

QM5-1	COMPLIANCE AND COST EFFICACY FOR CELLULAR THERAPIES, CAN THESE TWO GO HAND IN HAND? <i>Speaker:</i> Janik Adriaansen, US	08:30 - 08:30
QM5-2	HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR NURSES IN TIMES OF PANDEMIC <i>Speaker:</i> Sheila Saco, ES	08:30 - 08:30
QM5-3	THE RTN TRANSPLANT POLICY AND ACTIVITY DURING COVID-19 PANDEMIC	08:30 - 08:30

Speaker: Antonio Bruno, IT

QM5-4 **THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM IN NAPLES, ITALY** 08:30 - 08:30

Speaker: Lucia Ammirati, IT

Nurses Group

08:30 - 18:45

On-Demand Library

NG22 - Quality processes in JACIE

This session is available in our on-demand library throughout the whole congress

NG22-1	Quality indicators for nurses	-
	Speaker: Louise McNamara, GB	
NG22-2	JACIE: What's new?	-
	Speaker: Kim Orchard, GB	
NG22-3	What is the nurse role as JACIE Inspector?	-
	Speaker: Eugenia Trigos Arjona, ES	

Nurses Group

08:30 - 18:45

On-Demand Library

NG20 - How do I become an expert?

This session is available in our on-demand library throughout the whole congress

NG20-1	Conditioning regimen	-
	Speaker: Nicolas Kint, BE	
NG20-2	Immunosuppression	-
	Speaker: Tiene Bauters, BE	
NG20-3	Vaccinations	-
	Speaker: Bipin Savani, US	

Oral Session

08:30 - 18:45

On-Demand Library

OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and Chimerism

This session is available in our on-demand library throughout the whole congress

OS6-1	COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T CELL IMMUNE RECONSTITUTION PATTERNS	08:30 - 08:30
	Speaker: Saskia Leser, DE	
OS6-2	MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	08:30 - 08:30
	Speaker: Sandra Pennisi, DE	
OS6-3	SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR EXCISION CIRCLES (TRECS) AND K-DELETING RECOMBINATION EXCISION CIRCLES (KRECS) IN	08:30 - 08:30

	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) RECIPIENTS <i>Speaker:</i> Carlos De Miguel Jiménez, ES	
OS6-4	MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMANS <i>Speaker:</i> Mirjam Belderbos, NL	08:30 - 08:30
OS6-5	OVER-EXPRESSION OF HIF-1? IN MESENCHYMAL STROMAL CELLS INCREASES HUMAN CD34+ CELLS CLONOGENIC CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A XENOTRANSPLANTATION MODEL <i>Speaker:</i> Silvia Preciado, ES	08:30 - 08:30
OS6-6	ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-SPECIFIC T-CELLS <i>Speaker:</i> Rubiya Nadaf, GB	08:30 - 08:30
OS6-7	TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOID MALIGNANCIES <i>Speaker:</i> Simona Pagliuca, US	08:30 - 08:30
OS6-8	DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Patrizia Chiusolo, IT	08:30 - 08:30

Nurses Group
08:30 - 18:45

On-Demand Library

NG16 - Cellular therapy update

This session is available in our on-demand library throughout the whole congress

NG16-1	Update: What's new? <i>Speaker:</i> Rose Ellard, GB	-
NG16-2	Spotlight on the Lymphoma Patient Experience <i>Speaker:</i> Lorna Warwick, CA	-

Special Session
08:30 - 18:45

On-Demand Library

SS11 - The EBMT for Trainees

This session is available in our on-demand library throughout the whole congress

SS11-1	Being a Trainee in SCT / Cellular Therapy <i>Speaker:</i> Nico Gagelmann, DE <i>Speaker:</i> Claire Horgan, GB <i>Speaker:</i> Yasmina Serroukh, BE <i>Speaker:</i> Yuliya Rogacheva, RU <i>Speaker:</i> Tamar Azikuri, GE	-
SS11-2	Overview of allogeneic SCT for the trainee: 'Things I wish I'd	-

	known' <i>Speaker:</i> Helene Schoemans, BE	
SS11-3	Establishing a career in SCT/cellular therapy <i>Speaker:</i> Jordan Gauthier, US	-
SS11-4	Complications for trainees 1: How to manage acute GVHD <i>Speaker:</i> Zinaida Peric, HR	-
SS11-5	Complications for trainees 2: How to manage VOD <i>Speaker:</i> Ivan Moiseev, RU	-
<i>Joint Session</i> 08:30 - 18:45		
JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT		On-Demand Library
This session is available in our on-demand library throughout the whole congress		
JS5-2	COVID-19 vaccination in HSCT <i>Speaker:</i> Per Ljungman, SE	08:30 - 08:30
JS5-3	Global access to COVID-19 vaccines <i>Speaker:</i> Susan Brown, US	08:30 - 08:30
<i>Data Management</i> 08:30 - 18:45		
DM08 - Education session 8		On-Demand Library
This session is available in our on-demand library throughout the whole congress		
DM8-1	Infectious complications <i>Speaker:</i> Malgorzata Mikulska, IT	-
<i>Joint Session</i> 08:30 - 18:45		
JS04 - Joint session LABMT		On-Demand Library
This session is available in our on-demand library throughout the whole congress		
JS4-1	Transplant rates, Trends: WBMT/LABMT 2018 survey <i>Speaker:</i> Oscar González-Ramella, MX	-
JS4-2	Financing of HSCT in Latin America <i>Speaker:</i> Gregorio Jaimovich, AR	-
JS4-3	Selection, management and follow up of related donors: Overview <i>Speaker:</i> Nina Worel, AT	-
JS4-4	Selection, management and follow up of related donors: Development of an LABMT consensus <i>Speaker:</i> Gonzalo Ferini, AR	-
JS4-5	Haploidentical transplants in Latin America: Experience from Argentina/GATMO-TC in acute lymphoblastic leukemia <i>Speaker:</i> Ana Basquiera, AR	-

JS4-6	Haploidentical transplants in Latin America: Experience from Brazil/SBTMO in aplastic anemia <i>Speaker:</i> Carmem Bonfim, BR	-
-------	--	---

Nurses Group

08:30 - 18:45

On-Demand Library

NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG13-1	SARS-CoV-2 vaccines overview <i>Speaker:</i> Almudena Ramírez, ES	-
NG13-2	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation <i>Speaker:</i> Jose Luis Piñana, ES	-
NG13-3	COVID-19: The EBMT recommendations for management of HCT patients and donors <i>Speaker:</i> Per Ljungman, SE	-

Oral Session

08:30 - 18:45

On-Demand Library

OS07 - Oral session 7: Stem Cell Source and Donors

This session is available in our on-demand library throughout the whole congress

OS7-1	FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE RISK AFTER UNRELATED HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT <i>Speaker:</i> Annalisa Ruggeri, ES	08:30 - 08:40
OS7-2	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN MISMATCHED UNRELATED DONOR TRANSPLANTATION VERSUS HAPLOIDENTICAL TRANSPLANTATION: A RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Speaker:</i> Giorgia Battipaglia, IT	08:40 - 08:50
OS7-3	HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS AFFECTED BY MALIGNANT DISORDERS <i>Speaker:</i> Pietro Merli, IT	08:50 - 09:00
OS7-4	MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE FROM THE MADRID GROUP OF HEMATOPOIETIC TRANSPLANT <i>Speaker:</i> Rebeca Bailén, ES	09:00 - 09:10
OS7-5	LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH	09:10 - 09:20

HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS

Speaker: Jacopo Peccatori, IT

OS7-6 **INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REPORT** 09:20 - 09:30

Speaker: Andriyana Bankova, US

OS7-8 **CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH CRYOPRESERVED GRAFTS DURING THE COVID19 PANDEMIC** 09:30 - 09:40

Speaker: Maximilian Christopeit, DE

Special Session

08:30 - 18:45

On-Demand Library

SS09 - How to get published

This session is available in our on-demand library throughout the whole congress

SS9-1 **BMT: Official journal of the EBMT** -
Speaker: Hillard Lazarus, US

SS9-2 **How to get published** -
Speaker: Mohamad Mohty, FR

Special Session

08:30 - 18:45

On-Demand Library

SS07 - Young Ambassadors Session

This session is available in our on-demand library throughout the whole congress

SS7-1 **How build up a career in: Academia** -
Speaker: Didier Blaise, FR

SS7-2 **How build up a career in: In Pharmaceutical Industry** -
Speaker: Dan Tovar, FR

SS7-3 **How build up a career in: In Public domains** -
Speaker: Eva Hilgenfeld, DE

SS7-4 **What to avoid when writing a paper** -
Speaker: Jakob Passweg, CH

SS7-5 **How to write a successful grant** -
Speaker: Robert Zeiser, DE

SS7-6 **Introduction to medical statistics** -
Speaker: Simona Iacobelli, IT

SS7-7 **Social media in stem cell transplantation and cellular therapy** -
Speaker: Navneet Majhail, US

Educational
08:30 - 18:45

On-Demand Library

E13 - Allogeneic transplantation from alternative donors

This session is available in our on-demand library throughout the whole congress

E13-1	Haploidentical vs unrelated in AML <i>Speaker:</i> Didier Blaise, FR	-
E13-2	Haploidentical vs unrelated in ALL <i>Speaker:</i> Arnon Nagler, IL	-
E13-3	Haploidentical vs cord Blood in acute leukaemia <i>Speaker:</i> Frederic Baron, BE	-

Oral Session
08:30 - 18:45

On-Demand Library

OS14 - Oral session 14: Transplant Complications II

This session is available in our on-demand library throughout the whole congress

OS14-1	PREGNANCY AND PREGNANCY OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT PEDIATRIC WP <i>Speaker:</i> Tamara Diesch, CH	08:30 - 08:30
OS14-2	ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY: RESULTS OF A SURVEY FROM THE EBMT <i>Speaker:</i> Helene Schoemans, BE	08:30 - 08:30
OS14-3	CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Gertjan Lugthart, NL	08:30 - 08:30
OS14-4	NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP	08:30 - 08:30
OS14-5	AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) <i>Speaker:</i> Selim Corbacioglu, DE	08:30 - 08:30
OS14-6	PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA) ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Santosh Putta, US	08:30 - 08:30
OS14-7	OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Isabel Iturrate, ES	08:30 - 08:30

OS14-8	DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT-HOME ALLOGENEIC BONE MARROW TRANSPLANTATION MODELS <i>Speaker:</i> Marta Garcia-Recio, ES	08:30 - 08:30
--------	--	---------------

Educational
08:30 - 18:45

On-Demand Library

E10 - HSCT in paediatric non-malignant indications

This session is available in our on-demand library throughout the whole congress

E10-1	Haplo-identical SCT in hemoglobinopathy: Taking pole position? <i>Speaker:</i> Josu de la Fuente, GB	-
E10-2	Mismatched family donors in inherited immune disorders: A new perspective <i>Speaker:</i> Mary A. Slatter, GB	-
E10-3	HSCT for inherited bone marrow failure syndromes <i>Speaker:</i> Cristina Díaz de Heredia, ES	-
E10-4	Cord blood HSCT for non-malignant diseases in children <i>Speaker:</i> Vanderson Rocha, BR	-

Educational
08:30 - 18:45

On-Demand Library

E12 - Steroid-resistant/refractory GVHD

This session is available in our on-demand library throughout the whole congress

E12-1	GVHD - what's in a name? <i>Speaker:</i> Helene Schoemans, BE	-
E12-2	Treatment of SR/R acute GVHD <i>Speaker:</i> Olaf Penack, DE	-
E12-3	Treatment of SR/R chronic GVHD <i>Speaker:</i> Zinaida Peric, HR	-
E12-4	New technologies in the approach to GVHD <i>Speaker:</i> Amin Turki, DE	-

Workshop
08:30 - 18:45

On-Demand Library

W10 - Controversies in T-cell NHL

This session is available in our on-demand library throughout the whole congress

W10-1	Are we improving first-line therapy in TCL? <i>Speaker:</i> Eva Domingo Domenech, ES	08:30 - 08:30
W10-3	Insights in CAR-T therapy for T cell Lymphomas <i>Speaker:</i> Helen Heslop, US	08:30 - 08:30

Workshop

08:30 - 18:45

On-Demand Library

W11 - Key organ manifestations of chronic GVHD

This session is available in our on-demand library throughout the whole congress

W11-1	Pulmonary chronic GVHD <i>Speaker:</i> Hildegard Greinix, AT	-
W11-2	Ocular cGVHD diagnostics - Practical approach <i>Speaker:</i> Igor Petricek, HR	-
W11-3	Gastrointestinal manifestations of chronic GVHD <i>Speaker:</i> Daniel Wolff, DE	-

How do I ... ?

08:30 - 18:45

On-Demand Library

HDI6 - How Do I... manage toxicity in immunosuppressed patients?

This session is available in our on-demand library throughout the whole congress

HDI6-1	Transplant associated TMA <i>Speaker:</i> Sergio Giralt, US	-
HDI6-2	Infectious complication <i>Speaker:</i> Jan Styczynski, PL	-

Workshop

08:30 - 18:45

On-Demand Library

W12 - Donor HLA assessment and matching for allogeneic HSCT

This session is available in our on-demand library throughout the whole congress

W12-1	HLA laboratory perspective and recommendations <i>Speaker:</i> Pascale Loiseau, FR	-
W12-2	Clinical perspective and recommendations <i>Speaker:</i> Francesca Lorentino, IT	-
W12-3	Selection of unrelated donors and cord blood units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR <i>Speaker:</i> Stephen Spellman, US	-

Nurses Group

08:30 - 18:45

On-Demand Library

NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG14-1	Patient's experience <i>Speaker:</i> Ruth Tweedie, ES	-
NG14-2	Psychologist's point of view <i>Speaker:</i> Anna Lagerdahl, GB	-
NG14-3	Nurse's perspective	-

Speaker: Núria Ballestar, ES

Nurses Group

08:30 - 18:45

On-Demand Library

NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---|
| NG15-1 | Managing virtual conversations
Speaker: Lloyd Allen, GB | - |
| NG15-2 | Nurse perspective: Virtual long term follow up for BMT patients
Speaker: Michelle Kenyon, GB | - |
| NG15-3 | Back to the future: Emphasizing our new practices
Speaker: Ibrahim Yakoub-Agha, FR | - |

Special Session

08:30 - 18:45

On-Demand Library

SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell therapy community

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|--|---|
| SS8-1 | Social media beyond twitter for the HSCT and cell therapy community
Speaker: Navneet Majhail, US | - |
| SS8-2 | Do's and don'ts of interaction in social media: Nurse's perspective
Speaker: Johan De Munter, BE | - |
| SS8-3 | Do's and don'ts of interaction in social media: How social media can improve patient outcomes - The patient's perspective
Speaker: Gillian Adams, GB | - |

Nurses Group

08:30 - 18:45

On-Demand Library

NG17 - Care of the nurses

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---|
| NG17-1 | Mindfulness
Speaker: Ana M. Muñoz Cobo, ES | - |
| NG17-2 | Resilience and self-care
Speaker: Christian Williams, GB | - |
| NG17-3 | Tips and tricks for self care
Speaker: Jane Keep, GB | - |

Nurses Group

08:30 - 18:45

On-Demand Library

NG18 - Non-malignant diseases update

This session is available in our on-demand library throughout the whole congress

NG18-2	Multiple sclerosis <i>Speaker:</i> Helen Jessop, GB	08:30 - 08:30
NG18-3	Sickle cell disease <i>Speaker:</i> Jean-Hugues Dalle, FR	08:30 - 08:30
NG18-4	ITP <i>Speaker:</i> Maria Luisa Lozano, ES	08:30 - 08:30

Nurses Group

08:30 - 18:45

On-Demand Library

NG21 - Clinical trials in a transplant setting

This session is available in our on-demand library throughout the whole congress

NG21-1	Antimicrobial Lock Therapy for Prevention and Treatment of Catheter Related Infections in Hematological Patients <i>Speaker:</i> Isabel Salcedo, ES	-
NG21-2	Convalescent plasma clinical trials for COVID-19 <i>Speaker:</i> Rocío Layunta, ES	-
NG21-3	Post transplant relapse <i>Speaker:</i> Stephanie Heyes, GB	-

Nurses Group

08:30 - 18:45

On-Demand Library

NG19 - Disease update

This session is available in our on-demand library throughout the whole congress

NG19-1	Acute leukaemia <i>Speaker:</i> Inge Govaerts, BE	-
NG19-2	Managing lymphoma: What nurses and healthcare professionals need to know <i>Speaker:</i> Erik Aerts, CH	-
NG19-3	Multiple myeloma <i>Speaker:</i> Maaïke de Ruijter, NL	-
NG19-4	CML (ITK management) <i>Speaker:</i> Laura Borg, GB	-

Nurses Group

08:30 - 18:45

On-Demand Library

NG24 - Outreach projects

This session is available in our on-demand library throughout the whole congress

NG24-2	Outreach project India: EBMT MIC pediatric advanced care training (EMPACT)	08:30 - 08:30
--------	---	---------------

	<i>Speaker:</i> Lawrence Faulkner, IT	
NG24-3	Outreach project: LABMT	08:30 - 08:30
	<i>Speaker:</i> Sara Saez Carrasco, CO	

Special Session

08:30 - 18:45

On-Demand Library

SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer

This session is available in our on-demand library throughout the whole congress

SS10-1	General Overview of the HARMONY Alliance: Progress, Achievements & Results of HARMONY and HARMONY PLUS projects	-
	<i>Speaker:</i> Jesús Maria Hernández Rivas, ES	
SS10-2	Envisioned contribution of the EBMT to the HARMONY Alliance	-
	<i>Speaker:</i> Guillermo Sanz Santillana, ES	
	<i>Speaker:</i> Yann Guillevic, CH	
SS10-3	EBMT participation in the HARMONY Alliance	-
	<i>Speaker:</i> Anna Sureda, ES	
SS10-4	HARMONY & HARMONY PLUS Research Projects / Outcomes definition	-
	<i>Speaker:</i> Lars Bullinger, DE	
SS10-5	HARMONY Platform	-
	<i>Speaker:</i> Ana Heredia Casanoves, ES	

Working Party Session

08:30 - 18:45

On-Demand Library

ADWP - Autoimmune Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

ADWP-1	Welcome and Update from the EBMT registry	-
	<i>Speaker:</i> Raffaella Greco, IT	
ADWP-2	Introducing the session and speakers	-
	<i>Speaker:</i> Tobias Alexander, DE	
ADWP-3	HSCT for multiple sclerosis: Future directions in patient selection and conditioning regimen	-
	<i>Speaker:</i> Riccardo Saccardi, IT	
ADWP-4	HSCT for systemic sclerosis: Future directions in patient selection and conditioning regimen	-
	<i>Speaker:</i> Dominique Farge, FR	
ADWP-5	HSCT for Crohn's disease: future directions in patient selection, mobilization and conditioning regimen	-
	<i>Speaker:</i> Elena Ricart, ES	
ADWP-6	HSCT for autoimmune diseases: Current aspects on early and	-

	late complications <i>Speaker:</i> Majid Kazmi, GB	
ADWP-7	HSCT for autoimmune diseases: Conditioning regimen and outcomes from the Russian experience <i>Speaker:</i> Denis Fedorenko, RU	-
ADWP-8	Closing remarks <i>Speaker:</i> Tobias Alexander, DE	-

Working Party Session
08:30 - 18:45

On-Demand Library

ALWP - Acute Leukaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

ALWP-1	Introduction <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:30
ALWP-2	CAR-T cells in adult ALL <i>Speaker:</i> Arnon Nagler, IL	08:30 - 08:30
ALWP-3	Transplant in refractory AML: Comparison of the different FLAMSA approaches <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:30
ALWP-4	MRD in AML: Where do we stand? <i>Speaker:</i> Ali Bazarbachi, LB	08:30 - 08:30

Working Party Session
08:30 - 18:45

On-Demand Library

CTIWP - Cellular Therapy and Immunobiology Working Party Session

This session is available in our on-demand library throughout the whole congress

CTIWP-1	CTIWP Activity Report <i>Speaker:</i> Christian Chabannon, FR	-
CTIWP-2	Virus specific T cells post BMT- Broadening to SARS-CoV2 <i>Speaker:</i> Catherine Bollard, US	-
CTIWP-3	Are mesenchymal stromal cells the right arrow in the quiver to fight COVID-19? <i>Speaker:</i> Rachele Ciccocioppo, IT	-

Nurses Group
08:30 - 18:45

On-Demand Library

NG23 - Oral session 2: Abstracts session

This session is available in our on-demand library throughout the whole congress

NG23-1	EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL CARE PROTOCOL FOR THE PREVENTION AND TREATMENT OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT RECIPIENTS <i>Speaker:</i> Monica Guberti, IT	08:30 - 08:30
--------	--	---------------

NG23-2	PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING <i>Speaker:</i> Julia Ruiz Pato, ES	08:30 - 08:30
NG23-3	ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS <i>Speaker:</i> Franziska Michaela Lohmeyer, IT	08:30 - 08:30
NG23-4	MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANTATION SETTING AND THEIR MAINTENANCE OVER TIME <i>Speaker:</i> Alberto Castagna, IT	08:30 - 08:30
NG23-5	EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AND THEIR COHABITANTS <i>Speaker:</i> Maria Teresa Solano Moliner, ES	08:30 - 08:30

Working Party Session
08:30 - 18:45

On-Demand Library

SAAWP - Severe Aplastic Anaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

SAAWP-1	Introduction <i>Speaker:</i> Régis Peffault de Latour, FR	-
SAAWP-2	Registry Report <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-3	RACE – clinical update <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-4	RACE – what we learn on the biology of SAA? <i>Speaker:</i> Austin Kulakaseraraj, GB	-
SAAWP-5	Androgens in AA: Myth or reality in 2021? <i>Speaker:</i> Simona Pagliuca, US	-
SAAWP-6	GVHD and relapse free survival (GRFS) after HSCT for AA <i>Speaker:</i> Raynier Devillier, FR	-

Poster Sessions
08:30 - 18:45

ePoster Area

Cellular Therapies other than CARs

P027	PROLONGED REPEATEDLY ADMINISTERED LOW DOSE DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE LEUKEMIA <i>Speaker:</i> Panagiotis Tsirigotis, GR	08:30 - 08:30
------	--	---------------

P028	CD8⁺-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 <i>Speaker:</i> Mehmet Altan, US	08:30 - 08:30
P029	CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY® TCR⁺ AND CD19 DEPLETION <i>Speaker:</i> Katalin Dobos, HU	08:30 - 08:30
P031	COMPREHENSIVE ACTIVATION PROFILING OF TABELCELEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY <i>Speaker:</i> Fiona Ruiz, US	08:30 - 08:30
P030	IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS	08:30 - 08:30
P035	BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K-NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML AND MDS (NK-REALM) <i>Speaker:</i> Sumithira Vasu, US	08:30 - 08:30
P034	NEW, LN₂-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF CELL THERAPIES <i>Speaker:</i> Julie Meneghel, GB	08:30 - 08:30
P032	DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Virginia Escamilla Gómez, ES	08:30 - 08:30
P033	DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION. ONE SINGLE CENTER EXPERIENCE <i>Speaker:</i> Melissa Karina Torres Ochoa, ES	08:30 - 08:30

Poster Sessions

08:30 - 18:45

ePoster Area

CAR-based Cellular Therapy – Clinical

P016	HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Thomas Martin, US	08:30 - 08:30
P017	MANUFACTURING COMMERCIAL AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR RETROSPECTIVE ANALYSIS <i>Speaker:</i> Didier Hallard, NL	08:30 - 08:30
P015	RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT	08:30 - 08:30

	NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5 <i>Speaker:</i> Julio C. Chavez, US	
P019	COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY FOLLOWING BRUTON TYROSINE KINASE INHIBITOR TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ENGLAND <i>Speaker:</i> Martin Brown, GB	08:30 - 08:30
P018	EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL THERAPY IN THE REAL WORLD SETTING <i>Speaker:</i> Silvia Monsalvo, ES	08:30 - 08:30
P020	PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Adam D Cohen, US	08:30 - 08:30
P021	CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA <i>Speaker:</i> Pere Barba, ES	08:30 - 08:30
P022	CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR-DERIVED CD19 CAR-T CELLS MANUFACTURED FROM MEMORY T CELL (CD45RA-DEPLETED) FRACTION <i>Speaker:</i> Larisa Shelikhova, RU	08:30 - 08:30
P024	ICU RESOURCE UTILIZATION IN PEDIATRIC AND ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T THERAPY <i>Speaker:</i> Dristhi Ragoonanan, US	08:30 - 08:30
P023	HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED PROLONGED PANCYTOPENIA USING AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A LYMPHOMA PATIENT <i>Speaker:</i> Udo Holtick, DE	08:30 - 08:30
P025	ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB WITH AXICABTAGENE AUTOLEUCEL (AXI?CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) <i>Speaker:</i> Saad J. Kenderian, US	08:30 - 08:30

Poster Sessions
08:30 - 18:45

ePoster Area

Acute Leukaemia

P001	MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC INFLUENCE ON POST-TRANSPLANT OUTCOMES IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA	08:30 - 08:30
------	---	---------------

	<i>Speaker:</i> Rama Al Hamed, US	
P002	ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE REMISSION IN R/R B-ALL AFTER TREATMENT WITH MONOCLONAL ANTIBODIES <i>Speaker:</i> Inna Markova, RU	08:30 - 08:30
P003	AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER ANALYSIS <i>Speaker:</i> Semra Aydin, IT	08:30 - 08:30
P004	T-CELL-DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE CENTRE EXPERIENCE OF 90 PATIENTS <i>Speaker:</i> Alexandros Kanellopoulos, GB	08:30 - 08:30
P005	POST-REMISSION TREATMENT PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) IN THE CONNECT® MDS/AML DISEASE REGISTRY	08:30 - 08:30
P006	ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF RECIPIENT AGE AND DONOR TYPE <i>Speaker:</i> Tatiana Tzenou, GR	08:30 - 08:30
P007	GILTERITINIB MONOTHERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT PATIENTS <i>Speaker:</i> Sergey Bondarenko, RU	08:30 - 08:30
P009	ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL) <i>Speaker:</i> Alan S. Wayne, US	08:30 - 08:30
P008	VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA POST ALLOGENEIC STEM CELL TRANSPLANT <i>Speaker:</i> Sandra Easdale, GB	08:30 - 08:30
P010	LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA – FOCUS ON MORTALITY <i>Speaker:</i> Anna Lojko-Dankowska, PL	08:30 - 08:30
P011	SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Semra Aydin, IT	08:30 - 08:30

P012	BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE MONOCENTRIC REPORT <i>Speaker:</i> Elisabetta Metafuni, IT	08:30 - 08:30
P013	UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Sergey Bondarenko, RU	08:30 - 08:30
P014	SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A CENTER IN COLOMBIA <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	08:30 - 08:30
<i>Poster Sessions</i> 08:30 - 18:45		ePoster Area
Data Management		
P045	GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE MYELOMA <i>Speaker:</i> Ruth Paul, GB	08:30 - 08:30
<i>Poster Sessions</i> 08:30 - 18:45		ePoster Area
Nurses Posters – Research		
NP24	ROLE OF NURSING IN THE CARE OF PATIENT'S SKIN WITH CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY <i>Speaker:</i> Jacqui Stringer, GB	08:30 - 08:30
NP25	INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT <i>Speaker:</i> Lubov Shepeleva, RU	08:30 - 08:30
NP26	THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING DEVELOPMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: FROM PRACTICE TO SCIENCE <i>Speaker:</i> Natalya Rotan, RU	08:30 - 08:30
NP27	LONG TERM SURVIVORS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD AND ADOLESCENCE IN A DEVELOPING COUNTRY: HOW ARE THEY NOW? <i>Speaker:</i> Priscila Oliveira da Silva, BR	08:30 - 08:30
NP28	EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL	08:30 - 08:30

EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS

Speaker: Olga Prokofieva, RU

NP29 **EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY DISEASES** 08:30 - 08:30

Speaker: Silvia Sangüesa Domínguez, ES

Poster Sessions

08:30 - 18:45

ePoster Area

ePoster Area

Poster Sessions

08:30 - 18:45

ePoster Area

Myeloproliferative Neoplasm

Poster Sessions

08:30 - 18:45

ePoster Area

Statistics

P201 **EVALUATION OF MACHINE LEARNING ALGORITHMS APPLICABILITY FOR GRAFT FAILURE PREDICTION** 08:30 - 08:30

Speaker: Evgeny Bakin, RU

P202 **WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE** 08:30 - 08:30

Speaker: Maria Escolar, US

Poster Sessions

08:30 - 18:45

ePoster Area

Nurses Posters – Paediatric

NP17 **NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30

Speaker: Deepa Karmegam, IN

NP18 **NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS AFTER CAR-T INFUSION** 08:30 - 08:30

Speaker: Giulia Del Giorno, IT

NP19 **THE WORK OF THE REHABILITATION DEPARTMENT WITH VOLUNTEERS DURING THE COVID-19 PANDEMIC** 08:30 - 08:30

Speaker: Rashida Bikulova, RU

NP20 **EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC CATHETERIZATION AS A MEASURE OF NUTRITIONAL SUPPORT IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION** 08:30 - 08:30

Speaker: Eugenia Trigos Arjona, ES

NP21 **NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY.** 08:30 - 08:30

DESCRIPTION OF CLINICAL CASES

Speaker: Anton Silov, RU

NP22	INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-CENTER EXPERIENCE	08:30 - 08:30
------	--	---------------

Speaker: Alba Fernandez-Arroyo Garcia, ES

NP23	IMPLEMENTATION OF THE ADVANCED CELL THERAPY PROGRAM: &NBSP;EXPERIENCE AT LA PAZ UNIVERSITY HOSPITAL	08:30 - 08:30
------	--	---------------

Speaker: Alba Fernandez-Arroyo Garcia, ES

Poster Sessions

08:30 - 18:45

ePoster Area

Nurses Posters – Adult

NP01	NURSES' TRAINING NEEDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE NURSES GROUP OF THE EBMT	08:30 - 08:30
------	--	---------------

Speaker: Michelle Kenyon, GB

NP02	IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POVIDONE-IODINE MOUTHWASH UNDER DIRECT NURSING SUPERVISION	08:30 - 08:30
------	--	---------------

Speaker: Napassaya Khanthum, TH

NP03	COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL THERAPY	08:30 - 08:30
------	---	---------------

Speaker: Mercedes Montoro-Lorite, ES

NP04	CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE SYNDROME	08:30 - 08:30
------	--	---------------

Speaker: Naama Nevo, IL

NP05	HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM-CELL TRANSPLANTATION: IMPROVING HOME-CARE STRATEGIES DURING SARS-COV-2 PANDEMIC	08:30 - 08:30
------	---	---------------

Speaker: Laura Villa Rodríguez, ES

NP06	IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION	08:30 - 08:30
------	--	---------------

Speaker: Sarah Henshaw, GB

NP07	AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING SARS-CoV-2 PANDEMIC	08:30 - 08:30
------	---	---------------

NP08	THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED METROPOLITAN TRANSPLANT PROGRAM	08:30 - 08:30
------	--	---------------

Speaker: Antonio Bruno, IT

NP10	PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING WELL ESTABLISHED NURSING CARE STANDARDS <i>Speaker:</i> Isabel Salcedo, ES	08:30 - 08:30
NP11	A TALE OF 2 COLLECTIONS: CAR -T 'V' PBSC. OUR SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Caroline Jupp, GB	08:30 - 08:30
NP12	CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) NURSING IN LATIN AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY <i>Speaker:</i> Mariela Blanco, AR	08:30 - 08:30
NP13	MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO-ONCOLOGY MALIGNANCY AND THOSE UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION DURING THE COVID-19. HOW DO WE PROTECT THEM? <i>Speaker:</i> Anna Serrahima - Mackay, ES	08:30 - 08:30
NP14	PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Bakhtawar Altaf Hussain, PK	08:30 - 08:30
NP15	COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - THE REALITY <i>Speaker:</i> Lindsey Ashton, GB	08:30 - 08:30
NP16	TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED NURSE <i>Speaker:</i> Marijke Quaghebeur, BE	08:30 - 08:30
NP09	EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM <i>Speaker:</i> Mariela Blanco, AR	08:30 - 08:40

Poster Sessions
08:30 - 18:45

ePoster Area

Stem Cell Source

P216	THE BLOOD DONATION BEFORE BONE MARROW HARVEST HAS NO IMPACT ON EFFICIENCY OF COLLECTION <i>Speaker:</i> Iwona Mitrus, PL	08:30 - 08:30
P217	UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Vincenzo Federico, IT	08:30 - 08:30

Poster Sessions

08:30 - 18:45

ePoster Area

Pharmacology

- | | | |
|------|---|---------------|
| P195 | <p>PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE: INTERIM RESULTS FROM THE EQUATE STUDY</p> <p><i>Speaker:</i> John Koreth, US</p> | 08:30 - 08:30 |
| P196 | <p>EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE THERAPEUTIC DRUG MONITORING OF BUSULFAN</p> <p><i>Speaker:</i> Bushra Salman, OM</p> | 08:30 - 08:30 |
| P197 | <p>A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE PRECLINICAL MODELS OF AML</p> <p><i>Speaker:</i> Leanne Lanieri, US</p> | 08:30 - 08:30 |
| P199 | <p>PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE</p> <p><i>Speaker:</i> Sara M. Zimmerman, US</p> | 08:30 - 08:30 |
| P198 | <p>THE IMPACT OF LETERMIVIR PRESCRIBING ON THE RATE OF CYTOMEGALOVIRUS REACTIVATION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION</p> <p><i>Speaker:</i> Siobhan Smith, GB</p> | 08:30 - 08:30 |

Poster Sessions

08:30 - 18:45

ePoster Area

Solid Tumours

- | | | |
|------|--|---------------|
| P200 | <p>HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-WORLD EXPERIENCE IN ARGENTINA</p> <p><i>Speaker:</i> Adriana Vitriu, AR</p> | 08:30 - 08:30 |
|------|--|---------------|

Poster Sessions

08:30 - 18:45

ePoster Area

Stem Cell Mobilization, Collection and Engineering

- | | | |
|------|---|---------------|
| P206 | <p>INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON-INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE THE MOBILIZATION AND COLLECTION OF HSCS IN POOR MOBILIZERS AHEAD OF ASCT</p> <p><i>Speaker:</i> Katharina Kriegsmann, DE</p> | 08:30 - 08:30 |
| P207 | <p>TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES BETWEEN 2008 AND 2017</p> <p><i>Speaker:</i> James Dillon, IE</p> | 08:30 - 08:30 |
| P208 | <p>THE IMPACT OF THE “NEW NORMAL” ON STEM CELL</p> | 08:30 - 08:30 |

LABORATORY PRACTICES

Speaker: Sanja Mazi?, HR

P210	AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR USAGE WITH GCSF ALONE FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA <i>Speaker:</i> Mohamed Elemery, CA	08:30 - 08:30
P209	PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND FEASIBLE; A SINGLE CENTER ANALYSIS <i>Speaker:</i> Moussab Damraj, SA	08:30 - 08:30
P211	PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE <i>Speaker:</i> Nara Stepanyan, RU	08:30 - 08:30
P212	A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Joshua Richter, US	08:30 - 08:30
P213	PREDICTION OF THE MOBILIZATION SUCCESS FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES <i>Speaker:</i> Maria Eduarda Couto, PT	08:30 - 08:30
P214	DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR UTILIZATION DURING STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT? <i>Speaker:</i> Pilar Velarde López de Ayala, ES	08:30 - 08:30
P215	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Madeleine Powys, AU	08:30 - 08:30

Poster Sessions
08:30 - 18:45

ePoster Area

Non-infectious Late Effects, Quality of Life and Fertility

P177	IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS <i>Speaker:</i> Magdalena Corona de Lapuerta, ES	08:30 - 08:30
P178	OSTEONECROSIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-CENTRE STUDY OF INCIDENCE, RISK FACTORS, CHARACTERISTICS AND EVOLUTION <i>Speaker:</i> Giulia Prunotto, IT	08:30 - 08:30
P179	SECONDARY MALIGNANCIES AFTER AUTOLOGOUS	08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION

Speaker: João Gaião Santos, PT

- | | | |
|------|---|---------------|
| P181 | ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE CHEMOTHERAPY
<i>Speaker:</i> Walter Javier Zambrano Marquez, ES | 08:30 - 08:30 |
| P180 | SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN
<i>Speaker:</i> Yulia Skvortsova, RU | 08:30 - 08:30 |
| P182 | AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – AMYOPATHIC DERMATOMYOSITIS, PRIMARY BILIARY CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA
<i>Speaker:</i> Pedro de Vasconcelos M, PT | 08:30 - 08:30 |

Poster Sessions
08:30 - 18:45

ePoster Area

Non-infectious Early Complications

- | | | |
|------|--|---------------|
| P169 | POST HEMATOPOIETIC PROGENITORS TRANSPLANT LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR VIRUS (EBV): A CENTER'S EXPERIENCE
<i>Speaker:</i> Sara Garrido, ES | 08:30 - 08:30 |
| P171 | CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE | 08:30 - 08:30 |
| P170 | ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL ECOSYSTEM
<i>Speaker:</i> Daniele Zama, IT | 08:30 - 08:30 |
| P172 | HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC HYPERPLASI
<i>Speaker:</i> Eugenio Galli, IT | 08:30 - 08:30 |
| P173 | THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT RECPIENTS: SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Carlota Mayor Bastida, ES | 08:30 - 08:30 |
| P175 | EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY SUGAR ABSORBTION TEST: INTERIM ANALYSIS OF THE SINGLE-CENTER PROSPECTIVE STUDY
<i>Speaker:</i> Grzegorz Basak, PL | 08:30 - 08:30 |

P176	ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO-OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT <i>Speaker:</i> Zofia Szmit, PL	08:30 - 08:30
------	--	---------------

Poster Sessions
08:30 - 18:45

ePoster Area

New Drugs- and Cell-based Immune Therapies

P160	INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Speaker:</i> Vivek Sharma, US	08:30 - 08:30
P161	CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS <i>Speaker:</i> David Dingli, US	08:30 - 08:30
P162	IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL CELLS AND FAVORS MICROVASCULAR THROMBOSIS <i>Speaker:</i> Miriam Galbusera, IT	08:30 - 08:30
P165	MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC SARCOMA <i>Speaker:</i> Carla Martín-Cortázar, ES	08:30 - 08:30
P163	POST-HEMATOPOIETIC STEM CELL TRANSPLANT MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING HUSSEIN CANCER CENTRE EXPERIENCE	08:30 - 08:30
P166	PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT (HCT) (STUDY DESIGN) <i>Speaker:</i> Anna Thorner, US	08:30 - 08:30
P168	CLINICAL PHARMACOLOGY AND POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721)	08:30 - 08:30
P167	WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES <i>Speaker:</i> David Dingli, US	08:30 - 08:30

Poster Sessions
08:30 - 18:45

ePoster Area

Myelodysplastic Syndromes

P156	THE ROLE OF AGE IN OUTCOMES OF BONE MARROW	08:30 - 08:30
------	---	---------------

TRANSPLANTATION IN PATIENTS FROM THE LATIN AMERICAN REGISTRY

Speaker: Fernando Barroso Duarte, BR

- | | | |
|------|---|---------------|
| P157 | PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE MORTALITY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | <i>Speaker:</i> Isla Johnson, US | |
| P159 | SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE OF THE PREVIOUS SITUATION | 08:30 - 08:30 |
| P158 | SECONDARY AND TREATMENT-RELATED ACUTE MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION | 08:30 - 08:30 |
| | <i>Speaker:</i> Ioanna Sakellari, GR | |

Poster Sessions
08:30 - 18:45

ePoster Area

Multiple Myeloma

- | | | |
|------|--|---------------|
| P149 | HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS ? 70 YEARS IS SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS | 08:30 - 08:30 |
| | <i>Speaker:</i> Udo Holtick, DE | |
| P150 | PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS | 08:30 - 08:30 |
| | <i>Speaker:</i> Meilan Chen, CN | |
| P152 | RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | 08:30 - 08:30 |
| | <i>Speaker:</i> Jingli Gu, CN | |
| P151 | AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION | 08:30 - 08:30 |
| | <i>Speaker:</i> Rita Sousa Gomes, PT | |
| P153 | CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA | 08:30 - 08:30 |
| | <i>Speaker:</i> Carolina Afonso, PT | |
| P155 | INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MUTIPLE MYELOMA | 08:30 - 08:30 |
| | <i>Speaker:</i> Pilar Velarde López de Ayala, ES | |

Poster Sessions

08:30 - 18:45

ePoster Area

Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution

- | | | |
|------|---|---------------|
| P143 | EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH THYMOGLOBULIN: A CIBMTR ANALYSIS
<i>Speaker:</i> Nina Orfali, IE | 08:30 - 08:30 |
| P144 | PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT
<i>Speaker:</i> Nicolaus Kröger, DE | 08:30 - 08:30 |
| P145 | IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Amandine Pradier, CH | 08:30 - 08:30 |
| P146 | MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS COMPARABLE TO PREDICT AML RELAPSE?
<i>Speaker:</i> Valérie Dubois, FR | 08:30 - 08:30 |
| P148 | CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES OPEN A WINDOW FOR RELAPSE INTERVENTION?
<i>Speaker:</i> Jan Morf, GB | 08:30 - 08:30 |

Poster Sessions

08:30 - 18:45

ePoster Area

Lymphoma and Chronic Lymphocytic Leukemia

- | | | |
|------|---|---------------|
| P134 | RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER RETROSPECTIVE COHORT STUDY
<i>Speaker:</i> Fernando Warley, AR | 08:30 - 08:30 |
| P133 | 18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW CNS LYMPHOMA IMAGING TOOL
<i>Speaker:</i> Sandra Easdale, GB | 08:30 - 08:30 |
| P135 | THE OUTCOMES OF ALLOGENEIC STEM CELLS TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED THERAPY: SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Ivan Moiseev, RU | 08:30 - 08:30 |
| P137 | STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN BLOOD AND MARROW TRANSPLANTATION REGISTRY
<i>Speaker:</i> Yu-Hung Wang, TW | 08:30 - 08:30 |
| P136 | NIVOLUMAB 40 MG THERAPY IN RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS | 08:30 - 08:30 |

	OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY <i>Speaker:</i> Liudmila Fedorova, RU	
P138	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION EXPERIENCE <i>Speaker:</i> Joanna Romejko-Jarosinska, PL	08:30 - 08:30
P142	SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL LYMPHOMA WITH INTENSIFIED MYELOABLATIVE CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Yan-Li Zhao, CN	08:30 - 08:30
P140	POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R DIFFUSE LARGE B-CELL LYMPHOMA <i>Speaker:</i> Ivan Moiseev, RU	08:30 - 08:30
P141	NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF CONSOLIDATIVE AUTOLOGOUS STEM CELL TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL HOSPITAL <i>Speaker:</i> Christopher Shwei Wen Tham, SG	08:30 - 08:30
P139	AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG TERM OUTCOMES <i>Speaker:</i> Sudhir Kumar, IN	08:30 - 08:30
<i>Poster Sessions</i> 08:30 - 18:45		ePoster Area
Paediatric Issues		
P183	POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA <i>Speaker:</i> Andrey Kozlov, RU	08:30 - 08:30
P185	RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING EXVIVO T-CELL-DEPLETION <i>Speaker:</i> Iván López Torija, ES	08:30 - 08:30
P184	FREQUENCY AND CAUSES OF DEATH AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NON-MALIGNANT DISEASES <i>Speaker:</i> Koray Yalcin, TR	08:30 - 08:30
P186	SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM	08:30 - 08:30

CELL TRANSPLANTATION

Speaker: Denise Elbæk, DK

P187	LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH NONMALIGNANT DISEASES: A SINGLE CENTER COHORT ANALYSIS <i>Speaker:</i> Joëll Esmée Bense, NL	08:30 - 08:30
P188	PROSPECTIVE MULTICENTER STUDY OF A REDUCED-TOXICITY MYELOABLATIVE CONDITIONING REGIMEN USING FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE REGIMENS <i>Speaker:</i> Fanny Rialland, FR	08:30 - 08:30
P189	TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED DONOR IN PEDIATRIC PATIENTS <i>Speaker:</i> Luisa Sisinni, ES	08:30 - 08:30
P190	SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Charlotte Nazon, FR	08:30 - 08:30
P191	SAFETY AND PERFORMANCE OF CENTRAL VENOUS CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Sofia Martin-Consuegra, ES	08:30 - 08:30
P192	TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND – BLACKFAN ANEMIA <i>Speaker:</i> Svetlana Radygina, RU	08:30 - 08:30
P193	ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES <i>Speaker:</i> Maksymilian Deregowski, PL	08:30 - 08:30
P194	CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS <i>Speaker:</i> Taylor Fitch, US	08:30 - 08:30

Poster Sessions

08:30 - 18:45

ePoster Area

Infectious Complications

P118	COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION <i>Speaker:</i> Luisa Giaccone, IT	08:30 - 08:30
P119	INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE <i>Speaker:</i> Amir Ali Hamidieh, IR	08:30 - 08:30

P120	EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW <i>Speaker:</i> Aurore Bergamasco, FR	08:30 - 08:30
P122	EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Aleksandr Siniaev, RU	08:30 - 08:30
P121	ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT BACTERIA <i>Speaker:</i> Filippo Maraz, IT	08:30 - 08:30
P123	CLINICAL AND MICROBIOLOGICAL IMPACT OF DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE <i>Speaker:</i> Anke Verlinden, BE	08:30 - 08:30
P124	IRON CHELATION WITH DEFERASIROX SUPPRESSES THE APPEARANCE OF LPI DURING CONDITIONING CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Sonja Essmann, DE	08:30 - 08:30
P125	SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN MEXICO <i>Speaker:</i> Brenda Lizeth Acosta-Maldonado, MX	08:30 - 08:30
P126	ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE CENTER RETROSPECTIVE STUDY <i>Speaker:</i> Mohammed Essa, SA	08:30 - 08:30
P128	TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT <i>Speaker:</i> Tahereh Rostami, IR	08:30 - 08:30
P127	HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC CYSTITIS: RETROSPECTIVE COHORT STUDY <i>Speaker:</i> Nikola Pantic, RS	08:30 - 08:30
P132	CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Milena Todorovic Balint, RS	08:30 - 08:30
P129	PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL <i>Speaker:</i> Fernando Barroso Duarte, BR	08:30 - 08:30

P131 **SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION** 08:30 - 08:30
Speaker: Maurizio Caniglia, IT

P130 **CLINICAL CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT PATIENTS: A MONOCENTRIC 5 YEARS SURVEY** 08:30 - 08:30
Speaker: Gabriele Facchin, IT

Poster Sessions
 08:30 - 18:45

ePoster Area

Inborn Errors

P114 **ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH TREOSULFAN-BASED CONDITIONING** 08:30 - 08:30
Speaker: Matthias Blecke, DE

P115 **LONG-TERM NEURODEVELOPMENTAL, NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE METACHROMATIC LEUKODYSTROPHY** 08:30 - 08:30
Speaker: Maria Escolar, US

P116 **OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING PARTY** 08:30 - 08:30
Speaker: Su Han Lum, GB

Poster Sessions
 08:30 - 18:45

ePoster Area

Immunodeficiency Diseases and Macrophages

P111 **CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Speaker: Aishat Idarmacheva, RU

P112 **OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY** 08:30 - 08:30
Speaker: Liam Reilly, GB

P113 **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH CLERICUZIO SYNDROME (POIKILODERMA WITH NEUTROPENIA)** 08:30 - 08:30
Speaker: Alexandra Burya, RU

Poster Sessions
 08:30 - 18:45

ePoster Area

Stem Cell Donor

P203	HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A SINGLE-CENTER COMPARISON <i>Speaker:</i> Alisa Lörsch, DE	08:30 - 08:30
P204	CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS: SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND HAPLOIDENTICAL DONORS <i>Speaker:</i> Claudie Roy, CA	08:30 - 08:30
P205	HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE CENTER EXPERIENCE IN MEXICO <i>Speaker:</i> Katheryn Garzón-Velásquez, MX	08:30 - 08:30

Poster Sessions

08:30 - 18:45

ePoster Area

Haemoglobinopathy

P107	THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Mohammed Essa, SA	08:30 - 08:30
P108	HOW TO FACILITATE DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMOGLOBINOPATHIES - THE PERSPECTIVES OF HEALTH CARE PROFESSIONALS <i>Speaker:</i> Hilda Mekelenkamp, NL	08:30 - 08:30
P109	ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE: A RETROSPECTIVE COHORT ANALYSIS <i>Speaker:</i> Richelle Waldner, CA	08:30 - 08:30
P110	DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY – SHARED OR NOT? <i>Speaker:</i> Hilda Mekelenkamp, NL	08:30 - 08:30

Poster Sessions

08:30 - 18:45

ePoster Area

Haematopoietic Stem Cells

P078	RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF OUR HOSPITAL <i>Speaker:</i> Elena Paumard Rodríguez, ES	08:30 - 08:30
------	--	---------------

P076	LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION <i>Speaker:</i> Katrin Koch, DE	08:30 - 08:30
P077	KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION, REVISITED <i>Speaker:</i> Kazimierz Halaburda, PL	08:30 - 08:30
P079	THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER ALLOGENEIC TRANSPLANTATION <i>Speaker:</i> Sabrina Giammarco, IT	08:30 - 08:30
P081	OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES <i>Speaker:</i> Zohreh Nademi, GB	08:30 - 08:30
P080	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7 ANTIGEN EXPRESSION <i>Speaker:</i> Danilo De Novellis, IT	08:30 - 08:30
P082	OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS: A SINGLE CENTER STUDY <i>Speaker:</i> Eshrak Al-Shaibani, CA	08:30 - 08:30
P084	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL <i>Speaker:</i> Simona Piemontese, IT	08:30 - 08:30
P083	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A SINGLE-INSTITUTION EXPERIENCE <i>Speaker:</i> Marta Hidalgo Soto, ES	08:30 - 08:30
P086	EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA <i>Speaker:</i> Ma Liangming, CN	08:30 - 08:30
P085	IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE POLYMORPHISMS ON THE OUTCOMES OF TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS <i>Speaker:</i> Anastasia Beynarovich, RU	08:30 - 08:30
P087	AUTOMATED DRY THAWING OF CRYOPRESERVED HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER <i>Speaker:</i> Julie Meneghel, GB	08:30 - 08:30
P091	UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE	08:30 - 08:30

	LEUKEMIA: AN EXPERIENCE FROM THE LARGEST CHILDREN'S HOSPITAL IN IRAN <i>Speaker:</i> Amir Ali Hamidieh, IR	
P090	INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT IN PATIENTS OVER 65 YEARS OLD <i>Speaker:</i> Magdalena Corona de Lapuerta, ES	08:30 - 08:30
P089	LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN'S AND NON-HODGKIN'S LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN COLOMBIAN NORTHEAST <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	08:30 - 08:30
P092	ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF 195 CASES <i>Speaker:</i> Thierry Guillaume, FR	08:30 - 08:30
P097	DEFIBROTIDE AS TREATMENT FOR TRANSPLANT-ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Danilo De Novellis, IT	08:30 - 08:30
P096	IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: REPORT FROM A SINGLE CENTER <i>Speaker:</i> Sabrina Giammarco, IT	08:30 - 08:30
P095	IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HAPLO SCT) USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE IN SUB-SAHARAN AFRICA? <i>Speaker:</i> Justin du Toit, ZA	08:30 - 08:30
P099	IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Claudia Núñez-Torrón, ES	08:30 - 08:30
P098	THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT THE ROYAL MARSDEN HOSPITAL <i>Speaker:</i> Sandra Easdale, GB	08:30 - 08:30
P102	EBV COLITIS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA <i>Speaker:</i> Lucia Prezioso, IT	08:30 - 08:30
P100	BURNOUT SYNDROME IN ONCOLOGY PRACTICE: EXPERIENCE OF A LARGE HSCT CENTER <i>Speaker:</i> Irina Artemeva, RU	08:30 - 08:30
P103	MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION	08:30 - 08:30

(ASCT)

Speaker: Carolina Lilibeth Moreira-Ponce, MX

- | | | |
|------|---|---------------|
| P101 | FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA POST HEMATOPOIETIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A TERTIARY REFERRAL CENTRE IN INDIA | 08:30 - 08:30 |
|------|---|---------------|

Speaker: Rumesh Chandar, IN

- | | | |
|------|---|---------------|
| P104 | BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
|------|---|---------------|

Speaker: Katheryn Garzón-Velásquez, MX

- | | | |
|------|---|---------------|
| P106 | EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NARRATIVE REVIEW | 08:30 - 08:30 |
|------|---|---------------|

Speaker: Claudia Lucía Sossa Melo, CO

- | | | |
|------|--|---------------|
| P105 | STAFF EXPERIENCES AND LEARNING FROM WORKING ON A HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING COVID-19 | 08:30 - 08:30 |
|------|--|---------------|

Speaker: Sarah Airdrie, GB

Poster Sessions

08:30 - 18:45

ePoster Area

Graft-versus-Host Disease – Preclinical and Animal Models

- | | | |
|------|--|---------------|
| P074 | THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-MEDIATED TISSUE INJURY | 08:30 - 08:30 |
|------|--|---------------|

Speaker: Sascha Göttert, DE

- | | | |
|------|--|---------------|
| P075 | ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED MICE | 08:30 - 08:30 |
|------|--|---------------|

Poster Sessions

08:30 - 18:45

ePoster Area

Graft-versus-Host Disease – Clinical

- | | | |
|------|---|---------------|
| P051 | EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS | 08:30 - 08:30 |
|------|---|---------------|

Speaker: Arun Alfred, GB

- | | | |
|------|--|---------------|
| P056 | REDUCED GVHD WITH TRIPLE PTCY BASED GVHD PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS | 08:30 - 08:30 |
|------|--|---------------|

Speaker: Elisabetta Metafuni, IT

- | | | |
|------|--|---------------|
| P055 | PROLONGED SUPPRESSION OF BUTYRATE PRODUCING BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AND TRANSPLANT RELATED MORTALITY AFTER | 08:30 - 08:30 |
|------|--|---------------|

ALLOGENEIC STEM CELL TRANSPLANTATION

Speaker: Elisabeth Meedt, DE

P052	ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED PATIENTS AT DIFFERENT MATURATION STAGES <i>Speaker:</i> Matthias Alexander Fante, DE	08:30 - 08:30
P057	THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI-THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES <i>Speaker:</i> Osman Radhwi, CA	08:30 - 08:30
P060	A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> John Mallee, US	08:30 - 08:30
P061	CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE NIH 2014 CONSENSUS CRITERIA <i>Speaker:</i> Koray Yalcin, TR	08:30 - 08:30
P058	COMPARISON OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CR1 <i>Speaker:</i> Maximilian Christopeit, DE	08:30 - 08:30
P059	TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS <i>Speaker:</i> Eugenio Galli, IT	08:30 - 08:30
P063	A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4) <i>Speaker:</i> Franco Locatelli, IT	08:30 - 08:30
P062	AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S EIGHT-YEAR EXPERIENCE <i>Speaker:</i> Antonio Grasso, IT	08:30 - 08:30
P064	IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE FROM A SINGLE CENTER <i>Speaker:</i> Panayotis Kaloyannidis, SA	08:30 - 08:30
P065	ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST	08:30 - 08:30

DISEASE

Speaker: Angelo Ostuni, IT

P066	RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE IN 36 PATIENTS <i>Speaker:</i> Maria Teresa Lupo Stanghellini, IT	08:30 - 08:30
P067	PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS HOST DISEASE PREVENTION IN PATIENTS RECEIVING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Henry Hu, US	08:30 - 08:30
P068	BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS <i>Speaker:</i> Xiaodong Mo, CN	08:30 - 08:30
P069	FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES <i>Speaker:</i> Ivan Moiseev, RU	08:30 - 08:30
P070	A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5) <i>Speaker:</i> Franco Locatelli, IT	08:30 - 08:30
P071	PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Lars Klinge Gjærde, DK	08:30 - 08:30
P072	SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES	08:30 - 08:30
P073	Elevated REG3? predicts refractory aGVHD in Patients Who Received Steroids- Ruxolitinib as the First Line Therapy <i>Speaker:</i> Liping Dou, CN	08:30 - 08:30

Poster Sessions
08:30 - 18:45

ePoster Area

Gene Therapy

P050	BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN FOR β-THALASSEMIA) GENE THERAPY TREATMENT OF A GREEK PATIENT WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) <i>Speaker:</i> Evangelia Yannaki, GR	08:30 - 08:30
------	---	---------------

Poster Sessions

08:30 - 18:45

ePoster Area

Experimental Transplantation

- | | | |
|------|--|---------------|
| P048 | INFLUENCE OF POLYMORPHISMS RELATED TO DRUG METABOLISM IN ALLOGENEIC BONE MARROW TRANSPLANTATION
<i>Speaker:</i> Marta Santiago, ES | 08:30 - 08:30 |
| P049 | REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
<i>Speaker:</i> Tahereh Rostami, IR | 08:30 - 08:30 |

Poster Sessions

08:30 - 18:45

ePoster Area

Experimental Stem Cell Transplantation

- | | | |
|------|--|---------------|
| P046 | SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL MODULATION IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS ACUTE LEUKAEMIA
<i>Speaker:</i> Maryam Barkhordar, IR | 08:30 - 08:30 |
| P047 | DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE
<i>Speaker:</i> Elisabetta Metafuni, IT | 08:30 - 08:30 |

Poster Sessions

08:30 - 18:45

ePoster Area

Conditioning Regimens

- | | | |
|------|---|---------------|
| P036 | OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE LIMIT?
<i>Speaker:</i> Sara Fernández-Luis, ES | 08:30 - 08:30 |
| P037 | THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
<i>Speaker:</i> Bartosz Malecki, PL | 08:30 - 08:30 |
| P038 | CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN EARLY RELAPSED MULTIPLE MYELOMA PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Jaap van Doesum, NL | 08:30 - 08:30 |
| P039 | PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL WITH TBI AND ETOPOSIDE CONDITIONING
<i>Speaker:</i> Jane E Potter, GB | 08:30 - 08:30 |

P040	ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH FAVORABLE OUTCOMES	08:30 - 08:30
P041	LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Ioanna Sakellari, GR	08:30 - 08:30
P042	TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY <i>Speaker:</i> Raquel Olivas-Mazón, ES	08:30 - 08:30
P044	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED-RELATED SIBLING DONORS <i>Speaker:</i> Gabriella Storti, IT	08:30 - 08:30
P043	IMMUNE RECONSTITUTION AFTER SEQUENTIAL CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT DONOR TYPES <i>Speaker:</i> Alessia Fraccaroli, DE	08:30 - 08:30

Poster Sessions

08:30 - 18:45

ePoster Area

CAR-based Cellular Therapy – Preclinical

P026	NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY <i>Speaker:</i> Tobias Bexte, DE	08:30 - 08:30
------	--	---------------

CME Symposium

08:40 - 10:00

Auditorium 1

IS01 - GMMG Symposium

Chair: Hartmut Goldschmidt, DE

Chair: Christof Scheid, DE

IS1-1	Role of allo-TPX in multiple myeloma <i>Speaker:</i> Nicolaus Kröger, DE	08:40 - 08:51
IS1-2	Importance of achieving a Minimal Residual Disease Negativity in multiple myeloma <i>Speaker:</i> Stefanie Huhn, DE	08:51 - 09:00
IS1-3	Role of induction therapy in treatment of multiple myeloma <i>Speaker:</i> Hans Salwender, DE	09:00 - 09:11
IS1-4	Therapy and prognosis of high-risk multiple myeloma <i>Speaker:</i> Katja Weisel, DE	09:11 - 09:26
IS1-5	Therapeutic developments for refractory multiple myeloma	09:26 - 09:42

	<i>Speaker:</i> Marc Raab, DE	
IS1-6	Q&A	09:42 - 10:00
<i>Patient, Family Donor Day</i>		
09:15 - 10:30		Auditorium 6
PFD1 - Patient, Family and Donor Day: Post-transplant care		
<i>Chair:</i> Guy Bouguet, FR		
<i>Chair:</i> Sarah Hutton, GB		
PFD1-1	Welcome	09:15 - 09:30
	<i>Speaker:</i> Rafael Duarte, ES	
	<i>Speaker:</i> Natacha Bolaños, ES	
PFD1-2	Introduction to post-transplant care and GvHD	09:30 - 09:35
	<i>Speaker:</i> Guy Bouguet, FR	
	<i>Speaker:</i> Sarah Hutton, GB	
PFD1-3	A pathway for Post-Transplant Care	09:35 - 09:50
	<i>Speaker:</i> Fiona Dignan, GB	
PFD1-4	Chronic GVHD: The daily impact	09:50 - 10:05
	<i>Speaker:</i> John Murray, GB	
PFD1-5	Patient's experience with chronic GVHD	10:05 - 10:15
	<i>Speaker:</i> Sam Williams, GB	
PFD1-6	Q&A	10:15 - 10:30
<i>Breaks</i>		
10:00 - 10:30		Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition		
<i>Industry Symposium</i>		
10:30 - 12:00		Auditorium 2
IS05 - GVHD: What's new in 2021? - Sanofi Industry Symposium		
<i>Chair:</i> Mohamad Mohty, FR		
IS5-1	Welcome & Introduction	10:30 - 10:35
	<i>Speaker:</i> Mohamad Mohty, FR	
IS5-2	Antithymocyte Globulin for Matched Sibling Donor Transplantation: results of A Randomized trial	10:35 - 10:50
	<i>Speaker:</i> Xiaojun Huang, CN	
IS5-3	Combining ATG and post-transplant cyclophosphamide	10:50 - 11:05
	<i>Speaker:</i> Andrea Bacigalupo, IT	
IS5-4	Optimizing outcome: pre and post-transplant interventions	11:05 - 11:20
	<i>Speaker:</i> Mohamad Mohty, FR	
IS5-5	Nutritional supplements and stem cell transplantation	11:20 - 11:35
	<i>Speaker:</i> Bipin Savani, US	
IS5-6	Round table discussion and Closing Remarks	11:35 - 12:00

Industry Symposium

10:30 - 12:00

Auditorium 3

IS06 - Induction to beyond transplant: how do we increase long-term remission in high-risk AML*? - Jazz Pharmaceuticals Industry Symposium

*High-risk AML defined as newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

Chair: Rafael Duarte, ES

IS6-1	Welcome and introduction <i>Speaker:</i> Rafael Duarte, ES	10:30 - 10:32
IS6-2	How does induction choice impact outcomes in high-risk AML*? <i>Speaker:</i> Martin Börnhauser, DE	10:32 - 10:52
IS6-3	Panel discussion	10:52 - 11:07
IS6-4	What does real-world evidence tell us about the impact of induction on high-risk AML*? <i>Speaker:</i> Thomas Cluzeau, FR	11:07 - 11:22
IS6-5	Panel discussion	11:22 - 11:37
IS6-6	How we have continued intensive chemotherapy during the COVID pandemic <i>Speaker:</i> Rafael Duarte, ES <i>Speaker:</i> Thomas Cluzeau, FR <i>Speaker:</i> Martin Börnhauser, DE	11:37 - 11:57
IS6-7	Summary and close <i>Speaker:</i> Rafael Duarte, ES	11:57 - 12:00

Industry Symposium

10:30 - 12:00

Auditorium 5

IS07 - Is the gold standard for managing transplant eligible newly-diagnosed multiple myeloma still golden? - Janssen Industry Symposium

Chair: Philippe Moreau, FR

IS7-1	Introduction <i>Speaker:</i> Philippe Moreau, FR	10:30 - 10:35
IS7-2	Is there still a role for autologous stem cell transplantation (ASCT) in frontline management of patients with MM? <i>Speaker:</i> Francesca Gay, IT <i>Speaker:</i> Katja Weisel, DE	10:35 - 10:55
IS7-3	Panel discussion with Q&A	10:55 - 11:05
IS7-4	What is the optimal initial therapy for patients with MM receiving an ASCT? <i>Speaker:</i> Philippe Moreau, FR	11:05 - 11:20
IS7-5	Panel discussion with Q&A	11:20 - 11:35
IS7-6	What is the role of consolidation and maintenance therapy in 2021?	11:35 - 11:45

	<i>Speaker:</i> Jesús San Miguel, ES	
IS7-7	Panel discussion with Q&A	11:45 - 12:00
<i>Patient, Family Donor Day</i>		
10:45 - 11:45		Auditorium 6
	PFD2 - Patient, Family and Donor Day: Post-transplant care 2	
	<i>Chair:</i> Andrea Linke, DE	
	<i>Chair:</i> Isabel Salcedo, ES	
PFD2-1	Introduction to post-transplant care and sexuality and fertility	10:45 - 10:50
	<i>Speaker:</i> Andrea Linke, DE	
	<i>Speaker:</i> Isabel Salcedo, ES	
PFD2-2	Patient's experience on post-transplant	10:50 - 11:00
	<i>Speaker:</i> Rosan Boersma, NL	
PFD2-3	Pediatric and young adults fertility an HSCT	11:00 - 11:15
	<i>Speaker:</i> Mara Andrés Moreno, ES	
PFD2-4	The case for Psychosexual Therapy in Stem Cell Transplantation	11:15 - 11:30
	<i>Speaker:</i> Caroline Lovett, GB	
PFD2-5	Q&A	11:30 - 11:45
<i>Breaks</i>		
12:00 - 12:30		Auditorium 1
	Lunch Break, Poster Viewing, Visit Exhibition	
<i>Patient, Family Donor Day</i>		
12:00 - 12:35		Auditorium 6
	PFD3 - Patient, Family and Donor Day: COVID-19	
	<i>Chair:</i> Guy Bouguet, FR	
	<i>Chair:</i> Natacha Bolaños, ES	
PFD3-1	Panel discussion	12:00 - 12:35
	<i>Speaker:</i> Rafael de la Cámara, ES	
	<i>Speaker:</i> Dennis Heng Lin, ES	
	<i>Speaker:</i> Maja Koci?, RS	
<i>Industry Symposium</i>		
12:30 - 14:00		Auditorium 1
	IS08 - Survival in R/R NHL: CAR T as the standard of care - Kite-Gilead Industry Symposium	
	<i>Chair:</i> Wendy Osborne, GB	
IS8-1	Welcome and introduction	12:30 - 12:35
	<i>Speaker:</i> Wendy Osborne, GB	
IS8-2	Curative intent for R/R DLBCL: What are the current data?	12:35 - 13:10
	<i>Speaker:</i> Ran Reshef, US	
	<i>Speaker:</i> Wendy Osborne, GB	
IS8-3	How has the patient pathway evolved in R/R MCL?	13:10 - 13:30

Speaker: Tom van Meerten, NL

Speaker: Max Topp, DE

IS8-4 **Patient case interactive discussion** 13:30 - 14:00

Industry Symposium

12:30 - 14:00

Auditorium 2

IS09 - Learnings from 2020: Are we providing the best management approach for haematology patients with IMD? - Pfizer Industry Symposium

Chair: Cornelia Lass-Flörl, AT

IS9-1 **Welcome and introduction** 12:30 - 12:35

Speaker: Cornelia Lass-Flörl, AT

IS9-2 **The evolving landscape of IMD in the haematology unit: emerging risk factors and concerns in the COVID-19 era** 12:35 - 12:55

Speaker: Amit Patel, GB

IS9-3 **Navigating the complexities of the haematology patient and understanding the spectrum of antifungal therapeutics** 12:55 - 13:15

Speaker: Galina Klyasova, RU

IS9-4 **Managing invasive mould infections in an increasingly complex world: what has changed in 2020?** 13:15 - 13:35

Speaker: Cornelia Lass-Flörl, AT

IS9-5 **Discussion, Q&A and close** 13:35 - 14:00

Industry Symposium

12:30 - 14:00

Auditorium 3

IS10 - Evolution in GvHD treatment: expert perspective on the latest clinical data - Novartis Industry Symposium

Chair: Helene Schoemans, BE

IS10-1 **Welcome and introduction** 12:30 - 12:33

Speaker: Helene Schoemans, BE

IS10-2 **Current landscape of GvHD management** 12:33 - 12:41

Speaker: Helene Schoemans, BE

IS10-3 **Novel data and upcoming treatment options in acute and chronic GvHD** 12:41 - 13:11

Speaker: Mohamad Mohty, FR

Speaker: Nada Hamad, AU

IS10-4 **Novel data and upcoming treatment options: roundtable panel discussion** 13:11 - 13:32

Speaker: Mohamad Mohty, FR

Speaker: Nada Hamad, AU

Speaker: Dietger Niederwieser, DE

Speaker: Helene Schoemans, BE

IS10-5 **Expanding the horizon in GvHD management: panel discussion** 13:32 - 13:42

Speaker: Mohamad Mohty, FR

Speaker: Nada Hamad, AU

Speaker: Dietger Niederwieser, DE

Speaker: Helene Schoemans, BE

IS10-6 **Live audience Q&A and concluding remarks** 13:42 - 14:00

Industry Symposium

12:30 - 14:00

Auditorium 4

IS11 - Optimising the chance of survival for severe hepatic VOD patients: global expert insights - Jazz Pharmaceuticals Industry Symposium

Chair: Mohamad Mohty, FR

IS11-1 **Welcome and introduction** 12:30 - 12:35

Speaker: Mohamad Mohty, FR

IS11-2 **Global insight: risk assessment, with panel roundtable discussion** 12:35 - 12:50

Speaker: Paul Richardson, US

IS11-3 **Global insight: imaging for signs and symptoms, with panel roundtable discussion** 12:50 - 13:05

Speaker: Rafael Duarte, ES

Speaker: Antonio Colecchia, IT

IS11-4 **Global insight: severity grading, with panel roundtable discussion** 13:05 - 13:20

Speaker: Tony Pagliuca, GB

Speaker: Jae-Ho Yoon, KR

IS11-5 **Global insight: diagnosis, with panel roundtable discussion** 13:20 - 13:35

Speaker: Mohamad Mohty, FR

IS11-6 **Global insight: treatment and outcome, with panel roundtable discussion** 13:35 - 13:55

Speaker: Paul Richardson, US

Speaker: Mohamad Mohty, FR

IS11-7 **Summary and close** 13:55 - 14:00

Speaker: Mohamad Mohty, FR

Industry Symposium

12:30 - 14:00

Auditorium 5

IS12 - Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond - BMS Industry Symposium

Chair: Xavier Leleu, FR

IS12-1 **Welcome and introduction - Multiple myeloma: understanding the unmet need** 12:30 - 12:40

Speaker: Xavier Leleu, FR

IS12-2 **Addressing the unmet need in multiple myeloma: innovative immune treatment strategies** 12:40 - 13:05

Speaker: Niels van de Donk, NL

IS12-3 **A novel approach: targeting BCMA with CAR T cell therapy** 13:05 - 13:20

Speaker: Nikhil Munshi, US

IS12-4	The patient and the process: putting CAR T cell therapy into practice <i>Speaker:</i> Xavier Leleu, FR	13:20 - 13:35
--------	--	---------------

IS12-5	Live Q&A	13:35 - 14:00
--------	---------------------	---------------

Wellness session

12:45 - 13:05

Auditorium 6

Nutrition and healing: The anti-inflammatory plate

Patient, Family Donor Day

13:30 - 14:30

Auditorium 6

PFD4 - Patient, Family and Donor Day: New developments and donor focus

Chair: Julia Ruiz Pato, ES

Chair: Natacha Bolaños, ES

PFD4-1	Introduction <i>Speaker:</i> Julia Ruiz Pato, ES <i>Speaker:</i> Natacha Bolaños, ES	13:30 - 13:35
--------	---	---------------

PFD4-2	Patient's experience with CAR T <i>Speaker:</i> Kevin McNulty, GB	13:35 - 13:45
--------	---	---------------

PFD4-3	Could CAR T therapy cure cancer patients? <i>Speaker:</i> Marie Jose Kersten, NL	13:45 - 14:00
--------	--	---------------

PFD4-4	HSCT for autoimmune diseases and novel indications <i>Speaker:</i> John Snowden, GB	14:00 - 14:15
--------	---	---------------

PFD4-5	Q&A	14:15 - 14:30
--------	----------------	---------------

Breaks

14:00 - 14:30

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Industry Symposium

14:30 - 16:00

Auditorium 1

IS13 - Present and future approaches with CAR T cell therapy in B-cell malignancies - BMS Industry Symposium

Chair: Paolo Corradini, IT

IS13-1	Welcome and introduction <i>Speaker:</i> Paolo Corradini, IT	14:30 - 14:35
--------	--	---------------

IS13-2	Current state of CAR T cell therapy in DLBCL <i>Speaker:</i> Paolo Corradini, IT	14:35 - 14:55
--------	--	---------------

IS13-3	CAR T cell therapy in FL and CLL: achievements and perspectives <i>Speaker:</i> Guillaume Cartron, FR	14:55 - 15:15
--------	---	---------------

IS13-4	Implementation of CAR T cell therapy: practical considerations and future directions	15:15 - 15:35
--------	---	---------------

Speaker: Stephan Mielke, SE

IS13-5 **Q&A and discussion** 15:35 - 16:00

Industry Symposium

14:30 - 16:00

Auditorium 2

IS14 - Antifungal Therapy in the Era of New Treatments for Haematological Malignancies - Kite-Gilead Industry Symposium

Chair: Tony Pagliuca, GB

IS14-1 **Welcome, introduction and overview of agenda** 14:30 - 14:40

Speaker: Tony Pagliuca, GB

IS14-2 **Impact of the new haematological treatment landscape on invasive fungal infections** 14:40 - 15:00

Speaker: Livio Pagano, IT

IS14-3 **The challenge of drug-drug interactions and antifungal treatment choice** 15:00 - 15:20

Speaker: Dimitrios Kontoyiannis, US

IS14-4 **The role of liposomal amphotericin B in current haematology practice** 15:20 - 15:40

Speaker: Johan Maertens, BE

IS14-5 **Q&A/Panel discussion** 15:40 - 15:55

Speaker: Tony Pagliuca, GB

Speaker: Livio Pagano, IT

Speaker: Dimitrios Kontoyiannis, US

IS14-6 **Conclusions and close** 15:55 - 16:00

Speaker: Tony Pagliuca, GB

Industry Symposium

14:30 - 16:00

Auditorium 3

IS15 - Emerging Evidence on the Role of Complement Pathway in the Pathophysiology of HSCT-TMA - Omeros Industry Symposium

Chair: Miguel-Angel Perales, US

Chair: Jeffrey Laurence, US

Chair: Alessandro Rambaldi, IT

IS15-1 **Introduction** 14:30 - 14:33

Speaker: Miguel-Angel Perales, US

IS15-2 **From bench to clinics: what evidence do we have about the complement pathway's role in HSCT-TMA** 14:33 - 14:58

Speaker: Jeffrey Laurence, US

IS15-3 **Emerged clinical data (including pivotal trial data review with subgroup analysis)** 14:58 - 15:18

Speaker: Alessandro Rambaldi, IT

IS15-4 **Implications to clinical practice (with potential case study)** 15:18 - 15:33

Speaker: Miguel-Angel Perales, US

IS15-5 Q&A 15:33 - 16:00

CME Symposium

14:30 - 16:00

Auditorium 4

IS16 - Modernizing the Care of CMV in HCT Recipients: Management Updates and Reducing Risks - CME Symposium

Chair: Per Ljungman, SE

IS16-1	Introduction and panel discussion: Current Landscape of CMV in HCT	14:30 - 14:40
IS16-2	Case Scenario #1	14:40 - 14:45
IS16-3	Risk Stratification <i>Speaker:</i> Johan Maertens, BE	14:45 - 14:57
IS16-4	Panel discussion: Challenges of Patients at High Risk, and of R/R CMV	14:57 - 15:07
IS16-5	Best Practices <i>Speaker:</i> Rafael Duarte, ES	15:07 - 15:17
IS16-6	Case Scenario #2	15:17 - 15:22
IS16-7	Panel discussion: Challenges of CMV in the Intolerant Patient and in R/R CMV	15:22 - 15:30
IS16-8	New Treatment Paradigms <i>Speaker:</i> Catherine Cordonnier, FR	15:30 - 15:42
IS16-9	Panel discussion: Potential Effect of New Data and New Therapies	15:42 - 15:54
IS16-10	Audience Q&A	15:54 - 16:00

Industry Symposium

14:30 - 16:00

Auditorium 5

IS17 - Challenges in Relapse/Refractory Multiple Myeloma - Sanofi Industry Symposium

Chair: Jesús San Miquel, ES

IS17-1	Lenalidomide-refractory patients: evidence-based recommendations <i>Speaker:</i> Francesca Gay, IT	14:30 - 14:50
IS17-2	What is the value of MRD negativity in relapsed/refractory patients? <i>Speaker:</i> Mohamad Mohty, FR	14:50 - 15:10
IS17-3	Frail patients with Relapsed/Refractory Multiple Myeloma and health-related quality of life <i>Speaker:</i> María Victoria Mateos, ES	15:10 - 15:30
IS17-4	Q&A and round table discussion	15:30 - 16:00

Patient, Family Donor Day
14:45 - 15:40

Auditorium 6

PFD5 - Patient, Family and Donor Day: New developments and donor focus 2

Chair: Lola Manterola, ES

Chair: Gillian Adams, GB

PFD5-1	Introduction to speakers <i>Speaker:</i> Lola Manterola, ES <i>Speaker:</i> Gillian Adams, GB	14:45 - 14:50
PFD5-2	Donor Registry: "A lifesaver". General and spanish situation <i>Speaker:</i> Juliana Villa, ES	14:50 - 15:05
PFD5-3	Live dialogue: Pediatric transplantation: How does it work? <i>Speaker:</i> Antonio Pérez-Martínez, ES <i>Speaker:</i> Daniel Guerrero, ES	15:05 - 15:30
PFD5-4	Q&A	15:30 - 15:40

Breaks
16:00 - 16:30

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Special Session
16:00 - 17:30

Auditorium 6

SS01 - Interactive debate on patient engagement in transplantation and cell therapy

Chair: Helene Schoemans, BE

Chair: Guy Bouguet, FR

SS1-1	The patient's engagement experience <i>Speaker:</i> Chris Lewis, GB	16:00 - 16:10
SS1-2	Why consider patient engagement in research <i>Speaker:</i> Sabina De Geest, CH	16:10 - 16:25
SS1-3	Integrating patients in research projects – Practical considerations <i>Speaker:</i> Linda Burns, US	16:25 - 16:40
SS1-4	Using Patient Reported Outcomes in the clinic – Practical considerations <i>Speaker:</i> Sarah Liptrott, IT	16:40 - 16:55
SS1-5	Panel discussion - Interactive debate	16:55 - 17:15
SS1-6	Closing comments <i>Speaker:</i> Pavel Jindra, CZ <i>Speaker:</i> Guy Bouguet, FR	17:15 - 17:25

Industry Symposium
16:30 - 18:00

Auditorium 1

IS18 - Cell therapy & survival: An interactive focus on the future - Kite-Gilead Industry Symposium

Chair: Mohamad Mohty, FR

IS18-1	Welcome and introduction	16:30 - 16:32
--------	---------------------------------	---------------

	<i>Speaker:</i> Mohamad Mohty, FR	
IS18-2	What are the ongoing challenges for cell therapy? <i>Speaker:</i> Jim Kochenderfer, US	16:32 - 16:40
IS18-3	Does T-cell fitness change during the treatment journey? <i>Speaker:</i> Chiara Bonini, IT	16:40 - 16:48
IS18-4	How can we optimise safety? <i>Speaker:</i> Irit Avivi, IL	16:48 - 16:56
IS18-5	How can we improve efficacy? <i>Speaker:</i> David Miklos, US	16:56 - 17:04
IS18-6	When does survival translate into 'cure'? <i>Speaker:</i> Sarit Assouline, CA	17:04 - 17:12
IS18-7	What will the future of cell therapy look like? <i>Speaker:</i> Mohamad Mohty, FR	17:12 - 17:20
IS18-8	Live Q&A	17:20 - 18:00

Industry Symposium
16:30 - 18:00

Auditorium 2

IS19 - What is the New Evidence in the Era of CMV Prophylaxis? - MSD Industry Symposium

Chair: Rafael de la Cámara, ES

IS19-1	Welcome, and Opening Remarks <i>Speaker:</i> Rafael de la Cámara, ES	16:30 - 16:35
IS19-2	Do Cellular Immunity and Viral Load Kinetics Predict Clinical Outcomes of CMV Infection after HSCT? <i>Speaker:</i> Miguel-Angel Perales, US	16:35 - 16:55
IS19-3	Real World Evidence of CMV prophylaxis: a focus on CMV blips and treatment duration <i>Speaker:</i> Catherine Cordonnier, FR	16:55 - 17:15
IS19-4	Is CMV prophylaxis cost-effective? <i>Speaker:</i> Corrado Girmenia, IT	17:15 - 17:35
IS19-5	Closing remarks <i>Speaker:</i> Rafael de la Cámara, ES	17:35 - 17:40
IS19-6	Live Q&A and Closing remarks	17:40 - 18:00

Industry Symposium
16:30 - 17:15

Auditorium 3

IS20 - New maintenance strategies in AML - BMS Industry Symposium

Chair: Nicolaus Kröger, DE

IS20-1	Welcome and introduction <i>Speaker:</i> Nicolaus Kröger, DE	16:30 - 16:35
IS20-2	Clinical challenges in the management of AML patients in	16:35 - 16:50

	complete remission <i>Speaker:</i> Norbert Vey, FR	
IS20-3	Evolving treatment approaches to prolong complete remission in AML <i>Speaker:</i> Farhad Ravandi, US	16:50 - 17:05
IS20-4	Panel discussion and Closing remarks	17:05 - 17:15

Industry Symposium
16:30 - 18:00

Auditorium 4

IS21 - The nurse: essential at every step of hepatic VOD management - Jazz Pharmaceuticals Industry Symposium

Chair: Michelle Kenyon, GB

IS21-1	Welcome and introduction <i>Speaker:</i> Michelle Kenyon, GB	16:30 - 16:35
IS21-2	The essential role of the nurse in hepatic VOD management <i>Speaker:</i> Michelle Kenyon, GB	16:35 - 16:55
IS21-3	Theory in practice: the MDT perspective <i>Speaker:</i> Eleni Tholouli, GB <i>Speaker:</i> Marie Waller, GB	16:55 - 17:25
IS21-4	The reality of hepatic VOD <i>Speaker:</i> Zofia Szmit, PL	17:25 - 17:45
IS21-5	Empowering nurses through hepatic VOD education <i>Speaker:</i> Michelle Kenyon, GB <i>Speaker:</i> Julia Ruiz Pato, ES	17:45 - 17:55
IS21-6	Summary and close <i>Speaker:</i> Michelle Kenyon, GB	17:55 - 18:00

Industry Symposium
16:30 - 18:00

Auditorium 5

IS22 - Calibrating the intensity of GvHD therapy to allow clinical tolerance – a role for ECP Immunomodulation? - Therakos-Mallinckrodt Industry Symposium

Chair: Jane Apperley, GB

IS22-1	Introduction <i>Speaker:</i> Jane Apperley, GB	16:30 - 16:35
IS22-2	Evaluation of societal burden of chronic GvHD <i>Speaker:</i> Jonas Mattsson, CA	16:35 - 17:00
IS22-3	The Challenges of Implementing the NIH Consensus Criteria for Clinical Trials in chronic GvHD <i>Speaker:</i> Corey Cutler, US	17:00 - 17:25
IS22-4	How to reduce therapy-related toxicity in GvHD <i>Speaker:</i> Daniel Couriel, US	17:25 - 17:50
IS22-5	Q&A session	17:50 - 18:00

Wellness session

17:30 - 18:00

Auditorium 6

Therapeutic Origami session

General

18:00 - 19:15

Auditorium 1

GS1 - Opening Ceremony

GS1-1	Welcome and introduction <i>Speaker:</i> Nicolaus Kröger, DE	18:00 - 18:05
GS1-2	Welcome and introduction to the conference <i>Speaker:</i> Rafael Duarte, ES	18:05 - 18:10
GS1-3	Welcome from the Nurses Group <i>Speaker:</i> John Murray, GB	18:10 - 18:14
GS1-4	EBMT Patient Advocacy Committee: Welcome note <i>Speaker:</i> Natacha Bolaños, ES	18:14 - 18:18
GS1-5	Honorary Member Awards 2020 and Clinical Achievement Award 2021 <i>Speaker:</i> Andrea Bacigalupo, IT <i>Speaker:</i> Dietger Niederwieser, DE <i>Speaker:</i> Alejandro Madrigal, GB <i>Speaker:</i> Ernst Holler, DE <i>Speaker:</i> Manuel Abecasis, PT	18:18 - 18:48
GS1-6	Introduction of the Keynote speaker <i>Speaker:</i> Rafael Duarte, ES	18:48 - 18:50
GS1-7	Keynote lecture - Management of the COVID-19 pandemic: The perspective from Madrid-IFEMA Field Hospital <i>Speaker:</i> Antonio Zapatero, ES	18:50 - 19:15

Monday, 15. March 2021

Educational
09:15 - 10:30

Auditorium 1

E01 - Long-term management of alloHSCT recipients

Chair: Patrice Chevallier, FR

Chair: María del Mar Perera Álvarez, ES

E1-1	Survivorship care plans <i>Speaker:</i> Navneet Majhail, US	09:15 - 09:30
E1-2	Secondary malignancies <i>Speaker:</i> Christian Koenecke, DE	09:30 - 09:45
E1-3	Practical management of long-term organ complications <i>Speaker:</i> Mutlu Arat, TR	09:45 - 10:00
E1-4	Q&A	10:00 - 10:30

How do I ... ?
09:15 - 10:30

Auditorium 2

HDI1 - How do I... manage AML patients in first remission? - Supported through an unrestricted educational grant by BMS

Chair: Jordi Esteve, ES

HDI1-1	Transplant eligible patient <i>Speaker:</i> Christoph Schmid, DE	09:15 - 09:40
HDI1-2	Transplant ineligible patients <i>Speaker:</i> Arnold Ganser, DE	09:40 - 10:05
HDI1-3	Q&A	10:05 - 10:30

Nurses Group
09:15 - 10:30

Auditorium 3

NG01 - Nurses Group Opening Session

NG01-1	Welcome and overview <i>Speaker:</i> John Murray, GB	09:15 - 09:25
NG01-2	Presentation of the 13th Distinguished Merit Award and awardee acceptance speech <i>Speaker:</i> John Murray, GB	09:25 - 09:30
NG01-3	Nurses in the response to healthcare challenges <i>Speaker:</i> Adelaida Zabalegui, ES	09:30 - 10:00
NG01-4	Artificial Intelligence in healthcare <i>Speaker:</i> Sharukh Hashmi, US	10:00 - 10:30

Cell therapy

09:15 - 10:30

Auditorium 4

CTD1 - Cell Therapy Day: Novelties in Donor Management

Chair: Kristina Hölig, DE

CTD1-1	Use of plerixafor in donors <i>Speaker:</i> Nina Worel, AT	09:15 - 09:35
CTD1-2	Microbiota and hematopoietic stem cells <i>Speaker:</i> Florent Malard, FR	09:35 - 09:55
CTD1-3	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation <i>Speaker:</i> Mareike Frick, DE	09:55 - 10:10
CTD1-4	Q&A	10:10 - 10:30

Transplant and Search Coordinators Day

09:15 - 10:30

Auditorium 5

TSCD1 - Transplant and Search Coordinators Day: New HLA Typing Techniques and how they changed the way to transplant

Chair: Joannis Mytilineos, DE

Chair: Eric Spierings, NL

TSCD1-1	Introduction and overview <i>Speaker:</i> Eric Spierings, NL	09:15 - 09:30
TSCD1-2	Debate: Do we still need Verification Typing (VT) of the donor?	-
TSCD1-3	No, rely on initial high resolution typing <i>Speaker:</i> Martin Bornhäuser, DE	09:30 - 09:50
TSCD1-4	Yes, safety first <i>Speaker:</i> Rachel Pawson, GB	09:50 - 10:10
TSCD1-5	Panel discussion	10:10 - 10:30

Industrial Theatre

09:15 - 18:00

IT

Industry Theatre sessions

Industrial Theatre

09:15 - 18:00

IT

IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre session

This session is available throughout the whole congress

Chair: Dick Sundh, AU

Industrial Theatre

09:15 - 18:00

IT

IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session

This session is available throughout the whole congress

Chair: Amir Hefni, GB

Chair: David Kuzan, US

Chair: Carolin Barth, CH

Industrial Theatre

09:15 - 18:00

IT

IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session

This session is available throughout the whole congress

Chair: Volker Witt, AT

Educational

09:15 - 18:00

On-Demand Library

E08 - New challenges in infectious complications

This session is available in our on-demand library throughout the whole congress

- | | | |
|------|---|---|
| E8-1 | T-cell therapy for infections in SCT patients: An experimental treatment or a real choice for the practice?
<i>Speaker:</i> Patrizia Comoli, IT | - |
| E8-2 | Infectious complications with new drugs in Hematology
<i>Speaker:</i> Georg Maschmeyer, DE | - |
| E8-3 | The blood virome of HSCT Recipients: Much more than viremia by CMV, EBV, HH6V and adenovirus
<i>Speaker:</i> Marie-Celine Zanella, CH | - |

Data Management

09:15 - 18:00

On-Demand Library

DM09 - Education session 9

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|--|---|
| DM9-1 | Follow up forms - How to get a chronological overview of the patient history and follow up
<i>Speaker:</i> Elena Ferrer Martínez del Peral, ES | - |
|-------|--|---|

Working Party Session

09:15 - 18:00

On-Demand Library

IDWP - Infectious Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---|
| IDWP-1 | IDWP update
<i>Speaker:</i> Rafael de la Cámara, ES | - |
| IDWP-2 | Current scientific proposals of IDWP
<i>Speaker:</i> Dina Averbuch, IL | - |
| IDWP-3 | CMV T-cell immunity monitoring: is it time to incorporate it in clinical practices? | - |

	<i>Speaker:</i> Roy Chemaly, US	
IDWP-4	What is new in the field of Gram-negative infections in SCT patients? <i>Speaker:</i> Dina Averbuch, IL	-
IDWP-5	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation <i>Speaker:</i> Jose Luis Piñana, ES	-
IDWP-6	Hepatitis C and hepatitis E in SCT <i>Speaker:</i> Malgorzata Mikulska, IT	-
IDWP-7	Central nervous system (CNS) complications following HSCT <i>Speaker:</i> Martin Schmidt-Hieber, DE	-
<i>Data Management</i>		
09:15 - 18:00		On-Demand Library
DM06 - Education session 6		
This session is available in our on-demand library throughout the whole congress		
DM6-1	Response in Multiple Myeloma <i>Speaker:</i> Meral Beksac, TR	-
<i>Data Management</i>		
09:15 - 18:00		On-Demand Library
DM05 - Education session 5		
This session is available in our on-demand library throughout the whole congress		
DM5-1	Hematopoietic Cell Transplantation-Comorbidity Index 'Sorrow Score' <i>Speaker:</i> Bronwen Shaw, US	-
<i>On Demand Library</i>		
09:15 - 18:00		On-Demand Library
On Demand Library		
<i>Working Party Session</i>		
09:15 - 18:00		On-Demand Library
ALWP - Acute Leukaemia Working Party Session		
This session is available in our on-demand library throughout the whole congress		
ALWP-1	Introduction <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
ALWP-2	CAR-T cells in adult ALL <i>Speaker:</i> Arnon Nagler, IL	09:15 - 09:15
ALWP-3	Transplant in refractory AML: Comparison of the different FLAMSA approaches <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
ALWP-4	MRD in AML: Where do we stand?	09:15 - 09:15

Speaker: Ali Bazarbachi, LB

Educational
09:15 - 18:00

On-Demand Library

E13 - Allogeneic transplantation from alternative donors

This session is available in our on-demand library throughout the whole congress

E13-1	Haploidentical vs unrelated in AML Speaker: Didier Blaise, FR	-
E13-2	Haploidentical vs unrelated in ALL Speaker: Arnon Nagler, IL	-
E13-3	Haploidentical vs cord Blood in acute leukaemia Speaker: Frederic Baron, BE	-

Working Party Session
09:15 - 18:00

On-Demand Library

ADWP - Autoimmune Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

ADWP-1	Welcome and Update from the EBMT registry Speaker: Raffaella Greco, IT	-
ADWP-2	Introducing the session and speakers Speaker: Tobias Alexander, DE	-
ADWP-3	HSCT for multiple sclerosis: Future directions in patient selection and conditioning regimen Speaker: Riccardo Saccardi, IT	-
ADWP-4	HSCT for systemic sclerosis: Future directions in patient selection and conditioning regimen Speaker: Dominique Farge, FR	-
ADWP-5	HSCT for Crohn's disease: future directions in patient selection, mobilization and conditioning regimen Speaker: Elena Ricart, ES	-
ADWP-6	HSCT for autoimmune diseases: Current aspects on early and late complications Speaker: Majid Kazmi, GB	-
ADWP-7	HSCT for autoimmune diseases: Conditioning regimen and outcomes from the Russian experience Speaker: Denis Fedorenko, RU	-
ADWP-8	Closing remarks Speaker: Tobias Alexander, DE	-

Nurses Group
09:15 - 18:00

On-Demand Library

NG16 - Cellular therapy update

This session is available in our on-demand library throughout the whole congress

NG16-1	Update: What's new? <i>Speaker:</i> Rose Ellard, GB	-
NG16-2	Spotlight on the Lymphoma Patient Experience <i>Speaker:</i> Lorna Warwick, CA	-

Nurses Group
09:15 - 18:00

On-Demand Library

NG19 - Disease update

This session is available in our on-demand library throughout the whole congress

NG19-1	Acute leukaemia <i>Speaker:</i> Inge Govaerts, BE	-
NG19-2	Managing lymphoma: What nurses and healthcare professionals need to know <i>Speaker:</i> Erik Aerts, CH	-
NG19-3	Multiple myeloma <i>Speaker:</i> Maaïke de Ruijter, NL	-
NG19-4	CML (ITK management) <i>Speaker:</i> Laura Borg, GB	-

Oral Session
09:15 - 18:00

On-Demand Library

OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia

This session is available in our on-demand library throughout the whole congress

OS19-1	INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL) <i>Speaker:</i> Catherine Thieblemont, FR	09:15 - 09:15
OS19-2	LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) <i>Speaker:</i> Caron A. Jacobson, US	09:15 - 09:15
OS19-3	PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) <i>Speaker:</i> Caron A. Jacobson, US	09:15 - 09:15
OS19-4	ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH	09:15 - 09:15

RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)

Speaker: Michael L. Wang, US

OS19-5	VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE CRUCIAL CONSORTIUM <i>Speaker:</i> Antonio José Cabrera-Serrano, ES	09:15 - 09:15
OS19-6	EVALUATION OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) <i>Speaker:</i> Natalie L. Smith, US	09:15 - 09:15
OS19-7	ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA (DLBCL) IN A GERMAN TERTIARY HOSPITAL <i>Speaker:</i> Bernhard Alexander Mörtl, DE	09:15 - 09:15
OS19-8	LONG TERM OUTCOMES OF ALLOGENEIC TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Alexander Glover, GB	09:15 - 09:15

Oral Session
09:15 - 18:00

On-Demand Library

OS07 - Oral session 7: Stem Cell Source and Donors

This session is available in our on-demand library throughout the whole congress

OS7-1	FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE RISK AFTER UNRELATED HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT <i>Speaker:</i> Annalisa Ruggeri, ES	09:15 - 09:25
OS7-2	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN MISMATCHED UNRELATED DONOR TRANSPLANTATION VERSUS HAPLOIDENTICAL TRANSPLANTATION: A RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Speaker:</i> Giorgia Battipaglia, IT	09:25 - 09:35
OS7-3	HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS AFFECTED BY MALIGNANT DISORDERS <i>Speaker:</i> Pietro Merli, IT	09:35 - 09:45
OS7-4	MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE FROM THE MADRID GROUP OF HEMATOPOIETIC TRANSPLANT	09:45 - 09:55

	Speaker: Rebeca Bailén, ES	
OS7-5	LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS Speaker: Jacopo Peccatori, IT	09:55 - 10:05
OS7-6	INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REPORT Speaker: Andriyana Bankova, US	10:05 - 10:15
OS7-8	CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH CRYOPRESERVED GRAFTS DURING THE COVID19 PANDEMIC Speaker: Maximilian Christopeit, DE	10:15 - 10:25
Oral Session 09:15 - 18:00		
		On-Demand Library
OS09 - Oral session 9: Graft versus Host Disease II		
This session is available in our on-demand library throughout the whole congress		
OS9-1	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN HUMANS Speaker: Robert Zeiser, DE	09:15 - 09:15
OS9-2	RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL Speaker: Franco Locatelli, IT	09:15 - 09:15
OS9-3	DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT? Speaker: Ivan Moiseev, RU	09:15 - 09:15
OS9-4	A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) Speaker: Michelle Hudspeth, US	09:15 - 09:15
OS9-5	THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY Speaker: Junya Kanda, JP	09:15 - 09:15
OS9-6	EARLY RECONSTITUTION OF CD6+ T CELLS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST	09:15 - 09:15

DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL ANTIBODY ITOLIZUMAB

Speaker: Benedetta Rambaldi, US

- | | | |
|-------|--|---------------|
| OS9-7 | MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE | 09:15 - 09:15 |
| | <i>Speaker:</i> Erik Thiele Orberg, DE | |

- | | | |
|-------|---|---------------|
| OS9-8 | ASSOCIATION OF GENE POLYMORPHISMS IN CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION | 09:15 - 09:15 |
| | <i>Speaker:</i> Paula Muñoz, ES | |

Oral Session
09:15 - 18:00

On-Demand Library

OS02 - Oral session 2: CARs I

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|--|---------------|
| OS2-1 | CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA | 09:15 - 09:25 |
| | <i>Speaker:</i> Deepu Madduri, US | |
| OS2-2 | PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) | 09:25 - 09:35 |
| | <i>Speaker:</i> Olalekan O. Oluwole, US | |
| OS2-3 | MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA | 09:35 - 09:45 |
| | <i>Speaker:</i> David Maloney, US | |
| OS2-4 | STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO PREVENT EPI TOPE MASKING IN CAR+ B-CELL LEUKEMIA BLASTS | 09:45 - 09:55 |
| | <i>Speaker:</i> Concetta Quintarelli, IT | |
| OS2-5 | CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19 CAR T-CELL THERAPY | 09:55 - 10:05 |
| | <i>Speaker:</i> Jordan Gauthier, US | |
| OS2-6 | OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING: INITIAL RESULTS FROM THE OUTREACH STUDY | 10:05 - 10:15 |
| | <i>Speaker:</i> John E. Godwin, US | |

OS2-7	BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T CELLS AT EU OR EBMT AFFILIATED PROGRAMS <i>Speaker:</i> Christian Chabannon, FR	10:15 - 10:25
OS2-8	ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF THE SHELF” STRATEGY TO TREAT CD123^{POS} CHILDHOOD ACUTE MYELOID LEUKAEMIA <i>Speaker:</i> Simona Caruso, IT	10:25 - 10:35

Oral Session
09:15 - 18:00

On-Demand Library

OS13 - Oral session 13: Transplant Complications I

This session is available in our on-demand library throughout the whole congress

OS13-1	FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS13-2	ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE ANALYSIS FROM THE EBMT <i>Speaker:</i> Olaf Penack, DE	09:15 - 09:15
OS13-3	DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS13-4	EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS13-5	EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE MORTALITY AND THE RISK OF INTENSIVE CARE UNIT ADMISSION AT PRE-TRANSPLANT EVALUATION <i>Speaker:</i> Marta Peña Domingo, ES	09:15 - 09:15
OS13-6	THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Midori Nakagaki, AU	09:15 - 09:15
OS13-7	IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF	09:15 - 09:15

EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Speaker: Aldo A Acosta-Medina, US

OS13-8	RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD	09:15 - 09:15
	Speaker: Bernd Gruhn, DE	

Oral Session
09:15 - 18:00

On-Demand Library

OS14 - Oral session 14: Transplant Complications II

This session is available in our on-demand library throughout the whole congress

OS14-1	PREGNANCY AND PREGNANCY OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT PEDIATRIC WP	09:15 - 09:15
	Speaker: Tamara Diesch, CH	
OS14-2	ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY: RESULTS OF A SURVEY FROM THE EBMT	09:15 - 09:15
	Speaker: Helene Schoemans, BE	
OS14-3	CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	09:15 - 09:15
	Speaker: Gertjan Lugthart, NL	
OS14-4	NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP	09:15 - 09:15
OS14-5	AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)	09:15 - 09:15
	Speaker: Selim Corbacioglu, DE	
OS14-6	PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA) ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)	09:15 - 09:15
	Speaker: Santosh Putta, US	
OS14-7	OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTRE EXPERIENCE	09:15 - 09:15
	Speaker: Isabel Iturrate, ES	
OS14-8	DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT-HOME ALLOGENEIC BONE MARROW TRANSPLANTATION MODELS	09:15 - 09:15

Speaker: Marta Garcia-Recio, ES

Oral Session
09:15 - 18:00

On-Demand Library

OS15 - Oral session 15: Conditioning Regimens

This session is available in our on-demand library throughout the whole congress

OS15-1	BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA Speaker: Sylvie Lachance, CA	09:15 - 09:25
OS15-2	MICROBIOTA INJURY IS CONDITIONING REGIMEN-DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS Speaker: Roni Shouval, US	09:25 - 09:35
OS15-3	THE IMPACT OF PULMONARY FUNCTION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION Speaker: Jesus Duque-Afonso, DE	09:35 - 09:45
OS15-4	HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER EXPERIENCE Speaker: Khalid Halahleh, JO	09:45 - 09:55
OS15-5	THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION :A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369 CONTROLS Speaker: Federica Sora, IT	09:55 - 10:05
OS15-6	IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL BLOOD COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE ALONE Speaker: Giorgia Battipaglia, IT	10:05 - 10:15
OS15-7	HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS Speaker: Donata Backhaus, DE	10:15 - 10:25
OS15-8	SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT Speaker: Eduardo Rodríguez-Arbolí, ES	10:25 - 10:35

Oral Session
09:15 - 18:00

On-Demand Library

OS16 - Oral session 16: Acute Leukemia I

This session is available in our on-demand library throughout the whole congress

OS16-1	IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE EBMT <i>Speaker:</i> Justin Loke, GB	09:15 - 09:25
OS16-2	IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE ALWP AND THE CMWP <i>Speaker:</i> Eolia Brissot, FR	09:25 - 09:35
OS16-3	THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A STUDY FROM THE ALWP / EBMT <i>Speaker:</i> Arnon Nagler, IL	09:35 - 09:45
OS16-4	NON-T DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER ONE VS TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT <i>Speaker:</i> Arnon Nagler, IL	09:45 - 09:55
OS16-5	PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND ALL. A STUDY FROM THE ALWP-EBMT <i>Speaker:</i> Sabine Blum, CH	09:55 - 10:05
OS16-6	IMPACT OF ALLOGENIC TRANSPLANTATION IN THE TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS. COMPARISON BETWEEN MYELOABLATIVE VS REDUCE INTENSITY CONDITIONINGS <i>Speaker:</i> Claudia Núñez-Torrón, ES	10:05 - 10:15
OS16-7	THE DISEASE BURDEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE TO PATIENTS WITH SECONDARY LEUKEMIA <i>Speaker:</i> Claudia Núñez-Torrón, ES	10:15 - 10:25
OS16-8	PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL TRANSPLANTATION. STUDY OF 132 PATIENTS <i>Speaker:</i> Christelle Ferra Coll, ES	10:25 - 10:35

Oral Session
09:15 - 18:00

On-Demand Library

OS17 - Oral session 17: Acute Leukemia II

This session is available in our on-demand library throughout the whole congress

OS17-1	TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: IMPROVEMENT OF SURVIVAL IN RECENT YEARS <i>Speaker:</i> Ali Bazarbachi, LB	09:15 - 09:15
OS17-2	HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE NUCLEAR CONSORTIUM <i>Speaker:</i> José Sánchez Maldonado, ES	09:15 - 09:15
OS17-3	COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA <i>Speaker:</i> Annalisa Ruggeri, ES	09:15 - 09:15
OS17-4	REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION <i>Speaker:</i> Sarah Morin, CH	09:15 - 09:15
OS17-5	VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT (HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Vincenzo Federico, IT	09:15 - 09:15
OS17-6	TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Speaker:</i> Nico Gagelmann, DE	09:15 - 09:15
OS17-7	STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL DONOR FOR PEDIATRIC PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE STUDY <i>Speaker:</i> Charlotte Nazon, FR	09:15 - 09:15
OS17-8	COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD <i>Speaker:</i> Gabriele Magliano, IT	09:15 - 09:15

Oral Session
09:15 - 18:00

On-Demand Library

OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes

This session is available in our on-demand library throughout the whole congress

OS18-1	GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS	09:15 - 09:15
--------	--	---------------

WITH MYELOID NEOPLASIA

Speaker: Carmelo Gurnari, US

OS18-2	RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA. A STUDY OF THE EBMT-CMWP <i>Speaker:</i> Alicia Rovó, CH	09:15 - 09:15
OS18-3	CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A RETROSPECTIVE ANALYSIS FROM THE CHRONIC MALIGNANCIES WORKING PARTY <i>Speaker:</i> Christof Scheid, DE	09:15 - 09:15
OS18-4	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM AFTER BREAST CANCER TREATMENT: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT <i>Speaker:</i> Mitja Nabergoj, CH	09:15 - 09:15
OS18-5	IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-CMWP STUDY <i>Speaker:</i> Nicolaus Kröger, DE	09:15 - 09:15
OS18-6	ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Elena Morozova, RU	09:15 - 09:15
OS18-7	DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML <i>Speaker:</i> Christian Niederwieser, DE	09:15 - 09:15
OS18-8	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT PERIOD <i>Speaker:</i> Anna Czyz, PL	09:15 - 09:15

Special Session
09:15 - 18:00

On-Demand Library

SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell therapy community

This session is available in our on-demand library throughout the whole congress

SS8-1	Social media beyond twitter for the HSCT and cell therapy community <i>Speaker:</i> Navneet Majhail, US	-
SS8-2	Do's and don'ts of interaction in social media: Nurse's perspective	-

Speaker: Johan De Munter, BE

- | | | |
|-------|--|---|
| SS8-3 | Do's and don'ts of interaction in social media: How social media can improve patient outcomes - The patient's perspective
Speaker: Gillian Adams, GB | - |
|-------|--|---|

Special Session
09:15 - 18:00

On-Demand Library

SS07 - Young Ambassadors Session

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---|
| SS7-1 | How build up a career in: Academia
Speaker: Didier Blaise, FR | - |
| SS7-2 | How build up a career in: In Pharmaceutical Industry
Speaker: Dan Tovar, FR | - |
| SS7-3 | How build up a career in: In Public domains
Speaker: Eva Hilgenfeld, DE | - |
| SS7-4 | What to avoid when writing a paper
Speaker: Jakob Passweg, CH | - |
| SS7-5 | How to write a successful grant
Speaker: Robert Zeiser, DE | - |
| SS7-6 | Introduction to medical statistics
Speaker: Simona Iacobelli, IT | - |
| SS7-7 | Social media in stem cell transplantation and cellular therapy
Speaker: Navneet Majhail, US | - |

Nurses Group
09:15 - 18:00

On-Demand Library

NG20 - How do I become an expert?

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---|
| NG20-1 | Conditioning regimen
Speaker: Nicolas Kint, BE | - |
| NG20-2 | Immunosuppression
Speaker: Tiene Bauters, BE | - |
| NG20-3 | Vaccinations
Speaker: Bipin Savani, US | - |

Nurses Group
09:15 - 18:00

On-Demand Library

NG18 - Non-malignant diseases update

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---------------|
| NG18-2 | Multiple sclerosis
Speaker: Helen Jessop, GB | 09:15 - 09:15 |
|--------|--|---------------|

NG18-3	Sickle cell disease <i>Speaker:</i> Jean-Hugues Dalle, FR	09:15 - 09:15
--------	---	---------------

NG18-4	ITP <i>Speaker:</i> Maria Luisa Lozano, ES	09:15 - 09:15
--------	--	---------------

Nurses Group
09:15 - 18:00

On-Demand Library

NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG14-1	Patient's experience <i>Speaker:</i> Ruth Tweedie, ES	-
NG14-2	Psychologist's point of view <i>Speaker:</i> Anna Lagerdahl, GB	-
NG14-3	Nurse's perspective <i>Speaker:</i> Núria Ballestar, ES	-

Nurses Group
09:15 - 18:00

On-Demand Library

NG24 - Outreach projects

This session is available in our on-demand library throughout the whole congress

NG24-2	Outreach project India: EBMT MIC pediatric advanced care training (EMPACT) <i>Speaker:</i> Lawrence Faulkner, IT	09:15 - 09:15
NG24-3	Outreach project: LABMT <i>Speaker:</i> Sara Saez Carrasco, CO	09:15 - 09:15

Nurses Group
09:15 - 18:00

On-Demand Library

NG22 - Quality processes in JACIE

This session is available in our on-demand library throughout the whole congress

NG22-1	Quality indicators for nurses <i>Speaker:</i> Louise McNamara, GB	-
NG22-2	JACIE: What's new? <i>Speaker:</i> Kim Orchard, GB	-
NG22-3	What is the nurse role as JACIE Inspector? <i>Speaker:</i> Eugenia Trigos Arjona, ES	-

Educational
09:15 - 18:00

On-Demand Library

E11 - Management of early complications in an ambulatory/outpatient setting

This session is available in our on-demand library throughout the whole congress

E11-1	Early infectious complications	-
-------	---------------------------------------	---

	<i>Speaker:</i> Jan Styczynski, PL	
E11-2	Non-infective complications: GVHD and organ toxicity <i>Speaker:</i> Gerhard Hildebrandt, US	-
E11-3	The Hospital Clínic experience <i>Speaker:</i> Francesc Fernández-Avilés, ES	-
<i>Educational</i> 09:15 - 18:00		
On-Demand Library		
E12 - Steroid-resistant/refractory GVHD		
This session is available in our on-demand library throughout the whole congress		
E12-1	GVHD - what's in a name? <i>Speaker:</i> Helene Schoemans, BE	-
E12-2	Treatment of SR/R acute GVHD <i>Speaker:</i> Olaf Penack, DE	-
E12-3	Treatment of SR/R chronic GVHD <i>Speaker:</i> Zinaida Peric, HR	-
E12-4	New technologies in the approach to GVHD <i>Speaker:</i> Amin Turki, DE	-
<i>Workshop</i> 09:15 - 18:00		
On-Demand Library		
W10 - Controversies in T-cell NHL		
This session is available in our on-demand library throughout the whole congress		
W10-1	Are we improving first-line therapy in TCL? <i>Speaker:</i> Eva Domingo Domenech, ES	09:15 - 09:15
W10-3	Insights in CAR-T therapy for T cell Lymphomas <i>Speaker:</i> Helen Heslop, US	09:15 - 09:15
<i>Workshop</i> 09:15 - 18:00		
On-Demand Library		
W12 - Donor HLA assessment and matching for allogeneic HSCT		
This session is available in our on-demand library throughout the whole congress		
W12-1	HLA laboratory perspective and recommendations <i>Speaker:</i> Pascale Loiseau, FR	-
W12-2	Clinical perspective and recommendations <i>Speaker:</i> Francesca Lorentino, IT	-
W12-3	Selection of unrelated donors and cord blood units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR <i>Speaker:</i> Stephen Spellman, US	-

Workshop

09:15 - 18:00

On-Demand Library

W11 - Key organ manifestations of chronic GVHD

This session is available in our on-demand library throughout the whole congress

W11-1	Pulmonary chronic GVHD <i>Speaker:</i> Hildegard Greinix, AT	-
W11-2	Ocular cGVHD diagnostics - Practical approach <i>Speaker:</i> Igor Petricek, HR	-
W11-3	Gastrointestinal manifestations of chronic GVHD <i>Speaker:</i> Daniel Wolff, DE	-

Working Party Session

09:15 - 18:00

On-Demand Library

CMWP - Chronic Malignancies Working Party Session

This session is available in our on-demand library throughout the whole congress

CMWP-1	Scientific activity of the CMWP <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	09:15 - 09:15
CMWP-3	Who and when in the course of disease to transplant? - Myelofibrosis <i>Speaker:</i> Donal McLornan, GB	09:15 - 09:15
CMWP-4	Is Chronic Myeloid Leukaemia still an indication for allo-HCT? <i>Speaker:</i> Yves Chalandon, CH	09:15 - 09:15
CMWP-5	Is Chronic Lymphocytic Leukemia still an indication for allo-HCT? <i>Speaker:</i> Peter Dreger, DE	09:15 - 09:15

Lab Technicians Day

09:15 - 18:00

On-Demand Library

LT1 - Lab Technicians Day: Specialized cell processing

This session is available in our on-demand library throughout the whole congress

LT1-1	Bone marrow processing: Techniques and results <i>Speaker:</i> Boris Calmels, FR	-
LT1-2	Technical aspects and performance TCRab/CD19 depletion <i>Speaker:</i> Kasper Westinga, NL	-
LT1-3	Donor selection and GMP-compliant manufacturing of virus-specific T-cells <i>Speaker:</i> Britta Eiz-Vesper, DE	-

Joint Session

09:15 - 18:00

On-Demand Library

JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT

This session is available in our on-demand library throughout the whole congress

JS5-2	COVID-19 vaccination in HSCT	09:15 - 09:15
-------	-------------------------------------	---------------

	<i>Speaker:</i> Per Ljungman, SE	
JS5-3	Global access to COVID-19 vaccines <i>Speaker:</i> Susan Brown, US	09:15 - 09:15
<i>How do I ... ?</i> 09:15 - 18:00		
	HDI6 - How Do I... manage toxicity in immunosuppressed patients? This session is available in our on-demand library throughout the whole congress	On-Demand Library
HDI6-1	Transplant associated TMA <i>Speaker:</i> Sergio Giralt, US	-
HDI6-2	Infectious complication <i>Speaker:</i> Jan Styczynski, PL	-
<i>Data Management</i> 09:15 - 18:00		
	DM08 - Education session 8 This session is available in our on-demand library throughout the whole congress	On-Demand Library
DM8-1	Infectious complications <i>Speaker:</i> Malgorzata Mikulska, IT	-
<i>Joint Session</i> 09:15 - 18:00		
	JS04 - Joint session LABMT This session is available in our on-demand library throughout the whole congress	On-Demand Library
JS4-1	Transplant rates, Trends: WBMT/LABMT 2018 survey <i>Speaker:</i> Oscar González-Ramella, MX	-
JS4-2	Financing of HSCT in Latin America <i>Speaker:</i> Gregorio Jaimovich, AR	-
JS4-3	Selection, management and follow up of related donors: Overview <i>Speaker:</i> Nina Worel, AT	-
JS4-4	Selection, management and follow up of related donors: Development of an LABMT consensus <i>Speaker:</i> Gonzalo Ferini, AR	-
JS4-5	Haploidentical transplants in Latin America: Experience from Argentina/GATMO-TC in acute lymphoblastic leukemia <i>Speaker:</i> Ana Basquiera, AR	-
JS4-6	Haploidentical transplants in Latin America: Experience from Brazil/SBTMO in aplastic anemia <i>Speaker:</i> Carmem Bonfim, BR	-

Special Session

09:15 - 18:00

On-Demand Library

SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer

This session is available in our on-demand library throughout the whole congress

SS10-1	General Overview of the HARMONY Alliance: Progress, Achievements & Results of HARMONY and HARMONY PLUS projects <i>Speaker:</i> Jesús Maria Hernández Rivas, ES	-
SS10-2	Envisioned contribution of the EBMT to the HARMONY Alliance <i>Speaker:</i> Guillermo Sanz Santillana, ES <i>Speaker:</i> Yann Guillevic, CH	-
SS10-3	EBMT participation in the HARMONY Alliance <i>Speaker:</i> Anna Sureda, ES	-
SS10-4	HARMONY & HARMONY PLUS Research Projects / Outcomes definition <i>Speaker:</i> Lars Bullinger, DE	-
SS10-5	HARMONY Platform <i>Speaker:</i> Ana Heredia Casanoves, ES	-

Oral Session

09:15 - 18:00

On-Demand Library

OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering

This session is available in our on-demand library throughout the whole congress

OS1-1	MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT IMMUNOSUPPRESSIVE PROPERTIES <i>Speaker:</i> Kevin Goncalves, US	09:15 - 09:15
OS1-2	EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34⁺ CELL MOBILIZATION IN HEALTHY VOLUNTEERS <i>Speaker:</i> Hideki Goto, JP	09:15 - 09:15
OS1-3	THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Rumesh Chandar, IN	09:15 - 09:15
OS1-4	THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT REJECTION AND GRAFT VERSUS HOST DISEASE IN CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION <i>Speaker:</i> Satish Meena, IN	09:15 - 09:15
OS1-5	OUTCOME AND IMMUNE RECONSTITUTION AFTER TCR^{??}/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL RELATED DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE	09:15 - 09:15

EXPERIENCE

Speaker: Lucia Prezioso, IT

- | | | |
|-------|--|---------------|
| OS1-6 | THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE
<i>Speaker:</i> Muhammad Ameen, SA | 09:15 - 09:15 |
| OS1-7 | POST-TRANSPLANT OUTCOMES OF CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TREATED WITH EMAPALUMAB
<i>Speaker:</i> Michael Jordan, US | 09:15 - 09:15 |
| OS1-8 | WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE
<i>Speaker:</i> Maria Escolar, US | 09:15 - 09:15 |

Oral Session

09:15 - 18:00

On-Demand Library

OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and Chimerism

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|--|---------------|
| OS6-1 | COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T CELL IMMUNE RECONSTITUTION PATTERNS
<i>Speaker:</i> Saskia Leserer, DE | 09:15 - 09:15 |
| OS6-2 | MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
<i>Speaker:</i> Sandra Pennisi, DE | 09:15 - 09:15 |
| OS6-3 | SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR EXCISION CIRCLES (TRECS) AND K-DELETING RECOMBINATION EXCISION CIRCLES (KRECS) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) RECIPIENTS
<i>Speaker:</i> Carlos De Miguel Jiménez, ES | 09:15 - 09:15 |
| OS6-4 | MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMANS
<i>Speaker:</i> Mirjam Belderbos, NL | 09:15 - 09:15 |
| OS6-5 | OVER-EXPRESSION OF HIF-1α IN MESENCHYMAL STROMAL CELLS INCREASES HUMAN CD34⁺ CELLS CLONOGENIC CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A XENOTRANSPLANTATION MODEL
<i>Speaker:</i> Silvia Preciado, ES | 09:15 - 09:15 |
| OS6-6 | ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS- | 09:15 - 09:15 |

SPECIFIC T-CELLS

Speaker: Rubiya Nadaf, GB

- | | | |
|-------|--|---------------|
| OS6-7 | TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOID MALIGNANCIES
<i>Speaker:</i> Simona Pagliuca, US | 09:15 - 09:15 |
| OS6-8 | DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Patrizia Chiusolo, IT | 09:15 - 09:15 |

Oral Session
09:15 - 18:00

On-Demand Library

OS08 - Oral session 8: Graft versus Host Disease I

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---------------|
| OS8-1 | GVHD PROPHYLAXIS WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A / METHOTREXATE POST ALLOGENEIC TRANSPLANTATION (HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE ALWP/EBMT
<i>Speaker:</i> Arnon Nagler, IL | 09:15 - 09:15 |
| OS8-2 | BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE ROCKSTAR STUDY (KD025-213)
<i>Speaker:</i> Corey Cutler, US | 09:15 - 09:15 |
| OS8-3 | A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
<i>Speaker:</i> Hanaa A. Fatoum, SA | 09:15 - 09:15 |
| OS8-4 | RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM THE RANDOMIZED, PHASE 3 REACH2 STUDY
<i>Speaker:</i> Mohamad Mohty, FR | 09:15 - 09:15 |
| OS8-5 | IMPACT OF CHRONIC GVHD SEVERITY AND STEROID RESPONSE ON THE QUALITY OF LIFE IN PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: FINDINGS FROM A REAL-WORLD STUDY
<i>Speaker:</i> Sylvie Lachance, CA | 09:15 - 09:15 |
| OS8-6 | SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM
<i>Speaker:</i> Florent Malard, FR | 09:15 - 09:15 |
| OS8-7 | REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE | 09:15 - 09:15 |

PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER ALLO-HSCT

Speaker: Marie T Rubio, FR

OS8-8	PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD STUDY	09:15 - 09:15
	Speaker: Nada Hamad, AU	

Special Session
09:15 - 18:00

On-Demand Library

SS11 - The EBMT for Trainees

This session is available in our on-demand library throughout the whole congress

SS11-1	Being a Trainee in SCT / Cellular Therapy	-
	Speaker: Nico Gagelmann, DE Speaker: Claire Horgan, GB Speaker: Yasmina Serroukh, BE Speaker: Yuliya Rogacheva, RU Speaker: Tamar Azikuri, GE	
SS11-2	Overview of allogeneic SCT for the trainee: 'Things I wish I'd known'	-
	Speaker: Helene Schoemans, BE	
SS11-3	Establishing a career in SCT/cellular therapy	-
	Speaker: Jordan Gauthier, US	
SS11-4	Complications for trainees 1: How to manage acute GVHD	-
	Speaker: Zinaida Peric, HR	
SS11-5	Complications for trainees 2: How to manage VOD	-
	Speaker: Ivan Moiseev, RU	

Oral Session
09:15 - 18:00

On-Demand Library

OS21 - Oral session 21: Multiple Myeloma

This session is available in our on-demand library throughout the whole congress

OS21-1	MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA	09:15 - 09:15
	Speaker: Harsh Parmar, US	
OS21-2	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT – A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP	09:15 - 09:15
	Speaker: Joanna Drozd-Sokołowska, PL	
OS21-3	ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP	09:15 - 09:15

ANALYSIS

Speaker: Mohamad Mohty, FR

OS21-4	AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM STEM CELL TRANSPLANTATION AND MAINTENANCE WITH THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA (MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-STUDY <i>Speaker:</i> Nicolaus Kröger, DE	09:15 - 09:15
OS21-5	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL DISEASE <i>Speaker:</i> Jean Roy, CA	09:15 - 09:15
OS21-6	ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY <i>Speaker:</i> Laurent Garderet, FR	09:15 - 09:15
OS21-7	COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) <i>Speaker:</i> Sergio Giral, US	09:15 - 09:15
OS21-8	CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE-CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL TRIALS OF DARATUMUMAB <i>Speaker:</i> Katja Weisel, DE	09:15 - 09:15

Oral Session
09:15 - 18:00

On-Demand Library

OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II

This session is available in our on-demand library throughout the whole congress

OS5-1	HEMATOPOIETIC STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH): BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF EARLY CLINICAL RESPONSE <i>Speaker:</i> Maria Ester Bernardo, IT	09:15 - 09:25
OS5-2	OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH TABELCELEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Susan Prockop, US	09:25 - 09:35
OS5-3	RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES:	09:35 - 09:45

RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY

Speaker: Markus Mapara, US

OS5-4	DURABLE CLINICAL OUTCOMES FOLLOWING BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) <i>Speaker:</i> Franco Locatelli, IT	09:45 - 09:55
OS5-5	OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT) <i>Speaker:</i> Carolyn Mulroney, US	09:55 - 10:05
OS5-6	IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Francesca Patriarca, IT	10:05 - 10:15
OS5-7	MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR THE IDENTIFICATION OF HIGH-RISK PATIENTS AND TREATMENT WITH T-CELL IMMUNOTHERAPY <i>Speaker:</i> Anastasia Papadopoulou, GR	10:15 - 10:25
OS5-8	NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT TRANSDUCTION AND CROSS-CORRECTION MECHANISMS USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH <i>Speaker:</i> Jane E Potter, GB	10:25 - 10:35
Paed4-2	EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34⁺ HEMATOPOIETIC STEM AND PROGENITOR CELLS IN TRANSFUSION-DEPENDENT β-THALASSEMIA AND SICKLE CELL DISEASE <i>Speaker:</i> Selim Corbacioglu, DE	10:35 - 10:45

Educational
09:15 - 18:00

On-Demand Library

E09 - Allogeneic HSCT in MDS and MPN

This session is available in our on-demand library throughout the whole congress

E9-1	Definition of graft failure/relapse after allo-HCT in myelofibrosis <i>Speaker:</i> Donal McLornan, GB	-
E9-2	Allogeneic HSCT in patients with therapy-related MDS/AML <i>Speaker:</i> Marie Robin, FR	-

- E9-3 **The role of maintenance therapy after allogeneic HSCT in MDS** -
Speaker: Francesco Onida, IT

Nurses Group
 09:15 - 18:00

On-Demand Library

NG17 - Care of the nurses

This session is available in our on-demand library throughout the whole congress

- NG17-1 **Mindfulness** -
Speaker: Ana M. Muñoz Cobo, ES
- NG17-2 **Resilience and self-care** -
Speaker: Christian Williams, GB
- NG17-3 **Tips and tricks for self care** -
Speaker: Jane Keep, GB

Nurses Group
 09:15 - 18:00

On-Demand Library

NG21 - Clinical trials in a transplant setting

This session is available in our on-demand library throughout the whole congress

- NG21-1 **Antimicrobial Lock Therapy for Prevention and Treatment of Catheter Related Infections in Hematological Patients** -
Speaker: Isabel Salcedo, ES
- NG21-2 **Convalescent plasma clinical trials for COVID-19** -
Speaker: Rocío Layunta, ES
- NG21-3 **Post transplant relapse** -
Speaker: Stephanie Heyes, GB

Nurses Group
 09:15 - 18:00

On-Demand Library

NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

- NG13-1 **SARS-CoV-2 vaccines overview** -
Speaker: Almudena Ramírez, ES
- NG13-2 **Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation** -
Speaker: Jose Luis Piñana, ES
- NG13-3 **COVID-19: The EBMT recommendations for management of HCT patients and donors** -
Speaker: Per Ljungman, SE

Nurses Group
09:15 - 18:00

On-Demand Library

NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG15-1	Managing virtual conversations <i>Speaker:</i> Lloyd Allen, GB	-
NG15-2	Nurse perspective: Virtual long term follow up for BMT patients <i>Speaker:</i> Michelle Kenyon, GB	-
NG15-3	Back to the future: Emphasizing our new practices <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	-

Nurses Group
09:15 - 18:00

On-Demand Library

NG23 - Oral session 2: Abstracts session

This session is available in our on-demand library throughout the whole congress

NG23-1	EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL CARE PROTOCOL FOR THE PREVENTION AND TREATMENT OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT RECIPIENTS <i>Speaker:</i> Monica Guberti, IT	09:15 - 09:15
NG23-2	PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING <i>Speaker:</i> Julia Ruiz Pato, ES	09:15 - 09:15
NG23-3	ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS <i>Speaker:</i> Franziska Michaela Lohmeyer, IT	09:15 - 09:15
NG23-4	MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANTATION SETTING AND THEIR MAINTENANCE OVER TIME <i>Speaker:</i> Alberto Castagna, IT	09:15 - 09:15
NG23-5	EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AND THEIR COHABITANTS <i>Speaker:</i> Maria Teresa Solano Moliner, ES	09:15 - 09:15

Quality Management
09:15 - 18:00

On-Demand Library

QM5 - Quality Management Oral Abstracts

This session is available in our on-demand library throughout the whole congress

QM5-1	COMPLIANCE AND COST EFFICACY FOR CELLULAR THERAPIES, CAN THESE TWO GO HAND IN HAND?	09:15 - 09:15
-------	--	---------------

	<i>Speaker:</i> Janik Adriaansen, US	
QM5-2	HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR NURSES IN TIMES OF PANDEMIC <i>Speaker:</i> Sheila Saco, ES	09:15 - 09:15
QM5-3	THE RTN TRANSPLANT POLICY AND ACTIVITY DURING COVID-19 PANDEMIC <i>Speaker:</i> Antonio Bruno, IT	09:15 - 09:15
QM5-4	THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM IN NAPLES, ITALY <i>Speaker:</i> Lucia Ammirati, IT	09:15 - 09:15

Educational
09:15 - 18:00

On-Demand Library

E10 - HSCT in paediatric non-malignant indications

This session is available in our on-demand library throughout the whole congress

E10-1	Haplo-identical SCT in hemoglobinopathy: Taking pole position? <i>Speaker:</i> Josu de la Fuente, GB	-
E10-2	Mismatched family donors in inherited immune disorders: A new perspective <i>Speaker:</i> Mary A. Slatter, GB	-
E10-3	HSCT for inherited bone marrow failure syndromes <i>Speaker:</i> Cristina Díaz de Heredia, ES	-
E10-4	Cord blood HSCT for non-malignant diseases in children <i>Speaker:</i> Vanderson Rocha, BR	-

Oral Session
09:15 - 18:00

On-Demand Library

OS10 - Oral session 10: COVID-19

This session is available in our on-demand library throughout the whole congress

OS10-1	A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS ADOPTIVE THERAPY IN COVID19 <i>Speaker:</i> Antonio Pérez-Martínez, ES	09:15 - 09:25
OS10-2	THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY <i>Speaker:</i> Angharad Pryce, GB	09:25 - 09:35
OS10-3	IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT	09:35 - 09:45

	<i>Speaker:</i> Sara Ghorashian, GB	
OS10-4	OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE FROM A SEVERELY AFFECTED AREA (BERGAMO) <i>Speaker:</i> Maria Caterina Mico', IT	09:45 - 09:55
OS10-5	ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS AFTER COVID-19 INFECTION <i>Speaker:</i> Maximilian Christopeit, DE	09:55 - 10:05
OS10-6	INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION CENTERS AND THE PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE 2020 <i>Speaker:</i> Fernando Barroso Duarte, BR	10:05 - 10:15
OS10-7	CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC PROGENITOR CELLS IN THE CURRENT SARS-Cov-2 PANDEMIC: EXPERIENCE OF A SINGLE CENTRE <i>Speaker:</i> Dolores Moreno, ES	10:15 - 10:25
OS10-8	IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH CORD BLOOD UNITS. ON BEHALF THE AGENCY OF BIOMEDICINE, EUROCORD AND THE SFGM-TC <i>Speaker:</i> Hanadi Rafii - El Ayoubi, FR	10:25 - 10:35

Oral Session
09:15 - 18:00

On-Demand Library

OS11 - Oral session 11: Infectious Diseases I

This session is available in our on-demand library throughout the whole congress

OS11-1	POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE ASPBIOMICS CONSORTIUM <i>Speaker:</i> Ana Moniz-Díez, ES	09:15 - 09:25
OS11-2	THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Speaker:</i> Nipat Chuleerarux, TH	09:25 - 09:35
OS11-3	IMMUNE RECONSTITUTION DURING CMV PROPHYLAXIS BY LETERMIVIR: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Ilaria Cutini, IT	09:35 - 09:45
OS11-4	LETMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE <i>Speaker:</i> Massimo Martino, IT	09:45 - 09:55
OS11-5	PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO	09:55 - 10:05

	TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED APPROACH. RESULTS IN 112 PATIENTS	
	<i>Speaker:</i> Amado Karduss -Urueta, CO	
OS11-6	PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A TERTIARY REFERRAL CENTER IN INDIA	10:05 - 10:15
	<i>Speaker:</i> Harika Varla, IN	
OS11-7	THE MANAGEMENT OF CLOSTRIDIODES DIFFICILE INFECTIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY	10:15 - 10:25
	<i>Speaker:</i> Agnieszka Piekarska, PL	
OS11-8	CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH HEMATOLOGY MALIGNANCIES: A REAL-WORLD OBSERVATIONAL STUDY	10:25 - 10:35
	<i>Speaker:</i> Sizhou Feng, CN	
<i>Oral Session</i>		
09:15 - 18:00		On-Demand Library
OS12 - Oral session 12: Infectious Diseases II		
This session is available in our on-demand library throughout the whole congress		
OS12-1	NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY GROUP	09:15 - 09:15
	<i>Speaker:</i> Dina Averbuch, IL	
OS12-2	COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY	09:15 - 09:15
	<i>Speaker:</i> Marina Popova, RU	
OS12-3	COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION	09:15 - 09:15
	<i>Speaker:</i> Yuliya Rogacheva, RU	
OS12-4	FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTS	09:15 - 09:15
	<i>Speaker:</i> Chiara Rosignoli, IT	
OS12-5	CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL	09:15 - 09:15

TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE

Speaker: Anke Verlinden, BE

- | | | |
|--------|--|---------------|
| OS12-6 | COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS THAT AFFECT THE SURVIVAL OF PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Anna Czyz, PL | 09:15 - 09:15 |
| OS12-7 | IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Eshrak Al-Shaibani, CA | 09:15 - 09:15 |
| OS12-8 | STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6 REACTIVATION
<i>Speaker:</i> Kenichiro Takeda, JP | 09:15 - 09:15 |

Oral Session
09:15 - 18:00

On-Demand Library

OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|---|---------------|
| OS20-1 | HLA EVOLUTIONARY DIVERGENCE INFLUENCES CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
<i>Speaker:</i> Simona Pagliuca, US | 09:15 - 09:25 |
| OS20-2 | OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511 PATIENTS
<i>Speaker:</i> Richard K Burt, US | 09:25 - 09:35 |
| OS20-3 | EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A REAL WORLD EXPERIENCE
<i>Speaker:</i> Varun Mehra, GB | 09:35 - 09:45 |
| OS20-4 | THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
<i>Speaker:</i> Carmelo Gurnari, US | 09:45 - 09:55 |
| OS20-5 | HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS: CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES
<i>Speaker:</i> Alexey Polushin, RU | 09:55 - 10:05 |

OS20-6	HLA MUTATIONS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM OF IMMUNE ESCAPE <i>Speaker:</i> Carmelo Gurnari, US	10:05 - 10:15
OS20-7	HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	10:15 - 10:25
OS20-8	IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS <i>Speaker:</i> Alice Mariottini, IT	10:25 - 10:35

Industry Symposium
09:15 - 18:00

On-Demand Library

IS38 - CMV management in high-risk patients - Biotest Industry Symposium

This session is available in our on-demand library throughout the whole congress

Chair: Fabio Ciceri, IT

IS38-1	A scoring system to define patients at high risk for CMV <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	-
IS38-2	How to manage CMV high-risk patients <i>Speaker:</i> Michele Malagola, IT	-
IS38-3	The immunological benefits of CMV-specific immunoglobulins <i>Speaker:</i> Javier Carbone, ES	-

Lab Technicians Day
09:15 - 18:00

On-Demand Library

LT2 - Lab Technicians Day: Cell product testing, validation and characterization

This session is available in our on-demand library throughout the whole congress

LT2-1	Quality control assessment of ATMP phenotype and functionality using flow cytometry <i>Speaker:</i> Willemijn Hobo, NL	-
LT2-2	Flow cytometry-based CD34 enumeration <i>Speaker:</i> Harry Dolstra, NL	-
LT2-3	Flow cytometric in-process and quality control for CAR T cell manufacturing <i>Speaker:</i> Ulrike Köhl, DE	-

Data Management
09:15 - 18:00

On-Demand Library

DM07 - Education session 7

This session is available in our on-demand library throughout the whole congress

DM7-1	Minimal residual disease (MRD) <i>Speaker:</i> Johannes Schetelig, DE	-
-------	---	---

Workshop

09:15 - 18:00

On-Demand Library

W13 - CARs beyond T cells: A focus on next generation CAR-NK cells

This session is available in our on-demand library throughout the whole congress

W13-1	CAR NK cells as an "off the shelf" immunotherapy <i>Speaker:</i> Ulrike Köhl, DE	-
W13-2	CARs and ADCC to make off-the-shelf NK cells specific against hematologic malignancies <i>Speaker:</i> Jeffrey Miller, US	-
W13-3	Target NKG2D ligands on tumor cells <i>Speaker:</i> Antonio Pérez-Martínez, ES	-

Workshop

09:15 - 18:00

On-Demand Library

W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?

This session is available in our on-demand library throughout the whole congress

W14-1	A matched unrelated donor <i>Speaker:</i> Bronwen Shaw, US	-
W14-2	A haploidentical donor <i>Speaker:</i> Mi Kwon, ES	-
W14-3	When to choose cord blood <i>Speaker:</i> Filippo Milano, US	-
W14-4	Do we have to challenge our current donor hierarchy for patients with hemoglobinopathies? <i>Speaker:</i> Selim Corbacioglu, DE	-

Working Party Session

09:15 - 18:00

On-Demand Library

CTIWP - Cellular Therapy and Immunobiology Working Party Session

This session is available in our on-demand library throughout the whole congress

CTIWP-1	CTIWP Activity Report <i>Speaker:</i> Christian Chabannon, FR	-
CTIWP-2	Virus specific T cells post BMT- Broadening to SARS-CoV2 <i>Speaker:</i> Catherine Bollard, US	-
CTIWP-3	Are mesenchymal stromal cells the right arrow in the quiver to fight COVID-19? <i>Speaker:</i> Rachele Ciccocioppo, IT	-

Working Party Session

09:15 - 18:00

On-Demand Library

SAAWP - Severe Aplastic Anaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

SAAWP-1	Introduction	-
---------	---------------------	---

	<i>Speaker:</i> Régis Peffault de Latour, FR	
SAAWP-2	Registry Report <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-3	RACE – clinical update <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-4	RACE – what we learn on the biology of SAA? <i>Speaker:</i> Austin Kulakaseraraj, GB	-
SAAWP-5	Androgens in AA: Myth or reality in 2021? <i>Speaker:</i> Simona Pagliuca, US	-
SAAWP-6	GVHD and relapse free survival (GRFS) after HSCT for AA <i>Speaker:</i> Raynier Devillier, FR	-

Special Session

09:15 - 18:00

On-Demand Library

SS09 - How to get published

This session is available in our on-demand library throughout the whole congress

SS9-1	BMT: Official journal of the EBMT <i>Speaker:</i> Hillard Lazarus, US	-
SS9-2	How to get published <i>Speaker:</i> Mohamad Mohty, FR	-

Oral Session

09:15 - 18:00

On-Demand Library

OS03 - Oral session 3: CARs II

This session is available in our on-demand library throughout the whole congress

OS3-1	CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY OF THE APPROACH <i>Speaker:</i> Olga Molostova, RU	09:15 - 09:15
OS3-2	CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2 CARTITUDE-1 STUDY <i>Speaker:</i> Andrzej Jakubowiak, US	09:15 - 09:15
OS3-3	PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS WITH RELAPSED/REFRACTORY MCL IN ZUMA-2 <i>Speaker:</i> Michael L. Wang, US	09:15 - 09:15
OS3-4	REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN SPAIN <i>Speaker:</i> Mi Kwon, ES	09:15 - 09:15

OS3-5	HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY <i>Speaker:</i> Dasom Lee, US	09:15 - 09:15
OS3-6	DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS ARE ASSOCIATED WITH NEUROTOXICITY <i>Speaker:</i> Madhavi Lakkaraja, US	09:15 - 09:15
OS3-7	COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-T THERAPY <i>Speaker:</i> Zhao-Yanli Zhao, CN	09:15 - 09:15
OS3-8	THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF GD2+ SARCOMAS <i>Speaker:</i> Antonio Camera, IT	09:15 - 09:15

Oral Session
09:15 - 18:00

On-Demand Library

OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I

This session is available in our on-demand library throughout the whole congress

OS4-1	INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) TREATED IN THE PHASE 3 NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212) STUDIES <i>Speaker:</i> Isabelle Thuret, FR	09:15 - 09:25
OS4-2	NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE TREATMENT OF ADULT HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES <i>Speaker:</i> Alessandro Rambaldi, IT	09:25 - 09:35
OS4-3	CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T-CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Eliana Ruggiero, IT	09:35 - 09:45
OS4-4	CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY IN MPSIIIA <i>Speaker:</i> Jane Louise Kinsella, GB	09:45 - 09:55
OS4-5	EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Dalia Sheta, DE	09:55 - 10:05
OS4-6	REAL-WORLD EFFECTIVENESS AND SAFETY OF	10:05 - 10:15

BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST RELAPSE

Speaker: Alessandro Rambaldi, IT

OS4-7 **GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY** 10:15 - 10:25

Speaker: Paulien van Hauten, NL

OS4-8 **IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC ANALYSES FROM THE PEGASUS STUDY** 10:25 - 10:35

Speaker: David Cella, US

Poster Sessions

09:15 - 18:00

ePoster Area

Stem Cell Source

P216 **THE BLOOD DONATION BEFORE BONE MARROW HARVEST HAS NO IMPACT ON EFFICIENCY OF COLLECTION** 09:15 - 09:15

Speaker: Iwona Mitrus, PL

P217 **UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A SINGLE CENTER EXPERIENCE** 09:15 - 09:15

Speaker: Vincenzo Federico, IT

Poster Sessions

09:15 - 18:00

ePoster Area

Cellular Therapies other than CARs

P027 **PROLONGED REPEATEDLY ADMINISTERED LOW DOSE DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE LEUKEMIA** 09:15 - 09:15

Speaker: Panagiotis Tsirigotis, GR

P028 **CD8⁺-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1** 09:15 - 09:15

Speaker: Mehmet Altan, US

P029 **CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY® TCR⁺ AND CD19 DEPLETION** 09:15 - 09:15

Speaker: Katalin Dobos, HU

P031 **COMPREHENSIVE ACTIVATION PROFILING OF TABELCELEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-** 09:15 - 09:15

SPECIFIC T-CELL IMMUNOTHERAPY

Speaker: Fiona Ruiz, US

P030	IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS	09:15 - 09:15
P035	BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K-NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML AND MDS (NK-REALM) <i>Speaker:</i> Sumithira Vasu, US	09:15 - 09:15
P034	NEW, LN₂-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF CELL THERAPIES <i>Speaker:</i> Julie Meneghel, GB	09:15 - 09:15
P032	DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Virginia Escamilla Gómez, ES	09:15 - 09:15
P033	DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION. ONE SINGLE CENTER EXPERIENCE <i>Speaker:</i> Melissa Karina Torres Ochando, ES	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Conditioning Regimens

P036	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE LIMIT? <i>Speaker:</i> Sara Fernández-Luis, ES	09:15 - 09:15
P037	THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE <i>Speaker:</i> Bartosz Malecki, PL	09:15 - 09:15
P038	CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN EARLY RELAPSED MULTIPLE MYELOMA PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Jaap van Doesum, NL	09:15 - 09:15
P039	PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL WITH TBI AND ETOPOSIDE CONDITIONING <i>Speaker:</i> Jane E Potter, GB	09:15 - 09:15
P040	ENHANCED IMMUNOSUPPRESSION IN T-CELL REplete HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH	09:15 - 09:15

FAVORABLE OUTCOMES

P041	LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Ioanna Sakellari, GR	09:15 - 09:15
P042	TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY <i>Speaker:</i> Raquel Olivas-Mazón, ES	09:15 - 09:15
P044	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED-RELATED SIBLING DONORS <i>Speaker:</i> Gabriella Storti, IT	09:15 - 09:15
P043	IMMUNE RECONSTITUTION AFTER SEQUENTIAL CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT DONOR TYPES <i>Speaker:</i> Alessia Fraccaroli, DE	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Data Management

P045	GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE MYELOMA <i>Speaker:</i> Ruth Paul, GB	09:15 - 09:15
------	--	---------------

Poster Sessions

09:15 - 18:00

ePoster Area

Experimental Transplantation

P048	INFLUENCE OF POLYMORPHISMS RELATED TO DRUG METABOLISM IN ALLOGENEIC BONE MARROW TRANSPLANTATION <i>Speaker:</i> Marta Santiago, ES	09:15 - 09:15
P049	REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION <i>Speaker:</i> Tahereh Rostami, IR	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Gene Therapy

P050	BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN FOR β-THALASSEMIA) GENE THERAPY TREATMENT OF A	09:15 - 09:15
------	--	---------------

GREEK PATIENT WITH TRANSFUSION-DEPENDENT α -THALASSEMIA (TDT)

Speaker: Evangelia Yannaki, GR

Poster Sessions

09:15 - 18:00

ePoster Area

Graft-versus-Host Disease – Clinical

- | | | |
|------|---|---------------|
| P051 | EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS
<i>Speaker:</i> Arun Alfred, GB | 09:15 - 09:15 |
| P056 | REDUCED GVHD WITH TRIPLE PTCY BASED GVHD PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS
<i>Speaker:</i> Elisabetta Metafuni, IT | 09:15 - 09:15 |
| P055 | PROLONGED SUPPRESSION OF BUTYRATE PRODUCING BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Elisabeth Meedt, DE | 09:15 - 09:15 |
| P052 | ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED PATIENTS AT DIFFERENT MATURATION STAGES
<i>Speaker:</i> Matthias Alexander Fante, DE | 09:15 - 09:15 |
| P057 | THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI-THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
<i>Speaker:</i> Osman Radhwi, CA | 09:15 - 09:15 |
| P060 | A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT
<i>Speaker:</i> John Mallee, US | 09:15 - 09:15 |
| P061 | CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE NIH 2014 CONSENSUS CRITERIA
<i>Speaker:</i> Koray Yalcin, TR | 09:15 - 09:15 |
| P058 | COMPARISON OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CR1
<i>Speaker:</i> Maximilian Christopeit, DE | 09:15 - 09:15 |

P059	TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS <i>Speaker:</i> Eugenio Galli, IT	09:15 - 09:15
P063	A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4) <i>Speaker:</i> Franco Locatelli, IT	09:15 - 09:15
P062	AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S EIGHT-YEAR EXPERIENCE <i>Speaker:</i> Antonio Grasso, IT	09:15 - 09:15
P064	IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE FROM A SINGLE CENTER <i>Speaker:</i> Panayotis Kaloyannidis, SA	09:15 - 09:15
P065	ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST DISEASE <i>Speaker:</i> Angelo Ostuni, IT	09:15 - 09:15
P066	RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE IN 36 PATIENTS <i>Speaker:</i> Maria Teresa Lupo Stanghellini, IT	09:15 - 09:15
P067	PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS HOST DISEASE PREVENTION IN PATIENTS RECEIVING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Henry Hu, US	09:15 - 09:15
P068	BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS <i>Speaker:</i> Xiaodong Mo, CN	09:15 - 09:15
P069	FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
P070	A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5) <i>Speaker:</i> Franco Locatelli, IT	09:15 - 09:15
P071	PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER	09:15 - 09:15

MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Speaker: Lars Klingen Gjørde, DK

P072 **SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES** 09:15 - 09:15

P073 **Elevated REG3 γ predicts refractory aGVHD in Patients Who Received Steroids- Ruxolitinib as the First Line Therapy** 09:15 - 09:15

Speaker: Liping Dou, CN

Poster Sessions

09:15 - 18:00

ePoster Area

Graft-versus-Host Disease – Preclinical and Animal Models

P074 **THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-MEDIATED TISSUE INJURY** 09:15 - 09:15

Speaker: Sascha Göttert, DE

P075 **ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED MICE** 09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Haematopoietic Stem Cells

P078 **RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF OUR HOSPITAL** 09:15 - 09:15

Speaker: Elena Paumard Rodríguez, ES

P076 **LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION** 09:15 - 09:15

Speaker: Katrin Koch, DE

P077 **KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION, REVISITED** 09:15 - 09:15

Speaker: Kazimierz Halaburda, PL

P079 **THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER ALLOGENEIC TRANSPLANTATION** 09:15 - 09:15

Speaker: Sabrina Giammarco, IT

P081 **OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES** 09:15 - 09:15

Speaker: Zohreh Nademi, GB

P080 **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7 ANTIGEN EXPRESSION** 09:15 - 09:15

Speaker: Danilo De Novellis, IT

P082	OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS: A SINGLE CENTER STUDY <i>Speaker:</i> Eshrak Al-Shaibani, CA	09:15 - 09:15
P084	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL <i>Speaker:</i> Simona Piemontese, IT	09:15 - 09:15
P083	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A SINGLE-INSTITUTION EXPERIENCE <i>Speaker:</i> Marta Hidalgo Soto, ES	09:15 - 09:15
P086	EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA <i>Speaker:</i> Ma Liangming, CN	09:15 - 09:15
P085	IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE POLYMORPHISMS ON THE OUTCOMES OF TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS <i>Speaker:</i> Anastasia Beynarovich, RU	09:15 - 09:15
P087	AUTOMATED DRY THAWING OF CRYOPRESERVED HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER <i>Speaker:</i> Julie Meneghel, GB	09:15 - 09:15
P091	UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA: AN EXPERIENCE FROM THE LARGEST CHILDREN'S HOSPITAL IN IRAN <i>Speaker:</i> Amir Ali Hamidieh, IR	09:15 - 09:15
P090	INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT IN PATIENTS OVER 65 YEARS OLD <i>Speaker:</i> Magdalena Corona de Lapuerta, ES	09:15 - 09:15
P089	LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN'S AND NON-HODGKIN'S LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN COLOMBIAN NORTHEAST <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
P092	ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF 195 CASES <i>Speaker:</i> Thierry Guillaume, FR	09:15 - 09:15
P097	DEFIBROTIDE AS TREATMENT FOR TRANSPLANT-ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC	09:15 - 09:15

PATIENTS: A SINGLE CENTER EXPERIENCE

Speaker: Danilo De Novellis, IT

P096	IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: REPORT FROM A SINGLE CENTER	09:15 - 09:15
	<i>Speaker:</i> Sabrina Giammarco, IT	
P095	IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HAPLO SCT) USING POST- TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE IN SUB-SAHARAN AFRICA?	09:15 - 09:15
	<i>Speaker:</i> Justin du Toit, ZA	
P099	IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA	09:15 - 09:15
	<i>Speaker:</i> Claudia Núñez-Torrón, ES	
P098	THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT THE ROYAL MARSDEN HOSPITAL	09:15 - 09:15
	<i>Speaker:</i> Sandra Easdale, GB	
P102	EBV COLITIS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA	09:15 - 09:15
	<i>Speaker:</i> Lucia Prezioso, IT	
P100	BURNOUT SYNDROME IN ONCOLOGY PRACTICE: EXPERIENCE OF A LARGE HSCT CENTER	09:15 - 09:15
	<i>Speaker:</i> Irina Artemeva, RU	
P103	MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)	09:15 - 09:15
	<i>Speaker:</i> Carolina Lilibeth Moreira-Ponce, MX	
P101	FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA POST HEMATOPOIETIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A TERTIARY REFERRAL CENTRE IN INDIA	09:15 - 09:15
	<i>Speaker:</i> Rumesh Chandar, IN	
P104	BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC STEM CELL TRANSPLANTATION	09:15 - 09:15
	<i>Speaker:</i> Katheryn Garzón-Velásquez, MX	
P106	EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NARRATIVE REVIEW	09:15 - 09:15
	<i>Speaker:</i> Claudia Lucía Sossa Melo, CO	
P105	STAFF EXPERIENCES AND LEARNING FROM WORKING ON A HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING COVID-19	09:15 - 09:15
	<i>Speaker:</i> Sarah Airdrie, GB	

Poster Sessions

09:15 - 18:00

ePoster Area

Haemoglobinopathy

- | | | |
|------|---|---------------|
| P107 | THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Mohammed Essa, SA | 09:15 - 09:15 |
| P108 | HOW TO FACILITATE DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMOGLOBINOPATHIES - THE PERSPECTIVES OF HEALTH CARE PROFESSIONALS
<i>Speaker:</i> Hilda Mekelenkamp, NL | 09:15 - 09:15 |
| P109 | ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE: A RETROSPECTIVE COHORT ANALYSIS
<i>Speaker:</i> Richelle Waldner, CA | 09:15 - 09:15 |
| P110 | DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY – SHARED OR NOT?
<i>Speaker:</i> Hilda Mekelenkamp, NL | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

Immunodeficiency Diseases and Macrophages

- | | | |
|------|--|---------------|
| P111 | CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Aishat Idarmacheva, RU | 09:15 - 09:15 |
| P112 | OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY
<i>Speaker:</i> Liam Reilly, GB | 09:15 - 09:15 |
| P113 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH CLERICUZIO SYNDROME (POIKILODERMA WITH NEUTROPENIA)
<i>Speaker:</i> Alexandra Burya, RU | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

Paediatric Issues

- | | | |
|------|--|---------------|
| P183 | POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA
<i>Speaker:</i> Andrey Kozlov, RU | 09:15 - 09:15 |
| P185 | RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN | 09:15 - 09:15 |

	PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING EXVIVO T-CELL-DEPLETION <i>Speaker:</i> Iván López Torija, ES	
P184	FREQUENCY AND CAUSES OF DEATH AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NON-MALIGNANT DISEASES <i>Speaker:</i> Koray Yalcin, TR	09:15 - 09:15
P186	SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Denise Elbæk, DK	09:15 - 09:15
P187	LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH NONMALIGNANT DISEASES: A SINGLE CENTER COHORT ANALYSIS <i>Speaker:</i> Joëll Esmée Bense, NL	09:15 - 09:15
P188	PROSPECTIVE MULTICENTER STUDY OF A REDUCED-TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE REGIMENS <i>Speaker:</i> Fanny Riolland, FR	09:15 - 09:15
P189	TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED DONOR IN PEDIATRIC PATIENTS <i>Speaker:</i> Luisa Sisinni, ES	09:15 - 09:15
P190	SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Charlotte Nazon, FR	09:15 - 09:15
P191	SAFETY AND PERFORMANCE OF CENTRAL VENOUS CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Sofia Martin-Consuegra, ES	09:15 - 09:15
P192	TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND – BLACKFAN ANEMIA <i>Speaker:</i> Svetlana Radygina, RU	09:15 - 09:15
P193	ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES <i>Speaker:</i> Maksymilian Deregowski, PL	09:15 - 09:15
P194	CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS <i>Speaker:</i> Taylor Fitch, US	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Non-infectious Late Effects, Quality of Life and Fertility

- | | | |
|------|---|---------------|
| P177 | IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS
<i>Speaker:</i> Magdalena Corona de Lapuerta, ES | 09:15 - 09:15 |
| P178 | OSTEONECROSIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-CENTRE STUDY OF INCIDENCE, RISK FACTORS, CHARACTERISTICS AND EVOLUTION
<i>Speaker:</i> Giulia Prunotto, IT | 09:15 - 09:15 |
| P179 | SECONDARY MALIGNANCIES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> João Gaião Santos, PT | 09:15 - 09:15 |
| P181 | ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE CHEMOTHERAPY
<i>Speaker:</i> Walter Javier Zambrano Marquez, ES | 09:15 - 09:15 |
| P180 | SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN
<i>Speaker:</i> Yulia Skvortsova, RU | 09:15 - 09:15 |
| P182 | AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – AMYOPATHIC DERMATOMYOSITIS, PRIMARY BILIARY CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA
<i>Speaker:</i> Pedro de Vasconcelos M, PT | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

New Drugs- and Cell-based Immune Therapies

- | | | |
|------|--|---------------|
| P160 | INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
<i>Speaker:</i> Vivek Sharma, US | 09:15 - 09:15 |
| P161 | CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS
<i>Speaker:</i> David Dingli, US | 09:15 - 09:15 |
| P162 | IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL CELLS AND FAVORS MICROVASCULAR THROMBOSIS
<i>Speaker:</i> Miriam Galbusera, IT | 09:15 - 09:15 |
| P165 | MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC SARCOMA | 09:15 - 09:15 |

	<i>Speaker:</i> Carla Martín-Cortázar, ES	
P163	POST-HEMATOPOIETIC STEM CELL TRANSPLANT MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING HUSSEIN CANCER CENTRE EXPERIENCE	09:15 - 09:15
P166	PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT (HCT) (STUDY DESIGN) <i>Speaker:</i> Anna Thorner, US	09:15 - 09:15
P168	CLINICAL PHARMACOLOGY AND POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721) <i>Speaker:</i> William Pullman, US	09:15 - 09:15
P167	WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES <i>Speaker:</i> David Dingli, US	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 18:00		ePoster Area
Myeloproliferative Neoplasm		
<i>Poster Sessions</i> 09:15 - 18:00		ePoster Area
Myelodysplastic Syndromes		
P156	THE ROLE OF AGE IN OUTCOMES OF BONE MARROW TRANSPLANTATION IN PATIENTS FROM THE LATIN AMERICAN REGISTRY <i>Speaker:</i> Fernando Barroso Duarte, BR	09:15 - 09:15
P157	PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE MORTALITY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Isla Johnson, US	09:15 - 09:15
P159	SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE OF THE PREVIOUS SITUATION	09:15 - 09:15
P158	SECONDARY AND TREATMENT-RELATED ACUTE MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION <i>Speaker:</i> Ioanna Sakellari, GR	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution

- | | | |
|------|---|---------------|
| P143 | EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH THYMOGLOBULIN: A CIBMTR ANALYSIS
<i>Speaker:</i> Nina Orfali, IE | 09:15 - 09:15 |
| P144 | PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT
<i>Speaker:</i> Nicolaus Kröger, DE | 09:15 - 09:15 |
| P145 | IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Amandine Pradier, CH | 09:15 - 09:15 |
| P146 | MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS COMPARABLE TO PREDICT AML RELAPSE?
<i>Speaker:</i> Valérie Dubois, FR | 09:15 - 09:15 |
| P148 | CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES OPEN A WINDOW FOR RELAPSE INTERVENTION?
<i>Speaker:</i> Jan Morf, GB | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

Nurses Posters – Adult

- | | | |
|------|---|---------------|
| NP01 | NURSES' TRAINING NEEDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE NURSES GROUP OF THE EBMT
<i>Speaker:</i> Michelle Kenyon, GB | 09:15 - 09:15 |
| NP02 | IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POVIDONE-IODINE MOUTHWASH UNDER DIRECT NURSING SUPERVISION
<i>Speaker:</i> Napassaya Khanthum, TH | 09:15 - 09:15 |
| NP03 | COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL THERAPY
<i>Speaker:</i> Mercedes Montoro-Lorite, ES | 09:15 - 09:15 |
| NP04 | CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE SYNDROME
<i>Speaker:</i> Naama Nevo, IL | 09:15 - 09:15 |
| NP05 | HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM-CELL TRANSPLANTATION: IMPROVING HOME-CARE STRATEGIES DURING SARS-COV-2 PANDEMIC | 09:15 - 09:15 |

	<i>Speaker:</i> Laura Villa Rodríguez, ES	
NP06	IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION <i>Speaker:</i> Sarah Henshaw, GB	09:15 - 09:15
NP07	AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING SARS-CoV-2 PANDEMIC	09:15 - 09:15
NP08	THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED METROPOLITAN TRANSPLANT PROGRAM <i>Speaker:</i> Antonio Bruno, IT	09:15 - 09:15
NP10	PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING WELL ESTABLISHED NURSING CARE STANDARDS <i>Speaker:</i> Isabel Salcedo, ES	09:15 - 09:15
NP11	A TALE OF 2 COLLECTIONS: CAR -T 'V' PBSC. OUR SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Caroline Jupp, GB	09:15 - 09:15
NP12	CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) NURSING IN LATIN AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY <i>Speaker:</i> Mariela Blanco, AR	09:15 - 09:15
NP13	MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO-ONCOLOGY MALIGNANCY AND THOSE UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION DURING THE COVID-19. HOW DO WE PROTECT THEM? <i>Speaker:</i> Anna Serrahima - Mackay, ES	09:15 - 09:15
NP14	PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Bakhtawar Altaf Hussain, PK	09:15 - 09:15
NP15	COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - THE REALITY <i>Speaker:</i> Lindsey Ashton, GB	09:15 - 09:15
NP16	TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED NURSE <i>Speaker:</i> Marijke Quaghebeur, BE	09:15 - 09:15
NP09	EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM <i>Speaker:</i> Mariela Blanco, AR	09:15 - 09:25

Poster Sessions
09:15 - 18:00

ePoster Area

Stem Cell Mobilization, Collection and Engineering

P206	INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON-INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE THE MOBILIZATION AND COLLECTION OF HSCS IN POOR MOBILIZERS AHEAD OF ASCT <i>Speaker:</i> Katharina Kriegsmann, DE	09:15 - 09:15
P207	TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES BETWEEN 2008 AND 2017 <i>Speaker:</i> James Dillon, IE	09:15 - 09:15
P208	THE IMPACT OF THE “NEW NORMAL” ON STEM CELL LABORATORY PRACTICES <i>Speaker:</i> Sanja Mazi?, HR	09:15 - 09:15
P210	AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR USAGE WITH GCSF ALONE FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA <i>Speaker:</i> Mohamed Elemery, CA	09:15 - 09:15
P209	PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND FEASIBLE; A SINGLE CENTER ANALYSIS <i>Speaker:</i> Moussab Damlaj, SA	09:15 - 09:15
P211	PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE <i>Speaker:</i> Nara Stepanyan, RU	09:15 - 09:15
P212	A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Joshua Richter, US	09:15 - 09:15
P213	PREDICTION OF THE MOBILIZATION SUCCESS FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES <i>Speaker:</i> Maria Eduarda Couto, PT	09:15 - 09:15
P214	DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR UTILIZATION DURING STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT? <i>Speaker:</i> Pilar Velarde López de Ayala, ES	09:15 - 09:15
P215	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Madeleine Powys, AU	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Statistics

- | | | |
|------|---|---------------|
| P201 | EVALUATION OF MACHINE LEARNING ALGORITHMS APPLICABILITY FOR GRAFT FAILURE PREDICTION
<i>Speaker:</i> Evgeny Bakin, RU | 09:15 - 09:15 |
| P202 | WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE
<i>Speaker:</i> Maria Escolar, US | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

Nurses Posters – Paediatric

- | | | |
|------|---|---------------|
| NP17 | NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Deepa Karmegam, IN | 09:15 - 09:15 |
| NP18 | NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS AFTER CAR-T INFUSION
<i>Speaker:</i> Giulia Del Giorno, IT | 09:15 - 09:15 |
| NP19 | THE WORK OF THE REHABILITATION DEPARTMENT WITH VOLUNTEERS DURING THE COVID-19 PANDEMIC
<i>Speaker:</i> Rashida Bikulova, RU | 09:15 - 09:15 |
| NP20 | EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC CATHETERIZATION AS A MEASURE OF NUTRITIONAL SUPPORT IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
<i>Speaker:</i> Eugenia Trigos Arjona, ES | 09:15 - 09:15 |
| NP21 | NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY. DESCRIPTION OF CLINICAL CASES
<i>Speaker:</i> Anton Silov, RU | 09:15 - 09:15 |
| NP22 | INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-CENTER EXPERIENCE
<i>Speaker:</i> Alba Fernandez-Arroyo Garcia, ES | 09:15 - 09:15 |
| NP23 | IMPLEMENTATION OF THE ADVANCED CELL THERAPY PROGRAM: &NBSP;EXPERIENCE AT LA PAZ UNIVERSITY HOSPITAL
<i>Speaker:</i> Alba Fernandez-Arroyo Garcia, ES | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

Nurses Posters – Research

NP24	ROLE OF NURSING IN THE CARE OF PATIENT'S SKIN WITH CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY <i>Speaker:</i> Jacqui Stringer, GB	09:15 - 09:15
NP25	INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT <i>Speaker:</i> Lubov Shepeleva, RU	09:15 - 09:15
NP26	THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING DEVELOPMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: FROM PRACTICE TO SCIENCE <i>Speaker:</i> Natalya Rotan, RU	09:15 - 09:15
NP27	LONG TERM SURVIVORS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD AND ADOLESCENCE IN A DEVELOPING COUNTRY: HOW ARE THEY NOW? <i>Speaker:</i> Priscila Oliveira da Silva, BR	09:15 - 09:15
NP28	EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS <i>Speaker:</i> Olga Prokofieva, RU	09:15 - 09:15
NP29	EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY DISEASES <i>Speaker:</i> Silvia Sangüesa Domínguez, ES	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 18:00 ePoster Area		ePoster Area
<i>Poster Sessions</i> 09:15 - 18:00 Pharmacology		ePoster Area
P195	PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE: INTERIM RESULTS FROM THE EQUATE STUDY <i>Speaker:</i> John Koreth, US	09:15 - 09:15
P196	EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE THERAPEUTIC DRUG MONITORING OF BUSULFAN <i>Speaker:</i> Bushra Salman, OM	09:15 - 09:15
P197	A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANTIN ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE PRECLINICAL MODELS OF AML <i>Speaker:</i> Leanne Lanieri, US	09:15 - 09:15

P199	PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Sara M. Zimmerman, US	09:15 - 09:15
P198	THE IMPACT OF LETERMIVIR PRESCRIBING ON THE RATE OF CYTOMEGALOVIRUS REACTIVATION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Siobhan Smith, GB	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 18:00		ePoster Area
Solid Tumours		
P200	HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-WORLD EXPERIENCE IN ARGENTINA <i>Speaker:</i> Adriana Vitriu, AR	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 18:00		ePoster Area
Multiple Myeloma		
P149	HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS ≥ 70 YEARS IS SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Udo Holtick, DE	09:15 - 09:15
P150	PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS <i>Speaker:</i> Meilan Chen, CN	09:15 - 09:15
P152	RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Speaker:</i> Jingli Gu, CN	09:15 - 09:15
P151	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION <i>Speaker:</i> Rita Sousa Gomes, PT	09:15 - 09:15
P153	CLINICAL IMPLICATIONS OF T CELL RECONSTITUTION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Carolina Afonso, PT	09:15 - 09:15
P155	INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Pilar Velarde López de Ayala, ES	09:15 - 09:15

Poster Sessions

09:15 - 18:00

ePoster Area

Stem Cell Donor

- | | | |
|------|--|---------------|
| P203 | HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A SINGLE-CENTER COMPARISON
<i>Speaker:</i> Alisa Lörsch, DE | 09:15 - 09:15 |
| P204 | CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS: SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND HAPLOIDENTICAL DONORS
<i>Speaker:</i> Claudie Roy, CA | 09:15 - 09:15 |
| P205 | HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE CENTER EXPERIENCE IN MEXICO
<i>Speaker:</i> Katheryn Garzón-Velásquez, MX | 09:15 - 09:15 |

Poster Sessions

09:15 - 18:00

ePoster Area

Non-infectious Early Complications

- | | | |
|------|--|---------------|
| P169 | POST HEMATOPOIETIC PROGENITORS TRANSPLANT LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR VIRUS (EBV): A CENTER'S EXPERIENCE
<i>Speaker:</i> Sara Garrido, ES | 09:15 - 09:15 |
| P171 | CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE | 09:15 - 09:15 |
| P170 | ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL ECOSYSTEM
<i>Speaker:</i> Daniele Zama, IT | 09:15 - 09:15 |
| P172 | HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL TRANSPLANTATION: A POSSIBLE ROLE FOR PROSTATIC HYPERPLASIA
<i>Speaker:</i> Eugenio Galli, IT | 09:15 - 09:15 |
| P173 | THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Carlota Mayor Bastida, ES | 09:15 - 09:15 |
| P175 | EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY SUGAR ABSORPTION TEST: INTERIM ANALYSIS OF THE | 09:15 - 09:15 |

SINGLE-CENTER PROSPECTIVE STUDY

Speaker: Grzegorz Basak, PL

P176	ANICTERIC PRESENTATION OF SEVERE HEPATIC VENOCCLUSIVE DISEASE (VOD) WITH MULTIORGAN DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT	09:15 - 09:15
	Speaker: Zofia Szmit, PL	

Poster Sessions

09:15 - 18:00

ePoster Area

Acute Leukaemia

P001	MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC INFLUENCE ON POST-TRANSPLANT OUTCOMES IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA	09:15 - 09:15
	Speaker: Rama Al Hamed, US	
P002	ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE REMISSION IN R/R B-ALL AFTER TREATMENT WITH MONOCLONAL ANTIBODIES	09:15 - 09:15
	Speaker: Inna Markova, RU	
P003	AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER ANALYSIS	09:15 - 09:15
	Speaker: Semra Aydin, IT	
P004	T-CELL-DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE CENTRE EXPERIENCE OF 90 PATIENTS	09:15 - 09:15
	Speaker: Alexandros Kanellopoulos, GB	
P005	POST-REMISSION TREATMENT PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) IN THE CONNECT[®] MDS/AML DISEASE REGISTRY	09:15 - 09:15
P006	ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF RECIPIENT AGE AND DONOR TYPE	09:15 - 09:15
	Speaker: Tatiana Tzenou, GR	
P007	GILTERITINIB MONOTHERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT PATIENTS	09:15 - 09:15
	Speaker: Sergey Bondarenko, RU	
P009	ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL)	09:15 - 09:15

	<i>Speaker:</i> Alan S. Wayne, US	
P008	VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA POST ALLOGENEIC STEM CELL TRANSPLANT <i>Speaker:</i> Sandra Easdale, GB	09:15 - 09:15
P010	LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA – FOCUS ON MORTALITY <i>Speaker:</i> Anna Lojko-Dankowska, PL	09:15 - 09:15
P011	SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Semra Aydin, IT	09:15 - 09:15
P012	BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE MONOCENTRIC REPORT <i>Speaker:</i> Elisabetta Metafuni, IT	09:15 - 09:15
P013	UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Sergey Bondarenko, RU	09:15 - 09:15
P014	SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A CENTER IN COLOMBIA <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 18:00		ePoster Area
Graft-versus-Host Disease – Clinical		
P051	EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS <i>Speaker:</i> Arun Alfred, GB	09:15 - 09:15
P056	REDUCED GVHD WITH TRIPLE PTCY BASED GVHD PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS <i>Speaker:</i> Elisabetta Metafuni, IT	09:15 - 09:15
P055	PROLONGED SUPPRESSION OF BUTYRATE PRODUCING BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Elisabeth Meedt, DE	09:15 - 09:15

P052	ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED PATIENTS AT DIFFERENT MATURATION STAGES <i>Speaker:</i> Matthias Alexander Fante, DE	09:15 - 09:15
P057	THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI-THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES <i>Speaker:</i> Osman Radhwi, CA	09:15 - 09:15
P060	A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> John Mallee, US	09:15 - 09:15
P061	CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE NIH 2014 CONSENSUS CRITERIA <i>Speaker:</i> Koray Yalcin, TR	09:15 - 09:15
P058	COMPARISON OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CR1 <i>Speaker:</i> Maximilian Christopeit, DE	09:15 - 09:15
P059	TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS <i>Speaker:</i> Eugenio Galli, IT	09:15 - 09:15
P063	A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4) <i>Speaker:</i> Franco Locatelli, IT	09:15 - 09:15
P062	AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S EIGHT-YEAR EXPERIENCE <i>Speaker:</i> Antonio Grasso, IT	09:15 - 09:15
P064	IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE FROM A SINGLE CENTER <i>Speaker:</i> Panayotis Kaloyannidis, SA	09:15 - 09:15
P065	ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST DISEASE <i>Speaker:</i> Angelo Ostuni, IT	09:15 - 09:15

P066	RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE IN 36 PATIENTS <i>Speaker:</i> Maria Teresa Lupo Stanghellini, IT	09:15 - 09:15
P067	PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS HOST DISEASE PREVENTION IN PATIENTS RECEIVING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Henry Hu, US	09:15 - 09:15
P068	BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS <i>Speaker:</i> Xiaodong Mo, CN	09:15 - 09:15
P069	FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
P070	A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5) <i>Speaker:</i> Franco Locatelli, IT	09:15 - 09:15
P071	PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Lars Klinge Gjærde, DK	09:15 - 09:15
P072	SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES	09:15 - 09:15
P073	Elevated REG3? predicts refractory aGVHD in Patients Who Received Steroids- Ruxolitinib as the First Line Therapy <i>Speaker:</i> Liping Dou, CN	09:15 - 09:15

Poster Sessions
09:15 - 18:00

ePoster Area

Lymphoma and Chronic Lymphocytic Leukemia

P134	RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER RETROSPECTIVE COHORT STUDY <i>Speaker:</i> Fernando Warley, AR	09:15 - 09:15
P133	18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW CNS LYMPHOMA IMAGING TOOL <i>Speaker:</i> Sandra Easdale, GB	09:15 - 09:15

P135	THE OUTCOMES OF ALLOGENEIC STEM CELLS TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED THERAPY: SINGLE CENTER EXPERIENCE <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
P137	STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN BLOOD AND MARROW TRANSPLANTATION REGISTRY <i>Speaker:</i> Yu-Hung Wang, TW	09:15 - 09:15
P136	NIVOLUMAB 40 MG THERAPY IN RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY <i>Speaker:</i> Liudmila Fedorova, RU	09:15 - 09:15
P138	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION EXPERIENCE <i>Speaker:</i> Joanna Romejko-Jarosinska, PL	09:15 - 09:15
P142	SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL LYMPHOMA WITH INTENSIFIED MYELOABLATIVE CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Yan-Li Zhao, CN	09:15 - 09:15
P140	POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R DIFFUSE LARGE B-CELL LYMPHOMA <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
P141	NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF CONSOLIDATIVE AUTOLOGOUS STEM CELL TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL HOSPITAL <i>Speaker:</i> Christopher Shwei Wen Tham, SG	09:15 - 09:15
P139	AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG TERM OUTCOMES <i>Speaker:</i> Sudhir Kumar, IN	09:15 - 09:15

Poster Sessions
09:15 - 18:00

ePoster Area

Infectious Complications

P118	COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION <i>Speaker:</i> Luisa Giaccone, IT	09:15 - 09:15
P119	INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING	09:15 - 09:15

	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE <i>Speaker:</i> Amir Ali Hamidieh, IR	
P120	EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW <i>Speaker:</i> Aurore Bergamasco, FR	09:15 - 09:15
P122	EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Aleksandr Siniaev, RU	09:15 - 09:15
P121	ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT BACTERIA <i>Speaker:</i> Filippo Maraz, IT	09:15 - 09:15
P123	CLINICAL AND MICROBIOLOGICAL IMPACT OF DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE <i>Speaker:</i> Anke Verlinden, BE	09:15 - 09:15
P124	IRON CHELATION WITH DEFERASIROX SUPPRESSES THE APPEARANCE OF LPI DURING CONDITIONING CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Sonja Essmann, DE	09:15 - 09:15
P125	SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN MEXICO <i>Speaker:</i> Brenda Lizeth Acosta-Maldonado, MX	09:15 - 09:15
P126	ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE CENTER RETROSPECTIVE STUDY <i>Speaker:</i> Mohammed Essa, SA	09:15 - 09:15
P128	TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT <i>Speaker:</i> Tahereh Rostami, IR	09:15 - 09:15
P127	HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC CYSTITIS: RETROSPECTIVE COHORT STUDY <i>Speaker:</i> Nikola Pantic, RS	09:15 - 09:15
P132	CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Milena Todorovic Balint, RS	09:15 - 09:15

P129 **PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL** 09:15 - 09:15
Speaker: Fernando Barroso Duarte, BR

P131 **SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION** 09:15 - 09:15
Speaker: Maurizio Caniglia, IT

P130 **CLINICAL CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT PATIENTS: A MONOCENTRIC 5 YEARS SURVEY** 09:15 - 09:15
Speaker: Gabriele Facchin, IT

Poster Sessions
 09:15 - 18:00

ePoster Area

Inborn Errors

P114 **ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH TREOSULFAN-BASED CONDITIONING** 09:15 - 09:15
Speaker: Matthias Bleeke, DE

P115 **LONG-TERM NEURODEVELOPMENTAL, NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE METACHROMATIC LEUKODYSTROPHY** 09:15 - 09:15
Speaker: Maria Escolar, US

P116 **OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING PARTY** 09:15 - 09:15
Speaker: Su Han Lum, GB

Poster Sessions
 09:15 - 18:00

ePoster Area

Experimental Stem Cell Transplantation

P046 **SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL MODULATION IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS ACUTE LEUKAEMIA** 09:15 - 09:15
Speaker: Maryam Barkhordar, IR

P047 **DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE** 09:15 - 09:15
Speaker: Elisabetta Metafuni, IT

Poster Sessions
 09:15 - 18:00

ePoster Area

CAR-based Cellular Therapy – Clinical

P016	HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Thomas Martin, US	09:15 - 09:15
P017	MANUFACTURING COMMERCIAL AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR RETROSPECTIVE ANALYSIS <i>Speaker:</i> Didier Hallard, NL	09:15 - 09:15
P015	RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5 <i>Speaker:</i> Julio C. Chavez, US	09:15 - 09:15
P019	COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY FOLLOWING BRUTON TYROSINE KINASE INHIBITOR TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ENGLAND <i>Speaker:</i> Martin Brown, GB	09:15 - 09:15
P018	EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL THERAPY IN THE REAL WORLD SETTING <i>Speaker:</i> Silvia Monsalvo, ES	09:15 - 09:15
P020	PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Adam D Cohen, US	09:15 - 09:15
P021	CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA <i>Speaker:</i> Pere Barba, ES	09:15 - 09:15
P022	CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR-DERIVED CD19 CAR-T CELLS MANUFACTURED FROM MEMORY T CELL (CD45RA-DEPLETED) FRACTION <i>Speaker:</i> Larisa Shelikhova, RU	09:15 - 09:15
P024	ICU RESOURCE UTILIZATION IN PEDIATRIC AND ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T THERAPY <i>Speaker:</i> Drishti Ragoonanan, US	09:15 - 09:15
P023	HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED PROLONGED PANCYTOPENIA USING AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A LYMPHOMA PATIENT <i>Speaker:</i> Udo Holtick, DE	09:15 - 09:15
P025	ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS	09:15 - 09:15

WITH RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)

Speaker: Saad J. Kenderian, US

Poster Sessions

09:15 - 18:00

ePoster Area

CAR-based Cellular Therapy – Preclinical

P026

NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY

09:15 - 09:15

Speaker: Tobias Bexte, DE

Psy Day

09:35 - 10:30

Auditorium 6

Psy1 - Workshop 1: Survivorship Program

Chair: Alexandra Carpentier, ES

Chair: Frank Schulz-Kindermann, DE

Psy1-1

Introduction

09:35 - 09:41

Speaker: Anna Barata, US

Psy1-2

Cognitive outcomes on CAR T-cell therapy recipients

09:41 - 09:56

Speaker: Anna Barata, US

Psy1-3

Quality of life in childhood cancer survivors and their families after end of acute treatment

09:56 - 10:14

Speaker: Corinna Bergelt, DE

Psy1-4

Q&A

10:14 - 10:30

Breaks

10:30 - 11:00

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Wellness session

10:30 - 10:45

Auditorium 1

Meditation Session

Plenary Session

11:00 - 12:15

Auditorium 1

P1 - Landscape for CLL management in 2021

Chair: Peter Dreger, DE

Chair: José García-Marco, ES

P1-1

Dissecting CLL at a single-cell level - Implications for therapy and outcome

11:00 - 11:20

Speaker: Catherine Wu, US

P1-2

The broadening landscape of targets and therapeutic options for CLL

11:20 - 11:40

Speaker: Michael Hallek, DE

P1-3

HSCT and cellular therapy for CLL in 2021

11:40 - 12:00

	<i>Speaker:</i> John Gribben, GB	
P1-4	Q&A	12:00 - 12:15
<i>Educational</i>		
11:00 - 12:15		Auditorium 2
E02 - Plasma cell dyscrasias		
<i>Chair:</i> Ramón García Sanz, ES		
<i>Chair:</i> Meral Beksac, TR		
E2-1	Autologous HSCT in patients with light chain amyloidosis <i>Speaker:</i> Stefan Schönland, DE	11:00 - 11:20
E2-2	Novel immunotherapies in Multiple Myeloma: Bispecific antibodies and Anti-body Drug <i>Speaker:</i> Hermann Einsele, DE	11:20 - 11:40
E2-3	CAR-T cells in patients with multiple myeloma <i>Speaker:</i> Nikhil Munshi, US	11:40 - 12:00
E2-4	Q&A	12:00 - 12:15
<i>Nurses Group</i>		
11:00 - 12:15		Auditorium 3
NG02 - How do I... Understand blood counts?		
<i>Chair:</i> Julia Ruiz Pato, ES		
<i>Chair:</i> Almudena Pérez, ES		
NG02-1	Liver function test <i>Speaker:</i> Ignacio Gómez-Centurión, ES	11:00 - 11:15
NG02-2	Renal function test <i>Speaker:</i> Iván López Torija, ES	11:15 - 11:30
NG02-3	Full blood counts <i>Speaker:</i> Maria Esther Martínez Muñoz, ES	11:30 - 11:45
NG02-4	Cross matching <i>Speaker:</i> Josune Zubicaray Salegui, ES	11:45 - 12:00
NG02-5	Q&A	12:00 - 12:15
<i>Transplant and Search Coordinators Day</i>		
11:00 - 12:15		Auditorium 5
TSCD2 - Transplant and Search Coordinators Day: Cold cases - Stem cells to go?		
<i>Chair:</i> Salmah Ahmed, GB		
<i>Chair:</i> Anna Sureda, ES		
TSCD2-1	Preemptive cryopreservation of stem cells - DKMS perspective <i>Speaker:</i> Deborah Buk, DE	11:00 - 11:20
TSCD2-2	Preemptive cryopreservation of stem cells - NMDP perspective <i>Speaker:</i> Steven Devine, US	11:20 - 11:40
TSCD2-3	The use of banked products - Clinical perspective	11:40 - 12:00

	<i>Speaker:</i> Annoek Broers, NL	
TSCD2-4	Q&A	12:00 - 12:15
<i>Psy Day</i>		
11:00 - 12:15		Auditorium 6
Psy2 - Workshops 2: Donors, the transplant team and COVID-19		
<i>Chair:</i> Philip Alexander, GB		
Psy2-1	Family donors, who cares?	11:00 - 11:20
	<i>Speaker:</i> Suzanna van Walraven, NL	
Psy2-2	Supporting HCT care team: end of life issues	11:20 - 11:40
	<i>Speaker:</i> Alice Polomeni, FR	
Psy2-3	The psychological impact and management of patients, carers and staff during the COVID-19 pandemic: Lessons learnt	11:40 - 12:00
	<i>Speaker:</i> Troy Chase, GB	
Psy2-4	Q&A	12:00 - 12:15
<i>Cell therapy</i>		
11:15 - 12:15		Auditorium 4
CTD2 - Cell Therapy Day: Apheresis		
<i>Chair:</i> Halvard Bönig, DE		
<i>Chair:</i> Etienne Baudoux, FR		
CTD2-1	Apheresis in low weight children	11:15 - 11:32
	<i>Speaker:</i> Christian Chabannon, FR	
CTD2-2	Apheresis collections for hematopoietic cellular therapy manufacturing: Not all are created equal	11:32 - 11:54
	<i>Speaker:</i> Miquel Lozano, ES	
CTD2-3	Q&A	11:54 - 12:15
<i>Breaks</i>		
12:15 - 13:00		Auditorium 1
Lunch Break, Poster Viewing, Visit Exhibition		
<i>Industry Symposium</i>		
13:00 - 14:00		Auditorium 1
IS23 - CAR-T Cell Therapy in the Current and Emerging Treatment Landscape - Novartis Industry Symposium		
<i>Chair:</i> Ulrich Jäger, AT		
IS23-1	Introductions and Opening Remarks	13:00 - 13:03
	<i>Speaker:</i> Ulrich Jäger, AT	
IS23-2	Lessons Learned in CAR-T Cell Therapy for DLBCL: Navigating Between Clinical Trials and the Real World	13:03 - 13:23
	<i>Speaker:</i> Ulrich Jäger, AT	
	<i>Speaker:</i> Amit Patel, GB	

IS23-3	A Clinician's Guide to Treatment Sequence and Patient Referral for CAR-T Cell Therapy in DLBCL <i>Speaker:</i> Catherine Thieblemont, FR	13:23 - 13:33
IS23-4	Leading into New Landscapes: What's Next for the Treatment of r/r FL and 2nd-Line DLBCL <i>Speaker:</i> Martin Dreyling, DE	13:33 - 13:43
IS23-5	Live Q&A and Closing Remarks	13:43 - 14:00

Industry Symposium
13:00 - 14:00

Auditorium 2

IS24 - Current Developments in Allogeneic Haematopoietic Stem Cell Transplantation: Recent data on treosulfan - Medac Industry Symposium

Chair: Arnon Nagler, IL
Chair: Franco Locatelli, IT

IS24-1	Welcome and Introduction <i>Speaker:</i> Arnon Nagler, IL	13:00 - 13:05
IS24-2	Experience in Haploidentical Stem Cell Transplantation Using Trecondi® <i>Speaker:</i> Fabio Ciceri, IT	13:05 - 13:20
IS24-3	Trecondi® for Reduced Toxicity Conditioning in Malignant Neoplastic Diseases <i>Speaker:</i> Friedrich Stölzel, DE	13:20 - 13:35
IS24-4	Trecondi® – The Product of Choice for Myeloablative Conditioning in Non-Malignant Diseases <i>Speaker:</i> Selim Corbacioglu, DE	13:35 - 13:50
IS24-5	Wrap-Up <i>Speaker:</i> Franco Locatelli, IT	13:50 - 13:55
IS24-6	Q&A	13:55 - 14:00

Industry Symposium
13:00 - 14:00

Auditorium 3

IS25 - Nurse Symposium: Therakos ECP Immunomodulation – Getting the most out of your service - Therakos-Mallinckrodt Industry Symposium

Chair: Michelle Kenyon, GB

IS25-1	Introduction <i>Speaker:</i> Michelle Kenyon, GB	13:00 - 13:05
IS25-2	Overcoming the challenges of ECP service delivery 2020 <i>Speaker:</i> James Griffin, GB	13:05 - 13:20
IS25-3	The Patient pathway <i>Speaker:</i> John Murray, GB	13:20 - 13:35
IS25-4	2020 challenges – an Operator's perspective <i>Speaker:</i> Alba Pons Cornado, NO	13:35 - 13:50

IS25-5	Q&A session	13:50 - 14:00
<hr/>		
<i>Statistics</i>		
13:00 - 13:45		Auditorium 4
Stat1 - Statistics Workshop		
<i>Chair:</i> Hein Putter, NL		
Stat1-1	Different method to analyse time-dependent covariates: The example of GVL	13:00 - 13:45
	<i>Speaker:</i> Avichai Shimoni, IL	
	<i>Speaker:</i> Ariane Boumendil, FR	
<hr/>		
<i>Transplant and Search Coordinators Day</i>		
13:00 - 14:00		Auditorium 5
TSCD3 - Transplant and Search Coordinators Day: Donor Attrition and Backup Strategies		
<i>Chair:</i> Annette Rasche, DE		
<i>Chair:</i> Christian Chabannon, FR		
TSCD3-1	Ethics of donation and donor attrition at the search stage	13:00 - 13:15
	<i>Speaker:</i> Bernice Elger, CH	
TSCD3-2	***URGENT: DONOR CANCELLATION***	13:15 - 13:30
	<i>Speaker:</i> Juliana Villa, ES	
TSCD3-3	Back-up strategy along graft request	13:30 - 13:45
	<i>Speaker:</i> Irina Evseeva, GB	
TSCD3-4	Q&A	13:45 - 14:00
<hr/>		
<i>Psy Day</i>		
13:00 - 14:00		Auditorium 6
Psy3 - How do I		
<i>Chair:</i> Elena Valero, ES		
<i>Chair:</i> Alice Polomeni, FR		
Psy3-1	How do I... screen patients along the HCT continuum	13:00 - 13:15
	<i>Speaker:</i> Alex King, GB	
Psy3-2	How do I... address the psycho-oncologists well-being	13:15 - 13:30
	<i>Speaker:</i> Frank Schulz-Kindermann, DE	
Psy3-3	How do I... conduct e-health studies: Integrating educational and psychosocial aspects	13:30 - 13:45
	<i>Speaker:</i> Christian Ochoa, ES	
Psy3-4	Q&A	13:45 - 14:00
<hr/>		
<i>Industry Symposium</i>		
13:00 - 14:00		MTE rooms
IS27 - Exploring the latest data on severe hepatic VOD and current challenges in HCT* - Jazz		
Pharmaceuticals Industry Meet the Expert Lunch - Room MTE2		
<i>*This session is intended for physicians only</i>		
<i>Chair:</i> Tony Padliuca, GB		

IS27-1	Welcome and introduction <i>Speaker:</i> Tony Pagliuca, GB	13:00 - 13:01
IS27-2	Data update: severe hepatic VOD <i>Speaker:</i> Tony Pagliuca, GB	13:01 - 13:14
IS27-3	Discussion: current challenges in hepatic VOD and HCT	13:14 - 13:59
IS27-4	Summary and close <i>Speaker:</i> Tony Pagliuca, GB	13:59 - 14:00

Industry Symposium

13:00 - 13:45

MTE rooms

IS29 - Gene therapy for hemoglobinopathies* - Bluebird Bio Industry Meet the Expert Lunch - Room MTE4

*This session is only for HCP

Chair: Franco Locatelli, IT

Industry Symposium

13:00 - 14:00

MTE rooms

IS26 - Personalized Approach for Managing CMV Reactivation in HSCT Patients: Interactive patient case presentation - MSD Industry Meet the Expert Lunch 1 - Room MTE1

Chair: Per Ljungman, SE

Industry Symposium

13:00 - 14:00

MTE rooms

IS30 - Leukemia - 2nd ALLO SCT - Riemser Meet the Expert Lunch - Room MTE5

Chair: Jürgen Finke, DE

Industry Symposium

13:00 - 14:00

MTE rooms

Industry Meet the Expert lunch sessions

Breaks

14:00 - 14:30

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

General

14:30 - 16:00

Auditorium 1

GS2 - Presidential Symposium

GS2-1	Van Bekkum Award - Introduction <i>Speaker:</i> Nicolaus Kröger, DE	14:30 - 14:33
GS2-2	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN AFTER RIC REGIMEN ALLO-HCT: FIRST ANALYSIS OF A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL IN RECIPIENTS OF 10/10 MATCHED DONORS <i>Speaker:</i> Eolia Brissot, FR	14:33 - 14:48
GS2-3	Basic Science Award - Introduction	14:48 - 14:51

	<i>Speaker:</i> Rafael Duarte, ES	
GS2-4	HOST INTESTINAL TISSUE RESIDENT MACROPHAGES PROTECT AGAINST MURINE INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Duc-Dung Le, DE	14:51 - 15:06
GS2-5	MARIBAVIR VERSUS INVESTIGATOR-ASSIGNED THERAPY (IAT) FOR THE TREATMENT OF TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT (R/R) CYTOMEGALOVIRUS INFECTION: EFFICACY DATA FROM A RANDOMIZED PHASE 3 OPEN-LABEL STUDY <i>Speaker:</i> Rafael Duarte, ES	15:06 - 15:15
GS2-6	CALCINEURIN INHIBITOR-FREE GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN HEMATOPOIETIC CELL TRANSPLANTATION (HCT) WITH MYELOABLATIVE CONDITIONING REGIMENS (MAC) AND HLA-MATCHED DONORS: RESULTS OF THE BMT CTN 1301 <i>Speaker:</i> Leo Luznik, US	15:15 - 15:24
GS2-7	RESULTS OF A PHASE III RANDOMIZED, MULTICENTER STUDY COMPARING OMIIDUBICEL WITH STANDARD UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES FOLLOWING MYELOABLATION <i>Speaker:</i> Guillermo F. Sanz, ES	15:24 - 15:33
GS2-8	ELIVALDOGENE AUTOTEMCEL (ELI-CEL; LENTI-D) GENE THERAPY FOR CEREBRAL ADRENOLEUKODYSTROPHY: UPDATED RESULTS FROM THE PHASE 2/3 STUDY AND SAFETY OUTCOMES REPORT FROM THE PHASE 3 STUDY <i>Speaker:</i> Jörn-Sven Köhl, DE	15:33 - 15:42
GS2-9	A PROGNOSTIC SCORE INCLUDING MUTATION PROFILE AND CLINICAL FEATURES FOR CMML UNDERGOING STEM CELL TRANSPLANTATION <i>Speaker:</i> Nico Gagelmann, DE	15:42 - 15:51
GS2-10	IMMUNE ESCAPE DRIVEN BY SOMATIC MUTATIONS IN CLASS I/II HLA ALLELES IN AML RELAPSING AFTER ALLOGENEIC HSCT: A PIECE OF THE PUZZLE <i>Speaker:</i> Simona Pagliuca, US	15:51 - 16:00
<i>Nurses Group</i> 14:30 - 16:00		Auditorium 3
NG03 - Relapse management		
<i>Chair:</i> Marijke Quaghebeur, BE		
<i>Chair:</i> Carina Paixao, PT		
NG03-1	Decision-making: Ethical and multidisciplinary team issues <i>Speaker:</i> Hilda Mekelenkamp, NL	14:30 - 14:51
NG03-2	Treatment options after relapse in lymphoma <i>Speaker:</i> Daan Dierickx, BE	14:51 - 15:10

NG03-3	Psychological aspects <i>Speaker:</i> Laura Díaz Sayas, ES	15:10 - 15:30
NG03-4	Q&A	15:30 - 16:00

Cell therapy
14:30 - 16:00

Auditorium 4

CTD3 - Cell Therapy Day: How to manage cell collection and processing during COVID 19

Chair: Per Ljungman, SE

Chair: Annalisa Ruggeri, ES

CTD3-1	Should we have a backup donor always? <i>Speaker:</i> Catherine Faucher, FR	14:30 - 14:50
CTD3-2	Cryopreservation in case of unrelated donor <i>Speaker:</i> Jesus Fernandez, ES	14:50 - 15:10
CTD3-3	Cryopreservation in case of related donor <i>Speaker:</i> Boris Calmels, FR	15:10 - 15:25
CTD3-4	Role of Sars-Cov2 testing for donors in the workup <i>Speaker:</i> Rafael de la Cámara, ES	15:25 - 15:40
CTD3-5	Q&A	15:40 - 16:00

Transplant and Search Coordinators Day
14:30 - 16:00

Auditorium 5

TSCD4 - Transplant and Search Coordinators Day: Family Donations

Chair: Nina Worel, AT

Chair: Suzanna van Walraven, NL

TSCD4-1	Children as donors – Psychological aspects <i>Speaker:</i> Galen Switzer, US	14:30 - 14:50
TSCD4-2	International Family Donation – How Registries can help <i>Speaker:</i> Paul Johnson, GB	14:50 - 15:10
TSCD4-3	Follow up on related donors – the Swiss solution <i>Speaker:</i> Grazia Nicoloso, CH	15:10 - 15:30
TSCD4-4	Q&A	15:30 - 15:45

Psy Day
14:30 - 15:10

Auditorium 6

Psy4 - Abstract Session

Psy4-1	A CROSS-SECTIONAL STUDY OF THE PSYCHOSOCIAL ISSUES EXPERIENCED BY PATIENTS WITH LYMPHOMA TREATED WITH STEM CELL TRANSPLANT <i>Speaker:</i> Natalie Dren, CA	14:30 - 14:40
Psy4-2	THE EBMT PSY DAY HAS INSPIRED THE DEVELOPMENT OF A UK PSY DAY <i>Speaker:</i> Henrietta Saunders, GB	14:40 - 14:55

Psy4-3	PATIENT-CAREGIVER ADAPTATION TO HCT – THE ROLE OF THE EFFICACY BELIEFS AND RECEIVED SUPPORT <i>Speaker:</i> Malgorzata Sobczyk-Kruszelnicka, PL	14:55 - 15:05
--------	---	---------------

Psy4-4	Conclusions and remarks <i>Speaker:</i> Anna Barata, US	15:05 - 15:10
--------	---	---------------

Breaks

16:00 - 16:30

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Special Session

16:30 - 18:00

Auditorium 1

SS02 - COVID 1: Immunotherapy in COVID-19: a year's worth of experience

Chair: Christian Chabannon, FR

Chair: Malgorzata Mikulska, IT

SS2-1	Humoral immunotherapy with convalescent plasma <i>Speaker:</i> Liise-Anne Pirofski, US	16:30 - 16:48
-------	--	---------------

SS2-2	Adoptive cellular therapy with SARS-CoV-2 memory T cells <i>Speaker:</i> Antonio Pérez-Martínez, ES	16:48 - 17:06
-------	---	---------------

SS2-3	Immunomodulatory therapy with MSC <i>Speaker:</i> Rafael Duarte, ES	17:06 - 17:24
-------	---	---------------

SS2-4	SARS-CoV-2 Vaccination <i>Speaker:</i> Steve Pergam, US	17:24 - 17:42
-------	---	---------------

SS2-5	Q&A	17:42 - 18:00
-------	----------------	---------------

Joint Session

16:30 - 17:30

Auditorium 2

JS01 - Joint session KSBMT: Role of ATG in MUD and HLA identical sibling transplantation: Korean and European experience

Chair: Nicolaus Kröger, DE

Chair: Hoon Kook, KR

JS1-1	European Experience and recommendation <i>Speaker:</i> Francesca Bonifazi, IT	16:30 - 16:50
-------	---	---------------

JS1-2	Korean Experience and recommendation: Role of ATG in HLA-identical sibling transplantation <i>Speaker:</i> Byung-Sik Cho, KR	16:50 - 17:10
-------	--	---------------

JS1-3	Q&A	17:10 - 17:30
-------	----------------	---------------

How do I ... ?

16:30 - 17:45

Auditorium 3

HDI2 - How Do I... manage the evolving role of the haematology nurse – lifelong learning with new horizons? - Nurse Session - Supported through an unrestricted educational grant by Janssen

Chair: Michelle Kenyon, GB

HDI2-1	Introduction	16:30 - 16:35
--------	---------------------	---------------

	<i>Speaker:</i> Michelle Kenyon, GB	
HDI2-2	The Role of the Clinical Nurse Specialist <i>Speaker:</i> Emma Whitham, GB	16:35 - 16:50
HDI2-3	A typical day as an Advanced Nurse Practitioner in the out-patient clinic <i>Speaker:</i> Theo Nering Bögel, NL	16:50 - 17:05
HDI2-4	Educating with new therapies <i>Speaker:</i> Maaïke de Ruijter, NL	17:05 - 17:20
HDI2-5	Q&A and session close	17:20 - 17:45

Joint Session

16:30 - 18:00

Auditorium 5

JS02 - Joint session ASTCT/CIBMTR/APBMT: Transplantation and Cell Therapy During Pandemics

Chair: Nicolaus Kröger, DE

Chair: Stella Davies, US

Chair: Marcie Riches, US

Chair: Alok Srivastav, IN

JS2-1	US Experience: Pandemics and Transplantation/Cell therapy <i>Speaker:</i> Alpana Waghmare, US	16:30 - 16:48
JS2-2	The CIBMTR COVID Experience: Challenges for research and how COVID has changed transplant practice <i>Speaker:</i> Marcie Riches, US	16:48 - 17:06
JS2-3	The IDWP-EBMT COVID 19 Experience <i>Speaker:</i> Rafael de la Cámara, ES	17:06 - 17:24
JS2-4	Asian-Pacific Experience: Allo-HSCT and CAR-T cell treatment during COVID 19 pandemic <i>Speaker:</i> Yongxian Hu, CN	17:24 - 17:42
	Q&A	17:42 - 18:00

Special Session

16:30 - 18:00

Auditorium 6

SS03 - Global Committee Session: The present place of CAR T-cells in the context of stem cell transplantation throughout the world

Chair: Norbert-Claude Gorin, FR

SS3-1	Introduction and welcome <i>Speaker:</i> Norbert-Claude Gorin, FR	16:30 - 16:32
SS3-2	CAR T-cells and autologous stem cell transplantation: A chinese vision <i>Speaker:</i> He Huang, CN	16:32 - 16:46
SS3-3	CAR T cells and allogeneic stem cell transplantation: a vision from Israel <i>Speaker:</i> Arnon Nagler, IL	16:46 - 17:00

SS3-4	CAR T-cells and stem cell transplantation: A japanese vision <i>Speaker:</i> Shinichiro Okamoto, JP	17:00 - 17:14
SS3-5	A new target: CAR T-cells anti IL1 RAP for the treatment of AML? <i>Speaker:</i> Christophe Ferrand, FR	17:14 - 17:28
SS3-6	CAR T-cells and stem cell transplantation in Latin America <i>Speaker:</i> Renato Luis Guerino Cunha, BR	17:28 - 17:42
SS3-7	Summing up and conclusion	17:42 - 17:44
SS3-8	Q&A	17:44 - 18:00

Cell therapy
16:40 - 18:00

Auditorium 4

CTD4 - Cell Therapy Day: Point of care manufacturing for Immune Effector Cells based medicinal products

Chair: Ulrike Köhl, DE

Chair: Stephan Mielke, SE

CTD4-1	Donor derived CD19 CAR-T cell therapy of relapsed B-ALL post-allotransplant <i>Speaker:</i> Marcelo Pasquini, US	16:40 - 17:02
CTD4-2	TGFb-resistant NK cells for Cancer <i>Speaker:</i> Catherine Bollard, US	17:02 - 17:20
CTD4-3	Immunotherapies in Haplo HCT with PTCy <i>Speaker:</i> Nicole Santoro, IT	17:20 - 17:35
CTD4-4	Q&A	17:35 - 18:00

Meet the Expert
18:00 - 19:00

MTE rooms

Meet the Expert sessions

MTE-1	Allogeneic CAR T cells: Progress and challenges - Room MTE1 <i>Speaker:</i> Reuben Benjamin, GB	18:00 - 18:00
MTE-2	Current role of HSCT in Acute Promyelocytic Leukemia - Room MTE2 <i>Speaker:</i> Pau Montesinos, ES	18:00 - 18:00
MTE-3	Improving results of HSCT in adult ALL - Room MTE3 <i>Speaker:</i> Josep M. Ribera, ES	18:00 - 18:00
MTE-4	How to diagnose and manage TA-TMA in 2021 - Room MTE4 <i>Speaker:</i> Vincent Ho, US	18:00 - 18:00
MTE-5	The role of allogeneic HSCT in CLL in 2021 - Room MTE5 <i>Speaker:</i> Peter Dreger, DE	18:00 - 18:00

Abstract Awards

18:10 - 19:10

Auditorium 2

AA1 - EBMT Talks: Live with best abstracts

Chair: Nicolaus Kröger, DE

Chair: Rafael Duarte, ES

**VAN BEKKUM AWARD - POST-TRANSPLANTATION
CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN
AFTER RIC REGIMEN ALLO-HCT: FIRST ANALYSIS OF A
PROSPECTIVE RANDOMIZED MULTICENTER TRIAL IN
RECIPIENTS OF 10/10 MATCHED DONORS**

18:10 - 18:10

Speaker: Eolia Brissot, FR

**JON J. VAN ROOD AWARD - METABOLIC REPROGRAMMING
OF DONOR T CELLS ENHANCES GRAFT-VERSUS-LEUKEMIA
EFFECTS IN MICE AND HUMANS**

18:10 - 18:10

[Read Abstract](#)

Speaker: Franziska Uhl, DE

**BASIC SCIENCE AWARD - HOST INTESTINAL TISSUE
RESIDENT MACROPHAGES PROTECT AGAINST MURINE
INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE**

18:10 - 18:10

Speaker: Duc-Dung Le, DE

**JIAN JIAN LUAN AWARD - STANDARD-OF-CARE CAR-T CELL
THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD
DATA GERMANY**

18:10 - 18:10

Speaker: Wolfgang Andreas Bethge, DE

**PRESIDENTIAL ABSTRACT - MARIBAVIR VERSUS
INVESTIGATOR-ASSIGNED THERAPY (IAT) FOR THE
TREATMENT OF TRANSPLANT RECIPIENTS WITH
REFRACTORY/RESISTANT (R/R) CYTOMEGALOVIRUS
INFECTION: EFFICACY DATA FROM A RANDOMIZED PHASE 3
OPEN-LABEL STUDY**

18:10 - 18:10

Speaker: Rafael Duarte, ES

**PRESIDENTIAL ABSTRACT - RESULTS OF A PHASE III
RANDOMIZED, MULTICENTER STUDY COMPARING
OMIDUBICEL WITH STANDARD UMBILICAL CORD BLOOD
TRANSPLANTATION (UCBT) IN PATIENTS WITH HIGH-RISK
HEMATOLOGIC MALIGNANCIES FOLLOWING
MYELOABLATION**

18:10 - 18:10

Speaker: Guillermo F. Sanz, ES

**PRESIDENTIAL ABSTRACT - ELIVALDOGENE AUTOTEMCEL
(ELI-CEL; LENTI-D) GENE THERAPY FOR CEREBRAL
ADRENOLEUKODYSTROPHY: UPDATED RESULTS FROM THE
PHASE 2/3 STUDY AND SAFETY OUTCOMES REPORT FROM
THE PHASE 3 STUDY**

18:10 - 18:10

Speaker: Jörn-Sven Köhl, DE

**PRESIDENTIAL ABSTRACT - A PROGNOSTIC SCORE
INCLUDING MUTATION PROFILE AND CLINICAL FEATURES
FOR CMML UNDERGOING STEM CELL TRANSPLANTATION**

18:10 - 18:10

Speaker: Nico Gagelmann, DE

**PRESIDENTIAL ABSTRACT - IMMUNE ESCAPE DRIVEN BY
SOMATIC MUTATIONS IN CLASS I/ II HLA ALLELES IN AML
RELAPSING AFTER ALLOGENEIC HSCT: A PIECE OF THE
PUZZLE**

18:10 - 18:10

Speaker: Simona Pagliuca, US

Tuesday, 16. March 2021

Quality Management

08:00 - 09:00

MTE rooms

QM MTE - Quality Management Meet the Expert sessions (pre-registration required)

QM MTE-1	Risk & Change Management - Room MTE1 <i>Speaker:</i> Olga López Villar, ES <i>Speaker:</i> Dieter Klarmann, DE	-
QM MTE-2	Audits & Document Development and Control - Room MTE2 <i>Speaker:</i> Julie Dolva, NO <i>Speaker:</i> Renza Monteleone, IT	-
QM MTE-3	Adverse events & CAPA - Room MTE3 <i>Speaker:</i> Anne Emmett, GB	-
QM MTE-4	Maintaining the QM program and QM plan - Room MTE4 <i>Speaker:</i> Phuong Huynh, BE <i>Speaker:</i> Nick van Sinderen, NL	-
QM MTE-5	Outcome analysis and benchmarking & Validation and verification - Room MTE5 <i>Speaker:</i> Mara Magri, IT <i>Speaker:</i> Kim Orchard, GB	-
QM MTE-6	Personnel, Training and Competency - Room MTE6 <i>Speaker:</i> Sarah Holtby, GB	-

Educational

09:15 - 10:30

Auditorium 1

E03 - What's new in the pathophysiology and treatment of patient complications?

Chair: Francesca Bonifazi, IT

Chair: Gustavo Kusminsky, AR

E3-1	Updates on early transplant complications - VOD/SOS and TMA <i>Speaker:</i> Vincent Ho, US	09:15 - 09:30
E3-2	Regulation of GVHD by promoting tissue tolerance <i>Speaker:</i> Pavan Reddy, US	09:30 - 09:45
E3-3	Chronic GVHD <i>Speaker:</i> José Antonio Pérez-Simón, ES	09:45 - 10:00
E3-4	Q&A	10:00 - 10:30

Educational

09:15 - 10:30

Auditorium 2

E04 - Doubts and evidences in the treatment of Relapsed/Refractory Lymphoid Malignancies

Chair: Bertram Glass, DE

Chair: Dolores Caballero, ES

E4-1	The case of follicular lymphoma <i>Speaker:</i> Silvia Montoto, GB	09:15 - 09:30
------	--	---------------

E4-2	How to sequence cell-based therapies in Mantle Cell Lymphoma <i>Speaker:</i> Mehdi Hamadani, US	09:30 - 09:45
E4-3	The case of Hodgkin's lymphoma <i>Speaker:</i> Paolo Corradini, IT	09:45 - 10:00
E4-4	Q&A	10:00 - 10:30

Paediatric Day
09:15 - 10:30

Auditorium 4

Paed1 - Paediatric Diseases Working Party Session

Chair: Selim Corbacioglu, DE

Chair: Anita Lawitschka, AT

Paed1-1	CMV-associated thymus dysfunction independently increase the risk of chronic GVHD <i>Speaker:</i> Katrine Kielsen, DK	09:15 - 09:30
Paed1-2	Specific CAR-T targets in Pediatric AML <i>Speaker:</i> Tobias Feuchtinger, DE	09:30 - 09:45
Paed1-3	Is there a role for CNS boost with transplant in ALL? <i>Speaker:</i> Anna Marie Ewins, GB	09:45 - 10:00
Paed1-4	NIH Consensus Project 2020: Therapy of established cGvHD <i>Speaker:</i> Hildegard Greinix, AT	10:00 - 10:15
Paed1-5	Q&A	10:15 - 10:30

Pharmacists Day
09:15 - 10:30

Auditorium 5

Pharm1 - Pharmacotherapy in SCT

Chair: Maria Estela Moreno Martínez, ES

Chair: Claudia Langebrake, DE

Pharm1-1	Current evidence for TDM in HSCT: An overview <i>Speaker:</i> Vera Domingos, PT	09:15 - 09:35
Pharm1-2	Treosulfan-containing regimens for patients with malignant and non-malignant disorders <i>Speaker:</i> Krzysztof Kalwak, PL	09:35 - 09:55
Pharm1-3	Individualized treatment in pediatric stem cell transplantation: therapeutic drug monitoring and pharmacogenetics <i>Speaker:</i> Eileen van der Stoep, NL	09:55 - 10:15
Pharm1-4	Q&A	10:15 - 10:30

Special Session
09:15 - 10:30

Auditorium 6

SS04 - EBMT Benchmarking - A key quality improvement tool

Chair: Carlos Solano, ES

Chair: Eoin McGrath, ES

SS4-1	Project update <i>Speaker:</i> John Snowden, GB	09:15 - 09:30
SS4-2	Methodological aspects of EBMT benchmarking <i>Speaker:</i> Hein Putter, NL	09:30 - 09:45
SS4-3	Results so far <i>Speaker:</i> Riccardo Saccardi, IT	09:45 - 10:00
SS4-4	Next steps - Gaining confidence <i>Speaker:</i> Kim Orchard, GB	10:00 - 10:15
SS4-5	Round table: Will benchmarking replace the need for accreditation?	10:15 - 10:30

Industrial Theatre

09:15 - 17:30

IT

IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session

This session is available throughout the whole congress

Chair: Amir Hefni, GB

Chair: David Kuzan, US

Chair: Carolin Barth, CH

Industrial Theatre

09:15 - 17:30

IT

Industry Theatre sessions

Industrial Theatre

09:15 - 17:30

IT

IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre session

This session is available throughout the whole congress

Chair: Dick Sundh, AU

Industrial Theatre

09:15 - 17:30

IT

IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session

This session is available throughout the whole congress

Chair: Volker Witt, AT

Data Management

09:15 - 17:30

On-Demand Library

DM05 - Education session 5

This session is available in our on-demand library throughout the whole congress

DM5-1	Hematopoietic Cell Transplantation-Comorbidity Index 'Sorrow Score' <i>Speaker:</i> Bronwen Shaw, US	-
-------	--	---

Workshop

09:15 - 17:30

On-Demand Library

W13 - CARs beyond T cells: A focus on next generation CAR-NK cells

This session is available in our on-demand library throughout the whole congress

W13-1	CAR NK cells as an "off the shelf" immunotherapy <i>Speaker:</i> Ulrike Köhl, DE	-
W13-2	CARs and ADCC to make off-the-shelf NK cells specific against hematologic malignancies <i>Speaker:</i> Jeffrey Miller, US	-
W13-3	Target NKG2D ligands on tumor cells <i>Speaker:</i> Antonio Pérez-Martínez, ES	-

Workshop

09:15 - 17:30

On-Demand Library

W10 - Controversies in T-cell NHL

This session is available in our on-demand library throughout the whole congress

W10-1	Are we improving first-line therapy in TCL? <i>Speaker:</i> Eva Domingo Domenech, ES	09:15 - 09:15
W10-3	Insights in CAR-T therapy for T cell Lymphomas <i>Speaker:</i> Helen Heslop, US	09:15 - 09:15

Educational

09:15 - 17:30

On-Demand Library

E08 - New challenges in infectious complications

This session is available in our on-demand library throughout the whole congress

E8-1	T-cell therapy for infections in SCT patients: An experimental treatment or a real choice for the practice? <i>Speaker:</i> Patrizia Comoli, IT	-
E8-2	Infectious complications with new drugs in Hematology <i>Speaker:</i> Georg Maschmeyer, DE	-
E8-3	The blood virome of HSCT Recipients: Much more than viremia by CMV, EBV, HH6V and adenovirus <i>Speaker:</i> Marie-Celine Zanella, CH	-

Special Session

09:15 - 17:30

On-Demand Library

SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer

This session is available in our on-demand library throughout the whole congress

SS10-1	General Overview of the HARMONY Alliance: Progress, Achievements & Results of HARMONY and HARMONY PLUS projects <i>Speaker:</i> Jesús Maria Hernández Rivas, ES	-
SS10-2	Envisioned contribution of the EBMT to the HARMONY Alliance	-

	<p><i>Speaker:</i> Guillermo Sanz Santillana, ES</p> <p><i>Speaker:</i> Yann Guillevic, CH</p>	
SS10-3	<p>EBMT participation in the HARMONY Alliance</p> <p><i>Speaker:</i> Anna Sureda, ES</p>	-
SS10-4	<p>HARMONY & HARMONY PLUS Research Projects / Outcomes definition</p> <p><i>Speaker:</i> Lars Bullinger, DE</p>	-
SS10-5	<p>HARMONY Platform</p> <p><i>Speaker:</i> Ana Heredia Casanoves, ES</p>	-

On Demand Library
09:15 - 17:30

On-Demand Library

On Demand Library

Nurses Group
09:15 - 17:30

On-Demand Library

NG23 - Oral session 2: Abstracts session

This session is available in our on-demand library throughout the whole congress

NG23-1	<p>EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL CARE PROTOCOL FOR THE PREVENTION AND TREATMENT OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT RECIPIENTS</p> <p><i>Speaker:</i> Monica Guberti, IT</p>	09:15 - 09:15
NG23-2	<p>PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING</p> <p><i>Speaker:</i> Julia Ruiz Pato, ES</p>	09:15 - 09:15
NG23-3	<p>ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS</p> <p><i>Speaker:</i> Franziska Michaela Lohmeyer, IT</p>	09:15 - 09:15
NG23-4	<p>MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANTATION SETTING AND THEIR MAINTENANCE OVER TIME</p> <p><i>Speaker:</i> Alberto Castagna, IT</p>	09:15 - 09:15
NG23-5	<p>EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AND THEIR COHABITANTS</p> <p><i>Speaker:</i> Maria Teresa Solano Moliner, ES</p>	09:15 - 09:15

Oral Session

09:15 - 17:30

On-Demand Library

OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and Chimerism

This session is available in our on-demand library throughout the whole congress

OS6-1	COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T CELL IMMUNE RECONSTITUTION PATTERNS <i>Speaker:</i> Saskia Leserer, DE	09:15 - 09:15
OS6-2	MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Sandra Pennisi, DE	09:15 - 09:15
OS6-3	SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR EXCISION CIRCLES (TRECS) AND K-DELETING RECOMBINATION EXCISION CIRCLES (KRECS) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) RECIPIENTS <i>Speaker:</i> Carlos De Miguel Jiménez, ES	09:15 - 09:15
OS6-4	MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMANS <i>Speaker:</i> Mirjam Belderbos, NL	09:15 - 09:15
OS6-5	OVER-EXPRESSION OF HIF-1α IN MESENCHYMAL STROMAL CELLS INCREASES HUMAN CD34⁺ CELLS CLONOGENIC CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A XENOTRANSPLANTATION MODEL <i>Speaker:</i> Silvia Preciado, ES	09:15 - 09:15
OS6-6	ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-SPECIFIC T-CELLS <i>Speaker:</i> Rubiya Nadaf, GB	09:15 - 09:15
OS6-7	TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOID MALIGNANCIES <i>Speaker:</i> Simona Pagliuca, US	09:15 - 09:15
OS6-8	DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Patrizia Chiusolo, IT	09:15 - 09:15

Oral Session

09:15 - 17:30

On-Demand Library

OS11 - Oral session 11: Infectious Diseases I

This session is available in our on-demand library throughout the whole congress

OS11-1	POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI	09:15 - 09:25
--------	--	---------------

	INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE ASPBIOMICS CONSORTIUM <i>Speaker:</i> Ana Moniz-Díez, ES	
OS11-2	THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Speaker:</i> Nipat Chuleerarux, TH	09:25 - 09:35
OS11-3	IMMUNE RECONSTITUTION DURING CMV PROPHYLAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Ilaria Cutini, IT	09:35 - 09:45
OS11-4	LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE <i>Speaker:</i> Massimo Martino, IT	09:45 - 09:55
OS11-5	PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED APPROACH. RESULTS IN 112 PATIENTS <i>Speaker:</i> Amado Karduss -Urueta, CO	09:55 - 10:05
OS11-6	PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A TERTIARY REFERRAL CENTER IN INDIA <i>Speaker:</i> Harika Varla, IN	10:05 - 10:15
OS11-7	THE MANAGEMENT OF CLOSTRIDIODES DIFFICILE INFECTIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY <i>Speaker:</i> Agnieszka Piekarska, PL	10:15 - 10:25
OS11-8	CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH HEMATOLOGY MALIGNANCIES: A REAL-WORLD OBSERVATIONAL STUDY <i>Speaker:</i> Sizhou Feng, CN	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS12 - Oral session 12: Infectious Diseases II

This session is available in our on-demand library throughout the whole congress

OS12-1	NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING	09:15 - 09:15
--------	---	---------------

PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY GROUP

Speaker: Dina Averbuch, IL

OS12-2	COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY <i>Speaker:</i> Marina Popova, RU	09:15 - 09:15
OS12-3	COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Yuliya Rogacheva, RU	09:15 - 09:15
OS12-4	FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTS <i>Speaker:</i> Chiara Rosignoli, IT	09:15 - 09:15
OS12-5	CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE <i>Speaker:</i> Anke Verlinden, BE	09:15 - 09:15
OS12-6	COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS THAT AFFECT THE SURVIVAL OF PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Anna Czyz, PL	09:15 - 09:15
OS12-7	IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; SINGLE CENTER EXPERIENCE <i>Speaker:</i> Eshrak Al-Shaibani, CA	09:15 - 09:15
OS12-8	STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6 REACTIVATION <i>Speaker:</i> Kenichiro Takeda, JP	09:15 - 09:15

Oral Session
09:15 - 17:30

On-Demand Library

OS13 - Oral session 13: Transplant Complications I

This session is available in our on-demand library throughout the whole congress

OS13-1	FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION	09:15 - 09:15
--------	--	---------------

	<i>Speaker:</i> Mohamad Mohty, FR	
OS13-2	ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE ANALYSIS FROM THE EBMT <i>Speaker:</i> Olaf Penack, DE	09:15 - 09:15
OS13-3	DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS) <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS13-4	EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS13-5	EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE MORTALITY AND THE RISK OF INTENSIVE CARE UNIT ADMISSION AT PRE-TRANSPLANT EVALUATION <i>Speaker:</i> Marta Peña Domingo, ES	09:15 - 09:15
OS13-6	THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Midori Nakagaki, AU	09:15 - 09:15
OS13-7	IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY <i>Speaker:</i> Aldo A Acosta-Medina, US	09:15 - 09:15
OS13-8	RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD <i>Speaker:</i> Bernd Gruhn, DE	09:15 - 09:15

Oral Session
09:15 - 17:30

On-Demand Library

OS14 - Oral session 14: Transplant Complications II

This session is available in our on-demand library throughout the whole congress

OS14-1	PREGNANCY AND PREGNANCY OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT PEDIATRIC WP <i>Speaker:</i> Tamara Diesch, CH	09:15 - 09:15
OS14-2	ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN	09:15 - 09:15

	HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY: RESULTS OF A SURVEY FROM THE EBMT <i>Speaker:</i> Helene Schoemans, BE	
OS14-3	CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Gertjan Lugthart, NL	09:15 - 09:15
OS14-4	NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP	09:15 - 09:15
OS14-5	AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) <i>Speaker:</i> Selim Corbacioglu, DE	09:15 - 09:15
OS14-6	PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA) ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Santosh Putta, US	09:15 - 09:15
OS14-7	OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Isabel Iturrate, ES	09:15 - 09:15
OS14-8	DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT-HOME ALLOGENEIC BONE MARROW TRANSPLANTATION MODELS <i>Speaker:</i> Marta Garcia-Recio, ES	09:15 - 09:15

Oral Session
09:15 - 17:30

On-Demand Library

OS15 - Oral session 15: Conditioning Regimens

This session is available in our on-demand library throughout the whole congress

OS15-1	BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA <i>Speaker:</i> Sylvie Lachance, CA	09:15 - 09:25
OS15-2	MICROBIOTA INJURY IS CONDITIONING REGIMEN-DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS <i>Speaker:</i> Roni Shouval, US	09:25 - 09:35
OS15-3	THE IMPACT OF PULMONARY FUNCTION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION <i>Speaker:</i> Jesus Duque-Afonso, DE	09:35 - 09:45

OS15-4	HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Khalid Halahleh, JO	09:45 - 09:55
OS15-5	THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION :A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369 CONTROLS <i>Speaker:</i> Federica Sora, IT	09:55 - 10:05
OS15-6	IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL BLOOD COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE ALONE <i>Speaker:</i> Giorgia Battipaglia, IT	10:05 - 10:15
OS15-7	HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS <i>Speaker:</i> Donata Backhaus, DE	10:15 - 10:25
OS15-8	SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Speaker:</i> Eduardo Rodríguez-Arbolí, ES	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS16 - Oral session 16: Acute Leukemia I

This session is available in our on-demand library throughout the whole congress

OS16-1	IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE EBMT <i>Speaker:</i> Justin Loke, GB	09:15 - 09:25
OS16-2	IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE ALWP AND THE CMWP <i>Speaker:</i> Eolia Brissot, FR	09:25 - 09:35
OS16-3	THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A STUDY FROM THE ALWP / EBMT <i>Speaker:</i> Arnon Nagler, IL	09:35 - 09:45
OS16-4	NON-T DEPLETED HAPLOIDENTICAL STEM CELL	09:45 - 09:55

TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER ONE VS TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT

Speaker: Arnon Nagler, IL

OS16-5 **PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND ALL. A STUDY FROM THE ALWP-EBMT** 09:55 - 10:05

Speaker: Sabine Blum, CH

OS16-6 **IMPACT OF ALLOGENIC TRANSPLANTATION IN THE TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS. COMPARISON BETWEEN MYELOABLATIVE VS REDUCE INTENSITY CONDITIONINGS** 10:05 - 10:15

Speaker: Claudia Núñez-Torrón, ES

OS16-7 **THE DISEASE BURDEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE TO PATIENTS WITH SECONDARY LEUKEMIA** 10:15 - 10:25

Speaker: Claudia Núñez-Torrón, ES

OS16-8 **PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL TRANSPLANTATION. STUDY OF 132 PATIENTS** 10:25 - 10:35

Speaker: Christelle Ferra Coll, ES

Oral Session
09:15 - 17:30

On-Demand Library

OS17 - Oral session 17: Acute Leukemia II

This session is available in our on-demand library throughout the whole congress

OS17-1 **TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTION: IMPROVEMENT OF SURVIVAL IN RECENT YEARS** 09:15 - 09:15

Speaker: Ali Bazarbachi, LB

OS17-2 **HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE NUCLEAR CONSORTIUM** 09:15 - 09:15

Speaker: José Sánchez Maldonado, ES

OS17-3 **COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA** 09:15 - 09:15

Speaker: Annalisa Ruggeri, ES

OS17-4 **REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH** 09:15 - 09:15

RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION

Speaker: Sarah Morin, CH

OS17-5	VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT (HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Vincenzo Federico, IT	09:15 - 09:15
OS17-6	TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Speaker:</i> Nico Gagelmann, DE	09:15 - 09:15
OS17-7	STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL DONOR FOR PEDIATRIC PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE STUDY <i>Speaker:</i> Charlotte Nazon, FR	09:15 - 09:15
OS17-8	COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD <i>Speaker:</i> Gabriele Magliano, IT	09:15 - 09:15

Oral Session

09:15 - 17:30

On-Demand Library

OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes

This session is available in our on-demand library throughout the whole congress

OS18-1	GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS WITH MYELOID NEOPLASIA <i>Speaker:</i> Carmelo Gurnari, US	09:15 - 09:15
OS18-2	RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA. A STUDY OF THE EBMT-CMWP <i>Speaker:</i> Alicia Rovó, CH	09:15 - 09:15
OS18-3	CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A RETROSPECTIVE ANALYSIS FROM THE CHRONIC MALIGNANCIES WORKING PARTY <i>Speaker:</i> Christof Scheid, DE	09:15 - 09:15
OS18-4	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM AFTER BREAST CANCER TREATMENT: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT <i>Speaker:</i> Mitja Nabergoj, CH	09:15 - 09:15
OS18-5	IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-CMWP STUDY	09:15 - 09:15

	<i>Speaker:</i> Nicolaus Kröger, DE	
OS18-6	ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Elena Morozova, RU	09:15 - 09:15
OS18-7	DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML <i>Speaker:</i> Christian Niederwieser, DE	09:15 - 09:15
OS18-8	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT PERIOD <i>Speaker:</i> Anna Czyz, PL	09:15 - 09:15
<i>Oral Session</i> 09:15 - 17:30		
		On-Demand Library
OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia		
This session is available in our on-demand library throughout the whole congress		
OS19-1	INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL) <i>Speaker:</i> Catherine Thieblemont, FR	09:15 - 09:15
OS19-2	LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) <i>Speaker:</i> Caron A. Jacobson, US	09:15 - 09:15
OS19-3	PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) <i>Speaker:</i> Caron A. Jacobson, US	09:15 - 09:15
OS19-4	ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) <i>Speaker:</i> Michael L. Wang, US	09:15 - 09:15
OS19-5	VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE CRUCIAL CONSORTIUM <i>Speaker:</i> Antonio José Cabrera-Serrano, ES	09:15 - 09:15
OS19-6	EVALUATION OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL	09:15 - 09:15

LYMPHOMA (ALCL)

Speaker: Natalie L. Smith, US

- | | | |
|--------|--|---------------|
| OS19-7 | ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA (DLBCL) IN A GERMAN TERTIARY HOSPITAL
<i>Speaker:</i> Bernhard Alexander Mörtl, DE | 09:15 - 09:15 |
| OS19-8 | LONG TERM OUTCOMES OF ALLOGENEIC TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE EXPERIENCE
<i>Speaker:</i> Alexander Glover, GB | 09:15 - 09:15 |

Oral Session

09:15 - 17:30

On-Demand Library

OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|---|---------------|
| OS20-1 | HLA EVOLUTIONARY DIVERGENCE INFLUENCES CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
<i>Speaker:</i> Simona Pagliuca, US | 09:15 - 09:25 |
| OS20-2 | OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511 PATIENTS
<i>Speaker:</i> Richard K Burt, US | 09:25 - 09:35 |
| OS20-3 | EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A REAL WORLD EXPERIENCE
<i>Speaker:</i> Varun Mehra, GB | 09:35 - 09:45 |
| OS20-4 | THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
<i>Speaker:</i> Carmelo Gurnari, US | 09:45 - 09:55 |
| OS20-5 | HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS: CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES
<i>Speaker:</i> Alexey Polushin, RU | 09:55 - 10:05 |
| OS20-6 | HLA MUTATIONS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM OF IMMUNE ESCAPE
<i>Speaker:</i> Carmelo Gurnari, US | 10:05 - 10:15 |
| OS20-7 | HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS
<i>Speaker:</i> Claudia Lucía Sossa Melo, CO | 10:15 - 10:25 |

OS20-8	IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS <i>Speaker:</i> Alice Mariottini, IT	10:25 - 10:35
--------	--	---------------

Educational
09:15 - 17:30

On-Demand Library

E13 - Allogeneic transplantation from alternative donors

This session is available in our on-demand library throughout the whole congress

E13-1	Haploidentical vs unrelated in AML <i>Speaker:</i> Didier Blaise, FR	-
E13-2	Haploidentical vs unrelated in ALL <i>Speaker:</i> Arnon Nagler, IL	-
E13-3	Haploidentical vs cord Blood in acute leukaemia <i>Speaker:</i> Frederic Baron, BE	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG16 - Cellular therapy update

This session is available in our on-demand library throughout the whole congress

NG16-1	Update: What's new? <i>Speaker:</i> Rose Ellard, GB	-
NG16-2	Spotlight on the Lymphoma Patient Experience <i>Speaker:</i> Lorna Warwick, CA	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG20 - How do I become an expert?

This session is available in our on-demand library throughout the whole congress

NG20-1	Conditioning regimen <i>Speaker:</i> Nicolas Kint, BE	-
NG20-2	Immunosuppression <i>Speaker:</i> Tiene Bauters, BE	-
NG20-3	Vaccinations <i>Speaker:</i> Bipin Savani, US	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG13-1	SARS-CoV-2 vaccines overview <i>Speaker:</i> Almudena Ramírez, ES	-
NG13-2	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic	-

hematopoietic stem cell transplantation

Speaker: Jose Luis Piñana, ES

- | | | |
|--------|---|---|
| NG13-3 | COVID-19: The EBMT recommendations for management of HCT patients and donors | - |
| | Speaker: Per Ljungman, SE | |

Nurses Group

09:15 - 17:30

On-Demand Library

NG22 - Quality processes in JACIE

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|---|---|
| NG22-1 | Quality indicators for nurses | - |
| | Speaker: Louise McNamara, GB | |
| NG22-2 | JACIE: What's new? | - |
| | Speaker: Kim Orchard, GB | |
| NG22-3 | What is the nurse role as JACIE Inspector? | - |
| | Speaker: Eugenia Trigos Arjona, ES | |

Nurses Group

09:15 - 17:30

On-Demand Library

NG17 - Care of the nurses

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--------------------------------------|---|
| NG17-1 | Mindfulness | - |
| | Speaker: Ana M. Muñoz Cobo, ES | |
| NG17-2 | Resilience and self-care | - |
| | Speaker: Christian Williams, GB | |
| NG17-3 | Tips and tricks for self care | - |
| | Speaker: Jane Keep, GB | |

Nurses Group

09:15 - 17:30

On-Demand Library

NG21 - Clinical trials in a transplant setting

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|---|---|
| NG21-1 | Antimicrobial Lock Therapy for Prevention and Treatment of Catheter Related Infections in Hematological Patients | - |
| | Speaker: Isabel Salcedo, ES | |
| NG21-2 | Convalescent plasma clinical trials for COVID-19 | - |
| | Speaker: Rocío Layunta, ES | |
| NG21-3 | Post transplant relapse | - |
| | Speaker: Stephanie Heyes, GB | |

Nurses Group
09:15 - 17:30

On-Demand Library

NG19 - Disease update

This session is available in our on-demand library throughout the whole congress

NG19-1	Acute leukaemia <i>Speaker:</i> Inge Govaerts, BE	-
NG19-2	Managing lymphoma: What nurses and healthcare professionals need to know <i>Speaker:</i> Erik Aerts, CH	-
NG19-3	Multiple myeloma <i>Speaker:</i> Maaïke de Ruijter, NL	-
NG19-4	CML (ITK management) <i>Speaker:</i> Laura Borg, GB	-

Educational
09:15 - 17:30

On-Demand Library

E09 - Allogeneic HSCT in MDS and MPN

This session is available in our on-demand library throughout the whole congress

E9-1	Definition of graft failure/relapse after allo-HCT in myelofibrosis <i>Speaker:</i> Donal McLornan, GB	-
E9-2	Allogeneic HSCT in patients with therapy-related MDS/AML <i>Speaker:</i> Marie Robin, FR	-
E9-3	The role of maintenance therapy after allogeneic HSCT in MDS <i>Speaker:</i> Francesco Onida, IT	-

Data Management
09:15 - 17:30

On-Demand Library

DM09 - Education session 9

This session is available in our on-demand library throughout the whole congress

DM9-1	Follow up forms - How to get a chronological overview of the patient history and follow up <i>Speaker:</i> Elena Ferrer Martínez del Peral, ES	-
-------	--	---

Working Party Session
09:15 - 17:30

On-Demand Library

SAAWP - Severe Aplastic Anaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

SAAWP-1	Introduction <i>Speaker:</i> Régis Peffault de Latour, FR	-
SAAWP-2	Registry Report <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-3	RACE – clinical update <i>Speaker:</i> Antonio Risitano, IT	-

SAAWP-4	RACE – what we learn on the biology of SAA? <i>Speaker:</i> Austin Kulakaseraraj, GB	-
SAAWP-5	Androgens in AA: Myth or reality in 2021? <i>Speaker:</i> Simona Pagliuca, US	-
SAAWP-6	GVHD and relapse free survival (GRFS) after HSCT for AA <i>Speaker:</i> Raynier Devillier, FR	-

Lab Technicians Day
09:15 - 17:30

On-Demand Library

LT1 - Lab Technicians Day: Specialized cell processing

This session is available in our on-demand library throughout the whole congress

LT1-1	Bone marrow processing: Techniques and results <i>Speaker:</i> Boris Calmels, FR	-
LT1-2	Technical aspects and performance TCRab/CD19 depletion <i>Speaker:</i> Kasper Westinga, NL	-
LT1-3	Donor selection and GMP-compliant manufacturing of virus-specific T-cells <i>Speaker:</i> Britta Eiz-Vesper, DE	-

Working Party Session
09:15 - 17:30

On-Demand Library

ALWP - Acute Leukaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

ALWP-1	Introduction <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
ALWP-2	CAR-T cells in adult ALL <i>Speaker:</i> Arnon Nagler, IL	09:15 - 09:15
ALWP-3	Transplant in refractory AML: Comparison of the different FLAMSA approaches <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
ALWP-4	MRD in AML: Where do we stand? <i>Speaker:</i> Ali Bazarbachi, LB	09:15 - 09:15

Working Party Session
09:15 - 17:30

On-Demand Library

ADWP - Autoimmune Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

ADWP-1	Welcome and Update from the EBMT registry <i>Speaker:</i> Raffaella Greco, IT	-
ADWP-2	Introducing the session and speakers <i>Speaker:</i> Tobias Alexander, DE	-
ADWP-3	HSCT for multiple sclerosis: Future directions in patient	-

	selection and conditioning regimen <i>Speaker:</i> Riccardo Saccardi, IT	
ADWP-4	HSCT for systemic sclerosis: Future directions in patient selection and conditioning regimen <i>Speaker:</i> Dominique Farge, FR	-
ADWP-5	HSCT for Crohn's disease: future directions in patient selection, mobilization and conditioning regimen <i>Speaker:</i> Elena Ricart, ES	-
ADWP-6	HSCT for autoimmune diseases: Current aspects on early and late complications <i>Speaker:</i> Majid Kazmi, GB	-
ADWP-7	HSCT for autoimmune diseases: Conditioning regimen and outcomes from the Russian experience <i>Speaker:</i> Denis Fedorenko, RU	-
ADWP-8	Closing remarks <i>Speaker:</i> Tobias Alexander, DE	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG18 - Non-malignant diseases update

This session is available in our on-demand library throughout the whole congress

NG18-2	Multiple sclerosis <i>Speaker:</i> Helen Jessop, GB	09:15 - 09:15
NG18-3	Sickle cell disease <i>Speaker:</i> Jean-Hugues Dalle, FR	09:15 - 09:15
NG18-4	ITP <i>Speaker:</i> Maria Luisa Lozano, ES	09:15 - 09:15

Nurses Group
09:15 - 17:30

On-Demand Library

NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG14-1	Patient's experience <i>Speaker:</i> Ruth Tweedie, ES	-
NG14-2	Psychologist's point of view <i>Speaker:</i> Anna Lagerdahl, GB	-
NG14-3	Nurse's perspective <i>Speaker:</i> Núria Ballestar, ES	-

Nurses Group

09:15 - 17:30

On-Demand Library

NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG15-1	Managing virtual conversations <i>Speaker:</i> Lloyd Allen, GB	-
NG15-2	Nurse perspective: Virtual long term follow up for BMT patients <i>Speaker:</i> Michelle Kenyon, GB	-
NG15-3	Back to the future: Emphasizing our new practices <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	-

Nurses Group

09:15 - 17:30

On-Demand Library

NG24 - Outreach projects

This session is available in our on-demand library throughout the whole congress

NG24-2	Outreach project India: EBMT MIC pediatric advanced care training (EMPACT) <i>Speaker:</i> Lawrence Faulkner, IT	09:15 - 09:15
NG24-3	Outreach project: LABMT <i>Speaker:</i> Sara Saez Carrasco, CO	09:15 - 09:15

Educational

09:15 - 17:30

On-Demand Library

E11 - Management of early complications in an ambulatory/outpatient setting

This session is available in our on-demand library throughout the whole congress

E11-1	Early infectious complications <i>Speaker:</i> Jan Styczynski, PL	-
E11-2	Non-infective complications: GVHD and organ toxicity <i>Speaker:</i> Gerhard Hildebrandt, US	-
E11-3	The Hospital Clínic experience <i>Speaker:</i> Francesc Fernández-Avilés, ES	-

Workshop

09:15 - 17:30

On-Demand Library

W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?

This session is available in our on-demand library throughout the whole congress

W14-1	A matched unrelated donor <i>Speaker:</i> Bronwen Shaw, US	-
W14-2	A haploidentical donor <i>Speaker:</i> Mi Kwon, ES	-
W14-3	When to choose cord blood <i>Speaker:</i> Filippo Milano, US	-

W14-4	Do we have to challenge our current donor hierarchy for patients with hemoglobinopathies? <i>Speaker:</i> Selim Corbacioglu, DE	
<i>Workshop</i>		
09:15 - 17:30		On-Demand Library
W11 - Key organ manifestations of chronic GVHD		
This session is available in our on-demand library throughout the whole congress		
W11-1	Pulmonary chronic GVHD <i>Speaker:</i> Hildegard Greinix, AT	
W11-2	Ocular cGVHD diagnostics - Practical approach <i>Speaker:</i> Igor Petricek, HR	
W11-3	Gastrointestinal manifestations of chronic GVHD <i>Speaker:</i> Daniel Wolff, DE	
<i>Data Management</i>		
09:15 - 17:30		On-Demand Library
DM07 - Education session 7		
This session is available in our on-demand library throughout the whole congress		
DM7-1	Minimal residual disease (MRD) <i>Speaker:</i> Johannes Schetelig, DE	
<i>Data Management</i>		
09:15 - 17:30		On-Demand Library
DM08 - Education session 8		
This session is available in our on-demand library throughout the whole congress		
DM8-1	Infectious complications <i>Speaker:</i> Malgorzata Mikulska, IT	
<i>Special Session</i>		
09:15 - 17:30		On-Demand Library
SS09 - How to get published		
This session is available in our on-demand library throughout the whole congress		
SS9-1	BMT: Official journal of the EBMT <i>Speaker:</i> Hillard Lazarus, US	
SS9-2	How to get published <i>Speaker:</i> Mohamad Mohty, FR	
<i>Special Session</i>		
09:15 - 17:30		On-Demand Library
SS11 - The EBMT for Trainees		
This session is available in our on-demand library throughout the whole congress		
SS11-1	Being a Trainee in SCT / Cellular Therapy <i>Speaker:</i> Nico Gagelmann, DE	

Speaker: Claire Horgan, GB
 Speaker: Yasmina Serroukh, BE
 Speaker: Yuliya Rogacheva, RU
 Speaker: Tamar Azikuri, GE

SS11-2	Overview of allogeneic SCT for the trainee: 'Things I wish I'd known'	-
	Speaker: Helene Schoemans, BE	
SS11-3	Establishing a career in SCT/cellular therapy	-
	Speaker: Jordan Gauthier, US	
SS11-4	Complications for trainees 1: How to manage acute GVHD	-
	Speaker: Zinaida Peric, HR	
SS11-5	Complications for trainees 2: How to manage VOD	-
	Speaker: Ivan Moiseev, RU	

Special Session
 09:15 - 17:30

On-Demand Library

SS07 - Young Ambassadors Session

This session is available in our on-demand library throughout the whole congress

SS7-1	How build up a career in: Academia	-
	Speaker: Didier Blaise, FR	
SS7-2	How build up a career in: In Pharmaceutical Industry	-
	Speaker: Dan Tovar, FR	
SS7-3	How build up a career in: In Public domains	-
	Speaker: Eva Hilgenfeld, DE	
SS7-4	What to avoid when writing a paper	-
	Speaker: Jakob Passweg, CH	
SS7-5	How to write a successful grant	-
	Speaker: Robert Zeiser, DE	
SS7-6	Introduction to medical statistics	-
	Speaker: Simona Iacobelli, IT	
SS7-7	Social media in stem cell transplantation and cellular therapy	-
	Speaker: Navneet Majhail, US	

How do I ... ?
 09:15 - 17:30

On-Demand Library

HDI6 - How Do I... manage toxicity in immunosuppressed patients?

This session is available in our on-demand library throughout the whole congress

HDI6-1	Transplant associated TMA	-
	Speaker: Sergio Giral, US	
HDI6-2	Infectious complication	-
	Speaker: Jan Styczynski, PL	

Industry Symposium

09:15 - 17:30

On-Demand Library

IS38 - CMV management in high-risk patients - Biotest Industry Symposium

This session is available in our on-demand library throughout the whole congress

Chair: Fabio Ciceri, IT

IS38-1	A scoring system to define patients at high risk for CMV <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	-
IS38-2	How to manage CMV high-risk patients <i>Speaker:</i> Michele Malagola, IT	-
IS38-3	The immunological benefits of CMV-specific immunoglobulins <i>Speaker:</i> Javier Carbone, ES	-

Joint Session

09:15 - 17:30

On-Demand Library

JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT

This session is available in our on-demand library throughout the whole congress

JS5-2	COVID-19 vaccination in HSCT <i>Speaker:</i> Per Ljungman, SE	09:15 - 09:15
JS5-3	Global access to COVID-19 vaccines <i>Speaker:</i> Susan Brown, US	09:15 - 09:15

Oral Session

09:15 - 17:30

On-Demand Library

OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I

This session is available in our on-demand library throughout the whole congress

OS4-1	INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) TREATED IN THE PHASE 3 NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212) STUDIES <i>Speaker:</i> Isabelle Thuret, FR	09:15 - 09:25
OS4-2	NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE TREATMENT OF ADULT HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES <i>Speaker:</i> Alessandro Rambaldi, IT	09:25 - 09:35
OS4-3	CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T-CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Eliana Ruggiero, IT	09:35 - 09:45
OS4-4	CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY IN MPSIIIA <i>Speaker:</i> Jane Louise Kinsella, GB	09:45 - 09:55

OS4-5	EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Dalia Sheta, DE	09:55 - 10:05
OS4-6	REAL-WORLD EFFECTIVENESS AND SAFETY OF BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST RELAPSE <i>Speaker:</i> Alessandro Rambaldi, IT	10:05 - 10:15
OS4-7	GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY <i>Speaker:</i> Paulien van Hauten, NL	10:15 - 10:25
OS4-8	IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC ANALYSES FROM THE PEGASUS STUDY <i>Speaker:</i> David Cella, US	10:25 - 10:35

Quality Management

09:15 - 17:30

On-Demand Library

QM5 - Quality Management Oral Abstracts

This session is available in our on-demand library throughout the whole congress

QM5-1	COMPLIANCE AND COST EFFICACY FOR CELLULAR THERAPIES, CAN THESE TWO GO HAND IN HAND? <i>Speaker:</i> Janik Adriaansen, US	09:15 - 09:15
QM5-2	HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR NURSES IN TIMES OF PANDEMIC <i>Speaker:</i> Sheila Saco, ES	09:15 - 09:15
QM5-3	THE RTN TRANSPLANT POLICY AND ACTIVITY DURING COVID-19 PANDEMIC <i>Speaker:</i> Antonio Bruno, IT	09:15 - 09:15
QM5-4	THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM IN NAPLES, ITALY <i>Speaker:</i> Lucia Ammirati, IT	09:15 - 09:15

Oral Session

09:15 - 17:30

On-Demand Library

OS03 - Oral session 3: CARs II

This session is available in our on-demand library throughout the whole congress

OS3-1	CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY OF THE APPROACH <i>Speaker:</i> Olga Molostova, RU	09:15 - 09:15
-------	--	---------------

OS3-2	CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2 CARTITUDE-1 STUDY <i>Speaker:</i> Andrzej Jakubowiak, US	09:15 - 09:15
OS3-3	PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS WITH RELAPSED/REFRACTORY MCL IN ZUMA-2 <i>Speaker:</i> Michael L. Wang, US	09:15 - 09:15
OS3-4	REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN SPAIN <i>Speaker:</i> Mi Kwon, ES	09:15 - 09:15
OS3-5	HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY <i>Speaker:</i> Dasom Lee, US	09:15 - 09:15
OS3-6	DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS ARE ASSOCIATED WITH NEUROTOXICITY <i>Speaker:</i> Madhavi Lakkaraja, US	09:15 - 09:15
OS3-7	COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-T THERAPY <i>Speaker:</i> Zhao-Yanli Zhao, CN	09:15 - 09:15
OS3-8	THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF GD2+ SARCOMAS <i>Speaker:</i> Antonio Camera, IT	09:15 - 09:15

Oral Session
09:15 - 17:30

On-Demand Library

OS10 - Oral session 10: COVID-19

This session is available in our on-demand library throughout the whole congress

OS10-1	A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS ADOPTIVE THERAPY IN COVID19 <i>Speaker:</i> Antonio Pérez-Martínez, ES	09:15 - 09:25
OS10-2	THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY <i>Speaker:</i> Angharad Pryce, GB	09:25 - 09:35
OS10-3	IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL	09:35 - 09:45

THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT

Speaker: Sara Ghorashian, GB

OS10-4	OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE FROM A SEVERELY AFFECTED AREA (BERGAMO) <i>Speaker:</i> Maria Caterina Mico', IT	09:45 - 09:55
OS10-5	ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS AFTER COVID-19 INFECTION <i>Speaker:</i> Maximilian Christopeit, DE	09:55 - 10:05
OS10-6	INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION CENTERS AND THE PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE 2020 <i>Speaker:</i> Fernando Barroso Duarte, BR	10:05 - 10:15
OS10-7	CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC PROGENITOR CELLS IN THE CURRENT SARS-Cov-2 PANDEMIC: EXPERIENCE OF A SINGLE CENTRE <i>Speaker:</i> Dolores Moreno, ES	10:15 - 10:25
OS10-8	IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH CORD BLOOD UNITS. ON BEHALF THE AGENCY OF BIOMEDICINE, EUROCORD AND THE SFGM-TC <i>Speaker:</i> Hanadi Rafii - El Ayoubi, FR	10:25 - 10:35

Working Party Session

09:15 - 17:30

On-Demand Library

CTIWP - Cellular Therapy and Immunobiology Working Party Session

This session is available in our on-demand library throughout the whole congress

CTIWP-1	CTIWP Activity Report <i>Speaker:</i> Christian Chabannon, FR	-
CTIWP-2	Virus specific T cells post BMT- Broadening to SARS-CoV2 <i>Speaker:</i> Catherine Bollard, US	-
CTIWP-3	Are mesenchymal stromal cells the right arrow in the quiver to fight COVID-19? <i>Speaker:</i> Rachele Ciccocioppo, IT	-

Oral Session

09:15 - 17:30

On-Demand Library

OS02 - Oral session 2: CARs I

This session is available in our on-demand library throughout the whole congress

OS2-1	CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	09:15 - 09:25
-------	---	---------------

	<i>Speaker:</i> Deepu Madduri, US	
OS2-2	PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) <i>Speaker:</i> Olalekan O. Oluwole, US	09:25 - 09:35
OS2-3	MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA <i>Speaker:</i> David Maloney, US	09:35 - 09:45
OS2-4	STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA BLASTS <i>Speaker:</i> Concetta Quintarelli, IT	09:45 - 09:55
OS2-5	CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19 CAR T-CELL THERAPY <i>Speaker:</i> Jordan Gauthier, US	09:55 - 10:05
OS2-6	OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING: INITIAL RESULTS FROM THE OUTREACH STUDY <i>Speaker:</i> John E. Godwin, US	10:05 - 10:15
OS2-7	BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T CELLS AT EU OR EBMT AFFILIATED PROGRAMS <i>Speaker:</i> Christian Chabannon, FR	10:15 - 10:25
OS2-8	ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF THE SHELF” STRATEGY TO TREAT CD123^{POS} CHILDHOOD ACUTE MYELOID LEUKAEMIA <i>Speaker:</i> Simona Caruso, IT	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS09 - Oral session 9: Graft versus Host Disease II

This session is available in our on-demand library throughout the whole congress

OS9-1	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN HUMANS <i>Speaker:</i> Robert Zeiser, DE	09:15 - 09:15
OS9-2	RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL	09:15 - 09:15

	<i>Speaker:</i> Franco Locatelli, IT	
OS9-3	DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT? <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
OS9-4	A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Speaker:</i> Michelle Hudspeth, US	09:15 - 09:15
OS9-5	THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY <i>Speaker:</i> Junya Kanda, JP	09:15 - 09:15
OS9-6	EARLY RECONSTITUTION OF CD6+ T CELLS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL ANTIBODY ITOLIZUMAB <i>Speaker:</i> Benedetta Rambaldi, US	09:15 - 09:15
OS9-7	MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Erik Thiele Orberg, DE	09:15 - 09:15
OS9-8	ASSOCIATION OF GENE POLYMORPHISMS IN CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Paula Muñiz, ES	09:15 - 09:15

Special Session

09:15 - 17:30

On-Demand Library

SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell therapy community

This session is available in our on-demand library throughout the whole congress

SS8-1	Social media beyond twitter for the HSCT and cell therapy community <i>Speaker:</i> Navneet Majhail, US	-
SS8-2	Do's and don'ts of interaction in social media: Nurse's perspective <i>Speaker:</i> Johan De Munter, BE	-
SS8-3	Do's and don'ts of interaction in social media: How social media can improve patient outcomes - The patient's perspective <i>Speaker:</i> Gillian Adams, GB	-

Lab Technicians Day

09:15 - 17:30

On-Demand Library

LT2 - Lab Technicians Day: Cell product testing, validation and characterization

This session is available in our on-demand library throughout the whole congress

LT2-1	Quality control assessment of ATMP phenotype and functionality using flow cytometry <i>Speaker:</i> Willemijn Hobo, NL	-
LT2-2	Flow cytometry-based CD34 enumeration <i>Speaker:</i> Harry Dolstra, NL	-
LT2-3	Flow cytometric in-process and quality control for CAR T cell manufacturing <i>Speaker:</i> Ulrike Köhl, DE	-

Educational

09:15 - 17:30

On-Demand Library

E10 - HSCT in paediatric non-malignant indications

This session is available in our on-demand library throughout the whole congress

E10-1	Haplo-identical SCT in hemoglobinopathy: Taking pole position? <i>Speaker:</i> Josu de la Fuente, GB	-
E10-2	Mismatched family donors in inherited immune disorders: A new perspective <i>Speaker:</i> Mary A. Slatter, GB	-
E10-3	HSCT for inherited bone marrow failure syndromes <i>Speaker:</i> Cristina Díaz de Heredia, ES	-
E10-4	Cord blood HSCT for non-malignant diseases in children <i>Speaker:</i> Vanderson Rocha, BR	-

Educational

09:15 - 17:30

On-Demand Library

E12 - Steroid-resistant/refractory GVHD

This session is available in our on-demand library throughout the whole congress

E12-1	GVHD - what's in a name? <i>Speaker:</i> Helene Schoemans, BE	-
E12-2	Treatment of SR/R acute GVHD <i>Speaker:</i> Olaf Penack, DE	-
E12-3	Treatment of SR/R chronic GVHD <i>Speaker:</i> Zinaida Peric, HR	-
E12-4	New technologies in the approach to GVHD <i>Speaker:</i> Amin Turki, DE	-

Data Management

09:15 - 17:30

On-Demand Library

DM06 - Education session 6

This session is available in our on-demand library throughout the whole congress

DM6-1	Response in Multiple Myeloma <i>Speaker:</i> Meral Beksac, TR	-
-------	---	---

Workshop

09:15 - 17:30

On-Demand Library

W12 - Donor HLA assessment and matching for allogeneic HSCT

This session is available in our on-demand library throughout the whole congress

W12-1	HLA laboratory perspective and recommendations <i>Speaker:</i> Pascale Loiseau, FR	-
W12-2	Clinical perspective and recommendations <i>Speaker:</i> Francesca Lorentino, IT	-
W12-3	Selection of unrelated donors and cord blood units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR <i>Speaker:</i> Stephen Spellman, US	-

Working Party Session

09:15 - 17:30

On-Demand Library

CMWP - Chronic Malignancies Working Party Session

This session is available in our on-demand library throughout the whole congress

CMWP-1	Scientific activity of the CMWP <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	09:15 - 09:15
CMWP-3	Who and when in the course of disease to transplant? - Myelofibrosis <i>Speaker:</i> Donal McLornan, GB	09:15 - 09:15
CMWP-4	Is Chronic Myeloid Leukaemia still an indication for allo-HCT? <i>Speaker:</i> Yves Chalandon, CH	09:15 - 09:15
CMWP-5	Is Chronic Lymphocytic Leukemia still an indication for allo-HCT? <i>Speaker:</i> Peter Dreger, DE	09:15 - 09:15

Working Party Session

09:15 - 17:30

On-Demand Library

IDWP - Infectious Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

IDWP-1	IDWP update <i>Speaker:</i> Rafael de la Cámara, ES	-
IDWP-2	Current scientific proposals of IDWP <i>Speaker:</i> Dina Averbuch, IL	-

IDWP-3	CMV T-cell immunity monitoring: is it time to incorporate it in clinical practices? <i>Speaker:</i> Roy Chemaly, US	-
IDWP-4	What is new in the field of Gram-negative infections in SCT patients? <i>Speaker:</i> Dina Averbuch, IL	-
IDWP-5	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation <i>Speaker:</i> Jose Luis Piñana, ES	-
IDWP-6	Hepatitis C and hepatitis E in SCT <i>Speaker:</i> Malgorzata Mikulska, IT	-
IDWP-7	Central nervous system (CNS) complications following HSCT <i>Speaker:</i> Martin Schmidt-Hieber, DE	-

Oral Session

09:15 - 17:30

On-Demand Library

OS21 - Oral session 21: Multiple Myeloma

This session is available in our on-demand library throughout the whole congress

OS21-1	MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA <i>Speaker:</i> Harsh Parmar, US	09:15 - 09:15
OS21-2	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT – A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP <i>Speaker:</i> Joanna Drozd-Sokołowska, PL	09:15 - 09:15
OS21-3	ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP ANALYSIS <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS21-4	AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM STEM CELL TRANSPLANTATION AND MAINTENANCE WITH THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA (MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-STUDY <i>Speaker:</i> Nicolaus Kröger, DE	09:15 - 09:15
OS21-5	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL DISEASE <i>Speaker:</i> Jean Roy, CA	09:15 - 09:15

OS21-6	ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY <i>Speaker:</i> laurent Garderet, FR	09:15 - 09:15
OS21-7	COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) <i>Speaker:</i> Sergio Giralt, US	09:15 - 09:15
OS21-8	CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE-CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL TRIALS OF DARATUMUMAB <i>Speaker:</i> Katja Weisel, DE	09:15 - 09:15

Joint Session
09:15 - 17:30

On-Demand Library

JS04 - Joint session LABMT

This session is available in our on-demand library throughout the whole congress

JS4-1	Transplant rates, Trends: WBMT/LABMT 2018 survey <i>Speaker:</i> Oscar González-Ramella, MX	-
JS4-2	Financing of HSCT in Latin America <i>Speaker:</i> Gregorio Jaimovich, AR	-
JS4-3	Selection, management and follow up of related donors: Overview <i>Speaker:</i> Nina Worel, AT	-
JS4-4	Selection, management and follow up of related donors: Development of an LABMT consensus <i>Speaker:</i> Gonzalo Ferini, AR	-
JS4-5	Haploidentical transplants in Latin America: Experience from Argentina/GATMO-TC in acute lymphoblastic leukemia <i>Speaker:</i> Ana Basquiera, AR	-
JS4-6	Haploidentical transplants in Latin America: Experience from Brazil/SBTMO in aplastic anemia <i>Speaker:</i> Carmem Bonfim, BR	-

Oral Session
09:15 - 17:30

On-Demand Library

OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering

This session is available in our on-demand library throughout the whole congress

OS1-1	MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT IMMUNOSUPPRESSIVE PROPERTIES	09:15 - 09:25
-------	---	---------------

	<i>Speaker:</i> Kevin Goncalves, US	
OS1-2	EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34⁺ CELL MOBILIZATION IN HEALTHY VOLUNTEERS <i>Speaker:</i> Hideki Goto, JP	09:25 - 09:35
OS1-3	THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Rumesh Chandar, IN	09:35 - 09:45
OS1-4	THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT REJECTION AND GRAFT VERSUS HOST DISEASE IN CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION <i>Speaker:</i> Satish Meena, IN	09:45 - 09:55
OS1-5	OUTCOME AND IMMUNE RECONSTITUTION AFTER TCR$\alpha\beta$/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL RELATED DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Lucia Prezioso, IT	09:55 - 10:05
OS1-6	THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE <i>Speaker:</i> Muhammad Ameen, SA	10:05 - 10:15
OS1-7	POST-TRANSPLANT OUTCOMES OF CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TREATED WITH EMAPALUMAB <i>Speaker:</i> Michael Jordan, US	10:15 - 10:25
OS1-8	WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE <i>Speaker:</i> Maria Escolar, US	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II

This session is available in our on-demand library throughout the whole congress

OS5-1	HEMATOPOIETIC STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH): BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF EARLY CLINICAL RESPONSE <i>Speaker:</i> Maria Ester Bernardo, IT	09:15 - 09:25
OS5-2	OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH TABELCLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT	09:25 - 09:35

	<i>Speaker:</i> Susan Prockop, US	
OS5-3	RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY <i>Speaker:</i> Markus Mapara, US	09:35 - 09:45
OS5-4	DURABLE CLINICAL OUTCOMES FOLLOWING BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) <i>Speaker:</i> Franco Locatelli, IT	09:45 - 09:55
OS5-5	OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT) <i>Speaker:</i> Carolyn Mulroney, US	09:55 - 10:05
OS5-6	IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Francesca Patriarca, IT	10:05 - 10:15
OS5-7	MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR THE IDENTIFICATION OF HIGH-RISK PATIENTS AND TREATMENT WITH T-CELL IMMUNOTHERAPY <i>Speaker:</i> Anastasia Papadopoulou, GR	10:15 - 10:25
OS5-8	NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT TRANSDUCTION AND CROSS-CORRECTION MECHANISMS USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH <i>Speaker:</i> Jane E Potter, GB	10:25 - 10:35
Paed4-2	EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34⁺ HEMATOPOIETIC STEM AND PROGENITOR CELLS IN TRANSFUSION-DEPENDENT β-THALASSEMIA AND SICKLE CELL DISEASE <i>Speaker:</i> Selim Corbacioglu, DE	10:35 - 10:45

Oral Session
09:15 - 17:30

On-Demand Library

OS07 - Oral session 7: Stem Cell Source and Donors

This session is available in our on-demand library throughout the whole congress

OS7-1	FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE RISK AFTER UNRELATED HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE CELLULAR	09:15 - 09:25
-------	---	---------------

THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT

Speaker: Annalisa Ruggeri, ES

- | | | |
|-------|---|---------------|
| OS7-2 | POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN MISMATCHED UNRELATED DONOR TRANSPLANTATION VERSUS HAPLOIDENTICAL TRANSPLANTATION: A RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
<i>Speaker:</i> Giorgia Battipaglia, IT | 09:25 - 09:35 |
| OS7-3 | HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS AFFECTED BY MALIGNANT DISORDERS
<i>Speaker:</i> Pietro Merli, IT | 09:35 - 09:45 |
| OS7-4 | MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE FROM THE MADRID GROUP OF HEMATOPOIETIC TRANSPLANT
<i>Speaker:</i> Rebeca Bailén, ES | 09:45 - 09:55 |
| OS7-5 | LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS
<i>Speaker:</i> Jacopo Peccatori, IT | 09:55 - 10:05 |
| OS7-6 | INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REPORT
<i>Speaker:</i> Andriyana Bankova, US | 10:05 - 10:15 |
| OS7-8 | CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH CRYOPRESERVED GRAFTS DURING THE COVID19 PANDEMIC
<i>Speaker:</i> Maximilian Christopeit, DE | 10:15 - 10:25 |

Oral Session
09:15 - 17:30

On-Demand Library

OS08 - Oral session 8: Graft versus Host Disease I

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---------------|
| OS8-1 | GVHD PROPHYLAXIS WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A / METHOTREXATE POST ALLOGENEIC TRANSPLANTATION (HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE ALWP/EBMT
<i>Speaker:</i> Arnon Nagler, IL | 09:15 - 09:15 |
| OS8-2 | BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE | 09:15 - 09:15 |

	ROCKSTAR STUDY (KD025-213) <i>Speaker:</i> Corey Cutler, US	
OS8-3	A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Hanaa A. Fatoum, SA	09:15 - 09:15
OS8-4	RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM THE RANDOMIZED, PHASE 3 REACH2 STUDY <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS8-5	IMPACT OF CHRONIC GVHD SEVERITY AND STEROID RESPONSE ON THE QUALITY OF LIFE IN PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: FINDINGS FROM A REAL-WORLD STUDY <i>Speaker:</i> Sylvie Lachance, CA	09:15 - 09:15
OS8-6	SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM <i>Speaker:</i> Florent Malard, FR	09:15 - 09:15
OS8-7	REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER ALLO-HSCT <i>Speaker:</i> Marie T Rubio, FR	09:15 - 09:15
OS8-8	PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD STUDY <i>Speaker:</i> Nada Hamad, AU	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
CAR-based Cellular Therapy – Preclinical		
P026	NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY <i>Speaker:</i> Tobias Bexte, DE	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Cellular Therapies other than CARs		
P027	PROLONGED REPEATEDLY ADMINISTERED LOW DOSE DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE	09:15 - 09:15

LEUKEMIA

Speaker: Panagiotis Tsirigotis, GR

P028	CD8⁺-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 <i>Speaker:</i> Mehmet Altan, US	09:15 - 09:15
P029	CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY® TCR⁺ AND CD19 DEPLETION <i>Speaker:</i> Katalin Dobos, HU	09:15 - 09:15
P031	COMPREHENSIVE ACTIVATION PROFILING OF TABELCELEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY <i>Speaker:</i> Fiona Ruiz, US	09:15 - 09:15
P030	IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS	09:15 - 09:15
P035	BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K-NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML AND MDS (NK-REALM) <i>Speaker:</i> Sumithira Vasu, US	09:15 - 09:15
P034	NEW, LN₂-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF CELL THERAPIES <i>Speaker:</i> Julie Meneghel, GB	09:15 - 09:15
P032	DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Virginia Escamilla Gómez, ES	09:15 - 09:15
P033	DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION. ONE SINGLE CENTER EXPERIENCE <i>Speaker:</i> Melissa Karina Torres Ochoa, ES	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Conditioning Regimens

P036	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE LIMIT? <i>Speaker:</i> Sara Fernández-Luis, ES	09:15 - 09:15
P037	THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE	09:15 - 09:15

	<i>Speaker:</i> Bartosz Malecki, PL	
P038	CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN EARLY RELAPSED MULTIPLE MYELOMA PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Jaap van Doesum, NL	09:15 - 09:15
P039	PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL WITH TBI AND ETOPOSIDE CONDITIONING <i>Speaker:</i> Jane E Potter, GB	09:15 - 09:15
P040	ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH FAVORABLE OUTCOMES	09:15 - 09:15
P041	LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Ioanna Sakellari, GR	09:15 - 09:15
P042	TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY <i>Speaker:</i> Raquel Olivas-Mazón, ES	09:15 - 09:15
P044	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED-RELATED SIBLING DONORS <i>Speaker:</i> Gabriella Storti, IT	09:15 - 09:15
P043	IMMUNE RECONSTITUTION AFTER SEQUENTIAL CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT DONOR TYPES <i>Speaker:</i> Alessia Fraccaroli, DE	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Data Management		
P045	GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE MYELOMA <i>Speaker:</i> Ruth Paul, GB	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Experimental Stem Cell Transplantation		
P046	SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL MODULATION IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS ACUTE	09:15 - 09:15

LEUKAEMIA

Speaker: Maryam Barkhordar, IR

- | | | |
|------|--|---------------|
| P047 | DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE
<i>Speaker:</i> Elisabetta Metafunì, IT | 09:15 - 09:15 |
|------|--|---------------|

Poster Sessions
09:15 - 17:30

ePoster Area

Experimental Transplantation

- | | | |
|------|--|---------------|
| P048 | INFLUENCE OF POLYMORPHISMS RELATED TO DRUG METABOLISM IN ALLOGENEIC BONE MARROW TRANSPLANTATION
<i>Speaker:</i> Marta Santiago, ES | 09:15 - 09:15 |
| P049 | REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
<i>Speaker:</i> Tahereh Rostami, IR | 09:15 - 09:15 |

Poster Sessions
09:15 - 17:30

ePoster Area

Gene Therapy

- | | | |
|------|---|---------------|
| P050 | BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN FOR β-THALASSEMIA) GENE THERAPY TREATMENT OF A GREEK PATIENT WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT)
<i>Speaker:</i> Evangelia Yannaki, GR | 09:15 - 09:15 |
|------|---|---------------|

Poster Sessions
09:15 - 17:30

ePoster Area

Graft-versus-Host Disease – Preclinical and Animal Models

- | | | |
|------|--|---------------|
| P074 | THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-MEDIATED TISSUE INJURY
<i>Speaker:</i> Sascha Göttert, DE | 09:15 - 09:15 |
| P075 | ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED MICE | 09:15 - 09:15 |

Poster Sessions
09:15 - 17:30

ePoster Area

Haematopoietic Stem Cells

- | | | |
|------|--|---------------|
| P078 | RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF | 09:15 - 09:15 |
|------|--|---------------|

OUR HOSPITAL

Speaker: Elena Paumard Rodríguez, ES

P076	LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION <i>Speaker:</i> Katrin Koch, DE	09:15 - 09:15
P077	KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION, REVISITED <i>Speaker:</i> Kazimierz Halaburda, PL	09:15 - 09:15
P079	THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER ALLOGENEIC TRANSPLANTATION <i>Speaker:</i> Sabrina Giammarco, IT	09:15 - 09:15
P081	OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES <i>Speaker:</i> Zohreh Nademi, GB	09:15 - 09:15
P080	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7 ANTIGEN EXPRESSION <i>Speaker:</i> Danilo De Novellis, IT	09:15 - 09:15
P082	OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS: A SINGLE CENTER STUDY <i>Speaker:</i> Eshrak Al-Shaibani, CA	09:15 - 09:15
P084	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL <i>Speaker:</i> Simona Piemontese, IT	09:15 - 09:15
P083	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A SINGLE-INSTITUTION EXPERIENCE <i>Speaker:</i> Marta Hidalgo Soto, ES	09:15 - 09:15
P086	EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA <i>Speaker:</i> Ma Liangming, CN	09:15 - 09:15
P085	IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE POLYMORPHISMS ON THE OUTCOMES OF TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS <i>Speaker:</i> Anastasia Beynarovich, RU	09:15 - 09:15
P087	AUTOMATED DRY THAWING OF CRYOPRESERVED HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER <i>Speaker:</i> Julie Meneghel, GB	09:15 - 09:15

P091	UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA: AN EXPERIENCE FROM THE LARGEST CHILDREN'S HOSPITAL IN IRAN <i>Speaker:</i> Amir Ali Hamidieh, IR	09:15 - 09:15
P090	INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT IN PATIENTS OVER 65 YEARS OLD <i>Speaker:</i> Magdalena Corona de Lapuerta, ES	09:15 - 09:15
P089	LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN'S AND NON-HODGKIN'S LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN COLOMBIAN NORTHEAST <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
P092	ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF 195 CASES <i>Speaker:</i> Thierry Guillaume, FR	09:15 - 09:15
P097	DEFIBROTIDE AS TREATMENT FOR TRANSPLANT-ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Danilo De Novellis, IT	09:15 - 09:15
P096	IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: REPORT FROM A SINGLE CENTER <i>Speaker:</i> Sabrina Giammarco, IT	09:15 - 09:15
P095	IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HAPLO SCT) USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE IN SUB-SAHARAN AFRICA? <i>Speaker:</i> Justin du Toit, ZA	09:15 - 09:15
P099	IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Claudia Núñez-Torrón, ES	09:15 - 09:15
P098	THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT THE ROYAL MARSDEN HOSPITAL <i>Speaker:</i> Sandra Easdale, GB	09:15 - 09:15
P102	EBV COLITIS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA <i>Speaker:</i> Lucia Prezioso, IT	09:15 - 09:15
P100	BURNOUT SYNDROME IN ONCOLOGY PRACTICE: EXPERIENCE OF A LARGE HSCT CENTER <i>Speaker:</i> Irina Artemeva, RU	09:15 - 09:15

P103	MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) <i>Speaker:</i> Carolina Lilibeth Moreira-Ponce, MX	09:15 - 09:15
P101	FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA POST HEMATOPOIETIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A TERTIARY REFERRAL CENTRE IN INDIA <i>Speaker:</i> Rumesh Chandar, IN	09:15 - 09:15
P104	BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Katheryn Garzón-Velásquez, MX	09:15 - 09:15
P106	EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NARRATIVE REVIEW <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
P105	STAFF EXPERIENCES AND LEARNING FROM WORKING ON A HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING COVID-19 <i>Speaker:</i> Sarah Airdrie, GB	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Haemoglobinopathy

P107	THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Mohammed Essa, SA	09:15 - 09:15
P108	HOW TO FACILITATE DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMOGLOBINOPATHIES - THE PERSPECTIVES OF HEALTH CARE PROFESSIONALS <i>Speaker:</i> Hilda Mekelenkamp, NL	09:15 - 09:15
P109	ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE: A RETROSPECTIVE COHORT ANALYSIS <i>Speaker:</i> Richelle Waldner, CA	09:15 - 09:15
P110	DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY – SHARED OR NOT? <i>Speaker:</i> Hilda Mekelenkamp, NL	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Immunodeficiency Diseases and Macrophages

P111	CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Aishat Idarmacheva, RU	09:15 - 09:15
P112	OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY <i>Speaker:</i> Liam Reilly, GB	09:15 - 09:15
P113	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH CLERICUZIO SYNDROME (POIKILODERMA WITH NEUTROPENIA) <i>Speaker:</i> Alexandra Burya, RU	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Paediatric Issues		
P183	POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA <i>Speaker:</i> Andrey Kozlov, RU	09:15 - 09:15
P185	RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING EXVIVO T-CELL-DEPLETION <i>Speaker:</i> Iván López Torija, ES	09:15 - 09:15
P184	FREQUENCY AND CAUSES OF DEATH AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NON-MALIGNANT DISEASES <i>Speaker:</i> Koray Yalcin, TR	09:15 - 09:15
P186	SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Denise Elbæk, DK	09:15 - 09:15
P187	LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH NONMALIGNANT DISEASES: A SINGLE CENTER COHORT ANALYSIS <i>Speaker:</i> Joëll Esmée Bense, NL	09:15 - 09:15
P188	PROSPECTIVE MULTICENTER STUDY OF A REDUCED-TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE REGIMENS <i>Speaker:</i> Fanny Rialland, FR	09:15 - 09:15
P189	TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED DONOR IN PEDIATRIC PATIENTS	09:15 - 09:15

	<i>Speaker:</i> Luisa Sisinni, ES	
P190	SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Charlotte Nazon, FR	09:15 - 09:15
P191	SAFETY AND PERFORMANCE OF CENTRAL VENOUS CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Sofia Martin-Consuegra, ES	09:15 - 09:15
P192	TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND – BLACKFAN ANEMIA <i>Speaker:</i> Svetlana Radygina, RU	09:15 - 09:15
P193	ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES <i>Speaker:</i> Maksymilian Deregowski, PL	09:15 - 09:15
P194	CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS <i>Speaker:</i> Taylor Fitch, US	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Stem Cell Source		
P216	THE BLOOD DONATION BEFORE BONE MARROW HARVEST HAS NO IMPACT ON EFFICIENCY OF COLLECTION <i>Speaker:</i> Iwona Mitrus, PL	09:15 - 09:15
P217	UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Vincenzo Federico, IT	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Non-infectious Early Complications		
P169	POST HEMATOPOIETIC PROGENITORS TRANSPLANT LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR VIRUS (EBV): A CENTER'S EXPERIENCE <i>Speaker:</i> Sara Garrido, ES	09:15 - 09:15
P171	CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE	09:15 - 09:15
P170	ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE	09:15 - 09:15

	DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL ECOSYSTEM <i>Speaker:</i> Daniele Zama, IT	
P172	HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC HYPERPLASI <i>Speaker:</i> Eugenio Galli, IT	09:15 - 09:15
P173	THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT RECPIENTS: SINGLE CENTER EXPERIENCE <i>Speaker:</i> Carlota Mayor Bastida, ES	09:15 - 09:15
P175	EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY SUGAR ABSORBTION TEST: INTERIM ANALYSIS OF THE SINGLE-CENTER PROSPECTIVE STUDY <i>Speaker:</i> Grzegorz Basak, PL	09:15 - 09:15
P176	ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO-OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT <i>Speaker:</i> Zofia Szmit, PL	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Myelodysplastic Syndromes		
P156	THE ROLE OF AGE IN OUTCOMES OF BONE MARROW TRANSPLANTATION IN PATIENTS FROM THE LATIN AMERICAN REGISTRY <i>Speaker:</i> Fernando Barroso Duarte, BR	09:15 - 09:15
P157	PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE MORTALITY IN PATIENTS WITH MYELOYDYSPLASTIC SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Isla Johnson, US	09:15 - 09:15
P159	SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOYDYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE OF THE PREVIOUS SITUATION	09:15 - 09:15
P158	SECONDARY AND TREATMENT-RELATED ACUTE MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION <i>Speaker:</i> Ioanna Sakellari, GR	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
P143	EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G-	09:15 - 09:15

	CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH THYMOGLOBULIN: A CIBMTR ANALYSIS <i>Speaker:</i> Nina Orfali, IE	
P144	PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT <i>Speaker:</i> Nicolaus Kröger, DE	09:15 - 09:15
P145	IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Amandine Pradier, CH	09:15 - 09:15
P146	MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS COMPARABLE TO PREDICT AML RELAPSE? <i>Speaker:</i> Valérie Dubois, FR	09:15 - 09:15
P148	CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES OPEN A WINDOW FOR RELAPSE INTERVENTION? <i>Speaker:</i> Jan Morf, GB	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Stem Cell Mobilization, Collection and Engineering		
P206	INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON-INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE THE MOBILIZATION AND COLLECTION OF HSCS IN POOR MOBILIZERS AHEAD OF ASCT <i>Speaker:</i> Katharina Kriegsmann, DE	09:15 - 09:15
P207	TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES BETWEEN 2008 AND 2017 <i>Speaker:</i> James Dillon, IE	09:15 - 09:15
P208	THE IMPACT OF THE “NEW NORMAL” ON STEM CELL LABORATORY PRACTICES <i>Speaker:</i> Sanja Mazi?, HR	09:15 - 09:15
P210	AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR USAGE WITH GCSF ALONE FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA <i>Speaker:</i> Mohamed Elemery, CA	09:15 - 09:15
P209	PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND FEASIBLE; A SINGLE CENTER ANALYSIS <i>Speaker:</i> Moussab Damraj, SA	09:15 - 09:15
P211	PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE <i>Speaker:</i> Nara Stepanyan, RU	09:15 - 09:15

P212	A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Joshua Richter, US	09:15 - 09:15
P213	PREDICTION OF THE MOBILIZATION SUCCESS FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES <i>Speaker:</i> Maria Eduarda Couto, PT	09:15 - 09:15
P214	DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR UTILIZATION DURING STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT? <i>Speaker:</i> Pilar Velarde López de Ayala, ES	09:15 - 09:15
P215	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Madeleine Powys, AU	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Nurses Posters – Adult

NP01	NURSES' TRAINING NEEDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE NURSES GROUP OF THE EBMT <i>Speaker:</i> Michelle Kenyon, GB	09:15 - 09:15
NP02	IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POVIDONE-IODINE MOUTHWASH UNDER DIRECT NURSING SUPERVISION <i>Speaker:</i> Napassaya Khanthum, TH	09:15 - 09:15
NP03	COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL THERAPY <i>Speaker:</i> Mercedes Montoro-Lorite, ES	09:15 - 09:15
NP04	CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE SYNDROME <i>Speaker:</i> Naama Nevo, IL	09:15 - 09:15
NP05	HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM-CELL TRANSPLANTATION: IMPROVING HOME-CARE STRATEGIES DURING SARS-COV-2 PANDEMIC <i>Speaker:</i> Laura Villa Rodríguez, ES	09:15 - 09:15
NP06	IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION <i>Speaker:</i> Sarah Henshaw, GB	09:15 - 09:15

NP07	AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING SARS-CoV-2 PANDEMIC	09:15 - 09:15
NP08	THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED METROPOLITAN TRANSPLANT PROGRAM <i>Speaker:</i> Antonio Bruno, IT	09:15 - 09:15
NP10	PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING WELL ESTABLISHED NURSING CARE STANDARDS <i>Speaker:</i> Isabel Salcedo, ES	09:15 - 09:15
NP11	A TALE OF 2 COLLECTIONS: CAR -T 'V' PBSC. OUR SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Caroline Jupp, GB	09:15 - 09:15
NP12	CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) NURSING IN LATIN AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY <i>Speaker:</i> Mariela Blanco, AR	09:15 - 09:15
NP13	MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO-ONCOLOGY MALIGNANCY AND THOSE UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION DURING THE COVID-19. HOW DO WE PROTECT THEM? <i>Speaker:</i> Anna Serrahima - Mackay, ES	09:15 - 09:15
NP14	PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Bakhtawar Altaf Hussain, PK	09:15 - 09:15
NP15	COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - THE REALITY <i>Speaker:</i> Lindsey Ashton, GB	09:15 - 09:15
NP16	TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED NURSE <i>Speaker:</i> Marijke Quaghebeur, BE	09:15 - 09:15
NP09	EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM <i>Speaker:</i> Mariela Blanco, AR	09:15 - 09:25
<i>Poster Sessions</i> 09:15 - 17:30 Stem Cell Donor		ePoster Area
P203	HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A SINGLE-CENTER COMPARISON <i>Speaker:</i> Alisa Lörsch, DE	09:15 - 09:15

P204	CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS: SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND HAPLOIDENTICAL DONORS <i>Speaker:</i> Claudie Roy, CA	09:15 - 09:15
------	--	---------------

P205	HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE CENTER EXPERIENCE IN MEXICO <i>Speaker:</i> Katheryn Garzón-Velásquez, MX	09:15 - 09:15
------	---	---------------

Poster Sessions
09:15 - 17:30

ePoster Area

Nurses Posters – Research

NP24	ROLE OF NURSING IN THE CARE OF PATIENT'S SKIN WITH CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION: A QUESTIONNAIRE-BASED SURVEY <i>Speaker:</i> Jacqui Stringer, GB	09:15 - 09:15
------	--	---------------

NP25	INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT <i>Speaker:</i> Lubov Shepeleva, RU	09:15 - 09:15
------	--	---------------

NP26	THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING DEVELOPMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: FROM PRACTICE TO SCIENCE <i>Speaker:</i> Natalya Rotan, RU	09:15 - 09:15
------	--	---------------

NP27	LONG TERM SURVIVORS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD AND ADOLESCENCE IN A DEVELOPING COUNTRY: HOW ARE THEY NOW? <i>Speaker:</i> Priscila Oliveira da Silva, BR	09:15 - 09:15
------	--	---------------

NP28	EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS <i>Speaker:</i> Olga Prokofieva, RU	09:15 - 09:15
------	--	---------------

NP29	EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY DISEASES <i>Speaker:</i> Silvia Sangüesa Domínguez, ES	09:15 - 09:15
------	--	---------------

Poster Sessions
09:15 - 17:30

ePoster Area

Pharmacology

P195	PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY	09:15 - 09:15
------	---	---------------

	DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE: INTERIM RESULTS FROM THE EQUATE STUDY <i>Speaker:</i> John Koreth, US	
P196	EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE THERAPEUTIC DRUG MONITORING OF BUSULFAN <i>Speaker:</i> Bushra Salman, OM	09:15 - 09:15
P197	A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE PRECLINICAL MODELS OF AML <i>Speaker:</i> Leanne Lanieri, US	09:15 - 09:15
P199	PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Sara M. Zimmerman, US	09:15 - 09:15
P198	THE IMPACT OF LETERMIVIR PRESCRIBING ON THE RATE OF CYTOMEGALOVIRUS REACTIVATION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Siobhan Smith, GB	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Solid Tumours		
P200	HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-WORLD EXPERIENCE IN ARGENTINA <i>Speaker:</i> Adriana Vitriu, AR	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Statistics		
P201	EVALUATION OF MACHINE LEARNING ALGORITHMS APPLICABILITY FOR GRAFT FAILURE PREDICTION <i>Speaker:</i> Evgeny Bakin, RU	09:15 - 09:15
P202	WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE <i>Speaker:</i> Maria Escolar, US	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Multiple Myeloma		
P149	HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS ≥ 70 YEARS IS SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Udo Holtick, DE	09:15 - 09:15

P150	PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS <i>Speaker:</i> Meilan Chen, CN	09:15 - 09:15
P152	RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Speaker:</i> Jingli Gu, CN	09:15 - 09:15
P151	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION <i>Speaker:</i> Rita Sousa Gomes, PT	09:15 - 09:15
P153	CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Carolina Afonso, PT	09:15 - 09:15
P155	INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MUTIPLE MYELOMA <i>Speaker:</i> Pilar Velarde López de Ayala, ES	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Nurses Posters – Paediatric

NP17	NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Deepa Karmegam, IN	09:15 - 09:15
NP18	NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS AFTER CAR-T INFUSION <i>Speaker:</i> Giulia Del Giorno, IT	09:15 - 09:15
NP19	THE WORK OF THE REHABILITATION DEPARTMENT WITH VOLUNTEERS DURING THE COVID-19 PANDEMIC <i>Speaker:</i> Rashida Bikulova, RU	09:15 - 09:15
NP20	EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC CATHETERIZATION AS A MEASURE OF NUTRITIONAL SUPPORT IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION <i>Speaker:</i> Eugenia Trigos Arjona, ES	09:15 - 09:15
NP21	NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY. DESCRIPTION OF CLINICAL CASES <i>Speaker:</i> Anton Silov, RU	09:15 - 09:15

NP22 **INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-CENTER EXPERIENCE** 09:15 - 09:15

Speaker: Alba Fernandez-Arroyo Garcia, ES

NP23 **IMPLEMENTATION OF THE ADVANCED CELL THERAPY PROGRAM: &NBSP;EXPERIENCE AT LA PAZ UNIVERSITY HOSPITAL** 09:15 - 09:15

Speaker: Alba Fernandez-Arroyo Garcia, ES

Poster Sessions

09:15 - 17:30

ePoster Area

Non-infectious Late Effects, Quality of Life and Fertility

P177 **IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS** 09:15 - 09:15

Speaker: Magdalena Corona de Lapuerta, ES

P178 **OSTEONECROSIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-CENTRE STUDY OF INCIDENCE, RISK FACTORS, CHARACTERISTICS AND EVOLUTION** 09:15 - 09:15

Speaker: Giulia Prunotto, IT

P179 **SECONDARY MALIGNANCIES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:15 - 09:15

Speaker: João Gaião Santos, PT

P181 **ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE CHEMOTHERAPY** 09:15 - 09:15

Speaker: Walter Javier Zambrano Marquez, ES

P180 **SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN** 09:15 - 09:15

Speaker: Yulia Skvortsova, RU

P182 **AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – AMYOPATHIC DERMATOMYOSITIS, PRIMARY BILIARY CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA** 09:15 - 09:15

Speaker: Pedro de Vasconcelos M, PT

Poster Sessions

09:15 - 17:30

ePoster Area

New Drugs- and Cell-based Immune Therapies

P160 **INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA** 09:15 - 09:15

Speaker: Vivek Sharma, US

P161	CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS <i>Speaker:</i> David Dingli, US	09:15 - 09:15
P162	IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL CELLS AND FAVORS MICROVASCULAR THROMBOSIS <i>Speaker:</i> Miriam Galbusera, IT	09:15 - 09:15
P165	MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC SARCOMA <i>Speaker:</i> Carla Martín-Cortázar, ES	09:15 - 09:15
P163	POST-HEMATOPOIETIC STEM CELL TRANSPLANT MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING HUSSEIN CANCER CENTRE EXPERIENCE	09:15 - 09:15
P166	PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT (HCT) (STUDY DESIGN) <i>Speaker:</i> Anna Thorner, US	09:15 - 09:15
P168	CLINICAL PHARMACOLOGY AND POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721) <i>Speaker:</i> William Pullman, US	09:15 - 09:15
P167	WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES <i>Speaker:</i> David Dingli, US	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Myeloproliferative Neoplasm

Poster Sessions
09:15 - 17:30

ePoster Area

ePoster Area

Poster Sessions
09:15 - 17:30

ePoster Area

Acute Leukaemia

P001	MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC INFLUENCE ON POST-TRANSPLANT OUTCOMES IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Rama Al Hamed, US	09:15 - 09:15
P002	ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE	09:15 - 09:15

	REMISSION IN R/R B-ALL AFTER TREATMENT WITH MONOCLONAL ANTIBODIES <i>Speaker:</i> Inna Markova, RU	
P003	AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER ANALYSIS <i>Speaker:</i> Semra Aydin, IT	09:15 - 09:15
P004	T-CELL-DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE CENTRE EXPERIENCE OF 90 PATIENTS <i>Speaker:</i> Alexandros Kanellopoulos, GB	09:15 - 09:15
P005	POST-REMISSION TREATMENT PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) IN THE CONNECT[®] MDS/AML DISEASE REGISTRY	09:15 - 09:15
P006	ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF RECIPIENT AGE AND DONOR TYPE <i>Speaker:</i> Tatiana Tzenou, GR	09:15 - 09:15
P007	GILTERITINIB MONOTHERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT PATIENTS <i>Speaker:</i> Sergey Bondarenko, RU	09:15 - 09:15
P009	ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL) <i>Speaker:</i> Alan S. Wayne, US	09:15 - 09:15
P008	VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA POST ALLOGENEIC STEM CELL TRANSPLANT <i>Speaker:</i> Sandra Easdale, GB	09:15 - 09:15
P010	LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA – FOCUS ON MORTALITY <i>Speaker:</i> Anna Lojko-Dankowska, PL	09:15 - 09:15
P011	SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Semra Aydin, IT	09:15 - 09:15
P012	BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE SURVIVAL AFTER ALLOGENEIC STEM CELL	09:15 - 09:15

TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE MONOCENTRIC REPORT

Speaker: Elisabetta Metafuni, IT

- | | | |
|------|---|---------------|
| P013 | UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
<i>Speaker:</i> Sergey Bondarenko, RU | 09:15 - 09:15 |
| P014 | SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A CENTER IN COLOMBIA
<i>Speaker:</i> Claudia Lucía Sossa Melo, CO | 09:15 - 09:15 |

Poster Sessions
09:15 - 17:30

ePoster Area

Lymphoma and Chronic Lymphocytic Leukemia

- | | | |
|------|---|---------------|
| P134 | RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER RETROSPECTIVE COHORT STUDY
<i>Speaker:</i> Fernando Warley, AR | 09:15 - 09:15 |
| P133 | 18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW CNS LYMPHOMA IMAGING TOOL
<i>Speaker:</i> Sandra Easdale, GB | 09:15 - 09:15 |
| P135 | THE OUTCOMES OF ALLOGENEIC STEM CELLS TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED THERAPY: SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Ivan Moiseev, RU | 09:15 - 09:15 |
| P137 | STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN BLOOD AND MARROW TRANSPLANTATION REGISTRY
<i>Speaker:</i> Yu-Hung Wang, TW | 09:15 - 09:15 |
| P136 | NIVOLUMAB 40 MG THERAPY IN RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY
<i>Speaker:</i> Liudmila Fedorova, RU | 09:15 - 09:15 |
| P138 | AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION EXPERIENCE
<i>Speaker:</i> Joanna Romejko-Jarosinska, PL | 09:15 - 09:15 |
| P142 | SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL LYMPHOMA WITH INTENSIFIED MYELOABLATIVE CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED | 09:15 - 09:15 |

	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Yan-Li Zhao, CN	
P140	POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R DIFFUSE LARGE B-CELL LYMPHOMA <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
P141	NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF CONSOLIDATIVE AUTOLOGOUS STEM CELL TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL HOSPITAL <i>Speaker:</i> Christopher Shwei Wen Tham, SG	09:15 - 09:15
P139	AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG TERM OUTCOMES <i>Speaker:</i> Sudhir Kumar, IN	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Infectious Complications		
P118	COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION <i>Speaker:</i> Luisa Giaccone, IT	09:15 - 09:15
P119	INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE <i>Speaker:</i> Amir Ali Hamidieh, IR	09:15 - 09:15
P120	EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW <i>Speaker:</i> Aurore Bergamasco, FR	09:15 - 09:15
P122	EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Aleksandr Siniaev, RU	09:15 - 09:15
P121	ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT BACTERIA <i>Speaker:</i> Filippo Maraz, IT	09:15 - 09:15
P123	CLINICAL AND MICROBIOLOGICAL IMPACT OF DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE <i>Speaker:</i> Anke Verlinden, BE	09:15 - 09:15

P124	IRON CHELATION WITH DEFERASIROX SUPPRESSES THE APPEARANCE OF LPI DURING CONDITIONING CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Sonja Essmann, DE	09:15 - 09:15
P125	SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN MEXICO <i>Speaker:</i> Brenda Lizeth Acosta-Maldonado, MX	09:15 - 09:15
P126	ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE CENTER RETROSPECTIVE STUDY <i>Speaker:</i> Mohammed Essa, SA	09:15 - 09:15
P128	TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT <i>Speaker:</i> Tahereh Rostami, IR	09:15 - 09:15
P127	HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC CYSTITIS: RETROSPECTIVE COHORT STUDY <i>Speaker:</i> Nikola Pantic, RS	09:15 - 09:15
P132	CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Milena Todorovic Balint, RS	09:15 - 09:15
P129	PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL <i>Speaker:</i> Fernando Barroso Duarte, BR	09:15 - 09:15
P131	SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION <i>Speaker:</i> Maurizio Caniglia, IT	09:15 - 09:15
P130	CLINICAL CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT PATIENTS: A MONOCENTRIC 5 YEARS SURVEY <i>Speaker:</i> Gabriele Facchin, IT	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Inborn Errors

P114	ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH TREOSULFAN-BASED CONDITIONING <i>Speaker:</i> Matthias Bleeke, DE	09:15 - 09:15
P115	LONG-TERM NEURODEVELOPMENTAL, NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE	09:15 - 09:15

METACHROMATIC LEUKODYSTROPHY

Speaker: Maria Escolar, US

- | | | |
|------|--|---------------|
| P116 | OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING PARTY
<i>Speaker:</i> Su Han Lum, GB | 09:15 - 09:15 |
|------|--|---------------|

Poster Sessions
09:15 - 17:30

ePoster Area

CAR-based Cellular Therapy – Clinical

- | | | |
|------|---|---------------|
| P016 | HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
<i>Speaker:</i> Thomas Martin, US | 09:15 - 09:15 |
| P017 | MANUFACTURING COMMERCIAL AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR RETROSPECTIVE ANALYSIS
<i>Speaker:</i> Didier Hallard, NL | 09:15 - 09:15 |
| P015 | RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5
<i>Speaker:</i> Julio C. Chavez, US | 09:15 - 09:15 |
| P019 | COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY FOLLOWING BRUTON TYROSINE KINASE INHIBITOR TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ENGLAND
<i>Speaker:</i> Martin Brown, GB | 09:15 - 09:15 |
| P018 | EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL THERAPY IN THE REAL WORLD SETTING
<i>Speaker:</i> Silvia Monsalvo, ES | 09:15 - 09:15 |
| P020 | PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
<i>Speaker:</i> Adam D Cohen, US | 09:15 - 09:15 |
| P021 | CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA
<i>Speaker:</i> Pere Barba, ES | 09:15 - 09:15 |
| P022 | CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR-DERIVED CD19 CAR-T CELLS MANUFACTURED FROM MEMORY T CELL (CD45RA-DEPLETED) FRACTION
<i>Speaker:</i> Larisa Shelikhova, RU | 09:15 - 09:15 |

P024	ICU RESOURCE UTILIZATION IN PEDIATRIC AND ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T THERAPY <i>Speaker:</i> Dristhi Ragoonanan, US	09:15 - 09:15
P023	HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED PROLONGED PANCYTOPENIA USING AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A LYMPHOMA PATIENT <i>Speaker:</i> Udo Holtick, DE	09:15 - 09:15
P025	ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB WITH AXICABTAGENE CILOLEUCEL (AXI?CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) <i>Speaker:</i> Saad J. Kenderian, US	09:15 - 09:15
<i>Nurses Group</i> 09:35 - 10:30		Auditorium 3
NG04 - GVHD		
<i>Chair:</i> Kathy Goris, BE		
<i>Chair:</i> Francisco Xosé Román Losada, ES		
NG04-1	Update on treatments: New agents and strategy <i>Speaker:</i> Blanca Molina Angulo, ES	09:35 - 09:58
NG04-2	Pulmonary GVHD <i>Speaker:</i> Saskia Bos, BE	09:58 - 10:14
NG04-3	Q&A	10:14 - 10:30
<i>Breaks</i> 10:30 - 11:00		Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition		
<i>Educational</i> 11:00 - 12:15		Auditorium 1
E05 - Maintenance therapies after HSCT in acute leukaemia		
<i>Chair:</i> Mohamad Mohty, FR		
<i>Chair:</i> Pau Montesinos, ES		
E5-1	Novel targeted therapy post-HSCT for ALL <i>Speaker:</i> Eolia Brissot, FR	11:00 - 11:15
E5-2	Novel targeted therapy post-HSCT for AML/MDS <i>Speaker:</i> Gesine Bug, DE	11:15 - 11:30
E5-3	T-cell therapies after transplantation <i>Speaker:</i> Fred Falkenburg, NL	11:30 - 11:45
E5-4	Q&A	11:45 - 12:15

Educational

11:00 - 12:15

Auditorium 2

E06 - CAR-T toxicity and management

Chair: Maria Liz Paciello, ES

Chair: Olaf Penack, DE

E6-1	Cytokine release syndrome <i>Speaker:</i> Susana Rives, ES	11:00 - 11:15
E6-2	Neurotoxicity <i>Speaker:</i> Miguel-Angel Perales, US	11:15 - 11:30
E6-3	EBMT recommendations <i>Speaker:</i> Patrick Hayden, IE	11:30 - 11:45
E6-4	Q&A	11:45 - 12:15

Paediatric Day

11:00 - 12:15

Auditorium 4

Paed2 - Inborn Errors Working Party Session

Chair: Michael Albert, DE

Chair: Benedicte Neven, FR

Paed2-1	Antibody-based conditioning in SCID and beyond <i>Speaker:</i> Agnieszka Czechowicz, US	11:00 - 11:15
Paed2-2	Clinical and immunological outcome after HSCT in severe combined immune deficiency, a SCETIDE cohort study <i>Speaker:</i> Arjan Lankester, NL	11:15 - 11:30
Paed2-3	A prospective outcome study in profound combined immune deficiency <i>Speaker:</i> Stephan Ehl, DE	11:30 - 11:45
Paed2-4	Advances in stem cell therapy in metachromatic leukodystrophy <i>Speaker:</i> Valeria Calbi, IT	11:45 - 12:00
Paed2-5	Q&A	12:00 - 12:15

Pharmacists Day

11:00 - 12:15

Auditorium 5

Pharm2 - Supportive care 1

Chair: Nick Duncan, GB

Chair: Agnès Bonnin, FR

Pharm2-1	Drug-drug interactions between antifungals and immunosuppressive agents <i>Speaker:</i> Eline Muilwijk, NL	11:00 - 11:20
Pharm2-2	Drug interactions with complementary and alternatives herbs and medicines <i>Speaker:</i> Christoph Ritter, DE	11:20 - 11:40
Pharm2-3	New developments in the management of steroid-refractory	11:40 - 12:00

	GVHD <i>Speaker:</i> Raakhee Shah, GB	
Pharm2-4	Q&A	12:00 - 12:15
<i>Quality Management</i> 11:00 - 12:15		
		Auditorium 6
QM1 - Center Session <i>Chair:</i> Isabel Sánchez-Ortega, ES		
QM1-1	Accreditation Process <i>Speaker:</i> Carla Sánchez, ES	11:00 - 11:10
QM1-2	Basic quality management concepts <i>Speaker:</i> John Fitzgerald, IE	11:10 - 11:20
QM1-3	Lessons learned from first-time inspections and re-accreditation inspections <i>Speaker:</i> Carolina Herranz, ES	11:20 - 11:30
QM1-4	HSCT QM Book <i>Speaker:</i> Joaquim Vives Armengol, ES	11:30 - 11:45
QM1-5	Q&A	11:45 - 12:15
<i>Nurses Group</i> 11:25 - 12:15		
		Auditorium 3
NG05 - Joint session: Teamwork in the CAR T-cells setting <i>Chair:</i> Sara Marcos Corrales, ES <i>Chair:</i> John Murray, GB		
NG05-1	Training workforce <i>Speaker:</i> Ian Hollingsworth, GB	11:25 - 11:40
NG05-2	Quality of life in caregivers and patients undergoing CAR T therapy <i>Speaker:</i> Anna Barata, US	11:40 - 11:57
NG05-3	Q&A	11:57 - 12:15
<i>Breaks</i> 12:15 - 13:00		
		Auditorium 1
Lunch Break, Poster Viewing, Visit Exhibition		
<i>Wellness session</i> 12:20 - 12:50		
		Auditorium 1
Therapeutic Origami session		

CME Symposium

13:00 - 14:00

Auditorium 1

IS31 - Gene Therapies for Inherited and Rare Diseases in 2021: What Will They Mean for Patients? - CME Symposium

Chair: Janet Kwiatkowski, US

IS31-1	What do You Know About Gene Therapy? <i>Speaker:</i> Janet Kwiatkowski, US	13:00 - 13:10
IS31-2	Overview of Gene Therapy in Different Diseases <i>Speaker:</i> Andreas E. Kulozik, DE	13:10 - 13:20
IS31-3	Practical Considerations for Gene Therapy <i>Speaker:</i> Franco Locatelli, IT	13:20 - 13:30
IS31-4	Do Gene Therapies Have the Potential for Cure? <i>Speaker:</i> Franco Locatelli, IT <i>Speaker:</i> Andreas E. Kulozik, DE <i>Speaker:</i> Janet Kwiatkowski, US	13:30 - 13:50
IS31-5	Summary and Audience Q&A <i>Speaker:</i> Janet Kwiatkowski, US	13:50 - 14:00

Industry Symposium

13:00 - 14:00

Auditorium 2

IS32 - A look into the future: how will cellular therapies affect our clinical practice in multiple myeloma? - Janssen Industry Symposium

Chair: John Gribben, GB

IS32-1	Introduction and welcome <i>Speaker:</i> John Gribben, GB	13:00 - 13:05
IS32-2	Cellular therapies in MM – where are we now and where are we going? <i>Speaker:</i> John Gribben, GB	13:05 - 13:20
IS32-3	Panel discussion: What do we need to know about cellular therapies for our clinical practice? <i>Speaker:</i> María Victoria Mateos, ES <i>Speaker:</i> Saad Usmani, US	13:20 - 13:58
IS32-4	Close <i>Speaker:</i> John Gribben, GB	13:58 - 14:00

General

13:00 - 13:50

Auditorium 4

GS3 - General Assembly

Chair: Nicolaus Kröger, DE

GS3-1	President's Report <i>Speaker:</i> Nicolaus Kröger, DE	13:00 - 13:10
GS3-2	Treasurer's Financial Report <i>Speaker:</i> Harry Dolstra, NL	13:10 - 13:20

GS3-3	Secretary's Report <i>Speaker:</i> John Snowden, GB	13:20 - 13:30
GS3-4	2021 Election results <i>Speaker:</i> John Snowden, GB	13:30 - 13:35
GS3-5	Outgoing Board members <i>Speaker:</i> Nicolaus Kröger, DE	13:35 - 13:45
GS3-6	Q&A	13:45 - 13:50

Statistics

13:00 - 14:00

Auditorium 5

Stat2 - Statistical Symposium

Chair: Liesbeth de Wreede, NL

Stat2-1	Sensitivity Analysis: E-value based on directly adjusted survival probabilities <i>Speaker:</i> Mei-Jie Zhang, US	13:00 - 13:25
Stat2-2	Working with incomplete data: When one-size-fits-all does not fit <i>Speaker:</i> Nicole Erler, NL	13:25 - 13:50
Stat2-3	Q&A	13:50 - 14:00

Quality Management

13:00 - 14:00

Auditorium 6

QM2 - QMS and new activities in SC Program

Chair: Carlos Torrico, ES

QM2-1	Allogeneic SCT in the COVID era <i>Speaker:</i> Anna Grassi, IT	13:00 - 13:15
QM2-2	Integration of JACIE Quality Management System and Qualification for IEC <i>Speaker:</i> Helena Munro, GB	13:15 - 13:30
QM2-3	Investigational Products <i>Speaker:</i> Simon Hack, GB	13:30 - 13:45
QM2-4	Q&A	13:45 - 14:00

Industry Symposium

13:00 - 14:00

MTE rooms

IS36 - How do I manage the high-risk 'difficult-to-treat' stem cell transplant recipients with CMV infections (including refractory/resistant) - Takeda Industry Meet the Expert Lunch - Room MTE4

IS36-1	Identifying the high-risk 'difficult-to-treat' HSCT recipient <i>Speaker:</i> Per Ljungman, SE	13:00 - 13:10
IS36-2	Q&A and discussion	13:10 - 13:25
IS36-3	Managing the high-risk transplant recipient with CMV	13:25 - 13:40

	<i>Speaker:</i> Per Ljungman, SE	
IS36-4	Q&A and discussion	13:40 - 14:00
<i>Industry Symposium</i>		
13:00 - 14:00		MTE rooms
Industry Meet the Expert lunch sessions		
<i>Industry Symposium</i>		
13:00 - 14:00		MTE rooms
IS34 - Early use of ECP in aGvHD - Therakos-Mallinckrodt Industry Meet the Expert Lunch - Room MTE2		
<i>Chair:</i> Amin Alousi, US		
<i>Industry Symposium</i>		
13:00 - 14:00		MTE rooms
IS33 - New Agents and New Tools for the Management of CMV in HSCT Patients: Interactive patient case presentation - MSD Industry Meet the Expert Lunch 2 - Room MTE1		
<i>Chair:</i> Roy Chemaly, US		
<i>Breaks</i>		
14:00 - 14:30		Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition		
<i>Workshop</i>		
14:30 - 15:45		Auditorium 1
W01 - Battling acute leukemia relapse after allogeneic HSCT		
<i>Chair:</i> Thomas Cluzeau, FR		
<i>Chair:</i> David Valcárcel Ferreira, ES		
W1-1	CAR T-cells	14:30 - 14:45
	<i>Speaker:</i> Mohamad Mohty, FR	
W1-2	Maintenance strategies after allogeneic HSCT	14:45 - 15:00
	<i>Speaker:</i> Charles Craddock, GB	
W1-3	Second allogeneic HSCT	15:00 - 15:15
	<i>Speaker:</i> Bipin Savani, US	
W1-4	Q&A	15:15 - 15:45
<i>Workshop</i>		
14:30 - 15:45		Auditorium 2
W02 - Immune biology and therapy beyond CAR-T cells		
<i>Chair:</i> Harry Dolstra, NL		
<i>Chair:</i> José M. Moraleda, ES		
W2-1	Engineering hematopoietic stem and progenitor cells for gene and immunotherapy	14:30 - 14:45
	<i>Speaker:</i> Hans-Peter Kiem, US	
W2-2	Immunobiology of Mesenchymal Stromal Cells in allo- and auto-immune disorders	14:45 - 15:00

	<i>Speaker:</i> Willem Fibbe, NL	
W2-3	Mesenchymal stromal cells for respiratory distress and other organ failure <i>Speaker:</i> Sergio Querol, ES	15:00 - 15:15
W2-4	Q&A	15:15 - 15:45
<i>Nurses Group</i> 14:30 - 15:45		
Auditorium 3		
NG06 - Supportive and palliative care		
<i>Chair:</i> Sandra Schoenfeld, CH		
<i>Chair:</i> Cristina Canaleta, ES		
NG06-1	Meaning centered interventions <i>Speaker:</i> Silke Walter, CH <i>Speaker:</i> Sandra Eckstein, CH	14:30 - 14:50
NG06-2	Challenges of decision making - End of life <i>Speaker:</i> Jakob Passweg, CH	14:50 - 15:10
NG06-3	Early integration <i>Speaker:</i> Richard Towers, GB	15:10 - 15:30
NG06-4	Q&A	15:30 - 15:45
<i>Paediatric Day</i> 14:30 - 15:45		
Auditorium 4		
Paed3 - Paediatric Diseases Oral Session		
Paed3-1	TREOSULFAN- VERSUS BUSULFAN-BASED MYELOABLATIVE CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA. A REPORT FROM THE INTERNATIONAL ALL-SCTPED FORUM TRIAL <i>Speaker:</i> Herbert Pichler, AT	14:30 - 14:39
Paed3-2	SEROTHERAPY-FREE REGIMEN IMPROVES NON-RELAPSE MORTALITY AND EARLY IMMUNE RECOVERY AMONG THE RECIPIENTS OF ?? T CELL-DEPLETED HAPLOIDENTICAL GRAFTS: RETROSPECTIVE STUDY IN CHILDHOOD LEUKEMIA <i>Speaker:</i> Maria Dunaykina, RU	14:39 - 14:48
Paed3-3	EXCELLENT TRANSPLANT SURVIVAL FOR CHILDREN WITH ADENOSINE DEAMINASE (ADA) DEFICIENCY <i>Speaker:</i> Elisabetta Ghimenton, GB	14:48 - 14:57
Paed3-4	IMPACT OF EARLY LYMPHOCYTE IMMUNE RECONSTITUTION ON TRANSPLANT-RELATED MORTALITY AMONG CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH ALPHA-BETA T CELL DEPLETION <i>Speaker:</i> Svetlana Glushkova, RU	14:57 - 15:06
Paed3-5	AZACITIDINE AND PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL	15:06 - 15:15

	TRANSPLANTATION IN PEDIATRIC PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER COHORT STUDY <i>Speaker:</i> Natalie Booth, US	
Paed3-6	ENTERAL NUTRITION PROMOTES THE RECOVERY OF GUT MICROBIOME HOMEOSTASIS AND PROTECTS FROM BLOODSTREAM INFECTIONS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Daniele Zama, IT	15:15 - 15:24
Paed3-7	IN VIVO B-CELL DEPLETION WITH MYELOABLATIVE CONDITIONING FOR UMBILICAL CORD BLOOD TRANSPLANT IN HURLER SYNDROME ABOLISHES IMMUNE MEDIATED CYTOPENIA AND GRAFT REJECTION <i>Speaker:</i> Ramya Hanasoge Nataraj, GB	15:24 - 15:33
Paed3-8	ALEMTUZUMAB PROTECTS CHILDREN FROM SEVERE ACUTE AND FROM CHRONIC GVHD IN PBSC AS WELL AS MARROW GRAFT RECIPIENTS: A MULTICENTRE RETROSPECTIVE COHORT ANALYSIS <i>Speaker:</i> Su Han Lum, GB	15:33 - 15:42
<i>Pharmacists Day</i> 14:30 - 15:45		
Pharm3 - Supportive care 2 <i>Chair:</i> Vera Domingos, PT <i>Chair:</i> Vera Pires, PT		
Pharm3-1	What's new in antifungals? <i>Speaker:</i> Rodrigo Martino, ES	14:30 - 14:50
Pharm3-2	Chemotherapy Induced Nausea and Vomiting <i>Speaker:</i> Sumantha Gabriel, GB	14:50 - 15:10
Pharm3-3	Nutrition strategies in Hematopoietic Stem Cell Transplantation <i>Speaker:</i> Hartmut Bertz, DE	15:10 - 15:30
Pharm3-4	Q&A	15:30 - 15:45
<i>Quality Management</i> 14:30 - 15:45		
QM3 - Draft 8th Edition of the STD <i>Chair:</i> Riccardo Saccardi, IT		
QM3-1	Clinical standards <i>Speaker:</i> Kim Orchard, GB	14:30 - 14:42
QM3-2	Collections Standards <i>Speaker:</i> Nina Worel, AT	14:42 - 14:54
QM3-3	Processing Standards <i>Speaker:</i> Ivan van Riet, BE	14:54 - 15:06

QM3-4	Quality Management Standards <i>Speaker:</i> Simon Hack, GB	15:06 - 15:18
QM3-5	Immune Effector Cells Standards <i>Speaker:</i> Riccardo Saccardi, IT	15:18 - 15:30
QM3-6	Q&A	15:30 - 15:45

Breaks

15:45 - 16:15

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Plenary Session

16:15 - 17:30

Auditorium 1

P2 - Artificial Intelligence approaching Hemato-oncology and HSCT

Chair: Rafael Duarte, ES

Chair: Myriam Labopin, FR

P2-1	Basic concepts, applications, and limitations of Machine Learning: A primer for hematologists <i>Speaker:</i> Roni Shouval, US	16:15 - 16:30
P2-2	Artificial Intelligence in Hematology <i>Speaker:</i> Grzegorz Basak, PL	16:30 - 16:45
P2-3	Artificial Intelligence to support clinical decision making on infections in Hematology <i>Speaker:</i> Carolina García-Vidal, ES	16:45 - 17:00
P2-4	The role of technology and Artificial Intelligence in GVHD <i>Speaker:</i> Sharukh Hashmi, US	17:00 - 17:15
P2-5	Q&A	17:15 - 17:30

Workshop

16:15 - 17:30

Auditorium 2

W03 - Autoimmune diseases

Chair: Raffaella Greco, IT

Chair: Montserrat Rovira, ES

W3-1	Immunological basis of HSCT in autoimmune disorders <i>Speaker:</i> Paolo Muraro, GB	16:15 - 16:30
W3-2	Stem cells in System Sclerosis: Clinical experience and translational relevance <i>Speaker:</i> Nicoletta Del Papa, IT	16:30 - 16:45
W3-3	Autologous HSCT as a treatment for autoimmune disease of the nervous system <i>Speaker:</i> Harry Atkins, CA	16:45 - 17:00
W3-4	Q&A	17:00 - 17:30

Nurses Group
16:15 - 17:30

Auditorium 3

NG07 - Infections

Chair: Daphna Hutt, IL
Chair: Marta Pamias, ES

NG07-1	How to find a fungal infection <i>Speaker:</i> Toine Mercier, BE	16:15 - 16:30
NG07-2	CMV <i>Speaker:</i> Patrice Ceballos, FR	16:30 - 16:45
NG07-3	Polyoma virus <i>Speaker:</i> Marta Canesi, IT	16:45 - 17:00
NG07-4	Nursing leadership in antimicrobial stewardship interventions <i>Speaker:</i> Franky Buyle, BE	17:00 - 17:15
NG07-5	Q&A	17:15 - 17:30

Paediatric Day
16:15 - 17:30

Auditorium 4

Paed4 - Inborn Errors Oral Session

Paed4-1	T-REPLETE HLA-MATCHED GRAFTS VERSUS T-DEPLETED HLA-MISMATCHED GRAFTS IN INBORN ERRORS OF IMMUNITY: WHERE ARE WE NOW? <i>Speaker:</i> Su Han Lum, GB	16:15 - 16:24
Paed4-2	EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34⁺ HEMATOPOIETIC STEM AND PROGENITOR CELLS IN TRANSFUSION-DEPENDENT β-THALASSEMIA AND SICKLE CELL DISEASE <i>Speaker:</i> Selim Corbacioglu, DE	16:24 - 16:33
Paed4-3	INTERNATIONAL SURVEY AND RETROSPECTIVE ANALYSIS OF 28 PATIENTS WITH IFN-γ-RECEPTOR DEFICIENCY <i>Speaker:</i> Peter Olbrich, ES	16:33 - 16:42
Paed4-4	PHENOTYPE REVERSAL, EXCELLENT OVERALL, GVHD-FREE AND GRAFT FAILURE-FREE SURVIVAL IN 55 ADOLESCENTS AND ADULTS WITH INBORN ERRORS OF IMMUNITY FOLLOWING REDUCED INTENSITY ALLOGENEIC HSCT <i>Speaker:</i> Thomas A Fox, GB	16:42 - 16:51
Paed4-5	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY: OUTCOMES BY DONOR CELL SOURCE AND MATCH, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE <i>Speaker:</i> Robert Chiesa, GB	16:51 - 17:00
Paed4-6	ALLOGENEIC HSCT FOR ADOLESCENTS AND ADULTS WITH INBORN ERRORS OF IMMUNITY: A RETROSPECTIVE STUDY OF THE INBORN ERRORS WORKING PARTY (IEWP)	17:00 - 17:09

	<i>Speaker:</i> Michael Albert, DE	
Paed4-7	COMBINING ENZYME REPLACEMENT THERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANT FOR WOLMAN DISEASE: A NOVEL TREATMENT PARADIGM FOR OPTIMAL LONG TERM DISEASE CONTROL <i>Speaker:</i> Jane E Potter, GB	17:09 - 17:18
Paed4-8	FEASIBILITY OF PREMATURE SIROLIMUS CESSATION POST NON-MYELOABLATIVE TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE <i>Speaker:</i> Moussab Damla, SA	17:18 - 17:27
<i>Pharmacists Day</i> 16:15 - 17:30		
		Auditorium 5
Pharm4 - Pharmaceutical Research in HSCT		
<i>Chair:</i> Claudia Langebrake, DE <i>Chair:</i> Tiene Bauters, BE		
Pharm4-1	IRON CHELATION WITH DEFERASIROX INCREASES BUSULFAN AUC DURING CONDITIONING CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Sonja Essmann, DE	16:15 - 16:27
Pharm4-2	DOES TREATMENT WITH GLUCOCORTICOIDS INFLUENCE THE ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING CYSTATIN C? <i>Speaker:</i> Claudia Langebrake, DE	16:27 - 16:39
Pharm4-3	ORAL LEVETIRACETAM IS ASSOCIATED WITH DECREASED SYSTEMIC BUSULFAN EXPOSURE AFTER ORAL DOSING <i>Speaker:</i> Tareq Artul, IL	16:39 - 16:51
Pharm4-4	Pharmaceutical Research in HSCT <i>Speaker:</i> Rick Admiraal, NL	16:51 - 17:15
Pharm4-5	Discussion	17:15 - 17:30
<i>Quality Management</i> 16:15 - 17:30		
		Auditorium 6
QM4 - Inspectors Session		
<i>Chair:</i> Tuula Rintala, GB		
QM4-1	JACIE Activity Report & Update / Volunteers JACIE's most important resource <i>Speaker:</i> Raquel Espada, ES <i>Speaker:</i> Anna Pasztor, ES	16:15 - 16:25
QM4-2	Inspection team: Roles <i>Speaker:</i> Mara Magri, IT <i>Speaker:</i> Nick van Sinderen, NL	16:25 - 16:35
QM4-3	How to prepare the JACIE Inspection Report?	16:35 - 16:45

	<p><i>Speaker:</i> Renza Monteleone, IT</p> <p><i>Speaker:</i> Esther Zafra, ES</p>	
QM4-4	<p>Most frequent difficulties faced by JACIE Report Assessors</p> <p><i>Speaker:</i> Raquel Espada, ES</p> <p><i>Speaker:</i> Carolina Herranz, ES</p>	16:45 - 16:55
QM4-5	<p>Post Inspection Phase (Assessing CAPA) and Post Accreditation (Interim Audit)</p> <p><i>Speaker:</i> Carla Sánchez, ES</p> <p><i>Speaker:</i> Richard Olaussen, NO</p>	16:55 - 17:05
QM4-6	<p>Transparency in Reporting</p> <p><i>Speaker:</i> Yiskah Simons, SA</p>	17:05 - 17:15
QM4-7	Q&A	17:15 - 17:30
<p><i>Abstract Awards</i></p> <p>17:30 - 18:00</p> <p>AA2 - Abstracts Awards</p>		
AA2-1	<p>Jian-Jian Luan Award - Introduction</p> <p><i>Speaker:</i> Bertram Glass, DE</p>	17:30 - 17:31
AA2-2	<p>STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD DATA GERMANY</p> <p><i>Speaker:</i> Wolfgang Andreas Bethge, DE</p>	17:31 - 17:43
AA2-3	<p>Jon J. van Rood Award - Introduction</p> <p><i>Speaker:</i> Hans-Hochem Kolb, DE</p>	17:43 - 17:44
AA2-4	<p>METABOLIC REPROGRAMMING OF DONOR T CELLS ENHANCES GRAFT-VERSUS-LEUKEMIA EFFECTS IN MICE AND HUMANS</p> <p>Read Abstract</p> <p><i>Speaker:</i> Franziska Uhl, DE</p>	17:44 - 17:56
AA2-5	<p>Best Young Abstracts</p> <p><i>Speaker:</i> Harry Dolstra, NL</p>	17:56 - 18:00
<p><i>Meet the Expert</i></p> <p>17:30 - 18:30</p> <p>Meet the Expert sessions</p>		
MTE-6	<p>How to modulate the microbiome in HSCT - Room MTE1</p> <p><i>Speaker:</i> Florent Malard, FR</p>	17:30 - 17:30
MTE-7	<p>COVID-19 and other vaccines in HSCT recipients - Room MTE2</p> <p><i>Speaker:</i> Simone Cesaro, IT</p>	17:30 - 17:30
MTE-8	<p>What changes in conditioning regimens we should implement in 2021? - Room MTE3</p> <p><i>Speaker:</i> Andrea Bacigalupo, IT</p>	17:30 - 17:30
MTE-9	Update on biomarkers for GVHD - Room MTE4	17:30 - 17:30

	<i>Speaker:</i> Kirk Schultz, CA	
MTE-10	Management of EBV-PTLD in 2021 - Room MTE5	17:30 - 17:30
	<i>Speaker:</i> Jan Styczynski, PL	

Wednesday, 17. March 2021

Workshop

09:15 - 10:30

Auditorium 1

W04 - The expanding field of cellular therapies in inborn errors of immunity (IEI)

Chair: Arjan Lankester, NL

Chair: Cristina Díaz de Heredia, ES

W4-1	Curative options in X-CGD: HCT or gene therapy <i>Speaker:</i> Tayfun Gungor, CH	09:15 - 09:31
W4-2	HSCT in monogenic autoimmune disorders <i>Speaker:</i> Eleonora Gambineri, IT	09:31 - 09:55
W4-3	Challenges of HSCT in adult IEI patients <i>Speaker:</i> Emma Morris, GB	09:55 - 10:10
W4-4	Advances in gene editing to treat non-SCID IEI <i>Speaker:</i> Alessandro Aiuti, IT	10:10 - 10:25
W4-5	Q&A	10:25 - 10:30

Workshop

09:15 - 10:30

Auditorium 2

W05 - Transplantation and bone marrow failure in 2021

Chair: Béatrice Drexler, CH

Chair: Lucrecia Yañez, ES

W5-1	Up-front transplantation in aplastic anemia: Where are we? <i>Speaker:</i> Jean-Hugues Dalle, FR	09:15 - 09:30
W5-2	Haploidentical HSCT and idiopathic aplastic anaemia <i>Speaker:</i> Amy DeZern, US	09:30 - 09:45
W5-3	Haploidentical HSCT in Fanconi anaemia <i>Speaker:</i> Carmem Bonfim, BR	09:45 - 10:00
W5-4	Blackfan Diamond anaemia and HSCT <i>Speaker:</i> Brigitte Strahm, DE	10:00 - 10:15
W5-5	Q&A	10:15 - 10:30

Nurses Group

09:15 - 10:30

Auditorium 3

NG08 - How do I manage... Isolation practices and patient and donors preparation?

Chair: Janet Baker, GB

Chair: Alba Fernández Arroyo, ES

NG08-1	Evidence for Isolation <i>Speaker:</i> Iris Agreiter, IE	09:15 - 09:30
NG08-2	Evidence against Isolation <i>Speaker:</i> Cristina Gallego, ES	09:30 - 09:45

NG08-3	Hematopoietic Transplant patient's preparation <i>Speaker:</i> Manuela Salinero, ES	09:45 - 10:00
NG08-4	Donor work up <i>Speaker:</i> Annika Kisch, SE	10:00 - 10:15
NG08-5	Q&A	10:15 - 10:30

How do I ... ?
09:15 - 10:30

Auditorium 4

HDI3 - How Do I... Adapt my treatment approach for high risk GvHD patients? - Supported through an unrestricted educational grant by Therakos-Mallinckrodt

Chair: Daniel Wolff, DE

HDI3-1	Role of biomarker <i>Speaker:</i> Francis Ayuk, DE	09:15 - 09:40
HDI3-2	Role of microbiome <i>Speaker:</i> Henrik Sengeløv, DK	09:40 - 10:05
HDI3-3	Q&A	10:05 - 10:30

Data Management
09:15 - 10:30

Auditorium 5

DM01 - Education session 1 - Discussion forum: Cellular therapy

Chair: Lucas Stolarczyk, GB

DM1-1	Toxicities after CART: pathology clinical manifestations and grading <i>Speaker:</i> Jürgen Kuball, NL	09:15 - 09:35
DM1-2	Toxicities after CART: treatment and prognostic factors <i>Speaker:</i> Álvaro Urbano-Ispizua, ES	09:35 - 10:00
DM1-3	Discussion forum - Cellular therapy Q&A <i>Speaker:</i> Chiara Bonini, IT <i>Speaker:</i> Lawrence Vermeir, GB <i>Speaker:</i> Jürgen Kuball, NL <i>Speaker:</i> Álvaro Urbano-Ispizua, ES	10:00 - 10:30

Industrial Theatre
09:15 - 17:30

IT

IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session

This session is available throughout the whole congress

Chair: Volker Witt, AT

Industrial Theatre

09:15 - 17:30

IT

IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session

This session is available throughout the whole congress

Chair: Amir Hefni, GB

Chair: David Kuzan, US

Chair: Carolin Barth, CH

Industrial Theatre

09:15 - 17:30

IT

IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre session

This session is available throughout the whole congress

Chair: Dick Sundh, AU

Industrial Theatre

09:15 - 17:30

IT

Industry Theatre sessions

Educational

09:15 - 17:30

On-Demand Library

E09 - Allogeneic HSCT in MDS and MPN

This session is available in our on-demand library throughout the whole congress

E9-1	Definition of graft failure/relapse after allo-HCT in myelofibrosis <i>Speaker:</i> Donal McLornan, GB	-
E9-2	Allogeneic HSCT in patients with therapy-related MDS/AML <i>Speaker:</i> Marie Robin, FR	-
E9-3	The role of maintenance therapy after allogeneic HSCT in MDS <i>Speaker:</i> Francesco Onida, IT	-

Educational

09:15 - 17:30

On-Demand Library

E13 - Allogeneic transplantation from alternative donors

This session is available in our on-demand library throughout the whole congress

E13-1	Haploidentical vs unrelated in AML <i>Speaker:</i> Didier Blaise, FR	-
E13-2	Haploidentical vs unrelated in ALL <i>Speaker:</i> Arnon Nagler, IL	-
E13-3	Haploidentical vs cord Blood in acute leukaemia <i>Speaker:</i> Frederic Baron, BE	-

Working Party Session

09:15 - 17:30

On-Demand Library

ADWP - Autoimmune Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

ADWP-1	Welcome and Update from the EBMT registry <i>Speaker:</i> Raffaella Greco, IT	-
ADWP-2	Introducing the session and speakers <i>Speaker:</i> Tobias Alexander, DE	-
ADWP-3	HSCT for multiple sclerosis: Future directions in patient selection and conditioning regimen <i>Speaker:</i> Riccardo Saccardi, IT	-
ADWP-4	HSCT for systemic sclerosis: Future directions in patient selection and conditioning regimen <i>Speaker:</i> Dominique Farge, FR	-
ADWP-5	HSCT for Crohn's disease: future directions in patient selection, mobilization and conditioning regimen <i>Speaker:</i> Elena Ricart, ES	-
ADWP-6	HSCT for autoimmune diseases: Current aspects on early and late complications <i>Speaker:</i> Majid Kazmi, GB	-
ADWP-7	HSCT for autoimmune diseases: Conditioning regimen and outcomes from the Russian experience <i>Speaker:</i> Denis Fedorenko, RU	-
ADWP-8	Closing remarks <i>Speaker:</i> Tobias Alexander, DE	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG16 - Cellular therapy update

This session is available in our on-demand library throughout the whole congress

NG16-1	Update: What's new? <i>Speaker:</i> Rose Ellard, GB	-
NG16-2	Spotlight on the Lymphoma Patient Experience <i>Speaker:</i> Lorna Warwick, CA	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG19 - Disease update

This session is available in our on-demand library throughout the whole congress

NG19-1	Acute leukaemia <i>Speaker:</i> Inge Govaerts, BE	-
NG19-2	Managing lymphoma: What nurses and healthcare professionals need to know <i>Speaker:</i> Erik Aerts, CH	-
NG19-3	Multiple myeloma <i>Speaker:</i> Maaïke de Ruijter, NL	-

NG19-4	CML (ITK management) <i>Speaker:</i> Laura Borg, GB	-
--------	---	---

Nurses Group
09:15 - 17:30

On-Demand Library

NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG13-1	SARS-CoV-2 vaccines overview <i>Speaker:</i> Almudena Ramírez, ES	-
NG13-2	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation <i>Speaker:</i> Jose Luis Piñana, ES	-
NG13-3	COVID-19: The EBMT recommendations for management of HCT patients and donors <i>Speaker:</i> Per Ljungman, SE	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting

This session is available in our on-demand library throughout the whole congress

NG15-1	Managing virtual conversations <i>Speaker:</i> Lloyd Allen, GB	-
NG15-2	Nurse perspective: Virtual long term follow up for BMT patients <i>Speaker:</i> Michelle Kenyon, GB	-
NG15-3	Back to the future: Emphasizing our new practices <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	-

Nurses Group
09:15 - 17:30

On-Demand Library

NG24 - Outreach projects

This session is available in our on-demand library throughout the whole congress

NG24-2	Outreach project India: EBMT MIC pediatric advanced care training (EMPACT) <i>Speaker:</i> Lawrence Faulkner, IT	09:15 - 09:15
NG24-3	Outreach project: LABMT <i>Speaker:</i> Sara Saez Carrasco, CO	09:15 - 09:15

Educational
09:15 - 17:30

On-Demand Library

E11 - Management of early complications in an ambulatory/outpatient setting

This session is available in our on-demand library throughout the whole congress

E11-1	Early infectious complications	-
-------	---------------------------------------	---

	<i>Speaker:</i> Jan Styczynski, PL	
E11-2	Non-infective complications: GVHD and organ toxicity <i>Speaker:</i> Gerhard Hildebrandt, US	-
E11-3	The Hospital Clínic experience <i>Speaker:</i> Francesc Fernández-Avilés, ES	-
<i>Workshop</i> 09:15 - 17:30		
On-Demand Library		
W10 - Controversies in T-cell NHL		
This session is available in our on-demand library throughout the whole congress		
W10-1	Are we improving first-line therapy in TCL? <i>Speaker:</i> Eva Domingo Domenech, ES	09:15 - 09:15
W10-3	Insights in CAR-T therapy for T cell Lymphomas <i>Speaker:</i> Helen Heslop, US	09:15 - 09:15
<i>Workshop</i> 09:15 - 17:30		
On-Demand Library		
W13 - CARs beyond T cells: A focus on next generation CAR-NK cells		
This session is available in our on-demand library throughout the whole congress		
W13-1	CAR NK cells as an "off the shelf" immunotherapy <i>Speaker:</i> Ulrike Köhl, DE	-
W13-2	CARs and ADCC to make off-the-shelf NK cells specific against hematologic malignancies <i>Speaker:</i> Jeffrey Miller, US	-
W13-3	Target NKG2D ligands on tumor cells <i>Speaker:</i> Antonio Pérez-Martínez, ES	-
<i>Workshop</i> 09:15 - 17:30		
On-Demand Library		
W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?		
This session is available in our on-demand library throughout the whole congress		
W14-1	A matched unrelated donor <i>Speaker:</i> Bronwen Shaw, US	-
W14-2	A haploidentical donor <i>Speaker:</i> Mi Kwon, ES	-
W14-3	When to choose cord blood <i>Speaker:</i> Filippo Milano, US	-
W14-4	Do we have to challenge our current donor hierarchy for patients with hemoglobinopathies? <i>Speaker:</i> Selim Corbacioglu, DE	-

Workshop

09:15 - 17:30

On-Demand Library

W11 - Key organ manifestations of chronic GVHD

This session is available in our on-demand library throughout the whole congress

W11-1	Pulmonary chronic GVHD <i>Speaker:</i> Hildegard Greinix, AT	-
W11-2	Ocular cGVHD diagnostics - Practical approach <i>Speaker:</i> Igor Petricek, HR	-
W11-3	Gastrointestinal manifestations of chronic GVHD <i>Speaker:</i> Daniel Wolff, DE	-

Data Management

09:15 - 17:30

On-Demand Library

DM06 - Education session 6

This session is available in our on-demand library throughout the whole congress

DM6-1	Response in Multiple Myeloma <i>Speaker:</i> Meral Beksac, TR	-
-------	---	---

Data Management

09:15 - 17:30

On-Demand Library

DM08 - Education session 8

This session is available in our on-demand library throughout the whole congress

DM8-1	Infectious complications <i>Speaker:</i> Malgorzata Mikulska, IT	-
-------	--	---

Special Session

09:15 - 17:30

On-Demand Library

SS09 - How to get published

This session is available in our on-demand library throughout the whole congress

SS9-1	BMT: Official journal of the EBMT <i>Speaker:</i> Hillard Lazarus, US	-
SS9-2	How to get published <i>Speaker:</i> Mohamad Mohty, FR	-

Joint Session

09:15 - 17:30

On-Demand Library

JS04 - Joint session LABMT

This session is available in our on-demand library throughout the whole congress

JS4-1	Transplant rates, Trends: WBMT/LABMT 2018 survey <i>Speaker:</i> Oscar González-Ramella, MX	-
JS4-2	Financing of HSCT in Latin America <i>Speaker:</i> Gregorio Jaimovich, AR	-
JS4-3	Selection, management and follow up of related donors:	-

Overview

Speaker: Nina Worel, AT

JS4-4	Selection, management and follow up of related donors: Development of an LABMT consensus	-
	Speaker: Gonzalo Ferini, AR	
JS4-5	Haploidentical transplants in Latin America: Experience from Argentina/GATMO-TC in acute lymphoblastic leukemia	-
	Speaker: Ana Basquiera, AR	
JS4-6	Haploidentical transplants in Latin America: Experience from Brazil/SBTMO in aplastic anemia	-
	Speaker: Carmem Bonfim, BR	

Nurses Group
09:15 - 17:30

On-Demand Library

NG20 - How do I become an expert?

This session is available in our on-demand library throughout the whole congress

NG20-1	Conditioning regimen	-
	Speaker: Nicolas Kint, BE	
NG20-2	Immunosuppression	-
	Speaker: Tiene Bauters, BE	
NG20-3	Vaccinations	-
	Speaker: Bipin Savani, US	

Special Session
09:15 - 17:30

On-Demand Library

SS11 - The EBMT for Trainees

This session is available in our on-demand library throughout the whole congress

SS11-1	Being a Trainee in SCT / Cellular Therapy	-
	Speaker: Nico Gagelmann, DE	
	Speaker: Claire Horgan, GB	
	Speaker: Yasmina Serroukh, BE	
	Speaker: Yuliya Rogacheva, RU	
	Speaker: Tamar Azikuri, GE	
SS11-2	Overview of allogeneic SCT for the trainee: 'Things I wish I'd known'	-
	Speaker: Helene Schoemans, BE	
SS11-3	Establishing a career in SCT/cellular therapy	-
	Speaker: Jordan Gauthier, US	
SS11-4	Complications for trainees 1: How to manage acute GVHD	-
	Speaker: Zinaida Peric, HR	
SS11-5	Complications for trainees 2: How to manage VOD	-
	Speaker: Ivan Moiseev, RU	

How do I ... ?

09:15 - 17:30

On-Demand Library

HDI6 - How Do I... manage toxicity in immunosuppressed patients?

This session is available in our on-demand library throughout the whole congress

HDI6-1	Transplant associated TMA <i>Speaker:</i> Sergio Giralt, US	-
HDI6-2	Infectious complication <i>Speaker:</i> Jan Styczynski, PL	-

Industry Symposium

09:15 - 17:30

On-Demand Library

IS38 - CMV management in high-risk patients - Biotest Industry Symposium

This session is available in our on-demand library throughout the whole congress

Chair: Fabio Ciceri, IT

IS38-1	A scoring system to define patients at high risk for CMV <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	09:15 - 09:15
IS38-2	How to manage CMV high-risk patients <i>Speaker:</i> Michele Malagola, IT	09:15 - 09:15
IS38-3	The immunological benefits of CMV-specific immunoglobulins <i>Speaker:</i> Javier Carbone, ES	09:15 - 09:15

Special Session

09:15 - 17:30

On-Demand Library

SS07 - Young Ambassadors Session

This session is available in our on-demand library throughout the whole congress

SS7-1	How build up a career in: Academia <i>Speaker:</i> Didier Blaise, FR	-
SS7-2	How build up a career in: In Pharmaceutical Industry <i>Speaker:</i> Dan Tovar, FR	-
SS7-3	How build up a career in: In Public domains <i>Speaker:</i> Eva Hilgenfeld, DE	-
SS7-4	What to avoid when writing a paper <i>Speaker:</i> Jakob Passweg, CH	-
SS7-5	How to write a successful grant <i>Speaker:</i> Robert Zeiser, DE	-
SS7-6	Introduction to medical statistics <i>Speaker:</i> Simona Iacobelli, IT	-
SS7-7	Social media in stem cell transplantation and cellular therapy <i>Speaker:</i> Navneet Majhail, US	-

Oral Session
09:15 - 17:30

On-Demand Library

OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---------------|
| OS4-1 | INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) TREATED IN THE PHASE 3 NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212) STUDIES
<i>Speaker:</i> Isabelle Thuret, FR | 09:15 - 09:25 |
| OS4-2 | NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE TREATMENT OF ADULT HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES
<i>Speaker:</i> Alessandro Rambaldi, IT | 09:25 - 09:35 |
| OS4-3 | CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T-CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
<i>Speaker:</i> Eliana Ruggiero, IT | 09:35 - 09:45 |
| OS4-4 | CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY IN MPSIIIA
<i>Speaker:</i> Jane Louise Kinsella, GB | 09:45 - 09:55 |
| OS4-5 | EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Dalia Sheta, DE | 09:55 - 10:05 |
| OS4-6 | REAL-WORLD EFFECTIVENESS AND SAFETY OF BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST RELAPSE
<i>Speaker:</i> Alessandro Rambaldi, IT | 10:05 - 10:15 |
| OS4-7 | GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
<i>Speaker:</i> Paulien van Houten, NL | 10:15 - 10:25 |
| OS4-8 | IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC ANALYSES FROM THE PEGASUS STUDY
<i>Speaker:</i> David Cella, US | 10:25 - 10:35 |

Oral Session

09:15 - 17:30

On-Demand Library

OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes

This session is available in our on-demand library throughout the whole congress

OS18-1	GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS WITH MYELOID NEOPLASIA <i>Speaker:</i> Carmelo Gurnari, US	09:15 - 09:15
OS18-2	RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA. A STUDY OF THE EBMT-CMWP <i>Speaker:</i> Alicia Rovó, CH	09:15 - 09:15
OS18-3	CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A RETROSPECTIVE ANALYSIS FROM THE CHRONIC MALIGNANCIES WORKING PARTY <i>Speaker:</i> Christof Scheid, DE	09:15 - 09:15
OS18-4	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM AFTER BREAST CANCER TREATMENT: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT <i>Speaker:</i> Mitja Nabergoj, CH	09:15 - 09:15
OS18-5	IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-CMWP STUDY <i>Speaker:</i> Nicolaus Kröger, DE	09:15 - 09:15
OS18-6	ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Elena Morozova, RU	09:15 - 09:15
OS18-7	DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML <i>Speaker:</i> Christian Niederwieser, DE	09:15 - 09:15
OS18-8	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT PERIOD <i>Speaker:</i> Anna Czyz, PL	09:15 - 09:15

Data Management

09:15 - 17:30

On-Demand Library

DM09 - Education session 9

This session is available in our on-demand library throughout the whole congress

DM9-1	Follow up forms - How to get a chronological overview of the	-
-------	---	---

patient history and follow up

Speaker: Elena Ferrer Martínez del Peral, ES

Lab Technicians Day

09:15 - 17:30

On-Demand Library

LT2 - Lab Technicians Day: Cell product testing, validation and characterization

This session is available in our on-demand library throughout the whole congress

LT2-1	Quality control assessment of ATMP phenotype and functionality using flow cytometry <i>Speaker:</i> Willemijn Hobo, NL	-
LT2-2	Flow cytometry-based CD34 enumeration <i>Speaker:</i> Harry Dolstra, NL	-
LT2-3	Flow cytometric in-process and quality control for CAR T cell manufacturing <i>Speaker:</i> Ulrike Köhl, DE	-

Lab Technicians Day

09:15 - 17:30

On-Demand Library

LT1 - Lab Technicians Day: Specialized cell processing

This session is available in our on-demand library throughout the whole congress

LT1-1	Bone marrow processing: Techniques and results <i>Speaker:</i> Boris Calmels, FR	-
LT1-2	Technical aspects and performance TCRab/CD19 depletion <i>Speaker:</i> Kasper Westinga, NL	-
LT1-3	Donor selection and GMP-compliant manufacturing of virus-specific T-cells <i>Speaker:</i> Britta Eiz-Vesper, DE	-

Working Party Session

09:15 - 17:30

On-Demand Library

SAAWP - Severe Aplastic Anaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

SAAWP-1	Introduction <i>Speaker:</i> Régis Peffault de Latour, FR	-
SAAWP-2	Registry Report <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-3	RACE – clinical update <i>Speaker:</i> Antonio Risitano, IT	-
SAAWP-4	RACE – what we learn on the biology of SAA? <i>Speaker:</i> Austin Kulakaseraraj, GB	-
SAAWP-5	Androgens in AA: Myth or reality in 2021? <i>Speaker:</i> Simona Pagliuca, US	-

SAAWP-6	GVHD and relapse free survival (GRFS) after HSCT for AA <i>Speaker:</i> Raynier Devillier, FR	-
---------	---	---

Working Party Session
09:15 - 17:30

On-Demand Library

ALWP - Acute Leukaemia Working Party Session

This session is available in our on-demand library throughout the whole congress

ALWP-1	Introduction <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
ALWP-2	CAR-T cells in adult ALL <i>Speaker:</i> Arnon Nagler, IL	09:15 - 09:15
ALWP-3	Transplant in refractory AML: Comparison of the different FLAMSA approaches <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
ALWP-4	MRD in AML: Where do we stand? <i>Speaker:</i> Ali Bazarbachi, LB	09:15 - 09:15

Nurses Group
09:15 - 17:30

On-Demand Library

NG21 - Clinical trials in a transplant setting

This session is available in our on-demand library throughout the whole congress

NG21-1	Antimicrobial Lock Therapy for Prevention and Treatment of Catheter Related Infections in Hematological Patients <i>Speaker:</i> Isabel Salcedo, ES	-
NG21-2	Convalescent plasma clinical trials for COVID-19 <i>Speaker:</i> Rocío Layunta, ES	-
NG21-3	Post transplant relapse <i>Speaker:</i> Stephanie Heyes, GB	-

Working Party Session
09:15 - 17:30

On-Demand Library

CTIWP - Cellular Therapy and Immunobiology Working Party Session

This session is available in our on-demand library throughout the whole congress

CTIWP-1	CTIWP Activity Report <i>Speaker:</i> Christian Chabannon, FR	-
CTIWP-2	Virus specific T cells post BMT- Broadening to SARS-CoV2 <i>Speaker:</i> Catherine Bollard, US	-
CTIWP-3	Are mesenchymal stromal cells the right arrow in the quiver to fight COVID-19? <i>Speaker:</i> Rachele Ciccocioppo, IT	-

Special Session

09:15 - 17:30

On-Demand Library

SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer

This session is available in our on-demand library throughout the whole congress

SS10-1	General Overview of the HARMONY Alliance: Progress, Achievements & Results of HARMONY and HARMONY PLUS projects <i>Speaker:</i> Jesús Maria Hernández Rivas, ES	-
SS10-2	Envisioned contribution of the EBMT to the HARMONY Alliance <i>Speaker:</i> Guillermo Sanz Santillana, ES <i>Speaker:</i> Yann Guillevic, CH	-
SS10-3	EBMT participation in the HARMONY Alliance <i>Speaker:</i> Anna Sureda, ES	-
SS10-4	HARMONY & HARMONY PLUS Research Projects / Outcomes definition <i>Speaker:</i> Lars Bullinger, DE	-
SS10-5	HARMONY Platform <i>Speaker:</i> Ana Heredia Casanoves, ES	-

On Demand Library

09:15 - 17:30

On-Demand Library

On Demand Library

Educational

09:15 - 17:30

On-Demand Library

E08 - New challenges in infectious complications

This session is available in our on-demand library throughout the whole congress

E8-1	T-cell therapy for infections in SCT patients: An experimental treatment or a real choice for the practice? <i>Speaker:</i> Patrizia Comoli, IT	-
E8-2	Infectious complications with new drugs in Hematology <i>Speaker:</i> Georg Maschmeyer, DE	-
E8-3	The blood virome of HSCT Recipients: Much more than viremia by CMV, EBV, HH6V and adenovirus <i>Speaker:</i> Marie-Celine Zanella, CH	-

Data Management

09:15 - 17:30

On-Demand Library

DM05 - Education session 5

This session is available in our on-demand library throughout the whole congress

DM5-1	Hematopoietic Cell Transplantation-Comorbidity Index 'Sorrer Score' <i>Speaker:</i> Bronwen Shaw, US	-
-------	--	---

Nurses Group
09:15 - 17:30

On-Demand Library

NG23 - Oral session 2: Abstracts session

This session is available in our on-demand library throughout the whole congress

NG23-1	EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL CARE PROTOCOL FOR THE PREVENTION AND TREATMENT OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT RECIPIENTS <i>Speaker:</i> Monica Guberti, IT	09:15 - 09:15
NG23-2	PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING <i>Speaker:</i> Julia Ruiz Pato, ES	09:15 - 09:15
NG23-3	ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS <i>Speaker:</i> Franziska Michaela Lohmeyer, IT	09:15 - 09:15
NG23-4	MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANTATION SETTING AND THEIR MAINTENANCE OVER TIME <i>Speaker:</i> Alberto Castagna, IT	09:15 - 09:15
NG23-5	EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AND THEIR COHABITANTS <i>Speaker:</i> Maria Teresa Solano Moliner, ES	09:15 - 09:15

Oral Session
09:15 - 17:30

On-Demand Library

OS02 - Oral session 2: CARs I

This session is available in our on-demand library throughout the whole congress

OS2-1	CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Deepu Madduri, US	09:15 - 09:25
OS2-2	PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) <i>Speaker:</i> Olalekan O. Oluwole, US	09:25 - 09:35
OS2-3	MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA <i>Speaker:</i> David Maloney, US	09:35 - 09:45

OS2-4	STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA BLASTS <i>Speaker:</i> Concetta Quintarelli, IT	09:45 - 09:55
OS2-5	CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19 CAR T-CELL THERAPY <i>Speaker:</i> Jordan Gauthier, US	09:55 - 10:05
OS2-6	OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING: INITIAL RESULTS FROM THE OUTREACH STUDY <i>Speaker:</i> John E. Godwin, US	10:05 - 10:15
OS2-7	BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T CELLS AT EU OR EBMT AFFILIATED PROGRAMS <i>Speaker:</i> Christian Chabannon, FR	10:15 - 10:25
OS2-8	ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF THE SHELF” STRATEGY TO TREAT CD123^{POS} CHILDHOOD ACUTE MYELOID LEUKAEMIA <i>Speaker:</i> Simona Caruso, IT	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS03 - Oral session 3: CARs II

This session is available in our on-demand library throughout the whole congress

OS3-1	CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY OF THE APPROACH <i>Speaker:</i> Olga Molostova, RU	09:15 - 09:15
OS3-2	CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2 CARTITUDE-1 STUDY <i>Speaker:</i> Andrzej Jakubowiak, US	09:15 - 09:15
OS3-3	PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS WITH RELAPSED/REFRACTORY MCL IN ZUMA-2 <i>Speaker:</i> Michael L. Wang, US	09:15 - 09:15
OS3-4	REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN SPAIN <i>Speaker:</i> Mi Kwon, ES	09:15 - 09:15
OS3-5	HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY	09:15 - 09:15

	<i>Speaker:</i> Dasom Lee, US	
OS3-6	DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS ARE ASSOCIATED WITH NEUROTOXICITY <i>Speaker:</i> Madhavi Lakkaraja, US	09:15 - 09:15
OS3-7	COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-T THERAPY <i>Speaker:</i> Zhao-Yanli Zhao, CN	09:15 - 09:15
OS3-8	THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF GD2+ SARCOMAS <i>Speaker:</i> Antonio Camera, IT	09:15 - 09:15

Quality Management
09:15 - 17:30

On-Demand Library

QM5 - Quality Management Oral Abstracts

This session is available in our on-demand library throughout the whole congress

QM5-1	COMPLIANCE AND COST EFFICACY FOR CELLULAR THERAPIES, CAN THESE TWO GO HAND IN HAND? <i>Speaker:</i> Janik Adriaansen, US	09:15 - 09:15
QM5-2	HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR NURSES IN TIMES OF PANDEMIC <i>Speaker:</i> Sheila Saco, ES	09:15 - 09:15
QM5-3	THE RTN TRANSPLANT POLICY AND ACTIVITY DURING COVID-19 PANDEMIC <i>Speaker:</i> Antonio Bruno, IT	09:15 - 09:15
QM5-4	THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM IN NAPLES, ITALY <i>Speaker:</i> Lucia Ammirati, IT	09:15 - 09:15

Oral Session
09:15 - 17:30

On-Demand Library

OS10 - Oral session 10: COVID-19

This session is available in our on-demand library throughout the whole congress

OS10-1	A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS ADOPTIVE THERAPY IN COVID19 <i>Speaker:</i> Antonio Pérez-Martínez, ES	09:15 - 09:25
OS10-2	THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST	09:25 - 09:35

	WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY <i>Speaker:</i> Angharad Pryce, GB	
OS10-3	IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT <i>Speaker:</i> Sara Ghorashian, GB	09:35 - 09:45
OS10-4	OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE FROM A SEVERELY AFFECTED AREA (BERGAMO) <i>Speaker:</i> Maria Caterina Mico', IT	09:45 - 09:55
OS10-5	ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS AFTER COVID-19 INFECTION <i>Speaker:</i> Maximilian Christopeit, DE	09:55 - 10:05
OS10-6	INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION CENTERS AND THE PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE 2020 <i>Speaker:</i> Fernando Barroso Duarte, BR	10:05 - 10:15
OS10-7	CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC PROGENITOR CELLS IN THE CURRENT SARS-Cov-2 PANDEMIC: EXPERIENCE OF A SINGLE CENTRE <i>Speaker:</i> Dolores Moreno, ES	10:15 - 10:25
OS10-8	IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH CORD BLOOD UNITS. ON BEHALF THE AGENCY OF BIOMEDICINE, EUROCORD AND THE SFGM-TC <i>Speaker:</i> Hanadi Rafii - El Ayoubi, FR	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering

This session is available in our on-demand library throughout the whole congress

OS1-1	MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT IMMUNOSUPPRESSIVE PROPERTIES <i>Speaker:</i> Kevin Goncalves, US	09:15 - 09:15
OS1-2	EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34⁺ CELL MOBILIZATION IN HEALTHY VOLUNTEERS <i>Speaker:</i> Hideki Goto, JP	09:15 - 09:15
OS1-3	THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Rumesh Chandar, IN	09:15 - 09:15
OS1-4	THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT	09:15 - 09:15

REJECTION AND GRAFT VERSUS HOST DISEASE IN CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION

Speaker: Satish Meena, IN

OS1-5	OUTCOME AND IMMUNE RECONSTITUTION AFTER TCR$\alpha\beta$/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL RELATED DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE EXPERIENCE	09:15 - 09:15
	<i>Speaker:</i> Lucia Prezioso, IT	
OS1-6	THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE	09:15 - 09:15
	<i>Speaker:</i> Muhammad Ameen, SA	
OS1-7	POST-TRANSPLANT OUTCOMES OF CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TREATED WITH EMAPALUMAB	09:15 - 09:15
	<i>Speaker:</i> Michael Jordan, US	
OS1-8	WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE	09:15 - 09:15
	<i>Speaker:</i> Maria Escolar, US	

Oral Session
09:15 - 17:30

On-Demand Library

OS07 - Oral session 7: Stem Cell Source and Donors

This session is available in our on-demand library throughout the whole congress

OS7-1	FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE RISK AFTER UNRELATED HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT	09:15 - 09:25
	<i>Speaker:</i> Annalisa Ruggeri, ES	
OS7-2	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN MISMATCHED UNRELATED DONOR TRANSPLANTATION VERSUS HAPLOIDENTICAL TRANSPLANTATION: A RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	09:25 - 09:35
	<i>Speaker:</i> Giorgia Battipaglia, IT	
OS7-3	HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS AFFECTED BY MALIGNANT DISORDERS	09:35 - 09:45
	<i>Speaker:</i> Pietro Merli, IT	
OS7-4	MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE	09:45 - 09:55

FROM THE MADRID GROUP OF HEMATOPOIETIC TRANSPLANT

Speaker: Rebeca Bailén, ES

- | | | |
|-------|--|---------------|
| OS7-5 | LONG TERM OUTCOMES AFTER INTRABONE UNRELATED UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-EBMT ANALYSIS
<i>Speaker:</i> Jacopo Peccatori, IT | 09:55 - 10:05 |
| OS7-6 | INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REPORT
<i>Speaker:</i> Andriyana Bankova, US | 10:05 - 10:15 |
| OS7-8 | CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH CRYOPRESERVED GRAFTS DURING THE COVID19 PANDEMIC
<i>Speaker:</i> Maximilian Christopeit, DE | 10:15 - 10:25 |

Oral Session
09:15 - 17:30

On-Demand Library

OS08 - Oral session 8: Graft versus Host Disease I

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---------------|
| OS8-1 | GVHD PROPHYLAXIS WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A / METHOTREXATE POST ALLOGENEIC TRANSPLANTATION (HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE ALWP/EBMT
<i>Speaker:</i> Arnon Nagler, IL | 09:15 - 09:15 |
| OS8-2 | BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE ROCKSTAR STUDY (KD025-213)
<i>Speaker:</i> Corey Cutler, US | 09:15 - 09:15 |
| OS8-3 | A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
<i>Speaker:</i> Hanaa A. Fatoum, SA | 09:15 - 09:15 |
| OS8-4 | RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM THE RANDOMIZED, PHASE 3 REACH2 STUDY
<i>Speaker:</i> Mohamad Mohty, FR | 09:15 - 09:15 |
| OS8-5 | IMPACT OF CHRONIC GVHD SEVERITY AND STEROID RESPONSE ON THE QUALITY OF LIFE IN PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: FINDINGS FROM A REAL-WORLD STUDY
<i>Speaker:</i> Sylvie Lachance, CA | 09:15 - 09:15 |
| OS8-6 | SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD | 09:15 - 09:15 |

**WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA
BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT
OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT
PROGRAM**

Speaker: Florent Malard, FR

OS8-7	REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER ALLO-HSCT	09:15 - 09:15
-------	---	---------------

Speaker: Marie T Rubio, FR

OS8-8	PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD STUDY	09:15 - 09:15
-------	---	---------------

Speaker: Nada Hamad, AU

Oral Session
09:15 - 17:30

On-Demand Library

OS11 - Oral session 11: Infectious Diseases I

This session is available in our on-demand library throughout the whole congress

OS11-1	POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO- STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE ASPBIONICS CONSORTIUM	09:15 - 09:25
--------	--	---------------

Speaker: Ana Moniz-Díez, ES

OS11-2	THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS	09:25 - 09:35
--------	--	---------------

Speaker: Nipat Chuleerarux, TH

OS11-3	IMMUNE RECONSTITUTION DURING CMV PROPHYLAXIS BY LETERMOVIR: A SINGLE CENTER EXPERIENCE	09:35 - 09:45
--------	---	---------------

Speaker: Ilaria Cutini, IT

OS11-4	LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS REACTIVATION IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD EXPERIENCE	09:45 - 09:55
--------	---	---------------

Speaker: Massimo Martino, IT

OS11-5	PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED APPROACH. RESULTS IN 112 PATIENTS	09:55 - 10:05
--------	---	---------------

Speaker: Amado Karduss -Urueta, CO

OS11-6	PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM	10:05 - 10:15
--------	---	---------------

CELL TRANSPLANTATION FROM A TERTIARY REFERRAL CENTER IN INDIA

Speaker: Harika Varla, IN

- | | | |
|--------|---|---------------|
| OS11-7 | THE MANAGEMENT OF CLOSTRIDIODES DIFFICILE INFECTIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY | 10:15 - 10:25 |
|--------|---|---------------|

Speaker: Agnieszka Piekarska, PL

- | | | |
|--------|---|---------------|
| OS11-8 | CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH HEMATOLOGY MALIGNANCIES: A REAL-WORLD OBSERVATIONAL STUDY | 10:25 - 10:35 |
|--------|---|---------------|

Speaker: Sizhou Feng, CN

Oral Session
09:15 - 17:30

On-Demand Library

OS09 - Oral session 9: Graft versus Host Disease II

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---------------|
| OS9-1 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN HUMANS | 09:15 - 09:15 |
|-------|---|---------------|

Speaker: Robert Zeiser, DE

- | | | |
|-------|--|---------------|
| OS9-2 | RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL | 09:15 - 09:15 |
|-------|--|---------------|

Speaker: Franco Locatelli, IT

- | | | |
|-------|---|---------------|
| OS9-3 | DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT? | 09:15 - 09:15 |
|-------|---|---------------|

Speaker: Ivan Moiseev, RU

- | | | |
|-------|---|---------------|
| OS9-4 | A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) | 09:15 - 09:15 |
|-------|---|---------------|

Speaker: Michelle Hudspeth, US

- | | | |
|-------|---|---------------|
| OS9-5 | THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY | 09:15 - 09:15 |
|-------|---|---------------|

Speaker: Junya Kanda, JP

- | | | |
|-------|---|---------------|
| OS9-6 | EARLY RECONSTITUTION OF CD6+ T CELLS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL ANTIBODY ITOLIZUMAB | 09:15 - 09:15 |
|-------|---|---------------|

	<i>Speaker:</i> Benedetta Rambaldi, US	
OS9-7	MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Erik Thiele Orberg, DE	09:15 - 09:15
OS9-8	ASSOCIATION OF GENE POLYMORPHISMS IN CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Paula Muñiz, ES	09:15 - 09:15
<i>Oral Session</i> 09:15 - 17:30		
OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others This session is available in our on-demand library throughout the whole congress		On-Demand Library
OS20-1	HLA EVOLUTIONARY DIVERGENCE INFLUENCES CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Speaker:</i> Simona Pagliuca, US	09:15 - 09:25
OS20-2	OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511 PATIENTS <i>Speaker:</i> Richard K Burt, US	09:25 - 09:35
OS20-3	EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A REAL WORLD EXPERIENCE <i>Speaker:</i> Varun Mehra, GB	09:35 - 09:45
OS20-4	THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Speaker:</i> Carmelo Gurnari, US	09:45 - 09:55
OS20-5	HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS: CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES <i>Speaker:</i> Alexey Polushin, RU	09:55 - 10:05
OS20-6	HLA MUTATIONS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM OF IMMUNE ESCAPE <i>Speaker:</i> Carmelo Gurnari, US	10:05 - 10:15
OS20-7	HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT OF REFRACTORY MYASTHENIA GRAVIS <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	10:15 - 10:25

OS20-8	IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS PATIENTS <i>Speaker:</i> Alice Mariottini, IT	10:25 - 10:35
--------	--	---------------

Oral Session
09:15 - 17:30

On-Demand Library

OS21 - Oral session 21: Multiple Myeloma

This session is available in our on-demand library throughout the whole congress

OS21-1	MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA <i>Speaker:</i> Harsh Parmar, US	09:15 - 09:15
OS21-2	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT – A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP <i>Speaker:</i> Joanna Drozd-Sokołowska, PL	09:15 - 09:15
OS21-3	ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP ANALYSIS <i>Speaker:</i> Mohamad Mohty, FR	09:15 - 09:15
OS21-4	AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM STEM CELL TRANSPLANTATION AND MAINTENANCE WITH THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA (MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-STUDY <i>Speaker:</i> Nicolaus Kröger, DE	09:15 - 09:15
OS21-5	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL DISEASE <i>Speaker:</i> Jean Roy, CA	09:15 - 09:15
OS21-6	ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY <i>Speaker:</i> Laurent Garderet, FR	09:15 - 09:15
OS21-7	COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) <i>Speaker:</i> Sergio Giralt, US	09:15 - 09:15
OS21-8	CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE-	09:15 - 09:15

**CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL
TRIALS OF DARATUMUMAB**

Speaker: Katja Weisel, DE

Oral Session

09:15 - 17:30

On-Demand Library

OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---------------|
| OS19-1 | INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL)
<i>Speaker:</i> Catherine Thieblemont, FR | 09:15 - 09:15 |
| OS19-2 | LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)
<i>Speaker:</i> Caron A. Jacobson, US | 09:15 - 09:15 |
| OS19-3 | PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)
<i>Speaker:</i> Caron A. Jacobson, US | 09:15 - 09:15 |
| OS19-4 | ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
<i>Speaker:</i> Michael L. Wang, US | 09:15 - 09:15 |
| OS19-5 | VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE CRUCIAL CONSORTIUM
<i>Speaker:</i> Antonio José Cabrera-Serrano, ES | 09:15 - 09:15 |
| OS19-6 | EVALUATION OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
<i>Speaker:</i> Natalie L. Smith, US | 09:15 - 09:15 |
| OS19-7 | ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA (DLBCL) IN A GERMAN TERTIARY HOSPITAL
<i>Speaker:</i> Bernhard Alexander Mörtl, DE | 09:15 - 09:15 |
| OS19-8 | LONG TERM OUTCOMES OF ALLOGENEIC TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE EXPERIENCE
<i>Speaker:</i> Alexander Glover, GB | 09:15 - 09:15 |

Oral Session

09:15 - 17:30

On-Demand Library

OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and Chimerism

This session is available in our on-demand library throughout the whole congress

OS6-1	COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T CELL IMMUNE RECONSTITUTION PATTERNS <i>Speaker:</i> Saskia Leser, DE	09:15 - 09:15
OS6-2	MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Sandra Pennisi, DE	09:15 - 09:15
OS6-3	SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR EXCISION CIRCLES (TRECS) AND K-DELETING RECOMBINATION EXCISION CIRCLES (KRECS) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) RECIPIENTS <i>Speaker:</i> Carlos De Miguel Jiménez, ES	09:15 - 09:15
OS6-4	MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMANS <i>Speaker:</i> Mirjam Belderbos, NL	09:15 - 09:15
OS6-5	OVER-EXPRESSION OF HIF-1α IN MESENCHYMAL STROMAL CELLS INCREASES HUMAN CD34⁺ CELLS CLONOGENIC CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A XENOTRANSPLANTATION MODEL <i>Speaker:</i> Silvia Preciado, ES	09:15 - 09:15
OS6-6	ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-SPECIFIC T-CELLS <i>Speaker:</i> Rubiya Nadaf, GB	09:15 - 09:15
OS6-7	TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOID MALIGNANCIES <i>Speaker:</i> Simona Pagliuca, US	09:15 - 09:15
OS6-8	DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Patrizia Chiusolo, IT	09:15 - 09:15

Nurses Group

09:15 - 17:30

On-Demand Library

NG17 - Care of the nurses

This session is available in our on-demand library throughout the whole congress

NG17-1	Mindfulness	-
--------	--------------------	---

	<i>Speaker:</i> Ana M. Muñoz Cobo, ES	
NG17-2	Resilience and self-care <i>Speaker:</i> Christian Williams, GB	-
NG17-3	Tips and tricks for self care <i>Speaker:</i> Jane Keep, GB	-
<i>Nurses Group</i> 09:15 - 17:30		
On-Demand Library		
NG18 - Non-malignant diseases update		
This session is available in our on-demand library throughout the whole congress		
NG18-2	Multiple sclerosis <i>Speaker:</i> Helen Jessop, GB	09:15 - 09:15
NG18-3	Sickle cell disease <i>Speaker:</i> Jean-Hugues Dalle, FR	09:15 - 09:15
NG18-4	ITP <i>Speaker:</i> Maria Luisa Lozano, ES	09:15 - 09:15
<i>Nurses Group</i> 09:15 - 17:30		
On-Demand Library		
NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting		
This session is available in our on-demand library throughout the whole congress		
NG14-1	Patient's experience <i>Speaker:</i> Ruth Tweedie, ES	-
NG14-2	Psychologist's point of view <i>Speaker:</i> Anna Lagerdahl, GB	-
NG14-3	Nurse's perspective <i>Speaker:</i> Núria Ballestar, ES	-
<i>Nurses Group</i> 09:15 - 17:30		
On-Demand Library		
NG22 - Quality processes in JACIE		
This session is available in our on-demand library throughout the whole congress		
NG22-1	Quality indicators for nurses <i>Speaker:</i> Louise McNamara, GB	-
NG22-2	JACIE: What's new? <i>Speaker:</i> Kim Orchard, GB	-
NG22-3	What is the nurse role as JACIE Inspector? <i>Speaker:</i> Eugenia Trigos Arjona, ES	-

Educational
09:15 - 17:30

On-Demand Library

E10 - HSCT in paediatric non-malignant indications

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|--|---|
| E10-1 | Haplo-identical SCT in hemoglobinopathy: Taking pole position? | - |
| | <i>Speaker:</i> Josu de la Fuente, GB | |
| E10-2 | Mismatched family donors in inherited immune disorders: A new perspective | - |
| | <i>Speaker:</i> Mary A. Slatter, GB | |
| E10-3 | HSCT for inherited bone marrow failure syndromes | - |
| | <i>Speaker:</i> Cristina Díaz de Heredia, ES | |
| E10-4 | Cord blood HSCT for non-malignant diseases in children | - |
| | <i>Speaker:</i> Vanderson Rocha, BR | |

Educational
09:15 - 17:30

On-Demand Library

E12 - Steroid-resistant/refractory GVHD

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---|
| E12-1 | GVHD - what's in a name? | - |
| | <i>Speaker:</i> Helene Schoemans, BE | |
| E12-2 | Treatment of SR/R acute GVHD | - |
| | <i>Speaker:</i> Olaf Penack, DE | |
| E12-3 | Treatment of SR/R chronic GVHD | - |
| | <i>Speaker:</i> Zinaida Peric, HR | |
| E12-4 | New technologies in the approach to GVHD | - |
| | <i>Speaker:</i> Amin Turki, DE | |

Data Management
09:15 - 17:30

On-Demand Library

DM07 - Education session 7

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|--|---|
| DM7-1 | Minimal residual disease (MRD) | - |
| | <i>Speaker:</i> Johannes Schetelig, DE | |

Workshop
09:15 - 17:30

On-Demand Library

W12 - Donor HLA assessment and matching for allogeneic HSCT

This session is available in our on-demand library throughout the whole congress

- | | | |
|-------|---|---|
| W12-1 | HLA laboratory perspective and recommendations | - |
| | <i>Speaker:</i> Pascale Loiseau, FR | |
| W12-2 | Clinical perspective and recommendations | - |
| | <i>Speaker:</i> Francesca Lorentino, IT | |

W12-3	Selection of unrelated donors and cord blood units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR <i>Speaker:</i> Stephen Spellman, US	-
-------	---	---

Working Party Session
09:15 - 17:30

On-Demand Library

CMWP - Chronic Malignancies Working Party Session

This session is available in our on-demand library throughout the whole congress

CMWP-1	Scientific activity of the CMWP <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	09:15 - 09:15
CMWP-3	Who and when in the course of disease to transplant? - Myelofibrosis <i>Speaker:</i> Donal McLornan, GB	09:15 - 09:15
CMWP-4	Is Chronic Myeloid Leukaemia still an indication for allo-HCT? <i>Speaker:</i> Yves Chalandon, CH	09:15 - 09:15
CMWP-5	Is Chronic Lymphocytic Leukemia still an indication for allo-HCT? <i>Speaker:</i> Peter Dreger, DE	09:15 - 09:15

Working Party Session
09:15 - 17:30

On-Demand Library

IDWP - Infectious Diseases Working Party Session

This session is available in our on-demand library throughout the whole congress

IDWP-1	IDWP update <i>Speaker:</i> Rafael de la Cámara, ES	-
IDWP-2	Current scientific proposals of IDWP <i>Speaker:</i> Dina Averbuch, IL	-
IDWP-3	CMV T-cell immunity monitoring: is it time to incorporate it in clinical practices? <i>Speaker:</i> Roy Chemaly, US	-
IDWP-4	What is new in the field of Gram-negative infections in SCT patients? <i>Speaker:</i> Dina Averbuch, IL	-
IDWP-5	Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation <i>Speaker:</i> Jose Luis Piñana, ES	-
IDWP-6	Hepatitis C and hepatitis E in SCT <i>Speaker:</i> Malgorzata Mikulska, IT	-
IDWP-7	Central nervous system (CNS) complications following HSCT <i>Speaker:</i> Martin Schmidt-Hieber, DE	-

Oral Session
09:15 - 17:30

On-Demand Library

OS12 - Oral session 12: Infectious Diseases II

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---------------|
| OS12-1 | NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY GROUP
<i>Speaker:</i> Dina Averbuch, IL | 09:15 - 09:15 |
| OS12-2 | COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY
<i>Speaker:</i> Marina Popova, RU | 09:15 - 09:15 |
| OS12-3 | COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Yuliya Rogacheva, RU | 09:15 - 09:15 |
| OS12-4 | FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTS
<i>Speaker:</i> Chiara Rosignoli, IT | 09:15 - 09:15 |
| OS12-5 | CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
<i>Speaker:</i> Anke Verlinden, BE | 09:15 - 09:15 |
| OS12-6 | COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS THAT AFFECT THE SURVIVAL OF PATIENTS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Anna Czyz, PL | 09:15 - 09:15 |
| OS12-7 | IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Eshrak Al-Shaibani, CA | 09:15 - 09:15 |
| OS12-8 | STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6 REACTIVATION
<i>Speaker:</i> Kenichiro Takeda, JP | 09:15 - 09:15 |

Oral Session
09:15 - 17:30

On-Demand Library

OS13 - Oral session 13: Transplant Complications I

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|---|---------------|
| OS13-1 | FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION
<i>Speaker:</i> Mohamad Mohty, FR | 09:15 - 09:15 |
| OS13-2 | ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE ANALYSIS FROM THE EBMT
<i>Speaker:</i> Olaf Penack, DE | 09:15 - 09:15 |
| OS13-3 | DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): ANALYSIS OF A MULTICENTRE, MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT PASS)
<i>Speaker:</i> Mohamad Mohty, FR | 09:15 - 09:15 |
| OS13-4 | EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
<i>Speaker:</i> Mohamad Mohty, FR | 09:15 - 09:15 |
| OS13-5 | EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE MORTALITY AND THE RISK OF INTENSIVE CARE UNIT ADMISSION AT PRE-TRANSPLANT EVALUATION
<i>Speaker:</i> Marta Peña Domingo, ES | 09:15 - 09:15 |
| OS13-6 | THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Midori Nakagaki, AU | 09:15 - 09:15 |
| OS13-7 | IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY
<i>Speaker:</i> Aldo A Acosta-Medina, US | 09:15 - 09:15 |
| OS13-8 | RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD
<i>Speaker:</i> Bernd Gruhn, DE | 09:15 - 09:15 |

Oral Session
09:15 - 17:30

On-Demand Library

OS14 - Oral session 14: Transplant Complications II

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---------------|
| OS14-1 | PREGNANCY AND PREGNANCY OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT PEDIATRIC WP
<i>Speaker:</i> Tamara Diesch, CH | 09:15 - 09:15 |
| OS14-2 | ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY: RESULTS OF A SURVEY FROM THE EBMT
<i>Speaker:</i> Helene Schoemans, BE | 09:15 - 09:15 |
| OS14-3 | CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Gertjan Lugthart, NL | 09:15 - 09:15 |
| OS14-4 | NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP | 09:15 - 09:15 |
| OS14-5 | AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
<i>Speaker:</i> Selim Corbacioglu, DE | 09:15 - 09:15 |
| OS14-6 | PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA) ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
<i>Speaker:</i> Santosh Putta, US | 09:15 - 09:15 |
| OS14-7 | OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTRE EXPERIENCE
<i>Speaker:</i> Isabel Iturrate, ES | 09:15 - 09:15 |
| OS14-8 | DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT-HOME ALLOGENEIC BONE MARROW TRANSPLANTATION MODELS
<i>Speaker:</i> Marta Garcia-Recio, ES | 09:15 - 09:15 |

Oral Session
09:15 - 17:30

On-Demand Library

OS15 - Oral session 15: Conditioning Regimens

This session is available in our on-demand library throughout the whole congress

- | | | |
|--------|--|---------------|
| OS15-1 | BENDAMUSTINE-BASED CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED- | 09:15 - 09:25 |
|--------|--|---------------|

REFRACTORY NON-HODGKIN LYMPHOMA

Speaker: Sylvie Lachance, CA

OS15-2	MICROBIOTA INJURY IS CONDITIONING REGIMEN-DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS <i>Speaker:</i> Roni Shouval, US	09:25 - 09:35
OS15-3	THE IMPACT OF PULMONARY FUNCTION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION <i>Speaker:</i> Jesus Duque-Afonso, DE	09:35 - 09:45
OS15-4	HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Khalid Halahleh, JO	09:45 - 09:55
OS15-5	THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION :A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369 CONTROLS <i>Speaker:</i> Federica Sora, IT	09:55 - 10:05
OS15-6	IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL BLOOD COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE ALONE <i>Speaker:</i> Giorgia Battipaglia, IT	10:05 - 10:15
OS15-7	HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS <i>Speaker:</i> Donata Backhaus, DE	10:15 - 10:25
OS15-8	SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Speaker:</i> Eduardo Rodríguez-Arbolí, ES	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS16 - Oral session 16: Acute Leukemia I

This session is available in our on-demand library throughout the whole congress

OS16-1	IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE EBMT <i>Speaker:</i> Justin Loke, GB	09:15 - 09:25
OS16-2	IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO	09:25 - 09:35

	MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE ALWP AND THE CMWP <i>Speaker:</i> Eolia Brissot, FR	
OS16-3	THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A STUDY FROM THE ALWP / EBMT <i>Speaker:</i> Arnon Nagler, IL	09:35 - 09:45
OS16-4	NON-T DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER ONE VS TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT <i>Speaker:</i> Arnon Nagler, IL	09:45 - 09:55
OS16-5	PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND ALL. A STUDY FROM THE ALWP-EBMT <i>Speaker:</i> Sabine Blum, CH	09:55 - 10:05
OS16-6	IMPACT OF ALLOGENIC TRANSPLANTATION IN THE TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS. COMPARISON BETWEEN MYELOABLATIVE VS REDUCE INTENSITY CONDITIONINGS <i>Speaker:</i> Claudia Núñez-Torrón, ES	10:05 - 10:15
OS16-7	THE DISEASE BURDEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE TO PATIENTS WITH SECONDARY LEUKEMIA <i>Speaker:</i> Claudia Núñez-Torrón, ES	10:15 - 10:25
OS16-8	PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL TRANSPLANTATION. STUDY OF 132 PATIENTS <i>Speaker:</i> Christelle Ferra Coll, ES	10:25 - 10:35

Oral Session
09:15 - 17:30

On-Demand Library

OS17 - Oral session 17: Acute Leukemia II

This session is available in our on-demand library throughout the whole congress

OS17-1	TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: IMPROVEMENT OF SURVIVAL IN RECENT YEARS <i>Speaker:</i> Ali Bazarbachi, LB	09:15 - 09:15
OS17-2	HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE NUCLEAR CONSORTIUM	09:15 - 09:15

	Speaker: José Sánchez Maldonado, ES	
OS17-3	COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA Speaker: Annalisa Ruggeri, ES	09:15 - 09:15
OS17-4	REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION Speaker: Sarah Morin, CH	09:15 - 09:15
OS17-5	VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT (HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA Speaker: Vincenzo Federico, IT	09:15 - 09:15
OS17-6	TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS Speaker: Nico Gagelmann, DE	09:15 - 09:15
OS17-7	STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL DONOR FOR PEDIATRIC PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE STUDY Speaker: Charlotte Nazon, FR	09:15 - 09:15
OS17-8	COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD Speaker: Gabriele Magliano, IT	09:15 - 09:15
<i>Joint Session</i> 09:15 - 17:30		On-Demand Library
JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT This session is available in our on-demand library throughout the whole congress		
JS5-2	COVID-19 vaccination in HSCT Speaker: Per Ljungman, SE	09:15 - 09:15
JS5-3	Global access to COVID-19 vaccines Speaker: Susan Brown, US	09:15 - 09:15
<i>Oral Session</i> 09:15 - 17:30		On-Demand Library
OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II This session is available in our on-demand library throughout the whole congress		
OS5-1	HEMATOPOIETIC STEM CELL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH): BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF EARLY CLINICAL RESPONSE	09:15 - 09:25

	<i>Speaker:</i> Maria Ester Bernardo, IT	
OS5-2	OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH TABELCELEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Susan Prockop, US	09:25 - 09:35
OS5-3	RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY <i>Speaker:</i> Markus Mapara, US	09:35 - 09:45
OS5-4	DURABLE CLINICAL OUTCOMES FOLLOWING BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH TRANSFUSION-DEPENDENT α-THALASSEMIA (TDT) <i>Speaker:</i> Franco Locatelli, IT	09:45 - 09:55
OS5-5	OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT) <i>Speaker:</i> Carolyn Mulroney, US	09:55 - 10:05
OS5-6	IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Francesca Patriarca, IT	10:05 - 10:15
OS5-7	MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR THE IDENTIFICATION OF HIGH-RISK PATIENTS AND TREATMENT WITH T-CELL IMMUNOTHERAPY <i>Speaker:</i> Anastasia Papadopoulou, GR	10:15 - 10:25
OS5-8	NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT TRANSDUCTION AND CROSS-CORRECTION MECHANISMS USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH <i>Speaker:</i> Jane E Potter, GB	10:25 - 10:35
Paed4-2	EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34⁺ HEMATOPOIETIC STEM AND PROGENITOR CELLS IN TRANSFUSION-DEPENDENT α-THALASSEMIA AND SICKLE CELL DISEASE <i>Speaker:</i> Selim Corbacioglu, DE	10:35 - 10:45

Special Session

09:15 - 17:30

On-Demand Library

SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell therapy community

This session is available in our on-demand library throughout the whole congress

SS8-1	Social media beyond twitter for the HSCT and cell therapy community <i>Speaker:</i> Navneet Majhail, US	-
SS8-2	Do's and don'ts of interaction in social media: Nurse's perspective <i>Speaker:</i> Johan De Munter, BE	-
SS8-3	Do's and don'ts of interaction in social media: How social media can improve patient outcomes - The patient's perspective <i>Speaker:</i> Gillian Adams, GB	-

Poster Sessions

09:15 - 17:30

ePoster Area

CAR-based Cellular Therapy – Preclinical

P026	NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY <i>Speaker:</i> Tobias Bexte, DE	09:15 - 09:15
------	--	---------------

Poster Sessions

09:15 - 17:30

ePoster Area

Cellular Therapies other than CARs

P027	PROLONGED REPEATEDLY ADMINISTERED LOW DOSE DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE LEUKEMIA <i>Speaker:</i> Panagiotis Tsigotis, GR	09:15 - 09:15
P028	CD8⁺-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 <i>Speaker:</i> Mehmet Altan, US	09:15 - 09:15
P029	CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY® TCR⁺ AND CD19 DEPLETION <i>Speaker:</i> Katalin Dobos, HU	09:15 - 09:15
P031	COMPREHENSIVE ACTIVATION PROFILING OF TABELECLEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY <i>Speaker:</i> Fiona Ruiz, US	09:15 - 09:15
P030	IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL	09:15 - 09:15

TRANSPLANTATION IN PEDIATRIC PATIENTS

P035	BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K-NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML AND MDS (NK-REALM) <i>Speaker:</i> Sumithira Vasu, US	09:15 - 09:15
P034	NEW, LN₂-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF CELL THERAPIES <i>Speaker:</i> Julie Meneghel, GB	09:15 - 09:15
P032	DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Virginia Escamilla Gómez, ES	09:15 - 09:15
P033	DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION. ONE SINGLE CENTER EXPERIENCE <i>Speaker:</i> Melissa Karina Torres Ochando, ES	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Data Management

P045	GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE MYELOMA <i>Speaker:</i> Ruth Paul, GB	09:15 - 09:15
------	--	---------------

Poster Sessions
09:15 - 17:30

ePoster Area

Experimental Stem Cell Transplantation

P046	SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL MODULATION IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS ACUTE LEUKAEMIA <i>Speaker:</i> Maryam Barkhordar, IR	09:15 - 09:15
P047	DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Elisabetta Metafuni, IT	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Experimental Transplantation

P048	INFLUENCE OF POLYMORPHISMS RELATED TO DRUG METABOLISM IN ALLOGENEIC BONE MARROW TRANSPLANTATION	09:15 - 09:15
------	--	---------------

	<i>Speaker:</i> Marta Santiago, ES	
P049	REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION <i>Speaker:</i> Tahereh Rostami, IR	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		
Gene Therapy		ePoster Area
P050	BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN FOR β-THALASSEMIA) GENE THERAPY TREATMENT OF A GREEK PATIENT WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT) <i>Speaker:</i> Evangelia Yannaki, GR	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		
Graft-versus-Host Disease – Clinical		ePoster Area
P051	EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS <i>Speaker:</i> Arun Alfred, GB	09:15 - 09:15
P056	REDUCED GVHD WITH TRIPLE PTCY BASED GVHD PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS <i>Speaker:</i> Elisabetta Metafuni, IT	09:15 - 09:15
P055	PROLONGED SUPPRESSION OF BUTYRATE PRODUCING BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AND TRANSPLANT RELATED MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Elisabeth Meedt, DE	09:15 - 09:15
P052	ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED PATIENTS AT DIFFERENT MATURATION STAGES <i>Speaker:</i> Matthias Alexander Fante, DE	09:15 - 09:15
P057	THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI-THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES <i>Speaker:</i> Osman Radhwi, CA	09:15 - 09:15
P060	A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT	09:15 - 09:15

	<i>Speaker:</i> John Mallee, US	
P061	CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE NIH 2014 CONSENSUS CRITERIA <i>Speaker:</i> Koray Yalcin, TR	09:15 - 09:15
P058	COMPARISON OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CR1 <i>Speaker:</i> Maximilian Christopeit, DE	09:15 - 09:15
P059	TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED VERSUS HLA HAPLOIDENTICAL TRANSPLANTS <i>Speaker:</i> Eugenio Galli, IT	09:15 - 09:15
P063	A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4) <i>Speaker:</i> Franco Locatelli, IT	09:15 - 09:15
P062	AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S EIGHT-YEAR EXPERIENCE <i>Speaker:</i> Antonio Grasso, IT	09:15 - 09:15
P064	IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE FROM A SINGLE CENTER <i>Speaker:</i> Panayotis Kaloyannidis, SA	09:15 - 09:15
P065	ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST DISEASE <i>Speaker:</i> Angelo Ostuni, IT	09:15 - 09:15
P066	RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE IN 36 PATIENTS <i>Speaker:</i> Maria Teresa Lupo Stanghellini, IT	09:15 - 09:15
P067	PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS HOST DISEASE PREVENTION IN PATIENTS RECEIVING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT <i>Speaker:</i> Henry Hu, US	09:15 - 09:15
P068	BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS <i>Speaker:</i> Xiaodong Mo, CN	09:15 - 09:15

P069	FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES <i>Speaker:</i> Ivan Moiseev, RU	09:15 - 09:15
P070	A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5) <i>Speaker:</i> Franco Locatelli, IT	09:15 - 09:15
P071	PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Lars Klinge Gjørde, DK	09:15 - 09:15
P072	SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF CLINICAL CASES	09:15 - 09:15
P073	Elevated REG3γ predicts refractory aGVHD in Patients Who Received Steroids- Ruxolitinib as the First Line Therapy <i>Speaker:</i> Liping Dou, CN	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Graft-versus-Host Disease – Preclinical and Animal Models

P074	THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-MEDIATED TISSUE INJURY <i>Speaker:</i> Sascha Göttert, DE	09:15 - 09:15
P075	ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED MICE	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Haematopoietic Stem Cells

P078	RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF OUR HOSPITAL <i>Speaker:</i> Elena Paumard Rodríguez, ES	09:15 - 09:15
P076	LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV INFECTION AFTER STEM CELL TRANSPLANTATION <i>Speaker:</i> Katrin Koch, DE	09:15 - 09:15
P077	KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION, REVISITED <i>Speaker:</i> Kazimierz Halaburda, PL	09:15 - 09:15

P079	THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER ALLOGENEIC TRANSPLANTATION <i>Speaker:</i> Sabrina Giammarco, IT	09:15 - 09:15
P081	OUTCOME OF SECOND ALLOGENIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES <i>Speaker:</i> Zohreh Nademi, GB	09:15 - 09:15
P080	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7 ANTIGEN EXPRESSION <i>Speaker:</i> Danilo De Novellis, IT	09:15 - 09:15
P082	OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS: A SINGLE CENTER STUDY <i>Speaker:</i> Eshrak Al-Shaibani, CA	09:15 - 09:15
P084	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH AML AND MDS: RISK FACTORS FOR OVERALL SURVIVAL AND DISEASE FREE SURVIVAL <i>Speaker:</i> Simona Piemontese, IT	09:15 - 09:15
P083	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A SINGLE-INSTITUTION EXPERIENCE <i>Speaker:</i> Marta Hidalgo Soto, ES	09:15 - 09:15
P086	EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA <i>Speaker:</i> Ma Liangming, CN	09:15 - 09:15
P085	IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE POLYMORPHISMS ON THE OUTCOMES OF TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS <i>Speaker:</i> Anastasia Beynarovich, RU	09:15 - 09:15
P087	AUTOMATED DRY THAWING OF CRYOPRESERVED HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER <i>Speaker:</i> Julie Meneghel, GB	09:15 - 09:15
P091	UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA: AN EXPERIENCE FROM THE LARGEST CHILDREN'S HOSPITAL IN IRAN <i>Speaker:</i> Amir Ali Hamidieh, IR	09:15 - 09:15
P090	INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT IN PATIENTS OVER 65 YEARS OLD <i>Speaker:</i> Magdalena Corona de Lapuerta, ES	09:15 - 09:15

P089	LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN'S AND NON-HODGKIN'S LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN COLOMBIAN NORTHEAST <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
P092	ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF 195 CASES <i>Speaker:</i> Thierry Guillaume, FR	09:15 - 09:15
P097	DEFIBROTIDE AS TREATMENT FOR TRANSPLANT-ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Danilo De Novellis, IT	09:15 - 09:15
P096	IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: REPORT FROM A SINGLE CENTER <i>Speaker:</i> Sabrina Giammarco, IT	09:15 - 09:15
P095	IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HAPLO SCT) USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE IN SUB-SAHARAN AFRICA? <i>Speaker:</i> Justin du Toit, ZA	09:15 - 09:15
P099	IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Claudia Núñez-Torrón, ES	09:15 - 09:15
P098	THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT THE ROYAL MARSDEN HOSPITAL <i>Speaker:</i> Sandra Easdale, GB	09:15 - 09:15
P102	EBV COLITIS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA <i>Speaker:</i> Lucia Prezioso, IT	09:15 - 09:15
P100	BURNOUT SYNDROME IN ONCOLOGY PRACTICE: EXPERIENCE OF A LARGE HSCT CENTER <i>Speaker:</i> Irina Artemeva, RU	09:15 - 09:15
P103	MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) <i>Speaker:</i> Carolina Lilibeth Moreira-Ponce, MX	09:15 - 09:15
P101	FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA POST HEMATOPOIETIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A TERTIARY REFERRAL CENTRE IN INDIA <i>Speaker:</i> Rumesh Chandar, IN	09:15 - 09:15

P104	BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Katheryn Garzón-Velásquez, MX	09:15 - 09:15
P106	EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NARRATIVE REVIEW <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
P105	STAFF EXPERIENCES AND LEARNING FROM WORKING ON A HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING COVID-19 <i>Speaker:</i> Sarah Airdrie, GB	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Haemoglobinopathy

P107	THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Mohammed Essa, SA	09:15 - 09:15
P108	HOW TO FACILITATE DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMOGLOBINOPATHIES - THE PERSPECTIVES OF HEALTH CARE PROFESSIONALS <i>Speaker:</i> Hilda Mekelenkamp, NL	09:15 - 09:15
P109	ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE: A RETROSPECTIVE COHORT ANALYSIS <i>Speaker:</i> Richelle Waldner, CA	09:15 - 09:15
P110	DECISION-MAKING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY – SHARED OR NOT? <i>Speaker:</i> Hilda Mekelenkamp, NL	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

Immunodeficiency Diseases and Macrophages

P111	CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Aishat Idarmacheva, RU	09:15 - 09:15
P112	OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY <i>Speaker:</i> Liam Reilly, GB	09:15 - 09:15

P113	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH CLERICUZIO SYNDROME (POIKILODERMA WITH NEUTROPENIA) <i>Speaker:</i> Alexandra Burya, RU	09:15 - 09:15
------	--	---------------

Poster Sessions
09:15 - 17:30

ePoster Area

Stem Cell Source

P216	THE BLOOD DONATION BEFORE BONE MARROW HARVEST HAS NO IMPACT ON EFFICIENCY OF COLLECTION <i>Speaker:</i> Iwona Mitrus, PL	09:15 - 09:15
P217	UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A SINGLE CENTER EXPERIENCE <i>Speaker:</i> Vincenzo Federico, IT	09:15 - 09:15

Poster Sessions
09:15 - 17:30

ePoster Area

New Drugs- and Cell-based Immune Therapies

P160	INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA <i>Speaker:</i> Vivek Sharma, US	09:15 - 09:15
P161	CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS <i>Speaker:</i> David Dingli, US	09:15 - 09:15
P162	IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL CELLS AND FAVORS MICROVASCULAR THROMBOSIS <i>Speaker:</i> Miriam Galbusera, IT	09:15 - 09:15
P165	MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC SARCOMA <i>Speaker:</i> Carla Martín-Cortázar, ES	09:15 - 09:15
P163	POST-HEMATOPOIETIC STEM CELL TRANSPLANT MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING HUSSEIN CANCER CENTRE EXPERIENCE	09:15 - 09:15
P166	PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT (HCT) (STUDY DESIGN) <i>Speaker:</i> Anna Thorner, US	09:15 - 09:15

P168 **CLINICAL PHARMACOLOGY AND POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721)** 09:15 - 09:15
Speaker: William Pullman, US

P167 **WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES** 09:15 - 09:15
Speaker: David Dingli, US

Poster Sessions
 09:15 - 17:30

ePoster Area

Myeloproliferative Neoplasm

Poster Sessions
 09:15 - 17:30

ePoster Area

Myelodysplastic Syndromes

P156 **THE ROLE OF AGE IN OUTCOMES OF BONE MARROW TRANSPLANTATION IN PATIENTS FROM THE LATIN AMERICAN REGISTRY** 09:15 - 09:15
Speaker: Fernando Barroso Duarte, BR

P157 **PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE MORTALITY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:15 - 09:15
Speaker: Isla Johnson, US

P159 **SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE OF THE PREVIOUS SITUATION** 09:15 - 09:15

P158 **SECONDARY AND TREATMENT-RELATED ACUTE MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION** 09:15 - 09:15
Speaker: Ioanna Sakellari, GR

Poster Sessions
 09:15 - 17:30

ePoster Area

Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution

P143 **EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH THYMOGLOBULIN: A CIBMTR ANALYSIS** 09:15 - 09:15
Speaker: Nina Orfali, IE

P144 **PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT** 09:15 - 09:15
Speaker: Nicolaus Kröger, DE

P145 **IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON** 09:15 - 09:15

**IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Speaker: Amandine Pradier, CH

P146 **MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS
COMPARABLE TO PREDICT AML RELAPSE?** 09:15 - 09:15

Speaker: Valérie Dubois, FR

P148 **CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES
OPEN A WINDOW FOR RELAPSE INTERVENTION?** 09:15 - 09:15

Speaker: Jan Morf, GB

Poster Sessions

09:15 - 17:30

ePoster Area

Stem Cell Mobilization, Collection and Engineering

P206 **INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON-
INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE
THE MOBILIZATION AND COLLECTION OF HSCS IN POOR
MOBILIZERS AHEAD OF ASCT** 09:15 - 09:15

Speaker: Katharina Kriegsmann, DE

P207 **TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION
PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES
BETWEEN 2008 AND 2017** 09:15 - 09:15

Speaker: James Dillon, IE

P208 **THE IMPACT OF THE “NEW NORMAL” ON STEM CELL
LABORATORY PRACTICES** 09:15 - 09:15

Speaker: Sanja Mazi?, HR

P210 **AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR
USAGE WITH GCSF ALONE FOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA** 09:15 - 09:15

Speaker: Mohamed Elemery, CA

P209 **PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM
CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND
FEASIBLE; A SINGLE CENTER ANALYSIS** 09:15 - 09:15

Speaker: Moussab Damraj, SA

P211 **PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION
AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE
AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE** 09:15 - 09:15

Speaker: Nara Stepanyan, RU

P212 **A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION
STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR
AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH
MULTIPLE MYELOMA** 09:15 - 09:15

Speaker: Joshua Richter, US

P213 **PREDICTION OF THE MOBILIZATION SUCCESS FOR
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION
IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES** 09:15 - 09:15

	<i>Speaker:</i> Maria Eduarda Couto, PT	
P214	DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR UTILIZATION DURING STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT? <i>Speaker:</i> Pilar Velarde López de Ayala, ES	09:15 - 09:15
P215	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Madeleine Powys, AU	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		ePoster Area
Nurses Posters – Adult		
NP01	NURSES' TRAINING NEEDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE NURSES GROUP OF THE EBMT <i>Speaker:</i> Michelle Kenyon, GB	09:15 - 09:15
NP02	IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POVIDONE-IODINE MOUTHWASH UNDER DIRECT NURSING SUPERVISION <i>Speaker:</i> Napassaya Khanthum, TH	09:15 - 09:15
NP03	COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL THERAPY <i>Speaker:</i> Mercedes Montoro-Lorite, ES	09:15 - 09:15
NP04	CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE SYNDROME <i>Speaker:</i> Naama Nevo, IL	09:15 - 09:15
NP05	HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM-CELL TRANSPLANTATION: IMPROVING HOME-CARE STRATEGIES DURING SARS-COV-2 PANDEMIC <i>Speaker:</i> Laura Villa Rodríguez, ES	09:15 - 09:15
NP06	IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION <i>Speaker:</i> Sarah Henshaw, GB	09:15 - 09:15
NP07	AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING SARS-CoV-2 PANDEMIC	09:15 - 09:15
NP08	THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED METROPOLITAN TRANSPLANT PROGRAM <i>Speaker:</i> Antonio Bruno, IT	09:15 - 09:15

NP10	PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING WELL ESTABLISHED NURSING CARE STANDARDS <i>Speaker:</i> Isabel Salcedo, ES	09:15 - 09:15
NP11	A TALE OF 2 COLLECTIONS: CAR -T 'V' PBSC. OUR SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Caroline Jupp, GB	09:15 - 09:15
NP12	CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) NURSING IN LATIN AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY <i>Speaker:</i> Mariela Blanco, AR	09:15 - 09:15
NP13	MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO-ONCOLOGY MALIGNANCY AND THOSE UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION DURING THE COVID-19. HOW DO WE PROTECT THEM? <i>Speaker:</i> Anna Serrahima - Mackay, ES	09:15 - 09:15
NP14	PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Bakhtawar Altaf Hussain, PK	09:15 - 09:15
NP15	COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - THE REALITY <i>Speaker:</i> Lindsey Ashton, GB	09:15 - 09:15
NP16	TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED NURSE <i>Speaker:</i> Marijke Quaghebeur, BE	09:15 - 09:15
NP09	EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM <i>Speaker:</i> Mariela Blanco, AR	09:15 - 09:25
<i>Poster Sessions</i> 09:15 - 17:30 Stem Cell Donor		ePoster Area
P203	HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME: A SINGLE-CENTER COMPARISON <i>Speaker:</i> Alisa Lörsch, DE	09:15 - 09:15
P204	CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS: SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND HAPLOIDENTICAL DONORS <i>Speaker:</i> Claudie Roy, CA	09:15 - 09:15
P205	HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH	09:15 - 09:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE CENTER EXPERIENCE IN MEXICO

Speaker: Katheryn Garzón-Velásquez, MX

Poster Sessions

09:15 - 17:30

ePoster Area

Nurses Posters – Paediatric

NP17	NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Deepa Karmegam, IN	09:15 - 09:15
NP18	NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS AFTER CAR-T INFUSION <i>Speaker:</i> Giulia Del Giorno, IT	09:15 - 09:15
NP19	THE WORK OF THE REHABILITATION DEPARTMENT WITH VOLUNTEERS DURING THE COVID-19 PANDEMIC <i>Speaker:</i> Rashida Bikulova, RU	09:15 - 09:15
NP20	EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC CATHETERIZATION AS A MEASURE OF NUTRITIONAL SUPPORT IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION <i>Speaker:</i> Eugenia Trigos Arjona, ES	09:15 - 09:15
NP21	NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY. DESCRIPTION OF CLINICAL CASES <i>Speaker:</i> Anton Silov, RU	09:15 - 09:15
NP22	INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-CENTER EXPERIENCE <i>Speaker:</i> Alba Fernandez-Arroyo Garcia, ES	09:15 - 09:15
NP23	IMPLEMENTATION OF THE ADVANCED CELL THERAPY PROGRAM: &NBSP;EXPERIENCE AT LA PAZ UNIVERSITY HOSPITAL <i>Speaker:</i> Alba Fernandez-Arroyo Garcia, ES	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Nurses Posters – Research

NP24	ROLE OF NURSING IN THE CARE OF PATIENT'S SKIN WITH CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY <i>Speaker:</i> Jacqui Stringer, GB	09:15 - 09:15
------	--	---------------

NP25	INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT <i>Speaker:</i> Lubov Shepeleva, RU	09:15 - 09:15
NP26	THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING DEVELOPMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: FROM PRACTICE TO SCIENCE <i>Speaker:</i> Natalya Rotan, RU	09:15 - 09:15
NP27	LONG TERM SURVIVORS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD AND ADOLESCENCE IN A DEVELOPING COUNTRY: HOW ARE THEY NOW? <i>Speaker:</i> Priscila Oliveira da Silva, BR	09:15 - 09:15
NP28	EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS <i>Speaker:</i> Olga Prokofieva, RU	09:15 - 09:15
NP29	EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY DISEASES <i>Speaker:</i> Silvia Sangüesa Domínguez, ES	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30 Pharmacology		ePoster Area
P195	PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE: INTERIM RESULTS FROM THE EQUATE STUDY <i>Speaker:</i> John Koreth, US	09:15 - 09:15
P196	EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE THERAPEUTIC DRUG MONITORING OF BUSULFAN <i>Speaker:</i> Bushra Salman, OM	09:15 - 09:15
P197	A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE PRECLINICAL MODELS OF AML <i>Speaker:</i> Leanne Lanieri, US	09:15 - 09:15
P199	PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Speaker:</i> Sara M. Zimmerman, US	09:15 - 09:15
P198	THE IMPACT OF LETERMIVIR PRESCRIBING ON THE RATE OF CYTOMEGALOVIRUS REACTIVATION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Siobhan Smith, GB	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

Solid Tumours

- | | | |
|------|---|---------------|
| P200 | HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-WORLD EXPERIENCE IN ARGENTINA
<i>Speaker:</i> Adriana Vitriu, AR | 09:15 - 09:15 |
|------|---|---------------|

Poster Sessions

09:15 - 17:30

ePoster Area

Statistics

- | | | |
|------|---|---------------|
| P201 | EVALUATION OF MACHINE LEARNING ALGORITHMS APPLICABILITY FOR GRAFT FAILURE PREDICTION
<i>Speaker:</i> Evgeny Bakin, RU | 09:15 - 09:15 |
| P202 | WHITE MATTER DEVELOPMENT IN NEONATES WITH INFANTILE KRABBE DISEASE
<i>Speaker:</i> Maria Escolar, US | 09:15 - 09:15 |

Poster Sessions

09:15 - 17:30

ePoster Area

Non-infectious Early Complications

- | | | |
|------|--|---------------|
| P169 | POST HEMATOPOIETIC PROGENITORS TRANSPLANT LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR VIRUS (EBV): A CENTER'S EXPERIENCE
<i>Speaker:</i> Sara Garrido, ES | 09:15 - 09:15 |
| P171 | CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTER EXPERIENCE | 09:15 - 09:15 |
| P170 | ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL ECOSYSTEM
<i>Speaker:</i> Daniele Zama, IT | 09:15 - 09:15 |
| P172 | HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC HYPERPLASI
<i>Speaker:</i> Eugenio Galli, IT | 09:15 - 09:15 |
| P173 | THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTER EXPERIENCE
<i>Speaker:</i> Carlota Mayor Bastida, ES | 09:15 - 09:15 |
| P175 | EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY SUGAR ABSORPTION TEST: INTERIM ANALYSIS OF THE SINGLE-CENTER PROSPECTIVE STUDY | 09:15 - 09:15 |

Speaker: Grzegorz Basak, PL

- | | | |
|------|---|---------------|
| P176 | ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO-OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT
Speaker: Zofia Szmit, PL | 09:15 - 09:15 |
|------|---|---------------|

Poster Sessions

09:15 - 17:30

ePoster Area

Paediatric Issues

- | | | |
|------|--|---------------|
| P183 | POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA
Speaker: Andrey Kozlov, RU | 09:15 - 09:15 |
| P185 | RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING EXVIVO T-CELL-DEPLETION
Speaker: Iván López Torija, ES | 09:15 - 09:15 |
| P184 | FREQUENCY AND CAUSES OF DEATH AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NON-MALIGNANT DISEASES
Speaker: Koray Yalcin, TR | 09:15 - 09:15 |
| P186 | SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Denise Elbæk, DK | 09:15 - 09:15 |
| P187 | LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH NONMALIGNANT DISEASES: A SINGLE CENTER COHORT ANALYSIS
Speaker: Joëll Esmée Bense, NL | 09:15 - 09:15 |
| P188 | PROSPECTIVE MULTICENTER STUDY OF A REDUCED-TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE REGIMENS
Speaker: Fanny Rialland, FR | 09:15 - 09:15 |
| P189 | TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED DONOR IN PEDIATRIC PATIENTS
Speaker: Luisa Sisinni, ES | 09:15 - 09:15 |
| P190 | SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Charlotte Nazon, FR | 09:15 - 09:15 |
| P191 | SAFETY AND PERFORMANCE OF CENTRAL VENOUS CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE | 09:15 - 09:15 |

CENTRE EXPERIENCE

Speaker: Sofia Martin-Consuegra, ES

- | | | |
|------|--|---------------|
| P192 | TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND – BLACKFAN ANEMIA | 09:15 - 09:15 |
| | <i>Speaker:</i> Svetlana Radygina, RU | |
| P193 | ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES | 09:15 - 09:15 |
| | <i>Speaker:</i> Maksymilian Deregowski, PL | |
| P194 | CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS | 09:15 - 09:15 |
| | <i>Speaker:</i> Taylor Fitch, US | |

Poster Sessions
09:15 - 17:30

ePoster Area

Non-infectious Late Effects, Quality of Life and Fertility

- | | | |
|------|---|---------------|
| P177 | IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS | 09:15 - 09:15 |
| | <i>Speaker:</i> Magdalena Corona de Lapuerta, ES | |
| P178 | OSTEONECROSIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-CENTRE STUDY OF INCIDENCE, RISK FACTORS, CHARACTERISTICS AND EVOLUTION | 09:15 - 09:15 |
| | <i>Speaker:</i> Giulia Prunotto, IT | |
| P179 | SECONDARY MALIGNANCIES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION | 09:15 - 09:15 |
| | <i>Speaker:</i> João Gaião Santos, PT | |
| P181 | ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE CHEMOTHERAPY | 09:15 - 09:15 |
| | <i>Speaker:</i> Walter Javier Zambrano Marquez, ES | |
| P180 | SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN | 09:15 - 09:15 |
| | <i>Speaker:</i> Yulia Skvortsova, RU | |
| P182 | AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – AMYOPATHIC DERMATOMYOSITIS, PRIMARY BILIARY CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA | 09:15 - 09:15 |
| | <i>Speaker:</i> Pedro de Vasconcelos M, PT | |

Poster Sessions
09:15 - 17:30

ePoster Area

Multiple Myeloma

P149	HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS ? 70 YEARS IS SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS <i>Speaker:</i> Udo Holtick, DE	09:15 - 09:15
P150	PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS <i>Speaker:</i> Meilan Chen, CN	09:15 - 09:15
P152	RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Speaker:</i> Jingli Gu, CN	09:15 - 09:15
P151	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION <i>Speaker:</i> Rita Sousa Gomes, PT	09:15 - 09:15
P153	CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA <i>Speaker:</i> Carolina Afonso, PT	09:15 - 09:15
P155	INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MUTIPLE MYELOMA <i>Speaker:</i> Pilar Velarde López de Ayala, ES	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

ePoster Area

Poster Sessions

09:15 - 17:30

ePoster Area

Acute Leukaemia

P001	MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC INFLUENCE ON POST-TRANSPLANT OUTCOMES IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Rama Al Hamed, US	09:15 - 09:15
P002	ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE REMISSION IN R/R B-ALL AFTER TREATMENT WITH MONOCLONAL ANTIBODIES <i>Speaker:</i> Inna Markova, RU	09:15 - 09:15
P003	AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS RELAPSED AFTER ALLOGENEIC STEM CELL	09:15 - 09:15

	TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER ANALYSIS <i>Speaker:</i> Semra Aydin, IT	
P004	T-CELL-DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE CENTRE EXPERIENCE OF 90 PATIENTS <i>Speaker:</i> Alexandros Kanellopoulos, GB	09:15 - 09:15
P005	POST-REMISSION TREATMENT PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) IN THE CONNECT® MDS/AML DISEASE REGISTRY	09:15 - 09:15
P006	ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF RECIPIENT AGE AND DONOR TYPE <i>Speaker:</i> Tatiana Tzenou, GR	09:15 - 09:15
P007	GILTERITINIB MONOTHERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT PATIENTS <i>Speaker:</i> Sergey Bondarenko, RU	09:15 - 09:15
P009	ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL) <i>Speaker:</i> Alan S. Wayne, US	09:15 - 09:15
P008	VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA POST ALLOGENEIC STEM CELL TRANSPLANT <i>Speaker:</i> Sandra Easdale, GB	09:15 - 09:15
P010	LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA – FOCUS ON MORTALITY <i>Speaker:</i> Anna Lojko-Dankowska, PL	09:15 - 09:15
P011	SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA <i>Speaker:</i> Semra Aydin, IT	09:15 - 09:15
P012	BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE MONOCENTRIC REPORT <i>Speaker:</i> Elisabetta Metafuni, IT	09:15 - 09:15
P013	UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA	09:15 - 09:15

	<i>Speaker:</i> Sergey Bondarenko, RU	
P014	SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A CENTER IN COLOMBIA <i>Speaker:</i> Claudia Lucía Sossa Melo, CO	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30		
Conditioning Regimens		ePoster Area
P036	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE LIMIT? <i>Speaker:</i> Sara Fernández-Luis, ES	09:15 - 09:15
P037	THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE <i>Speaker:</i> Bartosz Malecki, PL	09:15 - 09:15
P038	CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN EARLY RELAPSED MULTIPLE MYELOMA PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Jaap van Doesum, NL	09:15 - 09:15
P039	PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL WITH TBI AND ETOPOSIDE CONDITIONING <i>Speaker:</i> Jane E Potter, GB	09:15 - 09:15
P040	ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH FAVORABLE OUTCOMES	09:15 - 09:15
P041	LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE CONDITIONING REGIMEN OF REDUCED TOXICITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Speaker:</i> Ioanna Sakellari, GR	09:15 - 09:15
P042	TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY <i>Speaker:</i> Raquel Olivas-Mazón, ES	09:15 - 09:15
P044	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED-RELATED SIBLING DONORS <i>Speaker:</i> Gabriella Storti, IT	09:15 - 09:15
P043	IMMUNE RECONSTITUTION AFTER SEQUENTIAL CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT	09:15 - 09:15

DONOR TYPES

Speaker: Alessia Fraccaroli, DE

Poster Sessions

09:15 - 17:30

ePoster Area

Lymphoma and Chronic Lymphocytic Leukemia

P134	RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER RETROSPECTIVE COHORT STUDY Speaker: Fernando Warley, AR	09:15 - 09:15
P133	18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW CNS LYMPHOMA IMAGING TOOL Speaker: Sandra Easdale, GB	09:15 - 09:15
P135	THE OUTCOMES OF ALLOGENEIC STEM CELLS TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED THERAPY: SINGLE CENTER EXPERIENCE Speaker: Ivan Moiseev, RU	09:15 - 09:15
P137	STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN BLOOD AND MARROW TRANSPLANTATION REGISTRY Speaker: Yu-Hung Wang, TW	09:15 - 09:15
P136	NIVOLUMAB 40 MG THERAPY IN RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY Speaker: Liudmila Fedorova, RU	09:15 - 09:15
P138	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION EXPERIENCE Speaker: Joanna Romejko-Jarosinska, PL	09:15 - 09:15
P142	SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL LYMPHOMA WITH INTENSIFIED MYELOABLATIVE CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION Speaker: Yan-Li Zhao, CN	09:15 - 09:15
P140	POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R DIFFUSE LARGE B-CELL LYMPHOMA Speaker: Ivan Moiseev, RU	09:15 - 09:15
P141	NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF CONSOLIDATIVE AUTOLOGOUS STEM CELL TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST	09:15 - 09:15

REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL HOSPITAL

Speaker: Christopher Shwei Wen Tham, SG

- | | | |
|------|--|---------------|
| P139 | AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG TERM OUTCOMES
<i>Speaker:</i> Sudhir Kumar, IN | 09:15 - 09:15 |
|------|--|---------------|

Poster Sessions
09:15 - 17:30

ePoster Area

Infectious Complications

- | | | |
|------|---|---------------|
| P118 | COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE-EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION
<i>Speaker:</i> Luisa Giaccone, IT | 09:15 - 09:15 |
| P119 | INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE
<i>Speaker:</i> Amir Ali Hamidieh, IR | 09:15 - 09:15 |
| P120 | EPIDEMIOLOGY OF RESISTANT AND REFRACTORY CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A SYSTEMATIC REVIEW
<i>Speaker:</i> Aurore Bergamasco, FR | 09:15 - 09:15 |
| P122 | EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
<i>Speaker:</i> Aleksandr Siniaev, RU | 09:15 - 09:15 |
| P121 | ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT BACTERIA
<i>Speaker:</i> Filippo Maraz, IT | 09:15 - 09:15 |
| P123 | CLINICAL AND MICROBIOLOGICAL IMPACT OF DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
<i>Speaker:</i> Anke Verlinden, BE | 09:15 - 09:15 |
| P124 | IRON CHELATION WITH DEFERASIROX SUPPRESSES THE APPEARANCE OF LPI DURING CONDITIONING CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION
<i>Speaker:</i> Sonja Essmann, DE | 09:15 - 09:15 |
| P125 | SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN MEXICO
<i>Speaker:</i> Brenda Lizeth Acosta-Maldonado, MX | 09:15 - 09:15 |

P126	ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE CENTER RETROSPECTIVE STUDY <i>Speaker:</i> Mohammed Essa, SA	09:15 - 09:15
P128	TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT <i>Speaker:</i> Tahereh Rostami, IR	09:15 - 09:15
P127	HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC CYSTITIS: RETROSPECTIVE COHORT STUDY <i>Speaker:</i> Nikola Pantic, RS	09:15 - 09:15
P132	CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - SINGLE CENTRE EXPERIENCE <i>Speaker:</i> Milena Todorovic Balint, RS	09:15 - 09:15
P129	PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL <i>Speaker:</i> Fernando Barroso Duarte, BR	09:15 - 09:15
P131	SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION <i>Speaker:</i> Maurizio Caniglia, IT	09:15 - 09:15
P130	CLINICAL CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT PATIENTS: A MONOCENTRIC 5 YEARS SURVEY <i>Speaker:</i> Gabriele Facchin, IT	09:15 - 09:15
<i>Poster Sessions</i> 09:15 - 17:30 Inborn Errors		ePoster Area
P114	ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH TREOSULFAN-BASED CONDITIONING <i>Speaker:</i> Matthias Bleeke, DE	09:15 - 09:15
P115	LONG-TERM NEURODEVELOPMENTAL, NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE METACHROMATIC LEUKODYSTROPHY <i>Speaker:</i> Maria Escolar, US	09:15 - 09:15
P116	OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING PARTY <i>Speaker:</i> Su Han Lum, GB	09:15 - 09:15

Poster Sessions

09:15 - 17:30

ePoster Area

CAR-based Cellular Therapy – Clinical

P016	HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Thomas Martin, US	09:15 - 09:15
P017	MANUFACTURING COMMERCIAL AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR RETROSPECTIVE ANALYSIS <i>Speaker:</i> Didier Hallard, NL	09:15 - 09:15
P015	RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5 <i>Speaker:</i> Julio C. Chavez, US	09:15 - 09:15
P019	COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY FOLLOWING BRUTON TYROSINE KINASE INHIBITOR TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ENGLAND <i>Speaker:</i> Martin Brown, GB	09:15 - 09:15
P018	EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL THERAPY IN THE REAL WORLD SETTING <i>Speaker:</i> Silvia Monsalvo, ES	09:15 - 09:15
P020	PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Speaker:</i> Adam D Cohen, US	09:15 - 09:15
P021	CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA <i>Speaker:</i> Pere Barba, ES	09:15 - 09:15
P022	CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR-DERIVED CD19 CAR-T CELLS MANUFACTURED FROM MEMORY T CELL (CD45RA-DEPLETED) FRACTION <i>Speaker:</i> Larisa Shelikhova, RU	09:15 - 09:15
P024	ICU RESOURCE UTILIZATION IN PEDIATRIC AND ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T THERAPY <i>Speaker:</i> Drishti Ragoonanan, US	09:15 - 09:15
P023	HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED PROLONGED PANCYTOPENIA USING AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A LYMPHOMA PATIENT <i>Speaker:</i> Udo Holtick, DE	09:15 - 09:15

P025	ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB WITH AXICABTAGENE CILOLEUCEL (AXI?CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL) <i>Speaker:</i> Saad J. Kenderian, US	09:15 - 09:15
------	--	---------------

Multi-stakeholder Forum on Innovative Cellular Therapies

09:30 - 10:30

Auditorium 6

MSF1 - Multi-stakeholder Forum on Innovative Cellular Therapies - Session 1

Chair: Christian Chabannon, FR

Chair: Rafael Duarte, ES

MSF1-1	Real-world regulatory issues in the implementation of Advanced Therapies <i>Speaker:</i> Teresa Chavarria, ES	09:30 - 09:44
MSF1-2	Regulatory issues in a pandemic: The COVID-19 experience <i>Speaker:</i> Cesar Hernandez, ES	09:44 - 09:58
MSF1-3	The development of new ATMPs from an academic perspective: Hurdles and opportunities <i>Speaker:</i> Collin de Haar, NL	09:58 - 10:15
MSF1-4	Q&A	10:15 - 10:30

Breaks

10:30 - 11:00

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Educational

11:00 - 12:15

Auditorium 1

E07 - CARs in childhood malignancy

Chair: Selim Corbacioglu, DE

Chair: Jose M. Pérez Hurtado, ES

E7-1	CAR therapies for lymphoid malignancies and beyond <i>Speaker:</i> Stephan Grupp, US	11:00 - 11:15
E7-2	Adapter CAR T-cells: Implications for childhood cancer <i>Speaker:</i> Patrick Schlegel, AU	11:15 - 11:30
E7-3	CAR NK-cells: The next generation of Cellular Cancer Therapy <i>Speaker:</i> May Daher, US	11:30 - 11:45
E7-4	Q&A	11:45 - 12:15

Workshop

11:00 - 12:15

Auditorium 2

W06 - Pretransplant risk management for allogeneic HSCT recipients and donors

Chair: Adrián Alegre, ES

Chair: Yela Figuera, ES

W6-1	Patient infectious risk factors: What they are and how to deal with them	11:00 - 11:15
------	---	---------------

	<i>Speaker:</i> Simone Cesaro, IT	
W6-2	Patient comorbidity and organ issues <i>Speaker:</i> Jaime Sanz Caballer, ES	11:15 - 11:30
W6-3	Donor issues posing a risk for themselves or for patients <i>Speaker:</i> Nina Worel, AT	11:30 - 11:45
W6-4	Q&A	11:45 - 12:15

Nurses Group
11:00 - 12:15

Auditorium 3

NG09 - Research session

Chair: Sarah Liptrott, IT

NG09-1	Hold on - A Swedish research study regarding support needs among family caregivers in allo-HSCT <i>Speaker:</i> Jeanette Winterling, SE	11:00 - 11:15
NG09-2	Getting involved in research: The experience of the junior member of the Research Committee <i>Speaker:</i> Marta Canesi, IT	11:15 - 11:30
NG09-3	A publication from scratch: My experience as the Infectious Diseases Working Party Nurse <i>Speaker:</i> Iris Agreiter, IE	11:30 - 11:45
NG09-4	EBMT Nurses Group guidelines for abstracts scoring: Development and evaluation <i>Speaker:</i> Isabel Salcedo, ES	11:45 - 12:00
NG09-5	Q&A <i>Speaker:</i> Hilda Mekelenkamp, NL <i>Speaker:</i> Annika Kisch, SE <i>Speaker:</i> Sandra Schoenfeld, CH <i>Speaker:</i> Jacqui Stringer, GB	12:00 - 12:15

How do I ... ?
11:00 - 12:15

Auditorium 4

HDI4 - How do I... best select patients for CAR T therapies? - Supported through an unrestricted educational grant by BMS

Chair: Alessandro Rambaldi, IT

HDI4-1	For NHL <i>Speaker:</i> Peter Dreger, DE	11:00 - 11:25
HDI4-2	For Myeloma <i>Speaker:</i> Philippe Moreau, FR	11:25 - 11:50
HDI4-3	Q&A	11:50 - 12:15

Data Management

11:00 - 12:15

Auditorium 5

DM02 - Education session 2 - Discussion forum - Med A Live session

Chair: Helen Baldomero, CH

Chair: Shelley Hewerdine, GB

DM2-1	Discussion forum - Med A <i>Speaker:</i> Per Ljungman, SE <i>Speaker:</i> Bertram Glass, DE <i>Speaker:</i> Johannes Schetelig, DE <i>Speaker:</i> Eolia Brissot, FR	11:00 - 11:45
-------	---	---------------

DM2-2	Q&A	11:45 - 12:15
-------	----------------	---------------

Multi-stakeholder Forum on Innovative Cellular Therapies

11:00 - 12:15

Auditorium 6

MSF2 - Multi-stakeholder Forum on Innovative Cellular Therapies - Session 2

Chair: Nicolaus Kröger, DE

Chair: Anna Sureda, ES

MSF2-1	EBMT Clinical Trials Office: Cell Therapy Data Capture <i>Speaker:</i> Sofie Terwel, NL	11:00 - 11:15
MSF2-2	EMA's Patient Registry Initiative <i>Speaker:</i> Xavier Kurz, NL	11:15 - 11:30
MSF2-3	How are new cellular therapies being rolled out? <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	11:30 - 11:45
MSF2-4	Pricing and real-life access to CAR-T therapy in the USA <i>Speaker:</i> Inmaculada Hernández Delso, US	11:45 - 12:00
MSF2-5	Q&A	12:00 - 12:15

Breaks

12:15 - 13:00

Auditorium 1

Lunch Break, Poster Viewing, Visit Exhibition

Wellness session

12:20 - 12:50

Auditorium 1

Nutrition and healing: The anti-inflammatory plate

Meet the Expert

12:30 - 13:30

MTE rooms

Meet the Expert sessions

MTE-11	Post-transplantation cyclophosphamide as universal GVHD prophylaxis - Room MTE1 <i>Speaker:</i> Ephraim Fuchs, US	12:30 - 12:30
MTE-12	Gene therapy for inborn errors 'come of age' in 2021 - Room MTE2 <i>Speaker:</i> Alain Fischer, FR	12:30 - 12:30

MTE-13	How can we manage DLBCL relapse after CART therapy? - Room MTE3 <i>Speaker:</i> Catherine Thieblemont, FR	12:30 - 12:30
MTE-14	Managing thalassemia and other inherited disorders with HSCT - Room MTE4 <i>Speaker:</i> Franco Locatelli, IT	12:30 - 12:30
MTE-15	Allogeneic HSCT in multiple myeloma in the era of new drugs - Room MTE5 <i>Speaker:</i> Sergio Giralt, US	12:30 - 12:30

Special Session
13:00 - 14:00

Auditorium 4

SS05 - Health inequalities and equality, diversity and inclusion at EBMT

Chair: Raffaella Greco, IT

Chair: John Murray, GB

SS5-1	Progress in ED&I at the EBMT <i>Speaker:</i> Ben Summerskill, GB	13:00 - 13:10
SS5-2	What have we learned? <i>Speaker:</i> Silvia Montoto, GB	13:10 - 13:20
SS5-3	Patient perspectives on health inequalities <i>Speaker:</i> Anne-Pierre Pickaert, FR	13:20 - 13:30
SS5-4	Health inequalities in BMT – A personal journey <i>Speaker:</i> Soulaïman Elias, SY	13:30 - 13:40
SS5-5	Q&A	13:40 - 14:00

Data Management
13:00 - 14:00

Auditorium 5

DM03 - Education session 3 - Registry Upgrade and Data Collection news in the EBMT

Chair: Shelley Hewerdine, GB

DM3-1	EBMT Registry update <i>Speaker:</i> Bas Middelkoop, NL	13:00 - 13:10
DM3-2	Updates from the Registry Committee <i>Speaker:</i> Per Ljungman, SE	13:10 - 13:30
DM3-3	Q&A	13:30 - 14:00

Patient Advocacy Sessions
13:00 - 14:00

Auditorium 6

PA1 - Patient Advocacy: Gathering data and shaping the research via patient inputs

Chair: Andrea Linke, DE

Chair: Natacha Bolaños, ES

PA1-1	Shaping the research via patient inputs <i>Speaker:</i> Lars Bullinger, DE	13:00 - 13:15
-------	--	---------------

PA1-2	A patient initiated study in autoimmune disease <i>Speaker:</i> Ellen Kramer, NL	13:15 - 13:30
PA1-3	Patient data and inputs: opportunities, challenges and a way forward in 5 examples <i>Speaker:</i> Hans Scheurer, BE	13:30 - 13:45
PA1-4	Round table discussion	13:45 - 14:00

Breaks

14:00 - 14:30

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Plenary Session

14:30 - 15:45

Auditorium 1

P3 - Patient Reported Outcomes - A new paradigm in HSCT

Chair: Rafael Duarte, ES

Chair: Helene Schoemans, BE

Chair: Nicolaus Kröger, DE

P3-1	Do PRO predict HSCT outcome? <i>Speaker:</i> Bronwen Shaw, US	14:30 - 14:45
P3-2	Optimizing the management of GVHD using PRO measures <i>Speaker:</i> Rubeta Matin, GB	14:45 - 15:00
P3-3	PRO in CAR T-cell therapy <i>Speaker:</i> Anna Barata, US	15:00 - 15:15
P3-4	Integrating the patient in HSCT research projects <i>Speaker:</i> Linda Burns, US	15:15 - 15:30
P3-5	Q&A	15:30 - 15:45

Workshop

14:30 - 15:45

Auditorium 2

W07 - Controversies in patients with DLBCL

Chair: Anna Sureda, ES

Chair: Bertram Glass, DE

W7-1	Anything better than R-CHOP for first-line therapy? <i>Speaker:</i> Umberto Vitolo, IT	14:30 - 14:45
W7-2	Has HSCT come to an end in relapsed disease? <i>Speaker:</i> Bertram Glass, DE	14:45 - 15:00
W7-3	CAR-T cells in relapsed/refractory DLBCL and beyond <i>Speaker:</i> Alberto Mussetti, ES	15:00 - 15:15
W7-4	Q&A	15:15 - 15:45

Nurses Group

14:30 - 15:45

Auditorium 3

NG10 - Oral session 1: Abstracts finalists

Chair: Isabel Salcedo, ES

Chair: Laura Vicente, ES

NG10-1	SUPPORTIVE AND PALLIATIVE CARE TEAM (SPCT) INVOLVEMENT FOR PATIENTS ELIGIBLE FOR CAR T-CELL THERAPY <i>Speaker:</i> Debbie Yeatman, GB	14:30 - 14:40
NG10-2	IMPLEMENTATION AND EVALUATION OF A NURSE-ALLIED HEALTH CLINIC FOR PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Speaker:</i> Midori Nakagaki, AU	14:40 - 14:50
NG10-3	NURSES' SLEEP QUALITY AND BURN-OUT LEVEL DURING PHASE 2 OF COVID-19 EMERGENCY IN ITALY: A MULTICENTRIC CROSS-SECTIONAL STUDY OF GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO <i>Speaker:</i> Chiara Cannici, IT	14:50 - 15:00
NG10-4	THE IMPACT OF COVID-19 AND CHANGES TO CLINICAL PRACTICE IN STEM-CELL TRANSPLANTATION - A HEALTHCARE PROFESSIONALS PERSPECTIVE <i>Speaker:</i> Hayley Leonard, GB	15:00 - 15:10
NG10-5	QUALITY OF LIFE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION AT ALFRED HEALTH <i>Speaker:</i> Bianca Cirone, AU	15:10 - 15:20
	Q&A	15:20 - 15:45

Workshop

14:30 - 15:45

Auditorium 4

W08 - When modern hematology and anti-infective drugs meet at CYP450

Chair: Oliver Cornely, DE

Chair: Juan Diego Vélez, CO

W8-1	Is it time TDM our recent hematologic advances? <i>Speaker:</i> Roger Brüggemann, NL	14:30 - 14:45
W8-2	Crossroads of life-saving drugs – Antifungal prophylaxis and novel agents in oncology <i>Speaker:</i> Jannik Stemler, DE	14:45 - 15:00
W8-3	Practical consequences of co-administration of life-saving drugs <i>Speaker:</i> Samir Agrawal, GB	15:00 - 15:15
W8-4	Q&A	15:15 - 15:45

Data Management

14:30 - 15:45

Auditorium 5

DM04 - Education session 4 - Data Managers' Discussion Forum: Centres, Registries and Study Offices

Chair: Helen Baldomero, CH

DM4-1	From computer to bed-side: improving patient care through data collection <i>Speaker:</i> Juana Schwartz Mota, ES	14:30 - 14:45
DM4-2	The BSBMTCT: The Role of National Registries in Data Management – The UK Experience <i>Speaker:</i> Julia Lee, GB	14:45 - 15:00
DM4-3	The EBMT Study offices: Using EBMT Registry data <i>Speaker:</i> Steffie van der Werf, NL	15:00 - 15:15
DM4-4	Discussion forum - Being a data manager: Practical issues	15:15 - 15:40
DM4-5	Closing speech and thanks <i>Speaker:</i> Shelley Hewerdine, GB	15:40 - 15:45

Patient Advocacy Sessions

14:45 - 15:45

Auditorium 6

PA2 - Patient Advocacy: Patient engagement in research: PRO, let's talk about it

Chair: Guy Bouguet, FR

Chair: Anne-Pierre Pickaert, FR

PA2-1	CAB concept and implementation - Key achievement form CAB program <i>Speaker:</i> Natacha Bolaños, ES	14:45 - 15:00
PA2-2	Perspectives from a researcher against patient engagement <i>Speaker:</i> Sam Salek, GB	15:00 - 15:14
PA2-3	Round table discussion with all participants: Arguments on whether patient involvement in research is needed and efficient <i>Speaker:</i> Pushpendra Goswami, GB	15:14 - 15:45

Breaks

15:45 - 16:15

Auditorium 1

Coffee Break, Poster Viewing, Visit Exhibition

Plenary Session

16:15 - 17:30

Auditorium 1

P4 - New developments in the field of CAR T cell therapy

Chair: Álvaro Urbano-Ispizua, ES

Chair: Christian Chabannon, FR

P4-1	CAR T cells to prevent antigen escape <i>Speaker:</i> Marcela Maus, US	16:15 - 16:30
P4-2	Anti-CD123 CAR-T cells for plasmacytoid dendritic cell leukaemia (BPDCN)	16:30 - 16:45

	<i>Speaker:</i> Francine Garnache-Ottou, FR	
P4-3	CRISPR-Case to engineer CAR-T cells <i>Speaker:</i> Edward Stadtmauer, US	16:45 - 17:00
P4-4	Q&A	17:00 - 17:30
<i>Workshop</i> 16:15 - 17:30		
		Auditorium 2
	W09 - HSCT for immune modulation of solid organ transplantation	
	<i>Chair:</i> Petr Sedlacek, CZ	
	<i>Chair:</i> Antonio Pérez-Martínez, ES	
W9-1	Basis and opportunities of HSCT as a tool to induce immunotolerance to SOT <i>Speaker:</i> Megan Sykes, US	16:15 - 16:30
W9-2	HSCT to induce immunotolerance to lung transplantation <i>Speaker:</i> Paul Szabolcs, US	16:30 - 16:45
W9-3	HSCT to induce immunotolerance to composite tissue transplantation <i>Speaker:</i> Sebastian Giebel, PL	16:45 - 17:00
W9-4	Q&A	17:00 - 17:30
<i>Nurses Group</i> 16:15 - 17:30		
		Auditorium 3
	NG11 - Paediatric session	
	<i>Chair:</i> Hilda Mekelenkamp, NL	
	<i>Chair:</i> Teija Schröder, FI	
NG11-1	Parent transplant decision making and good parent research <i>Speaker:</i> Pamela Hinds, US	16:15 - 16:35
NG11-2	eHealth, home care and self-management in paediatrics <i>Speaker:</i> Inger Kristensson Hallström, SE	16:35 - 16:55
NG11-3	Gamified mobile health intervention Triumf to prevent psychological problems and support behavior change: Learnings from a qualitative study among pediatric cancer patients <i>Speaker:</i> Kadri Haljas, EE	16:55 - 17:15
NG11-4	Q&A	17:15 - 17:30
<i>Special Session</i> 16:15 - 17:30		
		Auditorium 4
	SS06 - COVID 2: The Impact of COVID-19 in HSCT and Cellular Therapy: a year from the start of the pandemic	
	<i>Chair:</i> Anna Sureda, ES	
	<i>Chair:</i> Rafael de la Cámara, ES	
SS6-1	EBMT recommendations and prospective registry study	16:15 - 16:30

	<i>Speaker:</i> Per Ljungman, SE	
SS6-2	The challenge of COVID-19 a year on in Germany <i>Speaker:</i> Lutz Müller, DE <i>Speaker:</i> Judith Schaffrath, DE	16:30 - 16:45
SS6-3	The challenge of COVID-19 a year on in France <i>Speaker:</i> Alienor Xhaard, FR	16:45 - 17:00
SS6-4	The challenge of COVID-19 a year on in the Netherlands <i>Speaker:</i> Mette Hazenberg, NL	17:00 - 17:15
SS6-5	Q&A	17:15 - 17:30

How do I ... ?
16:15 - 17:30

Auditorium 5

HDI5 - How Do I... manage stem cell mobilisation in special cases? - Supported through an unrestricted educational grant by Sanofi

Chair: Nina Worel, AT

HDI5-1	Mobilisation of healthy donors - Standard procedures and perspectives <i>Speaker:</i> Kristina Hölig, DE	16:15 - 16:40
HDI5-2	Mobilisation in children <i>Speaker:</i> Claudia Del Fante, IT	16:40 - 17:05
HDI5-3	Q&A	17:05 - 17:30

Joint Session
16:15 - 17:15

Auditorium 6

JS03 - Joint session EHA

Chair: Nicolaus Kröger, DE

Chair: John Gribben, GB

JS3-1	Update of European management recommendation for CAR T cell therapies <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	16:15 - 16:35
JS3-2	CART, where are we going? <i>Speaker:</i> Michael Hudecek, DE	16:35 - 16:55
JS3-3	Q&A	16:55 - 17:15

Nurses Group
17:30 - 18:00

Auditorium 3

NG12 - Nurses Closing Session

Chair: John Murray, GB

Chair: Klara Kabatova-Maxova, CZ

NG12-3	Best of the best: Abstract prizes <i>Speaker:</i> John Murray, GB	17:30 - 17:35
NG12-4	Highlights from physician's sessions	17:35 - 17:50

	<i>Speaker:</i> Anna Sureda, ES	
NG12-5	Presentation of Prague 2022 <i>Speaker:</i> Klara Kabatova-Maxova, CZ	17:50 - 18:00
<i>General</i>		
17:35 - 18:10		Auditorium 1
	GS4 - Closing Ceremony	
	<i>Chair:</i> Nicolaus Kröger, DE	
	<i>Chair:</i> Rafael Duarte, ES	
GS4-1	Presentation of the Springer Nature Poster Awards <i>Speaker:</i> Nicolaus Kröger, DE	17:35 - 17:40
GS4-2	Congress President closing remarks <i>Speaker:</i> Rafael Duarte, ES	17:40 - 17:50
GS4-3	Local Co-Presidents for EBMT 2022 Prague: Welcome <i>Speaker:</i> Petr Sedlacek, CZ <i>Speaker:</i> Pavel Jindra, CZ	17:50 - 18:00
GS4-4	EBMT President closing remarks <i>Speaker:</i> Nicolaus Kröger, DE	18:00 - 18:10